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Neutrophils are recognised to play a pivotal role at the interface between the innate and 
adaptive immune responses following their rapid recruitment to inflamed tissues and 
lymphoid organs. Whilst neutrophil trafficking through blood vessels has been 
extensively studied, the molecular mechanisms regulating their migration into the 
lymphatic system are still poorly understood. This thesis therefore aimed to investigate 
the mechanisms involved in neutrophil migration across the lymphatic endothelium 
during TNF- or Complete Freund’s Adjuvant + antigen (CFA+Ag)-induced inflammation 
of cremaster muscles in vivo.  
 
This work revealed that TNF- or CFA+Ag-stimulation induces a rapid but transient entry 
of tissue-infiltrated neutrophils into lymphatic vessels, a response associated with the 
regulation and redistribution of the lymphatic endothelial cell glycocalyx. Interestingly, 
antigen sensitisation resulted in the production of endogenous TNF within cremaster 
muscles. Using anti-TNF blocking antibodies and mice deficient in both TNF receptors 
(p55 and p75), endogenous TNF was demonstrated for the first time to be involved in 
priming and triggering the migration of neutrophils into tissue-associated lymphatic 
vessels upon antigen challenge. Additionally, the use of chimeric mice exhibiting 
neutrophils deficient in both TNFRs demonstrated that TNF directly acts on leukocytes 
to induce neutrophil migration into lymphatic vessels. Furthermore, the results show that 
TNF-induced migration of neutrophils into the lymphatic system occurs in a strictly 
CCR7-dependent manner; blocking CXCR4 or CXCL1 signalling does not affect this 
response. Finally, both TNF- or CFA+AG-stimulation induced ICAM-1 up-regulation on 
lymphatic vessels, allowing neutrophils to crawl along the lumen; a response that was 
demonstrated to be TNF-dependent. 
 
These results have provided new insights into the mechanisms that mediate neutrophil 
migration into lymphatic vessels and their subsequent crawling within these vessels 
during inflammation. In particular, a new role for TNF as a key regulator of these 
processes has been demonstrated. Taken together, this work has highlighted potential and 




Publications arising from this work 
 
Samantha Arokiasamy, Christian Zakian, Jessica Dilliway, Wen Wang, Sussan 
Nourshargh and Mathieu-Benoit Voisin (2017). Endogenous TNF orchestrates the 
trafficking of neutrophils into and within lymphatic vessels during acute 






Table of Contents 
 
Acknowledgements ……………………………………………….……………………..… 2 
Statement of originality………………………………………….……………………….. 3 
List of presentations and prizes awarded at scientific meetings ……………… 4 
 
Abstract ……………………………………………………………………………………… 5 
 
Publications arising from this work ………………………………………………….. 6 
 
List of acronyms and abbreviations ……………………………………………….... 23 
 
Chapter : General Introduction ...................................................................... 29 
 Neutrophils in innate and adaptive immunity ............................................ 29 
 Neutrophils ................................................................................................... 29 
 Neutrophils in innate immunity.................................................................... 30 
 Neutrophils in adaptive immunity ................................................................ 41 
 Neutrophils in disease ................................................................................... 46 
 Sepsis ............................................................................................................ 46 
 Ischaemia reperfusion injury ........................................................................ 47 
 Rheumatoid arthritis and other autoimmune diseases .................................. 48 
 The lymphatic system ................................................................................... 50 
 Structural organisation of the lymphatic endothelium ................................. 54 
 Lymphatic and vascular endothelial cell glycocalyx ................................... 56 





 Lymphatic vessels in the pathology of diseases .......................................... 62 
 Lymphoedema .............................................................................................. 62 
 Chronic inflammation and cancer ................................................................ 63 
 Pathogen dissemination ................................................................................ 64 
 Leukocyte recruitment into the lymphatic system ..................................... 65 
 Leukocyte trafficking to lymphatics during innate and adaptive immunity .... 
  ..................................................................................................................... 65 
 Chemokine:chemokine receptor axes involved in lymphatic trafficking of 
leukocytes ..................................................................................................... 66 
 Leukocyte-endothelial cell adhesion molecules (CAMs) involved in 
leukocyte adhesion to and transmigration across lymphatic endothelium ... 73 
 Molecules involved in intraluminal crawling of leukocytes within initial 
lymphatic vessels.......................................................................................... 77 
 Identified mechanisms of neutrophil migration into the lymphatic system 
 ........................................................................................................................ 78 
 Neutrophil migration via HEVs ................................................................... 78 
 Migration via afferent lymphatics ................................................................ 79 
 Aims of this study .......................................................................................... 84 
 Investigate the dynamics of neutrophil migration from the blood circulation 
into the lymphatic system during inflammation and the potential role of TNF 
in driving these responses in vivo ................................................................. 85 
 Investigate potential chemokines and receptors involved in neutrophil 
migration into initial lymphatics in vivo ...................................................... 86 
 Examine the regulation and distribution of the LEC glycocalyx and 
chemokines during inflammation in vivo ..................................................... 86 
9 
 
 Analyse interactions between neutrophils and the lymphatic endothelium 
post-migration into the vessels in vivo. ........................................................ 86 
 
Chapter : Materials and methods ................................................................... 87 
 Animals .......................................................................................................... 87 
 Strains ........................................................................................................... 87 
 Generation of chimeric mice ........................................................................ 89 
 Genotyping and phenotyping ....................................................................... 90 
 Reagents ......................................................................................................... 95 
 Anaesthetics ................................................................................................. 95 
 Antibodies .................................................................................................... 95 
 Chemokine receptor antagonists ................................................................ 100 
 Fluorescent nuclei marker (viability) ......................................................... 100 
 Lectins and inhibitory sugars ..................................................................... 101 
 Enzymes ..................................................................................................... 102 
 Inflammatory stimuli .................................................................................. 102 
 Buffers ........................................................................................................ 103 
 Other miscellaneous reagents and solutions............................................... 103 
 Kits ............................................................................................................. 105 
 Preparation of Complete Freund’s Adjuvant (CFA) emulsion for inducing 
inflammation in the cremaster muscle ..................................................... 106 
 Inducing inflammation in murine tissues and analysis by 
immunofluorescence labelling and confocal microscopy ........................ 106 
 Inducing inflammatory reactions of murine cremaster muscles in vivo..... 106 
 Immunofluorescence labelling of whole-mounted murine cremaster muscles 
and cremaster draining lymph nodes .......................................................... 107 
10 
 
 Confocal analysis of neutrophil migration responses in immunostained 
whole-mounted murine cremaster muscles ................................................ 108 
 Quantification of neutrophil recruitment in immunostained cremaster 
draining LNs via confocal microscopy ...................................................... 110 
 Characterising the LEC glycocalyx of murine cremaster muscles ......... 110 
 Visualising sugar residues on lymphatic vessels........................................ 110 
 Ex vivo-fixed staining ................................................................................. 111 
 In vivo-live staining .................................................................................... 111 
 Analysis of sugar residues on lymphatic vessels and blood vessels .......... 111 
 Investigating heparan sulfate and chemokine expression by lymphatic 
vessels ........................................................................................................... 112 
 CCL21 immunostaining of TNF- or CFA+Ag-stimulated murine cremaster 
muscles ....................................................................................................... 112 
 Heparan sulfate immunostaining of TNF-stimulated murine cremaster 
muscles ....................................................................................................... 112 
 Investigating neutrophil migration responses following 
chemokine/chemokine receptor blockade ................................................ 113 
 Analysis of heparan sulfate and chemokine staining on lymphatic vessels ..... 
  ................................................................................................................... 114 
 Investigating the role of TNF in neutrophil migration responses during 
antigen sensitisation .................................................................................... 114 
 ICAM-1 expression on lymphatic vasculatures ........................................ 115 
 ICAM-1 immunostaining in TNF- or CFA+Ag-stimulated murine cremaster 
muscles with/without TNF signalling blockade ......................................... 115 




 Confocal Intravital Microscopy ................................................................. 116 
 Investigation of neutrophil migration responses in TNF- or CFA+Ag-
stimulated murine cremaster muscles ........................................................ 116 
 Investigation of neutrophil migration and intraluminal crawling responses 
with TNF and ICAM-1/MAC-1 blockade .................................................. 117 
 Investigating cytokine expression profile of cremaster muscles following 
inflammation ............................................................................................... 118 
 Inducing inflammation in the cremaster and tissue preparation ................ 118 
 ELISAs ....................................................................................................... 119 
 BCA Protein Assay .................................................................................... 121 
 Investigating the expression of CXCL12 by cremaster draining lymph 
nodes ............................................................................................................ 121 
 Investigating neutrophil expression of chemokine receptors following TNF 
stimulation ................................................................................................... 122 
 Isolation and TNF stimulation of leukocytes ............................................. 122 
 Inhibiting caveolae-dependent endocytic pathways ................................... 123 
 Immunofluorescence labelling of leukocytes and flow cytometry ............ 123 
 Verification of chimera reconstitution ...................................................... 124 
 CCR7KO LysM-eGFP/TNFRdbKO chimera verification ......................... 124 
 Statistical Analysis ...................................................................................... 124 
 
Chapter : Investigating the dynamics of neutrophil migration during 
inflammation and the importance of TNF in driving these 
responses in vivo .......................................................................... 125 
 Introduction ................................................................................................. 125 
12 
 
 Aims .............................................................................................................. 126 
 Results .......................................................................................................... 128 
 Structure of lymphatic vasculature in the murine cremaster muscle ......... 128 
 Time-course of TNF- or CFA+Ag-induced neutrophil migration across 
postcapillary venules and their migration into the lymphatic vessels and dLNs 
in the murine cremaster muscle .................................................................. 129 
 Confocal intravital microscopy to observe TNF- or CFA+Ag-induced 
migration of neutrophils into lymphatic vasculatures in real-time in vivo ....... 
  .................................................................................................................. .138 
 The effect of TNF signalling on neutrophil migration into lymphatic vessels 
following CFA+Ag-induced inflammation ................................................ 140 
 Discussion ..................................................................................................... 147 
 
Chapter :  Investigating the chemokine:chemokine receptor axes responsible 
for TNF-dependent migration of neutrophils into lymphatic 
vessels in vivo ............................................................................... 154 
 Introduction ................................................................................................. 154 
 Aims .............................................................................................................. 156 
 Results .......................................................................................................... 157 
 Effects of the CXCL1:CXCR1/2 chemokine axis on neutrophil migration 
during CFA+Ag-induced inflammation of the cremaster muscle .............. 157 
 Effects of the CXCL12:CXCR4 chemokine axis on neutrophil migration 
during CFA+Ag-induced inflammation of the cremaster muscle .............. 162 
 Expression profile of CCR7 by circulating neutrophils ............................. 166 
 Effects of the CCL21:CCR7 chemokine axis on neutrophil migration during 
TNF- or CFA+Ag-induced inflammation of the cremaster muscle ........... 169 
13 
 
 Discussion ..................................................................................................... 184 
 
Chapter :  Glycocalyx and chemokine regulation on lymphatic vessels during 
inflammation in vivo ................................................................... 189 
 Introduction ................................................................................................. 189 
 Aims .............................................................................................................. 191 
 Results .......................................................................................................... 192 
 Assessment of lectin staining on lymphatic vessels under naïve conditions 
and comparison with blood vessels ............................................................ 192 
 Effects of TNF- or CFA+Ag-induced inflammation on sugar residues and HS 
expression levels on lymphatic vessels in the cremaster muscle ............... 199 
 Expression of chemokine CCL21 on lymphatic vessels in TNF- or CFA+Ag-
stimulated cremaster muscles ..................................................................... 208 
 Discussion ..................................................................................................... 214 
 
Chapter :  Investigating the roles of TNF and ICAM-1 in driving neutrophil 
intraluminal crawling following their migration into lymphatic 
vessels in vivo ............................................................................... 220 
 Introduction ................................................................................................. 220 
 Aims .............................................................................................................. 221 
 Results .......................................................................................................... 222 
 Confocal intravital microscopy to observe TNF-induced crawling of 
neutrophils within lymphatic vessels in real-time and in 4D in vivo ............... 
  ................................................................................................................... 222 
14 
 
 Effects of TNF signalling on intraluminal crawling of neutrophils within 
lymphatic vessels following CFA+Ag-stimulation as observed by confocal 
intravital microscopy .................................................................................. 226 
 Role of ICAM-1 in mediating TNF-induced neutrophil intraluminal crawling 
within lymphatic vessels ............................................................................ 230 
 Discussion ..................................................................................................... 238 
 
Chapter : General Discussion ........................................................................ 242 
 Project Overview ......................................................................................... 242 
 Structure of murine cremaster muscle lymphatic vessels and neutrophil 
migration responses during TNF- or CFA+Ag-induced inflammation in vivo.
 243 
 Endogenous TNF controls the entry of neutrophils into initial lymphatic 
vessels following antigen sensitisation in vivo. .......................................... 245 
 The LEC glycocalyx is regulated and undergoes redistribution following 
TNF-induced inflammation of the cremaster muscle ................................. 247 
 TNF promotes the migration of neutrophils into lymphatic vessels in a strictly 
CCR7-dependent manner in vivo. .............................................................. 251 
 TNF is a key regulator of neutrophil crawling within initial lymphatic vessels 
through the induction of ICAM-1 up-regulation in vivo. ........................... 254 
 Open questions and future perspectives ................................................... 258 
 What is the source of endogenous TNF following antigen sensitisation? . 258 
 Which TNF receptor is involved in CCR7 up-regulation on neutrophils and 
in mediating their migration into lymphatic vessels?................................. 259 
15 
 
 Does TNF-induced CCR7-dependent neutrophil migration into lymphatic 
vessels occur with other stimuli and during chronic inflammatory conditions? 
  ................................................................................................................... 260 
 What is the functional consequence of the regulation and redistribution of the 
LEC glycocalyx? ........................................................................................ 261 
 Are ICAM-1/MAC-1 the only molecules involved in intraluminal neutrophil 
crawling on the luminal side of the lymphatic endothelium? What other 
molecules could be involved? .................................................................... 265 
 Concluding remarks ................................................................................... 267 
 
References …………………………………………….……………………………..…... 268 
Appendices ……………..……………………………………….……………………….. 304 







List of Tables 
Table 1.1: Major chemokines involved in murine neutrophil migration and their human 
orthologues/analogue. ..................................................................................................... 34 
 
Table 1.2: Other chemoattractants and ACKRs involved in neutrophil chemotaxis ......... 
 ......................................................................................................................................... 34 
 
Table 1.3: Chemokines and chemokine receptors involved in leukocyte trafficking 
through lymphatic vessels. .............................................................................................. 71 
 
Table 1.4: Adhesion molecules involved in in leukocyte trafficking through lymphatic 
vessels. ............................................................................................................................ 74 
 
Table 2.1: Primers used to amplify the CCR7 WT or mutant (knockout) allele ................ 
 ......................................................................................................................................... 91 
 
Table 2.2: PCR mastermix to amplify the CCR7 WT and mutant (knockout) allele ......... 
 ......................................................................................................................................... 92 
 
Table 2.3: PCR program for CCR7KO. ......................................................................... 93 
 
Table 5.1: Plant lectins used to access sugar expression of the glycocalyx present on the 
lymphatic endothelium, their sugar binding preferences, and their inhibiting sugars ........ 
 ....................................................................................................................................... 192 
 
List of Figures 
Figure 1.1: Neutrophil killing mechanisms .................................................................. 322 
 
Figure 1.2: Alterations in neutrophil chemokine receptors following inflammation.                  
 ....................................................................................................................................... 366 
 
Figure 1.3: The leukocyte adhesion cascade ................................................................ 388 
 
Figure 1.4: Invasion of pathogens (e.g. viruses and bacteria) or inflammation due to 
necrosis and cancer leads to extravasation of neutrophils across postcapillary venules ..... 
 ....................................................................................................................................... 433 
 
Figure 1.5: Fluid exchange between blood vessels and lymphatics. ............................ 531 
 




Figure 1.7: Button-like junctions in initial lymphatics border sites of fluid entry ....... 554 
 
Figure 1.8: Schematic of the vascular EC glycocalyx ................................................. 576 
 
Figure 1.9: Hypothetical model of the distinct steps involved in the embryonic 
development of the mammalian lymphatic vasculature. ............................................... 609 
 
Figure 1.10: Key molecules involved in DC adhesion and transmigration across the 
lymphatic endothelium .................................................................................................. 765 
 
Figure 1.11: DC crawling and transport within lymphatic vessels .............................. 776 
 
Figure 1.12: Chemokine axes potentially involved in neutrophil transmigration across 
lymphatic endothelium in vivo. ....................................................................................... 80 
 
Figure 1.13: Proposed model of neutrophil transmigration across lymphatic endothelium 
in vitro ............................................................................................................................. 93 
 
Figure 2.1: Example gel of expected bands for WT and CCR7KO samples. ................ 94 
 
Figure 2.2: Creating isosurface of lymphatic vessels using IMARIS software ......... 1098 
 
Figure 2.3: Surgical exteriorisation and preparation of the cremaster muscle for confocal 
intravital microscopy ................................................................................................... 1176 
 
Figure 2.4: Leukocyte subset gating strategies for cells of interest. ........................ 12423 
 
Figure 3.1: Lymphatic architecture of the murine cremaster muscle. ........................ 1287 
 
Figure 3.2: Neutrophil transmigration across postcapillary venules and into lymphatic 
vessels following TNF-induced inflammation in the cremaster muscle.. ................. 13130 
 
Figure 3.3: Neutrophil migration into dLNs following TNF-induced inflammation of the 
cremaster muscle ....................................................................................................... 13231 
 
Figure 3.4: CFA+Ag-induced migration of neutrophils into lymphatic vessels ..... Error! 
Bookmark not defined.33 
 
Figure 3.5: Time course of neutrophil migration into the lymphatic system following 
TNF-induced inflammation in the murine cremaster muscle ..................................... 1344 
 
Figure 3.6: Neutrophil migration into dLNs following CFA+Ag-induced inflammation 




Figure 3.7: Number of neutrophils within the stroma, HEVs and lymphatics of the 
cremaster dLNs ........................................................................................................... 1366 
 
Figure 3.8: Neutrophil breaching lymphatic endothelium during IVM of a TNF-
stimulated cremaster muscle ....................................................................................... 1378 
 
 
Figure 3.9: TNF release in murine cremaster muscles following antigen sensitisation 
(CFA+Ag) in vivo ......................................................................................................... 140 
 
Figure 3.10: Neutrophil migration responses of WT and TNFRdbKO mice following 
CFA+Ag-induced inflammation in the cremaster muscle ........................................ 14241 
 
Figure 3.11: Phenotypic analysis of blood neutrophils from TNFRs chimeric mice ......... 
 ..................................................................................................................................... 1443 
 
Figure 3.12: Neutrophil migration responses of WT and TNFRdbKO chimeric mice 
following CFA+Ag-induced inflammation in the cremaster muscle. ......................... 1465 
 
Figure 4.1: Neutrophil transmigration responses across postcapillary venules of WT mice 
following in vivo blockade of the chemokine CXCL1 in unstimulated and CFA+Ag-
stimulated cremasters .................................................................................................. 1598 
 
Figure 4.2: Neutrophil migration responses into lymphatic vessels of WT mice following 
in vivo blockade of the chemokine CXCL1 in unstimulated and CFA+Ag-stimulated 
cremasters .................................................................................................................... 1609 
 
Figure 4.3: Neutrophil migration responses into dLNs of WT mice following in vivo 
blockade of the chemokine CXCL1 in unstimulated and CFA+Ag-stimulated cremasters
 ................................................................................................................................... 16160 
 
Figure 4.4: Neutrophil migration responses of WT mice following in vivo blockade of 
the chemokine receptor CXCR4 in unstimulated and CFA+Ag-stimulated cremasters ..... 
 ................................................................................................................................... 16362 
 
Figure 4.5: Percentage of circulating neutrophils and their CXCR4 expression in 
CFA+Ag-stimulated and AMD3100-treated mice compared to unstimulated/vehicle 
controls ........................................................................................................................ 1654 
 
Figure 4.6: Neutrophil migration responses following 16 h CFA+Ag-induced 




Figure 4.7: CCR7 expression on surface of TNF-stimulated neutrophils following 
treatment with caveolae-dependent endocytosis inhibitor, nystatin ........................... 1687 
 
Figure 4.8: Neutrophil migration responses across postcapillary venules of WT and 
CCR7KO mice in unstimulated and TNF-stimulated cremaster muscles ................... 1709 
 
Figure 4.9: Neutrophil migration responses into lymphatic vessels of WT and CCR7KO 
mice in unstimulated and TNF-stimulated cremaster muscles ................................. 17170 
 
Figure 4.10: Neutrophil migration responses into dLNs of WT and CCR7KO mice in 
unstimulated and TNF-stimulated cremaster muscles .............................................. 17271 
 
Figure 4.11: Neutrophil migration responses of WT and CCR7KO mice in unstimulated 
and CFA+Ag-stimulated cremaster muscles ............................................................. 17473 
 
Figure 4.12: Phenotypic analysis of blood neutrophils from WT and CCR7KO chimeric 
mice ............................................................................................................................. 1754 
 
Figure 4.13: Neutrophil migration responses of WT and CCR7KO chimeric mice 
following CFA+Ag-induced inflammation in the cremaster muscle. ......................... 1776 
 
Figure 4.14: Neutrophil migration responses across postcapillary venules of CCR7KO 
mice following in vivo blockade of the chemokine receptor CXCR4 in CFA+Ag-
stimulated cremasters .................................................................................................. 1798 
 
Figure 4.15: Neutrophil migration responses into lymphatic vessels of CCR7KO mice 
following in vivo blockade of the chemokine receptor CXCR4 in CFA+Ag-stimulated 
cremasters .................................................................................................................... 1809 
 
Figure 4.16: Neutrophil migration responses into dLNs of CCR7KO mice following in 
vivo blockade of the chemokine receptor CXCR4 in CFA+Ag-stimulated cremasters ...... 
 ................................................................................................................................... 18180 
 
Figure 4.17: CXCR4 expression on neutrophils and CXCL12 generation in dLNs of 
naïve WT and CCR7KO mice ................................................................................... 18382 
 
Figure 5.1: Representative binding of IB4 to LECs of mouse cremaster muscles ............. 
 ................................................................................................................................... 19392 
 
Figure 5.2: MFI of IB4 binding to glycocalyx present on lymphatic vessels under naïve 




Figure 5.3: Representative binding of MAL-1 to LECs of mouse cremaster muscles ...... 
 ................................................................................................................................... 19594 
Figure 5.4: MFI of MAL-1 binding to glycocalyx present on lymphatic vessels under 
naïve conditions .......................................................................................................... 1965 
 
Figure 5.5: Representative confocal images of IB4 and MAL-1 binding to glycocalyx 
present on blood vessels under naïve conditions ........................................................ 1976 
 
Figure 5.6: MFI of IB4 and MAL-1 binding to glycocalyx present on blood vessels under 
naïve conditions .......................................................................................................... 1987 
 
Figure 5.7: IB4 staining (α D-Galactose expression) on lymphatic vessels following TNF 
and CFA+Ag-induced inflammation of the cremaster muscle ................................... 2009 
 
Figure 5.8: MFI of IB4 staining on lymphatic vessels following (A) ex vivo-fixed and (B) 
in vivo-live staining of cremaster muscles from unstimulated, TNF and CFA+Ag-
stimulated WT C57BL/6 mice ...................................................................................... 200 
 
Figure 5.9: Correlation between IB4 (α-D-galactose expression) and neutrophil 
migration into lymphatic vessels of inflamed cremaster tissues of WT mice............... 201 
 
Figure 5.10: α2,3-sialylated glycans expression on lymphatic vessels following TNF and 
CFA+Ag-induced inflammation of the cremaster muscle ............................................ 202 
 
Figure 5.11: MFI of MAL-1 staining on lymphatic vessels following ex vivo-fixed 
staining of cremaster muscles from unstimulated, TNF and CFA+Ag-stimulated WT 
C57BL/6 mice ............................................................................................................... 203 
 
Figure 5.12: Representative HS expression unstimulated and TNF-stimulated murine 
cremaster muscles ....................................................................................................... 2065 
 
Figure 5.13: MFI of HS expression by lymphatic vessels following ex vivo-fixed staining 
of cremaster muscles from unstimulated and TNF-stimulated WT C57BL/6 mice ........... 
 ..................................................................................................................................... 2076 
 
Figure 5.14: Co-localisation of IB4 and CCL21 on the surface of lymphatic vessels with 
ex vivo-fixed staining following TNF-induced inflammation ..................................... 2098 
 
Figure 5.15: CCL21 staining on lymphatic vessels in unstimulated, TNF- or CFA+Ag-




Figure 5.16: MFI of CCL21 expression and lymphatic vessel volume of unstimulated, 
TNF and CFA+Ag-stimulated cremaster muscles .................................................... 21211 
Figure 5.17: CCL21 gradient in unstimulated (PBS) and CFA+Ag-stimulated cremaster 
muscles. ..................................................................................................................... 21312 
 
Figure 6.1: Dynamics of neutrophil crawling within lymphatic vessels of TNF-stimulated 
cremaster muscles in real-time in vivo ...................................................................... 22423 
 
Figure 6.2: Crawling parameters within lymphatic vessels of TNF-stimulated cremaster 
muscles in real time in vivo ....................................................................................... 22524 
Figure 6.3: The effect of TNF signalling on neutrophil intraluminal crawling within 
lymphatic vessels ........................................................................................................ 2276 
 
Figure 6.4: Crawling parameters of intraluminal crawling within lymphatic vessels of 
CFA+Ag-stimulated cremaster muscles in real time in vivo with TNF signalling-blockade
 ..................................................................................................................................... 2298 
 
Figure 6.5: ICAM-1 expression on lymphatic endothelial cells in unstimulated, TNF and 
CFA+Ag-stimulated conditions in vivo .................................................................... 23130 
 
Figure 6.6: ICAM-1 expression on lymphatic vessels in unstimulated, TNF- or CFA+Ag-
stimulated cremaster muscles in vivo ........................................................................ 23231 
 
Figure 6.7: TNF controls ICAM-1 expression on lymphatic endothelial cells in vivo..
 ................................................................................................................................... 23433 
 
Figure 6.8: Correlation between ICAM-1 expression and neutrophil migration into 
lymphatic vessels of TNF-stimulated WT mice........................................................ 23534 
 
Figure 6.9: The effect of anti–ICAM-1 and anti-MAC-1 blocking antibodies on 
neutrophil intraluminal crawling parameters .............................................................. 2365 
 
Figure 7.1: Schematic illustration of TNF triggering the migration of neutrophils into 
initial lymphatic vessels upon antigen sensitisation ................................................. 24645 
 
Figure 7.2: Hypothetical scenario in which cleavage of α-D-Galactosyl moieties mediates 
neutrophil migration across the lymphatic endothelium ............................................. 2487 
 
Figure 7.3: TNF triggers the migration of neutrophils into initial lymphatics in a strictly 




Figure 7.4: TNF induces ICAM-1/MAC-1 dependent intraluminal crawling through the 
upregulation of ICAM expression by initial lymphatic vessels. ................................. 2576 
 
Figure 7.5: Schematic diagram illustrating the dual mechanisms of action of TNF leading 
to trafficking of neutrophils into initial lymphatic vessels, and their subsequent 
intraluminal crawling upon acute inflammation in vivo ............................................. 2687 
 
Appendix 1: Neutrophil migration response in the cremaster muscle following 
stimulation with CFA+Ag for 8 h in WT, TNRdbKO and CCR7KO mice .................. 304 
 
Appendix 2: GM-CSF and IL-17 release in the cremaster muscle following CFA+Ag-
induced inflammation in vivo ........................................................................................ 305 
 
Appendix 3: Representative binding of LEL and SNA to LECs of mice cremaster muscles
 ....................................................................................................................................... 306 
 
Appendix 4: Confirmation of lectin specificity ........................................................... 307 
 
Appendix 5: CCL21 expression in cremaster tissues ................................................... 308 
 
Appendix 6: ICAM-1 isotype control staining ............................................................. 309 
 
Appendix 7: The effect of ICAM-1/MAC-1 blockade on neutrophil intraluminal crawling 
within lymphatic vessels ............................................................................................... 310 
 
Appendix 8: The effect of anti–ICAM-1 and anti-MAC-1 blocking antibodies on 
neutrophil extravasation, and migration into lymphatic vessels and their associated dLN
 ....................................................................................................................................... 311 
 








ANCA Antineutrophil cytoplasm autoantibodies 
ANOVA Analysis of variance 
APCs Antigen presenting cells 
APRIL A proliferation-inducing ligand 
αLβ2 Alpha L Beta 2 integrin 
α4β1 Alpha 4 Beta 1 integrin 
α-SMA  Alpha-smooth muscle actin 
BAFF B cell activating factor 
BCA Bicinchoninic Acid 
BCG Mycobacterium bovis bacille Calmette-Guérin 
BECs Blood endothelial cells 
BM Bone marrow 
b.p Base pair 
BSA Bovine serum albumin 
Cat. # Catalogue number 
CAM Cell adhesion molecule 
C5a  Complement component C5a 
C5aR Complement component C5a receptor 
CCL Chemokine (C-C motif) ligand 
CCR Chemokine (C-C motif) receptor 
CCR7KO Chemokine (C-C motif) receptor 7 knockout 
CD Cluster of differentiation 
CFA Complete Freund’s adjuvant 




CS Chondroitin sulfate 
CTL Control 
CXCL Chemokine (C-X-C) ligand 
CXCR Chemokine (C-X-C) receptor 
DAPI 4’,6-diamidino-2-phenylindole dihydrochloride 
DAMPs Danger-associated molecular pattern 
DCs Dendritic cells 
dLNs Draining lymph nodes 
DNA Deoxyribonucleic acid 
DNase I Deoxyribonuclease I 
dNTPs Deoxynucleotide triphosphates 
DMSO Dimethyl sulfoxide 
ECs Endothelial cells 
EDTA Ethylenediaminetetraacetic acid   
eGFP Enhanced green fluorescent protein 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
ESAM Endothelial-cell selective adhesion molecule 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
fMLP N-formyl-methionyl-leucyl-phenylalanine 
FPR1 Formyl peptide receptor-1 
FSC Forward scatter 
GAG Glycosaminoglycan 
G-CSF Granulocyte-colony stimulating factor 
G-CSFR Granulocyte-colony stimulating factor receptor 
GM-CSF Granulocyte-macrophage colony-stimulating factor  





HDLECs Human dermal lymphatic endothelial cells 
HEVs High endothelial venules 
HRP Horseradish peroxidase 
HSPG Heparan sulfate proteoglycan 
HUVECs Human umbilical vein endothelial cells 
HS Heparan sulfate 
IB4 Griffonia (Bandeirafa) Simplicifolia Lectin I Isolectin B4 
ICAM-1 Intercellular cell adhesion molecule-1 
ICAM-2 Intercellular cell adhesion molecule-1 
Iso Isotype 
IFNα Interferon alpha 
IFNγ Interferon gamma 
IFZ Interfollicular zone 
Ig Immunoglobulin 
IL Interleukin 
IL-1β  Interleukin-1 beta 
i.p. Intraperitoneal 
I/R  Ischemia/reperfusion  
i.s. Intrascrotal 
IVM Intravital microscopy 
JAM Junctional adhesion molecule 
KC Keratinocyte-derived chemokine 
kg Kilogram 
KO Knockout 
LECs Lymphatic endothelial cells 
LEL Lycopersicon Esculentum (tomato) Lectin 
LFA-1 Lymphocyte function-associated antigen-1  




LTB4 Leukotriene B4 
LysM Lysozyme M 
LYVE-1 Lymphatic vessel endothelial receptor-1 
mAb Monoclonal antibody 
MAC-1 Macrophage-1 antigen 
MAL-1 Maackia Amurensis Lectin -1 
MFI Mean fluorescence intensity 
μg Microgram 
mg Milligram 
MgCl2 Magnesium chloride 
MHC Major histocompatibility complex 
MHC-I Major histocompatibility complex Class I 
MHC-II Major histocompatibility complex Class II 
MIP-2 Macrophage inflammatory protein-2 
min minutes 
MI Myocardial infarction 
μl Microlitre 
ml Millilitre 
MOF Multiple organ failure 
mM Micromolar 
MMP Matrix metalloproteinase 
MRP14 Myeloid-related protein-14 
NA Numerical aperture 
NADPH Nicotinamide adenine dinucleotide phosphate 
NETs Neutrophil extracellular traps 
NF-κB Nuclear factor- kappa B 
ng Nanogram 
NGS Normal goat serum 
NH4 Ammonium 
NO Nitric oxide 
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NSAIDs nonsteroidal anti-inflammatory drugs 
OVA Ovalbumin 
PAF Platelet-activating factor 
PAFR Platelet-activating factor receptor 
PAMPs Pathogen-associated molecular patterns 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PECAM-1 Platelet endothelial cell adhesion molecule-1  
PFA Paraformaldehyde 
Plt Paucity of lymph node T cells 
PMN Polymorphonuclear leukocytes 
Prox1 Prospero-related homeobox gene 1 
PSGL1 P-selectin glycoprotein ligand 1  
RA Rheumatoid arthritis 
RF Rheumatoid factor 
RFI Relative fluorescence intensity 
ROCK Rho-associated protein kinase 
ROS Reactive oxygen species 
RT Room temperature 
S1P Sphingosine-1-phosphate 
SA Sialic acids 
SDF-1α Stromal-derived factor 1 alpha  
SEM Standard error of mean 
SF Synovial fluid 
sIRNA Small interfering RNA 
SLE Systemic lupus erythematosus 
SNA Sambucus Nigra (Elderberry) Bark Lectin 
SSC Side scatter 






TEM Transendothelial migration 
TPA 12-O-tetradecanoylphorbol 13-acetate 
TLRs Toll-like receptors 
TMB 3,3',5,5'-Tetramethylbenzidine  
TNF Tumour necrosis factor (formerly known as tumour necrosis factor 
alpha) 
TNFRdbKO Tumour necrosis factor receptors double knockout 
TNFRI Tumour necrosis factor receptor type I (p55) 
TNFRII Tumour necrosis factor receptor type II (p75) 
V Volts 
VCAM-1 Vascular endothelial cell adhesion molecule-1 
VE-cadherin Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VLA-4 Very late antigen-4 
v/v Volume per volume 
WT Wild type 
w/v Weight per volume 
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 : General Introduction 
 Neutrophils in innate and adaptive immunity 
Inflammation is a physiological process crucial for the body’s immune response to 
harmful stimuli, such as viruses, bacteria, fungi or parasites and/or cell damage. The 
immune system of all mammals can be divided into two interdependent branches: innate 
and adaptive immune responses. The innate immune system comprises of cells and 
mechanisms that provides the host with general protection against all foreign antigens, 
whilst adaptive immunity occurs within lymphoid organs and results in an antigen-
specific response to each pathogen. Amongst all leukocytes, neutrophils are the first cells 
to arrive at sites of inflammation where they play a crucial role in the clearance of 
pathogens. Although neutrophils are indisputably major effectors of acute inflammation, 
increasing evidence has shown an emerging role for them in shaping adaptive immune 
responses.   
 Neutrophils 
Neutrophils are the most abundant type of white blood cells in humans, and are well 
recognised as one of the key players during acute inflammation (Amulic et al., 2012; Ley 
et al., 2007; Phillipson and Kubes, 2011). They are typically the first cells to arrive at 
sites of inflammation and are capable of eliminating pathogens by multiple mechanisms 
(see section 1.1.2.1); thus, providing a critical first line of defence in the immune response 
against invading pathogens. These immune cells are continuously generated in the bone 
marrow (BM) from myeloid precursors, with their daily production reaching up to 2 x 
1011 cells in humans (Borregaard, 2010). In humans, neutrophils make up 50-70% of 
circulating leukocytes, whereas in mice, 10-25% of neutrophils are present within the 
circulation under physiological conditions (Mestas and Hughes, 2004). Mature 
neutrophils are polymorphonuclear (PMN) leukocytes, and possess a distinctive multi-
lobed nucleus; they are distinguishable by their expression of Ly6G (recognised by the 
antibody, GR1) in the murine system (Fleming et al., 1993). In humans, CD66, CD16b, 
CD15 and myeloid peroxidase (MPO) have been used to identify neutrophils (Dransfield 
et al., 1994; Watt et al., 1991). In the circulation, these immune cells have an average 
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diameter of 7-10 µm and have a cytoplasm enriched with pre-formed granules and 
secretory vesicles (Borregaard, 2010). The lifespan of a circulating neutrophil is debated 
within the scientific community but has been reported to be between 1.5 and 12.5 hours 
in mice (Kolaczkowska and Kubes, 2013) and an unprecedented 5.4 days in humans 
(Pillay et al., 2010). Given their destructive potential, neutrophil extravasation into 
inflamed tissues has to be tightly regulated to avoid damage to the host. Numbers of 
circulating neutrophils are therefore controlled through rate of neutrophil precursor 
proliferation in the BM, egress of mature neutrophils from the BM into the circulation, 
and their clearance in the spleen, liver and BM (see section 1.1.2.3) (Sadik et al., 2011). 
 Neutrophils in innate immunity 
 Roles in innate immune responses 
The innate immune system is the first line of host defence against invading pathogens and 
neutrophils are indispensable to this response. This involves a series of cellular and 
molecular mechanisms that protect the host from infection and limits the expansion and 
dissemination of bacterial and viral infections, without relying on the second arm of the 
immune response - adaptive immunity (acquired immunity). Neutrophils are recruited to 
sites of inflammation by chemoattractants (see section 1.1.2.2), which provide a chemical 
gradient for them to migrate along; the highest concentration of chemoattractants are 
normally found at the site of infection in order to attract neutrophils for them to carry out 
their functions and resolve inflammation.  
During the innate immune response, neutrophils exert their functions in 3 ways: 
phagocytosis, degranulation and the newly discovered release of neutrophil extracellular 
traps (NETs). Neutrophils can engulf pathogens they encounter in a process called 
phagocytosis (Figure 1.1), whereby bacteria or cell debris are rapidly ingested, removing 
them from the body and thus limiting further damage (Phillipson and Kubes, 2011). 
Mature neutrophils possess three main types of granules (primary, secondary and tertiary) 
in the cellular cytoplasm containing a variety of proteases and antimicrobial peptides 
(Faurschou and Borregaard, 2003). Secretory vesicles containing membrane proteins 
(e.g.  β2 integrins) are also present within the cytoplasm, which can be rapidly mobilised 
to the cell surface upon activation (Hager et al., 2010). Upon engulfment of a pathogen, 
the contents of the resulting phagosomes are degraded by reactive oxygen species (ROS) 
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and lytic enzymes using granule stores of NADPH oxidase, or antibacterial proteins 
(cathepsins, defensins, lactoferrin and lysozyme), respectively (Borregaard, 2010; Hager 
et al., 2010). These antibacterial proteins can also be released by neutrophils into the 
extracellular milieu through a process called degranulation (Figure 1.1), thus promoting 
the killing of pathogens present in the tissue. Finally, highly activated neutrophils can 
eliminate extracellular microorganisms through the expulsion of NETs (Figure 1.1), 
which are composed of core DNA elements to histones, proteins and degrading enzymes 
(i.e. neutrophil elastase and MPO). This immobilises pathogens to prevent their 
dissemination and facilitates their subsequent phagocytosis (Brinkmann et al., 2004). 
However, in order for any of these killing mechanisms to occur, circulating neutrophils 
have to undergo a process known as “priming”, whereby cytokines such as tumour 
necrosis factor (TNF, formerly known as TNFα) or leukotriene B4 (LTB4), or contact with 
activated vascular endothelium, results in a markedly augmented responsiveness to 





Figure 1.1: Neutrophil killing mechanisms. This occurs through (A) phagocytosis, (B) 
degranulation and (C) the release of neutrophil extracellular traps (NETs). (A) Neutrophils 
recognise opsonised pathogens through Fc receptors (FcγRIIa) or complement receptors (MAC-
1) on their surface membrane via antibody molecules (e.g. IgG) or iC3B – a proteolytically 
inactive product of the complement cleavage fragment C3b. The pathogen is internalised into a 
nascent phagosome, which then matures by fusing with lysosomes forming a phagolysosome. (B) 
Granules (primary, secondary, tertiary and secretory vesicles) situated within neutrophils have 
complex immunomodulatory and anti-microbial effects, and are released by activated neutrophils 
during degranulation at inflammatory sites leading to the killing of pathogens. (C) NETs are 
formed when neutrophils release decondensed chromatin decorated with proteins possessing 
antimicrobial properties into the extracellular space to trap pathogens. This immobilises them and 
not only prevents their dissemination but also facilitates their subsequent phagocytosis. Once 
phagocytosed, neutrophils kill pathogens using NADPH oxygenase-dependent mechanisms 
(ROS) or anti-microbial proteins. NETS are also thought to directly kill pathogens through the 
release of anti-microbial histones and proteases. Anti-microbial proteins include myeloperoxidase 
(primary granules), lactoferrin (secondary granules), gelatinase (tertiary granules), cathepsin 
(secretory vesicles). Enzymes such as neutrophil elastase are also released from primary granules 





 Chemoattractants and their receptors involved in neutrophil 
recruitment and activation 
In order for neutrophils to be recruited from the circulation to sites of inflammation, they 
need to be mobilised from the BM into the bloodstream before transmigrating 
(extravasating) across blood vascular endothelial cells (ECs) into the inflamed tissue. The 
process by which inflammatory cells are recruited to the tissue involves cellular activation 
and subsequent secretion of cytokines, which in turn provides a gradient for leukocytes 
to follow towards sites of pathogen challenge. In mammals, this gradient is achieved by 
chemoattractant molecules, such as chemokines, which are small-secreted proteins 
(Mantovani et al., 2006). Chemokines form the largest family of cytokines, with 
approximately 50 endogenous chemokine ligands present in humans and mice (Griffith 
et al., 2014). Chemokines are subdivided into families based on the number and location 
of cysteine residues at the amino terminus: C, CC, CXC, CXXXC and CX3, whereby a 
succeeding ‘L’ indicates a ligand, ‘X’ represents an amino acid, and ‘R’ indicates a 
receptor (Luster, 1998; Charo and Ransohoff, 2006). The major chemokines involved in 
neutrophil recruitment from postcapillary venules to sites of inflammation are listed 
(Table 1.1). Following their secretion, chemokines bind to glycosaminoglycans (GAGs) 
on the luminal side of ECs, thus forming a chemotactic gradient and preventing their 
removal from the blood stream (Mantovani et al., 2006). On the leukocytes, chemokines 
bind to their cognate chemokine receptors, which are G-protein coupled receptors 
(GPCRs) that are differentially expressed amongst leukocyte subsets. Binding results in 
the activation of complex signalling cascades that trigger cellular activation, thereby 
orchestrating the inflammatory response to recruit specific leukocyte subsets to the site 
of infection. 
In addition to chemokines, other chemoattractants, such as the lipid mediator LTB4, 
complement component C5a (C5a), N-formyl-methionyl-leucyl-phenylalanine (fMLP), 
and platelet-activating factor (PAF) are also potent leukocyte chemoattractants (Table 
1.2). Atypical chemokine receptors (ACKRs), such as ACKR1 (DARC), expressed by 
blood vascular ECs also play a role in regulating the bioavailability of circulating 
chemokines by binding them with high affinity (Bonecchi and Graham, 2016). DARC is 
able to induce transcytosis of chemokines, thus facilitating the presentation of 
inflammatory chemokines on the luminal side of blood vascular ECs (Pruenster et al., 





Systemic Murine Human Murine Human 
CXCL1 KC GROα CXCR2 CXCR2 Macrophages  (Bozic et 
al., 1995) 
CXCL2 MIP-2 GROβ CXCR2 CXCR2 Macrophages  (Wuyts et 
al., 1998) 
CXCL5 LIX ENA-78 CXCR2 CXCR2 Macrophages, 
eosinophils, 





CXCL7 NAP-2 NAP-2 CXCR2 CXCR1/CXCR2 Platelets  (Schenk et 
al., 2002) 
















LTB4 BLT1 Macrophages  (Casale et al., 1992; 
Haribabu et al., 
2000) 
C5a C5A receptor 
(C5aR) 
Macrophages  (Hetland et al., 
1986; Monari et al., 
2002; Ooi et al., 
1980) 
PAF PAF Receptor 
(PAFR) 
Platelets, ECs, neutrophils, 
monocytes, macrophages 
(Casale et al., 1992; 
Wardlaw et al., 
1986) 
fMLP Formyl peptide 
receptor-1 (FPR1) 
Tissue bacteria (Casale et al., 1992; 







ACKR1 (DARC) CCL2, 5 7, 11, 13, 13, 17; CXCL1, 5, 6, 8, 11 (Bonecchi and 
Graham, 2016) 
 
Table 1.2: Other chemoattractants and ACKRs involved in neutrophil chemotaxis. 
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 Neutrophil mobilisation from bone marrow 
Before extravasating into interstitial tissue during inflammation, neutrophils need to be 
mobilised from the BM. The BM is both a large storage pool for immune cells and the 
site of neutrophil production; in mice, neutrophil reserves are estimated to be 120 million 
cells (Furze and Rankin, 2008). Leukocytes are continually being released into the 
circulation and upon inflammatory insult, the BM reserve is rapidly mobilised, thus 
amplifying neutrophil release. The molecular mechanism of sequestration and release is 
thought to be mediated by the co-ordinated actions of cytokines and chemokines. 
Interactions of the chemokine, CXCL12, with its chemokine receptor, CXCR4, are 
essential for normal BM development of multiple immune cell lineages, including B cells, 
monocytes, macrophages, neutrophils, natural killer (NK) cells and dendritic cells (DCs) 
(Mercier et al., 2012); this interaction also promotes the retention of both developing and 
mature neutrophils within the BM (Furze and Rankin, 2008; Ma et al., 1999). The 
blockade of CXCR4 by a specific antagonist, AMD3100, or repopulation of irradiated 
WT mice with CXCR4-deficient BM cells, resulted in a rapid increase in circulating 
neutrophils as a result of egress from the BM (Liu et al., 2014; Ma et al., 1999; Martin et 
al., 2003). This led to the conclusion that CXCR4 negatively regulates the egress of 
neutrophils from BM stores. In support of this, neutrophils’ expression of CXCR4 was 
also found to progressively decrease as they mature, thus permitting their release from 
the BM into the circulation (Eash et al., 2010). These observations along with constitutive 
expression of the CXCR4 ligand, CXCL12, by BM stromal cells suggests that the 
CXCL12:CXCR4 chemokine axis provides a key retention signal for neutrophils in the 
BM (Martin et al., 2003). Whilst CXCR4 blockade leads to the release of neutrophils into 
the circulation, the mechanism by which this occurs has been reported to be via CXCR2 
signalling (Eash et al., 2010). The CXCR2 ligands, CXCL1 (also known as KC or GROα) 
and CXCL2 (also known as MIP-2 or Groβ), are chemokines that are produced both 
remotely and constitutively expressed in BM ECs which act on neutrophil-expressed 
CXCR2 to promote their mobilisation (Eash et al., 2009). Thus, whilst the 
CXCL12:CXCR4 chemokine axis acts as a retention pathway for BM neutrophils, the 
CXCL1/2:CXCR2 axis acts antagonistically to promote neutrophil release (Eash et al., 
2010). Nevertheless, the CXCL12:CXCR4 chemokine axis plays a dominant role in 
neutrophil trafficking as neutrophils doubly deficient in both CXCR2 and CXCR4 
exhibited constitutive mobilisation of neutrophils similar to CXCR4-deficient cells (Eash 
et al., 2010). Interestingly, it has been reported that mice genetically deficient in either 
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the cytokine, granulocyte colony-stimulating factor (G-CSF), or the G-CSF receptor (G-
CSFR) had very few neutrophils within the circulation and BM, with evidence suggesting 
that G-CSF reduces the production of CXCL12 by BM stromal cells and down-regulates 
the expression of CXCR4 on neutrophils (Semerad et al., 2002; Sierra et al., 2007). Thus, 
G-CSF is believed to disrupt the retention signal delivered by CXCL12 in the BM and 
thereby facilitates the migration of neutrophils across the BM sinusoidal endothelium in 
response to the chemotactic gradients created by the blood-borne chemokines, CXCL1 
and CXCL2, leading to the mobilisation of neutrophils into the circulation (Figure 1.2). 
 
Figure 1.2: Alterations in neutrophil chemokine receptors following inflammation.                  
(1) Neutrophils are generated and stored in the bone marrow (BM) via CXCL12:CXCR4 
interactions. BM neutrophils progressively down-regulate CXCR4 and up-regulate CXCR2, 
which allows them to be mobilised in response to CXCL1 and CXCL2 produced following 
inflammation. Inflammation also results in the production of G-CSF, which aids this process via 
inhibition of the CXCL12:CXCR4 chemokine axis. (2) Neutrophils expressing high levels of 
CXCR2 gain entry into the circulation from the BM during inflammation. (3) Senescent 
neutrophils progressively down-regulate CXCR2 and up-regulate CXCR4. (4) High levels of 




 Recruitment to sites of inflammation 
During the initiation of an innate immune response, neutrophils extravasate out of blood 
vessels into interstitial tissue to get to the sites of inflammation; this takes place mainly 
in small blood vessels called postcapillary venules (PCVs) in vivo. This response occurs 
as neutrophils are guided by a plethora of chemotactic agents, acting on only a handful of 
cell surface receptors (Table 1.1 & Table 1.2). In response to infection or injury, sentinel 
cell-derived inflammatory mediators such as interleukin-1β (IL-1β) and TNF, activate 
nearby vascular ECs, thus inducing increased expression of adhesion molecules and 
vascular permeability (Nourshargh et al., 2010; Soehnlein and Lindbom, 2010). This 
promotes the adhesion and transmigration of neutrophils across the vascular endothelium, 
respectively. The CXCR2 ligands, CXCL1, CXCL2 and CXCL5, are imperative for 
neutrophil chemotaxis and activation (Bozic et al., 1995; Soehnlein and Lindbom, 2010; 
Wuyts et al., 1998). In vivo immunoneutralisation of CXCL1 and CXCL2 resulted in an 
85% abrogation of neutrophil migration into the glomeruli in a model of toxin-induced 
renal injury (Roche et al., 2007). Similarly, neutralisation of both these chemokines 
resulted in an 84% decrease in neutrophil mobilisation in a model of peritonitis (Wengner 
et al., 2008). The potency of these chemokines in aiding neutrophil chemotaxis can be 
further increased through enzymatic cleavage by the metalloproteinases (MMPs), MMP9 
and MMP8, both of which are proteases released by neutrophils, macrophages and ECs 
(Soehnlein and Lindbom, 2010). In addition to this, it is reported that macrophage-
specific, MMP12, inactivates both chemokines through their cleavage, a vital step for the 
orchestration and regulation of neutrophil influx (Dean et al., 2008). In humans, the 
chemokine, CXCL8 (or IL-8), is analogous to the murine CXCR2 ligands; this acts via 
CXCR2 in the same way as CXCL1/2 to induce the same potent recruitment of 
neutrophils to sites of infection (Baggiolini et al., 1989).  
In addition to recruitment of neutrophils within the circulation, chemokines also promote 
mobilisation of the BM store as previously discussed (see section 1.1.2.3), to ensure 
adequate supplies of circulating neutrophils. Furthermore, chemokines critically activate 
integrins during the multi-step leukocyte adhesion cascade (see section 1.1.2.4.1). On the 
whole, these mechanisms ensure influx of neutrophils to sites of infection or injury to 
rapidly eliminate any pathogens or damaged tissue by phagocytosis, ROS and protease 
production. However, it is worth mentioning that many neutrophil functions can be 
potentially harmful to the host and thus may have causative roles in many diseases (refer 
to section 1.2).  
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1.1.2.4.1 The multi-step adhesion cascade 
During inflammation, leukocytes have to cross the blood vessel wall; a process involving 
the penetration of multiple barriers including vascular ECs, pericytes and a basement 
membrane that is generated by both of these cell types (Nourshargh et al., 2010; Voisin 
and Nourshargh, 2013). This process requires the induction of cellular machinery to 
physically aid the process of extravasation. In addition to leukocyte-targeted chemokines, 
activated tissue resident macrophages also release inflammatory mediators (such as, TNF 
and IL-1β) that activate and alter the phenotype of the vascular endothelium (Nourshargh 
et al., 2010). The cellular mechanisms that support the efficient extravasation of 
inflammatory cells from the circulation, through the blood vessel wall, and into the 
interstitial tissue is a well-characterised phenomenon that involves 5 main stages: 
thethering/rolling, firm adhesion, luminal crawling, transendothelial migration (TEM), 
and abluminal crawling/interactions with pericytes and basement membrane penetration 
(Figure 1.3); collectively, this process is termed the ‘multi-step leukocyte adhesion 
cascade’ (Ley et al., 2007).  
 
Figure 1.3: The multi-step leukocyte adhesion cascade. Following inflammatory insult, 
circulating leukocytes migrate into peripheral tissues in response to secretion of cytokines and 
chemokines by resident immune cells. Leukocytes are first captured on the vascular endothelium 
before beginning the rolling process, which is mediated by selectins. Chemokines drive activation 
of rolling and leukocyte activation, which enables arrest and firm adhesion to the endothelium 
followed by subsequent crawling. The leukocyte eventually transmigrates by either the 
transcellular or paracellular route (depicted). This is followed by abluminal crawling/interactions 
with pericytes and basement membrane penetration before it detaches from the blood vascular 
endothelium and goes into the interstial tissue. Figure adapted from (Nourshargh et al., 2010). 
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Circulating leukocytes, including neutrophils, are captured and begin rolling along the 
venular wall by interaction of leukocyte-expressed L-selectin and activated endothelium-
expressed E- and P-selectin, with both endothelium and leukocyte-expressed P-selectin 
glycoprotein ligand 1 (PSGL1) (McEver and Cummings, 1997). Leukocyte integrins also 
take part in rolling and play a pivotal role in the subsequent arrest of leukocytes and their 
firm adhesion to the endothelium. Chemokines are essential for the activation of these 
integrins leading to inside-out signalling, which results in conformational changes in the 
functionally inactive integrin to an active adhesive configuration (Abram and Lowell, 
2009). This causes an increase in ligand binding affinity and clustering of integrins in the 
cell membrane, which allows cell attachment (Abram and Lowell, 2009).  
The recruitment of leukocytes into tissue is regulated by a sequence of interactions 
between the circulating leukocytes and the endothelial cells. In the case of neutrophils, 
this occurs via the leukocyte-expressed β2-integrins, namely, lymphocyte function-
associated antigen 1 (LFA-1, αLβ2-integrin) and macrophage-1 antigen (MAC-1, αMβ2-
integrin), interactions with the endothelial intracellular adhesion molecule 1 (ICAM-1) 
(Ley et al., 2007). In the case of monocytes and lymphocytes, this occurs via the β1-
integrin, very late antigen 4 (VLA-4, α4β1-integrin) interactions with vascular cell-
adhesion molecule 1 (VCAM-1) (Ley et al., 2007). These integrins support intraluminal 
crawling of firmly adhered leukocytes; a process involving the formation of membrane 
protrusions and microvilli that interact with adhesion molecules expressed on the 
inflamed vascular endothelium (Kansas, 1996). In neutrophils, LFA-1 has been shown to 
be more important for adhesion, whilst MAC-1 has been shown to be key for intraluminal 
crawling; both integrins interact with ICAM-1 and this ultimately leads to efficient 
emigration out of the vasculature (Phillipson et al., 2006). ICAM-2 also plays a role in 
facilitating luminal interactions between neutrophils and ECs (Halai et al., 2014). 
Chemokines expressed on the luminal side of the endothelium activate leukocytes 
through GPCR signalling, thus inducing conformational changes of leukocyte integrins 
that allow adhesion whilst chemotactic gradients along the endothelium provide 
directional cues for leukocyte crawling and TEM. This involves other endothelial-
expressed adhesion molecules, including platelet/endothelial cell adhesion molecule 1 
(PECAM-1), junctional adhesion molecules (JAMs), ICAM-1, ICAM-2, CD99, CD99L2 
and endothelial cell-selective adhesion molecule (ESAM) (Bixel et al., 2007; Huang et 
al., 2006; Muller, 2003; Thompson et al., 2001; Wegmann et al., 2006; Woodfin et al., 
2007). TEM occurs either by the paracellular route (between ECs) or the transcellular 
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route (through individual cells), thus allowing extravasated leukocytes to contribute to 
the immune response within inflamed tissues (Kolaczkowska and Kubes, 2013). 
Paracellular TEM is considered to be the most prevalent in the peripheral circulation 
(Schulte et al., 2011; Woodfin et al., 2011). The blood EC layer is surrounded by 
pericytes, which are embedded within the vascular basement membrane (Diazflores et al., 
1991; Shimada et al., 1992; Voisin et al., 2010), thus forming an additional barrier for 
transmigrating leukocytes. Once through the endothelium, abluminal crawling of 
neutrophils along the pericyte layer occurs (through MAC-1/LFA-1 interactions with 
ICAM-1). At this step, neutrophils also interact with the basement membrane, presumably 
via integrin-mediated mechanisms (VLA-3/6 interactions with laminin), before breaching 
the pericyte layer by migrating through gaps between adjacent cells, and regions of low 
matrix protein deposition (LERs) in the basement membrane (Voisin and Nourshargh, 
2013). Finally, neutrophils detach from the vessel through the formation of an elongated 
uropod that must be disengaged before they can initiate their movement towards the site 
of inflammation (Hyun et al., 2012). 
 Neutrophil fate 
During inflammation, neutrophils become activated resulting in increased viability and 
survival within the tissue; this ensures the presence of primed neutrophils at the 
inflammatory foci before they undergo cell death (Colotta et al., 1992; Summers et al., 
2010). Daily, more than 1011 neutrophils undergo cell death in humans (Athens et al., 
1961). It is generally agreed upon that the physiological form of cell death in neutrophils 
is apoptosis. Under homeostatic conditions, neutrophils are thought to be cleared from 
the circulation in the liver, spleen and BM; increased CXCR4 expression is seen in 
senescent neutrophils, which presumably aids in directing them back to the BM for their 
elimination (Furze and Rankin, 2008). For the resolution of inflammation, the control of 
neutrophil cell death and their subsequent clearance is crucial. Neutrophils undergo 
programmed cell death by apoptosis at inflamed sites and in addition, they are also killed 
at these sites by death receptor-induced apoptosis (Rae and MacEwan, 2004; Renshaw et 
al., 2000). Infiltrating macrophages have been shown to release death receptor ligands, 
such as TNF and Fas-ligand, which triggers neutrophil apoptosis (Renshaw et al., 2000). 
Additionally, phagocytosis of certain bacteria by neutrophils has been shown to augment 
their apoptosis at sites of infection (DeLeo, 2004). Finally, a new mode of neutrophil 
death via the prolonged expulsion of NETs has been discovered; the remnants of such 
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neutrophils and NETs themselves are cleared by macrophages along with extracellular 
DNase I degradation (Colotta et al., 1992; Farrera and Fadeel, 2013; Fuchs et al., 2007). 
Neutrophil cell death and their subsequent clearance is a crucial process that not only 
contributes to the maintenance of homeostatic cell numbers, but also ensures the safe 
disposal of phagocytosed bacteria and resolution of inflammation (DeLeo, 2004). It also 
drives the production of anti-inflammatory cytokines through clearance by resident or 
infiltrating macrophages (Hellberg et al., 2011). The interplay of all of these mechanisms 
ultimately promotes the resolution of inflammation. 
 Neutrophils in adaptive immunity 
 The adaptive immune response 
Adaptive - or acquired - immunity is the second defence strategy found within all 
vertebrates (the other being innate immunity) (Boehm, 2012). The primary functions of 
adaptive immune responses are to recognise specific “non-self” antigens in the presence 
of “self antigens”, generate immunity against pathogen-specific antigens (e.g. bacterial, 
viral, toxins) to eliminate them as well as infected cells, and develop immunologic 
memory for rapid elimination of a specific pathogen should subsequent infections occur 
(Bonilla and Oettgen, 2010; Warrington et al., 2011). Cells of the adaptive immune 
system include T cells, which are activated through the presentation of antigens to them 
by APCs (e.g. DCs, macrophages, monocytes, neutrophils) (Ni and ONeill, 1997; Radsak 
et al., 2000), and B cells within secondary lymphoid tissues. Adaptive immune responses 
are subdivided into two branches: cell-mediated and antibody-mediated immunity. Cell-
mediated immunity is governed mainly by effector T cells and is directed primarily at 
pathogens that survive in phagocytes as well as those that infect other cells. This response 
specifically targets virus-infected cells, fungi, protozoa and intracellular bacteria, but can 
also participate in eliminating cancer cells (Warrington et al., 2011). Antibody-mediated 
immunity is mainly facilitated by B cell antibody production, which binds to antigens on 
the surface of pathogens, thus flagging them for destruction through classical complement 
activation and/or opsonisation supporting phagocytosis (Bonilla and Oettgen, 2010). 
During the initiation of adaptive immunity, naïve T cells are activated within lymphoid 
organs when they encounter an APC that has processed an antigen, which then displays 
it on cell-surface proteins known as the major histocompatibility complex (MHCs) 
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(Janeway, 1999). Interactions between naïve T cells (CD8+ and CD4+) and APCs 
displaying antigens on MHC-I and -II, respectively, stimulates the former to differentiate 
into mature cytotoxic T cells (CD8+ cells) or T-helper cells and regulatory T cells (CD4+ 
cells), respectively. The main function of cytotoxic T cells are to destroy cells infected 
by foreign agents. Clonal expansion of these cells results in the effector T cells, which 
release enzymes, such as perforin and granzyme (induces lysis of target cells), and 
granulysin (induces apoptosis of target cells) (Janeway, 1999). Following the clearance 
of infection, most effector T cells die and are removed by macrophages (Krammer et al., 
2007). The few remaining cells develop into memory T cells, which will quickly 
differentiate into effector T cells that are able to rapidly respond upon subsequent 
encounters with the same antigen (Warrington et al., 2011). On the other hand, T-helper 
cells have no cytotoxic or phagocytic activity, and are therefore unable to directly destroy 
infected cells or pathogens. However, they mediate the immune response by directing 
other immune cells within the body to perform these tasks. They are known to produce 
various pro-inflammatory cytokines (e.g. IFNγ, TNF, IL-1β, IL-2, 4, 5, 6 and 17) that 
activate many cell types, including APCs, to indirectly assist the destruction of invading 
microbes (Janeway, 2005). In particular, the cytokines (IL-4, 5, 6) they produce stimulate 
activated B cells, which allows them to undergo proliferation and maturation into short-
lived antibody-secreting plasma cells or memory B cells (Warrington et al., 2011). 
Memory B cells express antigen-binding receptors, and like memory T cells can rapidly 
respond and eliminate specific antigens upon re-exposure. Finally, another subclass of T 
lymphocytes, called regulatory T cells, exert their functions to maintain tolerance to self-
antigens, and thus the prevention of autoimmune diseases. Overall, these processes take 
place over several weeks, ultimately resulting in the development of antigen-specific T 
and B cell clones, and the formation of a pool of effector and memory lymphocytes, which 
are indispensable for the elimination of  invading pathogens, foreign agents and tumour 
cells (Alberts, 2002). 
 Role of neutrophils in shaping adaptive immune responses 
Neutrophils have always been classically thought of as being cells pivotal for the first line 
of defence against invading pathogens. However, recent evidence has mounted 
suggesting their importance in the orchestration of adaptive immunity. During the early 
phase of infection, a characteristic influx of neutrophils and monocytes precedes the 
establishment of adaptive immune response. During this phase, small numbers of tissue-
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resident effector memory T cells are also recruited to the site of infection, some of which 
can be activated and proliferate “in situ” in response to antigen presentation by DCs 
(McGill and Legge, 2009). Additionally, inflammatory cytokines produced by activated 
macrophages cause the proliferation and activation of non-specific T cells in a process 
called “bystander response”; one that was first observed in viral infections (Tough et al., 
1996). It is thought that a large and uncontrolled bystander response might influence auto-
immunity and self-reactivity through the activation and proliferation of self-reactive T 
cells (Burroughs et al., 2011). Thus, there is a possibility that neutrophils are involved to 
limit and control this response as the timing of en masse neutrophil recruitment into 
inflamed tissues and the bystander response coincide (Figure 1.4). 
 
Figure 1.4: Invasion of pathogens (e.g. viruses and bacteria) or inflammation due to necrosis 
and cancer leads to extravasation of neutrophils across postcapillary venules. (1) Interaction 
of neutrophils with T cells within the inflamed tissue leading to the bystander response. (2) 
Migration of neutrophils to draining lymph nodes (dLNs) via afferent lymphatics during 
inflammation (mechanisms discussed in section 1.6. (3) IL-17 and CXCL12-mediated migration 
of neutrophils via HEVs to the LN that requires MAC-1, LFA-1, L-selectin and CXCR4. (4) 
Activation of humoral responses by neutrophils in the IFZ and medullary region through the 
secretion of APRIL, BAFF and IL-21. HEV, high endothelial venule; IFZ, interfollicular zone; 
APRIL, a proliferation-inducing ligand; BAFF, B cell activating factors. 
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Contrary to previous generally held views that neutrophils die within peripheral tissues 
following their recruitment to inflamed sites, it has since been shown that infection-
induced inflammation results in neutrophils being the first lymph-born antigen-carrying 
cell type found within draining lymph nodes (dLNs) (Abadie et al., 2005; Chtanova et al., 
2008; Hampton et al., 2015; Mocsai, 2013). To date, most studies investigating the 
cellular transport of antigens to LNs for the initiation of adaptive immune responses have 
focused on the ability of DCs to exert this function, which will be discussed in section 
1.5. DC mobilisation to dLNs is a slow process that typically only peaks a couple of days 
after activation of the inflammatory response. In contrast, neutrophils have been found 
within dLNs as early as 4-6 h following inflammatory insult, suggesting that this early 
neutrophil influx may influence the developing immune response (Beauvillain et al., 
2011; Hampton et al., 2015; Yang and Unanue, 2013). Neutrophils have been shown to 
migrate to dLNs in response to tissue inflammation in various murine models, such as 
following injection of bacteria such as Staphylococcus aureus (Hampton et al., 2015; 
Kamenyeva et al., 2015), Listeria monocytogenes (Chtanova et al., 2008), Pseudomonas 
aeruginosa (Lammermann et al., 2013), Yersinia pestis (St John et al., 2014) or BCG 
(Abadie et al., 2005). Neutrophils have also been found within dLNs following infections 
with the protozoan parasites Toxoplasma gondii (Chtanova et al., 2008) and Leishmania 
major (Tacchini-Cottier et al., 2000), as well as after intradermal administration of viruses 
like modified vaccinia virus Ankara (Abadie et al., 2009; Sagoo et al., 2016). Neutrophils 
have also been demonstrated to play roles in many models of vaccination and allergy, 
which are mainly used to study the development of adaptive immune responses (Leliefeld 
et al., 2015). These cells are able to effectively cross-prime CD8+ T cells in a MHC-I-
dependent manner (Beauvillain et al., 2007), function as APCs (Abi Abdallah et al., 2011; 
Maletto et al., 2006), or influence the capacity of other APCs to present antigens (Schuster 
et al., 2013). For example, DCs have been shown to uptake antigens from phagocytosed 
apoptotic neutrophils (Schuster et al., 2013). 
The localisation of different immune cells within LNs is strongly linked to their particular 
functions. Therefore, the localisation of neutrophils within LNs will determine which 
cells they encounter and may elucidate LN-specific neutrophil functions (Figure 1.4). 
Afferent lymphatic vessels drain lymph into the subcapsular sinus of dLNs. This region 
is located between the capsule and cortex, and has been shown to be the site of entry for 
pathogens and innate immune cells, including neutrophils (Chtanova et al., 2008; 
Kastenmuller et al., 2012; Yang et al., 2010). Neutrophils have also been observed in the 
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interfollicular zone (IFZ) of the LN following bacterial-induced infections; the IFZ is the 
region located directly below the subcapsular sinus (Cheminay et al., 2004; Kamenyeva 
et al., 2015; Kastenmuller et al., 2012). In this region, neutrophils are located in close 
proximity to T and B cells, as well as innate-like lymphocytes such as γδ T, NK and NKT 
cells, and they have been found to amplify the anti-pathogenic activities of these 
lymphocytes by enhancing their IFN-γ production (Kastenmuller et al., 2012; Kamenyeva 
et al., 2015). Within this region, they also exhibit short- and long-term interactions with 
B cells, thus inhibiting the production of antibodies and subsequently the humoral 
immune response (Kamenyeva et al., 2015). Conversely, neutrophils have been observed 
to contribute to antibody production as well as activating B cells through the production 
of B cell activating factors (BAFF), a proliferation-inducing ligand (APRIL) and the 
cytokine, IL-21 (Figure 1.4) (Puga et al., 2014). A small number of neutrophils have also 
been detected in the T cell zone following bacterial infection (Abadie et al., 2005; 
Kamenyeva et al., 2015) (Figure 1.4). Here, neutrophils have been shown to present 
antigens to T cells in vitro; whether or not this occurs in vivo is currently unknown 
(Takashima and Yao, 2015). Finally, neutrophils have also been detected within the 
medullary regions of lymph nodes following bacterial-induced infections (Kamenyeva et 
al., 2015; Kastenmuller et al., 2012). Little is known about their precise role in this 
location, but it is thought they are localised within this region to prevent pathogen 
dissemination via the efferent lymphatic vessels. Collectively, all of these results provide 
evidence that alongside their roles in innate immunity within inflamed tissue, neutrophils 
may also play roles in regulating adaptive immune responses (Figure 1.4). Thus, further 
investigations into the mechanisms of neutrophil migration (also known as intravasation) 
into the lymphatic system are key in increasing our understanding and potentially allow 




 Neutrophils in disease 
Leukocyte recruitment to sites of infection or injury is an essential response for the 
clearance of pathogens and cell debris, leading to the subsequent restoration of tissue 
homeostasis. Immune cells involved in the inflammatory response clearly have powerful 
functions, which have to be tightly regulated in order to not cause any damage to the host. 
Whilst the pathogenesis of many diseases is highly complex and thus poorly understood, 
increasing evidence has pointed to the dysregulation of immune cell infiltration, 
particularly in the context of neutrophils, as the underlying cause of many diseases. 
Therefore, understanding the exact context of dangers to the host versus the importance 
of leukocyte infiltration could provide potential new targets for the treatment of 
inflammatory conditions. 
 Sepsis 
Sepsis is a rare but life-threatening condition that arises when the body’s responses to 
infection results in injury to its own tissues and organs. The pathogenesis of sepsis is 
unclear, although most cases are initiated by gram-negative bacterial infection of the 
blood, abdomen, lungs or urinary tract (Cohen, 2002). Activation of leukocytes and the 
vascular endothelium by bacteria results in the activation of complement, imbalance of 
coagulation pathways, and the production of cytokines and subsequent oxygen and lipid 
intermediates. The result is a combination of vascular instability triggered by an 
uncontrolled and systemic inflammatory response responsible for the classical signs of 
septic shock (fever, vasodilation, increased vascular permeability), characterised by 
multiple organ failure (MOF) and profound immune suppression (Angus and van der Poll, 
2013). 
The recruitment and migration of neutrophils to sites of infection is significantly reduced 
during sepsis, thus resulting in the loss of a crucial arm of the innate immune response to 
infection (Benjamim et al., 2000). Several mechanisms responsible for this impairment 
in the directed migration of neutrophils include cytoskeletal changes, disruption of 
leukocyte–EC interactions, and alterations in GPCR expression or signalling, as well as 
nitric oxide (NO)-mediated alterations in neutrophil chemotaxis (Fialkow et al., 2007; 
Freitas et al., 2006; Yoshida et al., 2006). Moreover, the function of neutrophils are 
affected during sepsis via toll-like receptors (TLRs) and GPCR signalling, as well as 
47 
 
NETs formation, all of which lead to overexpression or enhanced activity of pro-
inflammatory mediators resulting in tissue damage and MOF (Clark et al., 2007; Hakkim 
et al., 2010). TLRs are expressed by immune cells and recognise self and non-self 
structures, such as pathogen-associated molecular patterns (PAMPs) derived from 
microbes, and danger-associated molecular patterns (DAMPs) released during tissue 
injury. It is therefore clear that the dysregulation of neutrophil function results in sepsis. 
However, exactly how this response becomes both aberrant and systemic to culminate in 
sepsis is considered a complex web of events that are not entirely clear. 
 Ischaemia reperfusion injury 
Ischaemia reperfusion (I/R) injury is another example of neutrophil recruitment having a 
causative role in tissue damage. Ischemia occurs during myocardial infarction (MI), 
stroke, or organ transplantation, followed by the essential reperfusion phase, whereby 
oxygen is reintroduced to the tissue (Eltzschig and Eckle, 2011). Absence of the 
reperfusion phase would result in tissue death due to the lack of oxygenation. Restoration 
of blood flow in the reperfusion phase is accompanied by the release of cytokines and 
chemokines, activation of vascular ECs, up-regulation of adhesion molecules and 
activated neutrophil accumulation within the reperfused area (Eltzschig and Eckle, 2011; 
Vinten-Johansen, 2004). Recruitment and activation of neutrophils results in ROS 
generation and subsequent imbalances of superoxide (O2-) and NO; these imbalances 
promote the accumulation of highly toxic oxygen products, such as peroxynitrite (OONO-
), hypochlorous acid (HOCI) and hydrogen peroxide (H2O2), all of which have the 
capacity to oxidise DNA, proteins and lipids, thus resulting in cell destruction and 
ultimately tissue damage (Thannickal and Fanburg, 2000). The release of inflammatory 
mediators and activated leukocytes into the circulation during the reperfusion phase 
therefore results in remote organ damage, and is a severe problem following ischaemic 
events as it could potentially result in MOF (Pierro and Eaton, 2004; Woodfin et al., 
2011). The role of neutrophil infiltration in enhancing the progression of disease has been 
demonstrated in neutrophil depletion experiments that resulted in suppression of 
neutrophil toxic activities in models of myocardial (Kohtani et al., 2002), kidney 




 Rheumatoid arthritis and other neutrophil-related autoimmune 
diseases 
Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation in the 
affected joints. Amongst all the cells implicated in the pathology of RA, neutrophils are 
the ones that retain the greatest cytotoxic potential, due to their capacity to release 
degradative enzymes and ROS (Wright et al., 2014). During the acute phase of the disease 
in RA patients, neutrophils are the most abundant immune cells found within the synovial 
fluid (SF) of the affected joints; they have also been found at the pannus/cartilage 
boundary in synovial tissue, where active destruction of cartilage and bone occurs (Mohr, 
2003). Following their migration into RA joints, activated neutrophils encounter 
complexes of immunoglobulins, such as rheumatoid factor (RF), within the SF and on the 
surface of the joint. These immune complexes bind to Fcγ receptors expressed by 
neutrophils and results in their degranulation and production of ROS, either into the SF 
or directly onto the joint surface in a process called ‘frustrated phagocytosis’ (Kraan et 
al., 2000). Oxidative stress resulting from the inappropriate release of ROS by activated 
neutrophils is implicated in the pathology of RA, and neutrophils isolated from SF of RA 
patients have shown evidence of initiated ROS production in vivo (Elferink et al., 1997). 
These oxygen radicals result in DNA damage, oxidation of lipids, proteins and 
lipoproteins, and have potentially been implicated in causing immunoglobulin mutations 
that lead to the formation of RF (Akahoshi et al., 1997; Wandall, 1991). Degranulation 
has also been demonstrated to contribute to host tissue damage, particularly in the 
destruction of the collagen matrix within cartilage (Hoenderdos et al., 2016). Emerging 
evidence suggests that neutrophil release of NETs, which is a killing mechanism for 
extracellular microorganisms, also provide a source of autoantigens, such as citrullinated 
proteins (Romero et al., 2013). In fact, citrullinated proteins have been detected within 
SF before the onset of symptoms in RA patients, and can be predictive of erosive disease 
(Romero et al., 2013). Furthermore, neutrophils isolated from patients with RA have been 
found to have an increased tendency to form NETs containing citrullinated proteins, in 
addition to autoantibodies recognising these proteins being present in the sera of these 
patients (Pratesi et al., 2014). Thus, this suggests that neutrophils may be a source of the 
autoantigens that drive the autoimmune processes underlying RA. In line with this, one 
of the crucial pathogenetic features of another autoimmune disorder, systemic lupus 
erythematosus (SLE), is the presence of DNA-containing immune complexes, which 
triggers interferon-α (IFNα) production by plasmocytoid DCs (Ronnblom and Pascual, 
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2008). The source of this extracellular DNA has been shown to originate from NETs, thus 
implicating neutrophils in this disease (Garcia-Romo et al., 2011; Lande et al., 2011).  
In small vessel vasculitis (SVV), a chronic autoinflammatory condition linked to 
antineutrophil cytoplasm autoantibodies (ANCA), ANCA-stimulated neutrophils release 
NETs which contain autoantigens and MPO (Kessenbrock et al., 2009). The deposition 
of these NETs in inflamed kidneys and circulating MPO-DNA complexes indicates that 
NET formation triggers vasculitis and thus results in the autoimmune response against 
neutrophil components in SVV patients (Kessenbrock et al., 2009). 
The introduction of TNF inhibitors, or anti-TNF therapies, has majorly improved the 
treatment of RA, providing a mechanism to treat even patients severely affected by the 
disease. TNF is a pro-inflammatory cytokine that influences many elements of immune 
dysregulation that contributes to disease, such as cellular infiltration into RA-affected 
joints, cytokine synthesis and the production of autoantibodies. TNF has been shown to 
prime neutrophil respiratory bursts, up-regulate the expression of adhesion molecules, 
cytokines and chemokines, as well as stimulate ROS production when present locally at 
high concentrations (Cross et al., 2008; Dewas et al., 2003; Fujishima et al., 1993; Ginis 
and Tauber, 1990). Anti-TNF therapy is able to successfully block cytokine and 
chemokine synthesis in synovial tissue, lower concentrations of MMPs, reduce the influx 
of immune cells (neutrophils in particular) to synovial joints by down-regulating the 
expression of adhesion molecules, induce the apoptosis of monocytes and macrophages, 
as well as restore regulatory T cell function, which is important in maintaining tolerance 
to self-antigens and in the prevention of autoimmune diseases (Feldmann et al., 2010). 
Anti-TNF therapy also results in the down-regulation of neutrophil activation through 
decreasing cytokine production and (nuclear factor- kappa B) NF-κB expression, all of 
which are associated with improvements in disease activity (Wright et al., 2011). 
Treatment for SVV incorporates cytotoxic drugs and glucocorticoids (Molloy and 
Langford, 2006). However, these are associated with significant risks of relapse and 
treatment-related toxicity (Molloy and Langford, 2006). Existing treatment for SLE 
include nonsteroidal anti-inflammatory drugs (NSAIDs) and immunosuppresants 
(Haubitz, 2010). However, the first ever targeted drug, Belimumab, for the treatments of 
these patients has been approved by the Food and Drug Administration (FDA), and results 
have been positive (Dubey et al., 2011). Belimumab works by decreasing B cell survival 
and the production of autoantibodies (Halpern et al., 2006). 
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RA, sepsis and I/R injuries are 3 diverse examples of inflammatory conditions, where 
neutrophil infiltration along with their associated functions no longer result in helpful 
responses, but instead result in host attack. These conditions are a result of dysfunctional 
regulation and therefore demonstrate the importance of understanding mechanisms of 
leukocyte recruitment both into peripheral tissues and the lymphatic system, in the 
clearance of infection and tissue damage along with the restoration of normal tissue 
homeostasis. 
 The lymphatic system 
The lymphatic vascular system is the second circulatory system within the human body 
that is crucial for tissue homeostasis and a vital part of the immune system. It is composed 
of a unidirectional system of conduits interrupted by LNs that run in parallel to the blood 
vascular system (Figure 1.5) (Teijeira et al., 2013). The lymphatic system works in 
conjunction with the blood vascular system and plays an important role in the regulation 
of tissue fluid resorption, facilitating interstitial protein transport, and immune 
surveillance through the initiation of adaptive immunity (Pepper and Skobe, 2003). It is 
the afferent lymphatics that control the trafficking of antigen-presenting leukocytes into 
LNs, where initiation of the adaptive immune response takes place. Lymphatic vessels 
carry a clear fluid called lymph, which comprises of lymphocytes, APCs, lipids, waste 
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products and cellular debris (pathogens and proteins), directionally towards the heart 
(Figure 1.6 &  
Figure 1.5). 
Lymph is formed when constituents of the blood exit blood vessels and enter initial 
lymphatic vessels along with interstitial fluid and its constituents (Figure 1.5). The lymph 
is then transported along the lymphatic vessel network through either intrinsic 
contractions of the vessels themselves or through extrinsic compression of the vessels via 
external tissue forces, such as skeletal muscle contractions, respiratory movement and 
contraction of smooth muscle cells in walls of collecting lymphatic vessels  (Cueni and 
Detmar, 2008). The function of initial lymphatics is heavily dependent on its connections 
with the extracellular matrix (ECM); anchoring filaments attach lymphatic endothelial 
cells (LECs) to interstitial collagen, which provides structural integrity and prevents the 
collapse of these vessels when interstitial pressure rises (Figure 1.5) (Gerli et al., 1990; 
Leak and Burke, 1966). Eventually, the lymph is returned to the blood circulation through 
drainage into thoracic or lymphatic ducts, which join up to one of the two subclavian 




Figure 1.5: Fluid exchange between blood vessels and lymphatics. Initial lymphatics are 
uniquely adapted for the uptake of fluid, lipids, macromolecules, cellular debris and cells from 
the interstitial tissue. In contrast to blood vessels, afferent lymphatic vessels have a relatively 
undeveloped basal lamina (BM) and lack pericytes (P). LECs are connected directly to the 
interstitial collagen via anchoring filaments (AF). BM, bone marrow; DC, dendritic cell; APC, 






Figure 1.6: The circulatory system. The lymphatic vasculature collects fluid from the interstitial 
space that has exited the blood vessels, and transports it towards the heart via the filtering 
mechanism of the LNs into collecting vessels that connect through the thoracic ducts into the 




 Structural organisation of the lymphatic endothelium 
Despite many advances in the investigation towards understanding lymphatic function, 
the cellular features responsible for entry of fluid and cells into the lymphatic system are 
still not completely understood (Oliver and Alitalo, 2005). It has since been reported that 
the unique junctional organisation of the lymphatic endothelium plays an important role 
in the recirculation of fluid and cells in normal tissue homeostasis, inflammatory diseases 
and cancer (Baluk et al., 2007; Dejana et al., 2009). Initial lymphatic vessels express the 
lymphatic vessel endothelial receptor-1 (LYVE-1) and Prox-1 (prospero-related 
homeobox gene 1) (Baluk et al., 2007). Initial lymphatic vessels are characterised by 
round blinded-ends and have been found to exhibit overlapping flaps at borders of 
oakleaf-shaped LECs, which lack junctions at the tips but are anchored on the sides by 
discontinuous button-like junctions (buttons); this is in contrast to collecting lymphatic 
vessels and blood vessels, which exhibit continuous, zipper-like junctions (zippers) 
(Figure 1.7) (Baluk et al., 2007; Dejana et al., 2009). Buttons are found at the perimeter 
of LYVE-1–positive LECs. Both buttons and zippers are composed of vascular 
endothelial cadherin (VE-cadherin) and tight junction-associated proteins including 
claudin-5, occludin, occludens-1, junctional adhesion molecule-A (JAM-A), and ESAM 
(Baluk et al., 2007). Additionally, PECAM-1 and LYVE-1 partially co-localise at flaps 
on the borders of oak leaf–shaped LECs of initial lymphatics, and at zippers of collecting 
lymphatics (Baluk et al., 2007). 
In initial lymphatics, the free overlapping cell edges form ‘flap valves’ through which 
fluid flows unidirectionally along pressure gradients from the interstitium into the initial 
lymphatic lumen. Whole mount experiments have also revealed that these loose flaps are 
about 2–3 μm in diameter, through which leukocytes (DCs and T cells) are thought to 
migrate into the lymphatic vessel lumen; they have been shown to do this by squeezing 
through and subsequently displacing the flap valves towards the lumen of the lymphatic 
vessel (Baluk et al., 2007; Pflicke and Sixt, 2009). It has been described that actively 
sprouting lymphatics have zippers rather than buttons, which suggests that these button-
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like junctions are a specialised characteristic of quiescent and functionally active initial 
lymphatics (Baluk et al., 2007). 
 
Figure 1.7: Button-like junctions in initial lymphatics border sites of fluid entry. (A) 
Schematic diagram showing distinctive, discontinuous buttons in endothelium of initial 
lymphatics and continuous zippers in collecting lymphatics. The magnified insert (green box) 
shows a more detailed view of oakleaf-shaped LECs with button-like junctions. Buttons (green) 
appear to be perpendicular to cell borders but are actually parallel to the sides of flaps. (B) 
Enlarged view of oakleaf-shaped LECs showing that flaps of adjacent LECs have complementary 
shapes with overlapping edges. Adherens and tight junctions parallel to flaps direct fluid entry 
(black arrows) to the junction-free region without disruption and reformation of junctions.  
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 Lymphatic and vascular endothelial cell glycocalyx  
Amongst the few universal biological findings, it has been established that all mammalian 
cells are covered with a dense coating of glycans (Varki and Varki, 2007). This layer, 
known as the glycocalyx, spans between several hundred nanometres to a few 
micrometres; and lines the surface of cells (Reitsma et al., 2007). In particular, blood 
vascular endothelial cells (BECs) cover the entire luminal surface of the vascular system, 
where the glycocalyx forms a barrier between circulating blood and the venular wall 
(Haldenby et al., 1994; Wang, 2007).  It is worth pointing out that a considerable lack of 
literature is available regarding the composition of the glycocalyx on lymphatic 
vasculatures, with the presence of a glycocalyx on LECs being largely unknown. 
However, it has recently been reported that the LEC glycocalyx exists on the LEC 
membrane of rat mesenteric collecting lymphatic vessels, with an indication that it is 
highly likely that the composition of the LEC glycocalyx is similar to that of the 
glycocalyx found on blood vessels (Zolla et al., 2015). This suggests that the LEC 
glycocalyx may play similar roles to the BEC glycocalyx. 
The majority of studies investigating the glycocalyx involves the blood vasculatures, 
therefore the role of the LEC glycocalyx could potentially be inferred from them 
(Kolarova et al., 2014; Reitsma et al., 2007; Tarbell et al., 2005; Van Teeffelen et al., 
2007; Wang, 2007). Studies have indicated that the BEC glycocalyx plays an important 
role in numerous physiological processes, including regulation of vascular permeability, 
regulation of leukocyte adhesion during TEM, mechanotransduction of shear stress and 
the modulation of inflammatory processes (Kolarova et al., 2014; Reitsma et al., 2007; 
Tarbell et al., 2005; Wang, 2007). A number of studies have shown that perturbation of 
the glycocalyx structure in response to inflammatory mediators, such as cytokines and 
chemoattractants, promote inflammatory processes in vessels and contribute to the 
development of vascular diseases, such as atherosclerosis (Nieuwdorp et al., 2007; van 
den Berg et al., 2006; Vink et al., 2000).  
Theoretical models and experimental research over the years have shown that the 
glycocalyx is a complex carbohydrate layer comprised of membrane-bound 
macromolecules from plasma proteins and the glycoproteins (e.g. adhesion molecules, 
selectins and integrins) to the sulfated proteoglycans (e.g. syndecans, glypicans, 
mimecans, biglycan) along with their associated glycosaminoglycan (GAG) side chains 
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(Figure 1.8) (Kolarova et al., 2014). These molecules have also been recently reported to 
be found on the LEC glycocalyx (Zolla et al., 2015). 
 
 
Figure 1.8: Schematic of the vascular EC glycocalyx.  Situated within the luminal side of the 
vessel wall, the EC glycocalyx consists of glycoproteins (adhesion molecules, selectins and 
integrins), membrane-bound proteoglycans (syndecans and glypicans), as well as secreted 
proteoglycans (mimecans, biglycans, perlecans). All proteoglycans are attached to GAG chains, 
made up of HS, HA, DS and CS. HS occurs as a proteoglycan (HSPG) 
GAGs are linear polymers of repeating disaccharides that are composed of D-glucoronic 
acid, L-iduronic acid, or D-galactose linked to either D-N-acetylglucosamine or D-N-
acetylgalactosamine (Kolarova et al., 2014). Specific combinations of these sugar 
residues give rise to different GAG families, such as heparan sulfate (HS), chondroitin 
sulfate (CS), and hyaluronan (HA), with HS being the most abundant in the BEC 
glycocalyx (Oohira et al., 1983). These GAGs interact with a variety of proteins and are 
involved in the mediation of numerous physiological and pathological functions, 
including inflammation.  
Glycoproteins are small transmembrane molecules bound to the glycocalyx bearing acidic 
oligosaccharides and terminal sialic acids (SAs) (Van Teeffelen et al., 2007). Established 
oligosaccharides of glycoproteins include a variety of saccharide motives, including 
galactosyl residues, as well as N-acetyl-glucosamine and N-acetylgalactosamine (Pries et 
al., 2000; Weinbaum et al., 2007). Key glycoprotein players known to play significant 
roles in leukocyte TEM during an inflammatory response include the adhesion molecules 
such as intercellular adhesion molecules -1 and -2 (ICAM-1 and -2), platelet endothelial 
cell adhesion molecule-1 (PECAM-1), vascular cell adhesion molecule-1 (VCAM-1) and 
junctional adhesion molecule (JAM) family members (Muller, 2009). 
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As a whole, the BEC glycocalyx is involved in the regulation of leukocyte transmigration 
following inflammatory stimuli. The GAG, HS, is involved in the initial adhesion of 
leukocytes to the endothelium following inflammation by interacting with 
cytokines/chemokines and participating in leukocyte-selectin binding during TEM 
(Reitsma et al., 2007). Additionally, degradation of the glycocalyx has been shown to 
stimulate immobilisation of leukocytes at the endothelial surface prior to TEM 
(Constantinescu et al., 2003). A recent study also found that sepsis-associated acute lung 
injury was initiated by degradation of the pulmonary endothelial glycocalyx, leading to 
neutrophil adherence and inflammation (Schmidt et al., 2012). In lymphatic vessels, a 
recent report has shown that a decrease in the thickness of the LEC glycocalyx and its 
associated molecules is observed in aging lymphatic vessels; this is linked to enhanced 
permeability that results in increased extravasation of bacteria and fungi into peripheral 
tissues (Zolla et al., 2015). This decrease in the ability to transport bacteria to the dLNs, 
where adaptive immune responses are initiated, likely contributes to the reduced ability 
of the immune system to clear pathogens in the elderly. Furthermore, a reduction in the 
LEC glycocalyx and its associated molecules has been implicated in senescence-
associated lymphatic vessel hyperpermeability leading to impaired fluid homeostasis 
(Zolla et al., 2015). This could also affect the transport of large molecules, lipids, proteins 
and products of tissue metabolism/catabolism, all of which are important for normal 
tissue homeostasis (Ahn and Simpson, 2007; Clement et al., 2011; Kolarova et al., 2014).  
 Development and phenotypic characteristics of lymphatic vessels 
In the early twentieth century, Florence Sabin proposed the most widely accepted view 
of lymphatic development. Following ink injection experiments, she proposed that the 
peripheral lymphatic system originated by the sprouting of ECs from embryonic veins, 
leading to the formation of primitive lymph sacs from which LECs then sprout into 
surrounding tissues and organs to form mature lymphatic networks; a process known as 
lymphangiogenesis (Sabin, 1902, 1904). An alternative model has also been suggested 
where these primary lymph sacs arise in the mesenchyme independently from veins and 
secondarily established venous connections (Huntington and McClure, 1910). Following 
these pioneering studies, the field of lymphatic research remained neglected up till the 
discovery of new markers for LECs and identification of lymphatic growth factors, which 
has allowed the molecular mechanisms that control lymphatic development to be 
investigated (Oliver and Detmar, 2002). Importantly, these studies have generally 
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provided evidence to support Sabin’s original hypotheses regarding lymphatic 
development within the mammalian system (Figure 1.9). 
Prospero-related homeobox gene 1 (Prox1) was the first gene demonstrated to be essential 
for early lymphatic development. From embryonic day (E) 9.5 of murine development, 
Prox1 starts being specifically expressed in a sub-population of ECs located on one side 
of the anterior cardinal vein (Wigle et al., 1999). At this stage, the vascular endothelium 
also expresses the hyaluronan receptor, LYVE-1, which is a CD44 homologue (Banerji 
et al., 1999). The vascular EC growth factor receptor 3 (VEGFR-3), which is a receptor 
for the lymphangiogenesis factors, vascular endothelial growth factor (VEGF)-C and 
VEGF-D, is also expressed at this point (Alitalo and Carmeliet, 2002). The expression of 
both receptors, LYVE-1 and VEGFR-3 (now well-known LEC markers), becomes 
specific to the lymphatic endothelium during the later stages of development along with 
Prox1 (Kaipainen et al., 1995). Subsequently, polarised budding and migration of 
progenitor Prox1+ LECs leads to a gradual down-regulation of the blood vascular genes, 
such as CD34, CD31 and laminin, and increased expression of the lymphatic markers, 
VEGFR-3 and the lymphoid chemokine CCL21 (Wigle et al., 2002; Wigle and Oliver, 
1999). Studies have revealed that mice express two functional isoforms of CCL21: 
CCL21Ser, which is found in both lymphatics and LNs, and CCL21Leu, which is only found 
within tissue-associated LECs (Nakano and Gunn, 2001; Vassileva et al., 1999). 
The budding and sprouting of LECs from the veins of Prox1 knockout (KO) mice is halted 
at around E11.5-E12.0; these mice have been observed to lack lymph sacs and lymphatic 
vessels, in conjunction with low survival rates due to multiple developmental defects 
(Wigle and Oliver, 1999). Additionally, EC-specific KO of Prox1 has been shown to 
result in lymphatic vasculature defects, as well as postnatal lethality (Harvey et al., 2005). 
Nonetheless, the exact mechanisms of action of Prox1 during and after switching over to 
the lymphatic from the blood vascular phenotype remain unknown. The only existing 
evidence is that overexpression of Prox1 leads vascular ECs towards a LEC fate both in 
vitro (Hong et al., 2002) and in vivo (Kim et al., 2010). Collectively, these results identify 
Prox1 as a master regulator gene in the programme specifying LEC fate (Figure 1.9) 





Figure 1.9: Hypothetical model of the distinct steps involved in the embryonic development of 
the mammalian lymphatic vasculature. (1) Embryonic veins are the origin of both the vein and 
lymph plexus. Lymphatic endothelial cell competence is the autonomous ability of venous ECs 
to respond to a specific, inductive signal. This stage is characterised by the appearance or 
disappearance of a receptor or by different expression levels of certain transcription factors. 
Specifically, two receptors are expressed on the surfaces of embroyonic cardinal veins: LYVE-1 
and VEGFR-3. At this stage, it is not possible to determine whether lymphatic or venous vessels 
are involved, although both receptors characterise lymphatic vessels in adults. (2)  An inductive 
signal, the origin of which is still unknown, triggers the expression of the homeobox gene Prox1. 
Prox1 starts being specifically expressed in a sub-population of ECs located on one side of the 
anterior cardinal vein. This results in LEC specification and the budding of lymphatic precursors 
signalling the first step towards the differentiation of embryonic cardinal ECs into LECs. (3) 
Specified LECs sprout towards VEGF-C producing mesodermal cells and aggregate to form 
lymph sacs. (4) Subsequently, polarised budding and migration of progenitor Prox1+ LECs leads 
to a gradual down-regulation of the blood vascular genes, such as CD34, CD31 and laminin, and 
increased expression of the lymphatic markers, VEGFR-3 and the lymphoid chemokine CCL21. 
The density of the VEGFR-3 receptors increases, and angiopoetins together with their Tie-2 
receptors are produced, both of which are responsible for the further maturation of the newly 











During the final developmental steps of the mature lymphatic network and their 
patterning, studies in angiopoietin-2 KO mice have suggested crucial roles of 
angiopoietins and their receptor, Tie2 (Figure 1.9) (Gale et al., 2002). However, the 
mechanisms controlling the sprouting of LECs from primitive lymph sacs followed by 
their migration into adjacent organs and tissues during lymphangiogenesis is still unclear. 
VEGF-C has been demonstrated to be a potent inducer of lymphatic sprouting and in 
addition to VEGFR-3, its interaction with its other known receptor, VEGFR-2, is also 
likely to be required for this process (Saaristo et al., 2002). Continual investigations into 
the development of lymphatic vessels, as well as the molecular cues governing their 
formation and morphogenesis are still missing, as further understanding of these 
processes may provide us with essential knowledge that might improve our ability to treat 
lymphatic-related diseases. 
 Neo-lymphangiogenesis 
Once adulthood is reached, lymphangiogenesis primarily occurs during tissue 
regeneration, tumour growth, as well as during acute and chronic inflammation (Jones 
and Min, 2011). During inflammation, macrophages have been extensively shown to 
produce VEGF-C and VEGF-D, which leads to lymphangiogenesis (Cursiefen et al., 
2004). In a murine model of Mycoplasma pulmonis infection, TNF signalling has been 
demonstrated to be involved in neo-lymphangiogenesis, but its effects on driving this 
process requires inflammatory mediators produced by recruited leukocytes (Baluk et al., 
2009). Inflammation creates a hostile microenvironment, from which antigens, toxins and 
debris have to be immunologically removed. In parallel, excess interstitial fluid and 
oedema has to be drained, thus lymphangiogenesis occurs for efficient lymphatic draining 
and clearance of pathogens, as well as enhanced antigen presentation within dLNs to 
initiate an adaptive immune response (Kim et al., 2012). Indeed, the activation of 
lymphangiogenesis by overexpression of VEGFR-3-specific ligands has been 
demonstrated to result in the inhibition of acute and chronic inflammation (Huggenberger 
et al., 2011; Huggenberger et al., 2010). Nevertheless, neo-lymphangiogenesis can also 
result in adverse effects within the human body (see section 1.4.2), thus proper regulation 
of this process is key. 
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 Lymphatic vessels in the pathology of diseases 
Lymphatic vessels have unique roles in regulating fluid homeostasis, assisting in immune 
surveillance, as well as transporting dietary lipids. However, dysfunctional lymphatic 
vessels can result in severe pathologies, whilst normal lymphatic functions can also 
contribute to the exacerbation of diseases. 
 Lymphoedema 
Infections, surgery, radiotherapy or genetic defects can result in the absence or 
dysfunction of lymphatic vessels, which leads to a set of pathological conditions called 
lymphoedema (Rockson, 2016). Lymphoedema is characterised by chronic accumulation 
of protein-rich fluid in tissues that results in swelling (oedema), usually of extremities. 
There are two classifications of lymphoedema: primary and secondary lymphedema. 
Primary lymphoedema has a genetic aetiology that results in the lymphatics being unable 
to drain fluid away from parts of the body; this can present at birth or arise later in life 
(Jones and Min, 2011). Milroy’s disease is an example, which results in congenital 
lymphoedema that has been linked with a mutation in the tyrosine kinase domain of the 
VEGFR-3 gene (Ferrell et al., 1998; Evans et al., 2003) 
Secondary lymphoedema is the most common cause of oedema. In industrialised 
countries, this is caused by damage or obstruction to normal lymphatic vessels, stemming 
from surgery, radiotherapy and infections (Rockson, 2016). In tropical and subtropical 
countries, pathogenic filarial parasites are the main cause of lymphoedema, which often 
leads to a disease known as elephantiasis that is characterised by severe swelling of the 
extremities (Pfarr et al., 2009). These mosquito-borne parasites reside in and cause 
damage to the lymphatic vessels, leading to an inhibition of lymphatic function. No cure 
currently exists for lymphoedema but therapies including compression bandages, 
exercises, and manual lymphatic draining massages exist. Therefore further research into 
lymphatic vessels has to be carried out for the identification of potential therapeutic 
targets to cure this condition. 
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 Chronic inflammation and cancer 
Several reports have demonstrated that the generation of new lymphatic vessels during 
inflammation are not beneficial to the host (Jeon et al., 2008; Wu et al., 2006). In a murine 
model of ovarian cancer, significant generation of lymphatic vessels occurred; these 
vessels, however, were found to be non-functional (Jeon et al., 2008). Similarly, 
lymphatic contractile activity was found to be compromised in a model of intestinal 
inflammation (Ileitis) (Wu et al., 2006); this could be linked to the autoimmune 
inflammatory bowel disease, Crohn’s disease, which is often associated with a 
dysfunction in lymphatic vessels (von der Weid et al., 2011). Cytokines, such as IL-1β 
and IFNγ, normally generated during inflammation have negative effects on LEC growth, 
activation and barrier function, thus may affect lymphatic clearance and increase tissue 
oedema (Chaitanya et al., 2010). 
Lymphatic vessels have also been implicated in the metastasis of primary tumour cells to 
dLNs and distant organs; tumour cells have been widely shown to disseminate in the body 
through pre-existing lymphatic vessels (Karaman and Detmar, 2014). Additionally, 
tumours have been shown to release the growth factors, VEGF-A, VEGF-C and VEGF-
D, which induces lymphangiogenesis in primary tumours and sentinel dLNs, thereby 
promoting LN metastasis to distant organs (Schoppmann et al., 2002). Specifically, 
tumour-derived VEGF-C upregulates CCL21 production by the lymphatic endothelium, 
thus promoting the entry of CCR7-expressing tumour cells into those vessels (Issa et al., 
2009). VEGF-C overexpression in human melanomas transplanted onto nude mice 
resulted in the formation of intratumoral lymphatics and enlargement of these vessels 
(Skobe et al., 2001). Additionally, mice bearing VEGF-D overexpressing xenographs 
resulted in a higher rate of LN metastasis and greater tumour volume (Du et al., 2014). 
This therefore sheds light on why a high level of VEGF-C and VEGF-D is associated 
with increased metastasis and poor prognosis in cancer patients (Tobler and Detmar, 
2006).  The blockade of lymphangiogenesis as an independent therapeutic concept does 
not exist, although therapies with anti-VEGF-C antibodies (Abs) have been tested in 
preclinical studies (Visuri et al., 2015). However, no positive results in human tumour 
studies have been published in the peer-reviewed literature. 
Collectively, all of these studies demonstrate that further characterisation of the 
underlying molecular mechanisms of lymphangiogenesis is required, in order to identify 
therapeutic avenues for the selective inhibition of lymphatic vessels in diseases, such as 
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cancer. In addition, identifying components of lymphatic vessels that could be targeted to 
prevent the metastasis of cancers via this route is also important.  
 Pathogen dissemination 
Similar to the metastasis of tumour cells, pathogens are also known to invade the host via 
the lymphatic system. There has been increasing evidence showing that infection results 
in neutrophils being the first lymph-born antigen-carrying cell type found within dLNs, 
indicating that pathogens use neutrophils as shuttles in order to disseminate (Abadie et 
al., 2005; Chtanova et al., 2008; Hampton et al., 2015; Lynskey et al., 2015; Mocsai, 
2013). For example, following S. aureus infection, neutrophils within lymphatic vessels 
and dLNs were observed to carry S. aureus bioparticles, which had been fluorescently 
labelled (Hampton et al., 2015). Similarly, vaccination with mycobacterium bovis BCG 
resulted in BCG-infected neutrophils being observed within the lumen of lymphatic 
vessels, as well as accumulating within the subcapsular sinuses of dLNs (Abadie et al., 
2005).  
Furthermore, there has been clear clinical evidence that pathogens using lymphatic 
vessels as their dissemination route, for instance Group A streptococcus, can induce 
pathology within the lymphatic system. This includes lymphangitis (inflammation of 
lymphatic vessel walls) and lymphadenitis (infection of the LNs) (Bisno and Stevens, 
1996; Vindenes and McQuillen, 2015). It has recently been demonstrated that the 
hyaluronan capsule secreted by group A streptococcus is imperative for bacterial 
dissemination to dLNs; this occurs through specific interactions with the hyaluronan 
receptor, LYVE-1 (Lynskey et al., 2015). Additionally, injections of an obligatory 
intracellular pathogen, live Toxoplasma gondii, into the earflaps of mice resulted in the 
parasites being found within the subcapsular sinus of dLNs in association with LYVE1+ 
lymphatic vessels, thus indicating they had arrived from afferent lymphatics (Chtanova 
et al., 2008).The recognition that the lymphatic system plays such an important role in 
the dissemination of pathogens has brought the field to the forefront in immunology and 
cell biology. Therefore, research is ongoing in a race to find therapeutic targets within the 
lymphatic system to prevent the spread of pathogens within the human body. 
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 Leukocyte recruitment into the lymphatic system 
Of the immune cells that migrate into sites of inflammation, only certain types of 
leukocytes are able to exit peripheral tissues and migrate towards LNs through lymphatic 
vessels. DCs, macrophages, tissue-resident (memory) T cells, and more recently 
neutrophils have been shown to partake on a journey through the afferent lymphatic vessel 
towards dLNs (Abadie et al., 2005; Harmsen et al., 1985; Mackay et al., 1990; Maletto et 
al., 2006; Randolph et al., 2005). HEVs are also another route of entry into the lymphatic 
system (Hampton and Chtanova, 2016). In the following sections, the mechanisms of 
leukocyte trafficking into the lymphatic system will be discussed. In particular, 
mechanisms of DC and T cell migration across the lymphatic endothelium will be covered 
as literature on this subject is most abundant due to the intrinsic nature of adaptive 
immune responses. Neutrophil trafficking into the lymphatic system is sparse but studies 
that exist are heavily influenced by mechanisms used by other leukocytes. The currently 
known mechanisms for neutrophil migration into the lymphatic system will be covered 
separately in section 1.6. 
 Leukocyte trafficking to lymphatics during innate and adaptive 
immunity 
The adaptive immune response is initiated within the LNs, where naïve T and B cells 
encounter APCs, and results in lymphocyte activation and clonal expansion. Naïve T cells 
migrate from the blood circulation across the LN postcapillary venules (HEVs) to enter 
the paracortical regions of these organs. Unlike activated effector or memory T cells 
which can be found within peripheral tissues, naïve T cells are generally unable to enter 
the interstitium and thus mainly rely on DCs to deliver antigens from these tissues to them 
within the LN; DCs do this by “picking up” antigens from inflamed tissues and migrating 
to LNs via afferent lymphatics (Austyn, 1989). They are also required to process antigens 
for presentation to the T lymphocytes (Blum et al., 2013). Whilst other immune cells, 
such as monocytes, macrophages, and B cells can act as APCs to activate memory T cells, 
DCs are the main class of APCs that are able to activate naïve T cells, leading to the 
stimulation of clonal expansion and initiation of the adaptive immune response 
(Randolph, 2001). Immature DCs are resident within epithelial and connective tissues, 
where they acquire foreign antigens from pathogens during any potential infection of 
peripheral tissue. It was widely thought that the entry of leukocytes into the afferent 
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lymphatics is a passive process. However, the discovery of chemokines promoting the 
migration of DCs into lymphatic vessels and their subsequent trafficking to LNs has 
provided compelling evidence that this migration is a highly regulated process (Merad 
and Manz, 2009; Randolph, 2001).  
 Chemokine:chemokine receptor axes involved in lymphatic 
trafficking of leukocytes  
In steady state, immature and semi-mature DCs migrate constitutively from inflamed 
peripheral tissues into LNs via afferent lymphatic vessels, allowing both normal immune 
surveillance and the induction of peripheral tolerance (Huang et al., 2000; Johnson and 
Jackson, 2014). Following infection or inflammation, the number of migrating DCs 
rapidly increases as a result of their inflammation-induced maturation that promotes 
increased DC motility and responsiveness to LN chemoattractants. These maturation 
events result in the conversion of DCs from phagocytes to professional APCs (Steinman 
et al., 2003). There are a large number of factors that induce maturation of DCs, including 
components of microbial cell wall, such as bacterial lipopolysaccharides (LPS), and the 
classical inflammatory cytokines, such as IL-1β and TNF (Steinman et al., 2003). DC 
maturation results in several phenotypic changes that enhance antigen uptake and 
presentation by the MHCs, and expression of co-stimulatory molecules, such as CD83 
and CD86, for T cell activation. Mature DCs have also been shown to down-regulate their 
expression of pro-inflammatory chemokine receptors CCR1, CCR2, CCR5, and CXCR1, 
all of which are required for chemotaxis within peripheral tissues; they have also been 
shown to up-regulate chemokine receptors required for efficient migration from the skin 
to dLNs (Ardeshna et al., 2002; Foti et al., 1999) - detailed in the following sections. 
 CCL21/CCL19:CCR7 chemokine axis 
There has been compelling evidence showing that CCR7 is a key regulator of DC 
migration into the lymphatic system. Seminal studies involving the chemokine receptor, 
CCR7, and its major ligands, CCL21 and CCL19, have implicated the 
CCL21/CCL19:CCR7 chemokine axis in DC migration into the lymphatic system 
through the development of a unique mouse strain exhibiting genetic deficiency for CCR7 
(CCR7KO mice) (Forster et al., 1999). Currently, the accepted paradigm is that CCR7 
governs the two distinct migratory paths of DCs and T cells, which converge in the T cell 
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zones of secondary lymphoid organs (Sanchez-Sanchez et al., 2006). CCR7 plays a 
critical role in the homing and positioning of naïve T cells and DCs within secondary 
lymphoid organs, and the resulting effects on the immune response is demonstrated by 
the profoundly disrupted cellular architecture of the LNs in CCR7KO mice (Forster et al., 
1999; Schneider et al., 2007). As a consequence, CCR7KO mice have a reduced ability 
to mount primary immune responses (Forster et al., 1999). It has been shown that these 
mice lack contact sensitivity and delayed hypersensitivity responses, resulting in failure 
to mobilise epidermal DCs to dLNs as assessed by Fluorescein isothiocyanate (FITC) 
skin painting (technique to induce DC maturation and mobilisation) (Hill et al., 1990). 
However, recent evidence has emerged demonstrating that whilst CCR7 can be bypassed 
for the induction of immunity, its expression by T regulatory cells is required for their 
migration into LNs and contributes to their suppressive function in vivo (Schneider et al., 
2007). Schneider et al. used CHS reactions in CCR7KO mice to show that T cell-
mediated immunity to contact antigens develops in the absence of CCR7 (Schneider et 
al., 2007). Furthermore, they showed that these responses are exacerbated in CCR7KO 
mice as compared to WT BALB/c mice, and that these responses are ameliorated by the 
transfer of WT regulatory T cells. Thus, this suggests that T regulatory cells require CCR7 
for their in vivo suppressive activity. On the basis of this, CCR7 plays a role in balancing 
immunity and its regulation. The absence of this chemokine receptor in CCR7KO mice 
has also been shown to result in DC retention within the dermis and loss of their 
accumulation within dermal lymphatics, under both inflammatory and steady state 
conditions (Ohl et al., 2004). Other studies have used a naturally occurring mutant mouse 
strain, plt (paucity of lymph node T cells) mice, which exhibit defects in the production 
of CCL19 and CCL21Ser but retain the expression of CCL21Leu in peripheral lymphatics 
(Gunn et al., 1999; Vassileva et al., 1999). As the plt mutation disrupts the expression of 
CCL21 specifically in lymphoid tissue, it is logically assumed that CCL21Ser regulates 
homing within LNs and CCL21Leu regulates DC entry to afferent lymphatics (Nakano and 
Gunn, 2001). Consequently, DCs in plt mice are still able to migrate into dermal afferent 
lymphatics, but their infiltration into the dLNs is impaired (Gunn et al., 1999; Luther et 
al., 2000). The involvement of LECs in generating CCL21 for transmigration across the 
lymphatic endothelium was proposed from studies that visualised skin-derived DCs 
migrating into CCL21+ lymphatic vessels, where the use of anti-CCL21 Abs resulted in 
the inhibition of DC migration to the dLNs (Saeki et al., 1999). Other studies have since 
directly visualised CCL21 production in the lymphatic endothelium through the use of 
immunohistochemistry studies, in situ RNA hybridisation and confocal microscopy 
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(Johnson and Jackson, 2010; Martin-Fontecha et al., 2003). LECs constitutively express 
CCL21, but this expression has been demonstrated to increase in response to the pro-
inflammatory cytokines, TNF and IL-1α, which promote DC migration into the lymphatic 
system in vivo (Johnson and Jackson, 2010; Martin-Fontecha et al., 2003). This suggests 
that increased availability of CCL21 could contribute to the enhancement of DC 
migration into the lymphatic system, which is typically found during inflammation in vivo 
(Martin-Fontecha et al., 2003; Vigl et al., 2011). Several additional studies using in vitro 
cultured primary dermal LECs since confirmed the production of CCL21, but not CCL19, 
by the lymphatic endothelium (Johnson and Jackson, 2010; Kriehuber et al., 2001; Wick 
et al., 2007). More recently, extracellular staining of CCL21 showed that a gradient of 
CCL21 forms around dermal lymphatic vessels, whereby the chemokine is immobilised 
in the interstitium on heparan sulfates (HS); CCL19 was also found to be dispensable 
during DC migration into afferent lymphatic vessels (Britschgi et al., 2010; Weber et al., 
2013). Taken together, these results suggests that the CCL21:CCR7 chemokine axis 
appears to be indispensable during DC migration across the lymphatic endothelium. 
The CCL21/CCL19:CCR7 chemokine axis has also been shown to be key for the 
regulation of T cell trafficking into the lymphatic system. The sole function of CCR7 was 
previously thought to be in stimulating motility of naïve and central memory T cells, 
which recirculate between the blood and LNs (via HEVs) (Worbs et al., 2007). However, 
CCR7 has been shown to be expressed by a subset of T cells found within the interstitium 
that resemble central memory T cells, but are able to further exit peripheral tissues 
through afferent lymphatic vessels (Bromley et al., 2005; Debes et al., 2005). Effector 
memory T cells are negative for CCR7 and instead express receptors (e.g. CCR1, CCR3, 
CCR5) for inflammatory cytokines used for migration to inflamed tissues to display 
immediate effector function (Sallusto et al., 1999). Thus CCR7 seems to be important in 
regulating central memory T cells to LNs via both the blood and lymphatic routes.  
 CXCL12:CXCR4 chemokine axis 
Genetic deletion of neither CCR7 (CCR7KO mice) nor its ligands, CCL19 and CCL21 
(plt mice), results in full impairment of DC migration to LNs, suggesting that the process 
is far more complex and that additional chemokine:chemokine receptor axes are likely to 
be involved. The chemokine, CXCL12, is a potential candidate as it has been 
demonstrated to be expressed by murine dermal lymphatics and its receptor, CXCR4, has 
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been shown to be expressed by dermal DCs both in vivo and in vitro (Kabashima et al., 
2007; Vigl et al., 2011). During tissue inflammation, LECs up-regulate the expression of 
CXCL12, which was demonstrated to enhance the migration of CXCR4-expressing 
dermal DCs to dLNs (Kabashima et al., 2007; Vigl et al., 2011). Moreover, 
pharmacological blockade with the CXCR4 antagonist, 4F-benzoyl-TN14003, resulted in 
a 50% reduction of the migration of skin DCs into LNs during the sensitisation phase of 
contact hypersensitivity (CHS) in mice (Kabashima et al., 2007). Interestingly, the 
chemotactic effects of CXCL12 and CCL21 were reported to be non-additive (Kabashima 
et al., 2007), suggesting that these chemokine:chemokine receptor pairs may either have 
sequential modes of action or may function independently of one another.  
 CX3CL1:CX3CR1 chemokine axis 
In addition to the CCL21:CCR7 and CXCL12:CXCR4 chemokine axes, one other 
chemokine axis, CX3CL1:CX3CR1, was recently discovered to play a role in DC 
migration into the lymphatic system (Johnson and Jackson, 2013). Membrane-bound 
CX3CL1 found on activated ECs promote strong adhesion of those leukocytes thus aiding 
in their transmigration across the blood vascular endothelium (Bazan et al., 1997). The 
soluble isoform of CX3CL1 has been shown to have strong chemoattractant activity for 
monocytes, NK cells and T cells (Bazan et al., 1997). In the case of lymphatics, CX3CL1 
was found to promote basolateral-to-luminal migration of DCs across monolayers of 
human dermal lymphatic endothelial cells (HDLECs) in vitro (Johnson and Jackson, 
2013). Furthermore, neutralisation of CX3CL1 in mice resulted in reduced allergen-
induced trafficking of dermal DCs to dLNs as assessed by FITC skin painting. Finally, 
mice with DCs lacking CX3CR1 exhibited significant delays in cell trafficking into 
lymphatics in vivo and impaired DC migration across LECs in vitro. Collectively, these 
results have established a previously unrecognised role of the CX3CL1:CX3CR1 
chemokine axis in regulating DC trafficking into the lymphatic system. 
 Other chemokines and chemokine receptors involved in leukocyte 
trafficking into the lymphatic system 
Besides CCL21, CXCL12 and CX3CL1, a number of lymphocyte, and neutrophil 
chemokines, such as CCL1, CCL2, CCL5, CCL20, CXCL2, CXCL5, CXCL9, CXCL10, 
CXCL13, and XCL1 may potentially regulate the migration of DCs or other leukocytes 
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into the lymphatic system (Johnson and Jackson, 2010; Mancardi et al., 2003). This is on 
the basis of their transcriptional upregulation in primary HDLECs in response to TNF or 
their expression in LECs derived from adjuvant-induced murine lymphangiomas 
(Johnson and Jackson, 2010; Mancardi et al., 2003). Monocyte-derived DCs have been 
shown to use CCR8, the chemokine receptor for CCL1, in addition to CCR7, during 
migration from the peripheral tissues to dLNs (Qu et al., 2004).  
Lastly, the atypical chemokine-scavenging receptor D6, which binds to inflammatory CC 
(β) chemokines but not homeostatic chemokines, such as CCL21, has been shown to be 
expressed by the lymphatic endothelium in various different tissues (McKimmie et al., 
2013; Nibbs et al., 2001). Unlike the other chemokine receptors described in the previous 
sections, D6 does not signal via G-proteins or chemotaxis following ligand binding. 
Instead, it acts as an endocytic receptor that efficiently internalises and degrades 
inflammatory chemokines during the resolution of inflammation (Fra et al., 2003; Weber 
et al., 2004). D6 ensures that the only chemokines presented on the lymphatic 
endothelium are those for CCR7, which could contribute to the selective presentation of 
CCR7 ligands, such as CCL21, on afferent lymphatic vessels during inflammation 
(McKimmie et al., 2013). Mice genetically deficient in D6 have been shown to display 
impairments in their ability to initiate adaptive immune responses; this is associated with 
aberrant leukocyte adhesion to afferent lymphatic vessels and accumulation of 
inflammatory leukocytes within dLNs (Lee et al., 2011). A summary of the 
chemokine:chemokine receptors involved in leukocyte trafficking via afferent lymphatics 
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 Other chemoattractants/molecules involved in leukocyte trafficking 
into the lymphatic system – S1P and Galectins 
Sphingosine 1-phosphate (S1P) is indispensable for T cell egress from LNs into efferent 
lymphatics, and has also been implicated in the regulation of T cell entry into afferent 
lymphatics, where increased levels of S1P in inflamed tissue potentially resulted in T cell 
retention within peripheral tissues and inhibition of T cell entry into lymphatic vessels 
(Cyster and Schwab, 2012; Ledgerwood et al., 2008). Thus, whilst the CCL21:CCR7 
chemokine axis (discussed previously in section 1.5.2.1) promotes constitutive T cell 
migration into afferent lymphatic vessels, S1P acts as an antagonist during immunisation 
challenge to retain T cells within inflamed tissues until the inflammation resolves. 
A role for galectins in leukocyte migration across the lymphatic endothelium has also 
been reported in two fairly recent studies (Fulcher et al., 2009; Hsu et al., 2009). Galectins 
are a family of carbohydrate-binding proteins (lectins) that are expressed by both vascular 
and lymphatic ECs, and have been shown to regulate immune cell migration during 
inflammation (Fulcher et al., 2009; Hsu et al., 2009; Rabinovich et al., 2007; Thijssen et 
al., 2008). Fifteen galectins have been identified to date and they share the carbohydrate 
recognition domain (CRD) responsible for β-galactoside binding, such as N-
acetyllactosamine (Barondes et al., 1994). In particular, galectin-1 and galectin-3 have 
been demonstrated to be involved in the exit of tissue-resident DCs into the afferent 
lymphatics and thus their subsequent migration to the dLNs (Fulcher et al., 2009; Hsu et 
al., 2009). Galectin-1 has been shown to activate monocyte-derived DCs and specifically 
increase the expression of genes related to DC cell motility and migration within the ECM 
(Fulcher et al., 2006). Mice with defects in skin-derived DCs to dLNs were found to 
exhibit an increase in migration to dLNs in vivo following intradermal injection of 
galectin-1 (Fulcher et al., 2009). Galectin-3 has been shown to be expressed on DCs and 
macrophages during their activation and maturation (Liu, 2005). It is involved in a 
number of different intracellular and extracellular functions, including regulation of cell 
apoptosis, cell activation, as well as cell aggregation and adhesion to the substratum 
within the ECM (Hughes, 2001; Liu, 2005; Nakahara et al., 2005). Experiments using 
galectin-3 KO mice have demonstrated that galectin-3-deficient DCs exhibit signalling 
defects in response to chemokines in vitro and impaired cell migration to dLNs via 
lymphatic vessels in vivo (Hsu et al., 2009). These results collectively suggest that 




 Leukocyte-endothelial cell adhesion molecules (CAMs) involved 
in leukocyte adhesion to and transmigration across lymphatic 
endothelium  
Since the exit of DCs from peripheral tissues into lymphatic vessels involves basolateral 
to luminal migration, some studies have tried to mimic this process by growing LECs on 
the bottom of transwell inserts before the addition of exogenous DCs to investigate their 
migration responses (Johnson et al., 2006; Johnson and Jackson, 2010; Miteva et al., 
2010). It is worth mentioning that a potential limitation of these in vitro experiments is 
the fact that LECs grown in monolayers form continuous zipper-like junctions (Dunworth 
et al., 2008; Kriehuber et al., 2001), resembling the architecture of collecting lymphatic 
vessels rather than the button-like junctions found on initial lymphatic vessels, which are 
thought to be the site of leukocyte entry. Despite this, in vitro transmigration assays have 
provided evidence that the same adhesion molecules that mediate leukocyte migration 
across the blood vascular endothelium, also mediate key events in this process. Some of 
the key adhesion molecules expressed by LECs that are also involved in in vitro DC 
migration across the lymphatic endothelium as demonstrated with the use of blocking 
mAbs include PECAM-1 (Torzicky, 2012), CD99 (Torzicky, 2012), VCAM-1 (Johnson 
et al., 2006), ICAM-1 (Johnson et al., 2006), L1CAM (Maddaluno et al., 2009), CD137 
(Teijeira et al., 2012) (Table 1.4). Most of these adhesion molecules were also confirmed 
to affect DC migration in vivo (Johnson et al., 2006; Maddaluno et al., 2009). Notably, 
transmural lymph flow was shown to augment DC transmigration, likely through 
inducing the upregulation of CCL21 and ICAM-1 expression by LECs (Miteva et al., 
2010).  
In particular, the LEC-expressed adhesion molecule that has been identified as being 
fundamental in the process of DC migration is ICAM-1. FITC skin painting and adoptive 
transfer experiments have shown that in ICAM-1 KO mice, DC migration from skin to 
dLNs was significantly reduced, demonstrating a critical role for ICAM-1 in this process 
(Sligh et al., 1993; Xu et al., 2001). It has also been reported that ICAM-1 and ICAM-2, 
but not VCAM-1 are expressed at low levels in murine dermal LECs (Johnson et al., 
2006). However, both ICAM-1 and VCAM-1 were massively upregulated (40- to 80-fold 
increase) on LECs in response to TNF-induced inflammation, which is similar to 














FITC painting in the 
presence of blocking Abs 
or in ICAM-1 KO mice, 
BMDC adoptive transfer in 
the presence of blocking 
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ears after DC injection, in 
vitro transwell assays 
In inflammatory and high 
flow conditions. blockade 
of ICAM-1 and blockade 
of β2 integrins inhibit 
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In vitro transwell assays, ex 
vivo human skin culture in 
the presence of blocking 
Ab, immunofluorescence, 
and DC count inside LVs 
Impaired trans-
endothelial migration and 
intravasation in human 
skin explants, evidence 




FITC painting assays in 
mice deficient in L1CAM 
under Tie 2 promoter, 
transwell, and adhesion 
assays 
Impaired adhesion, 
transmigration in human 
and mice (BMDC), 
impaired migration to 
LN. 
(Maddalu
no et al., 
2009) 
CD99 PILR 
In vitro transwell assays, ex 
vivo human skin culture in 
the presence of blocking 
Ab, immunofluorescence, 
and DC count inside LVs 
Impaired trans-
endothelial migration and 
intravasation in human 
skin explants, evidence 




CD137 cross-linking with 
agonistic or natural ligand 
(CD137L), in vitro 
transwell assays, ex vivo 
human explants treated 
with CD137 blocking Ab 
Cross-linking with 
agonistic mAb or 
CD137L leads to increase 
in CCL21 production and 
enhanced CCR7-
dependent migration 
across LECs in vitro. 
Blocking Ab induces 
CCL21 expression and 
DC accumulation close to 





CHS response and FITC 
painting in JAM-A KO 
mice and adoptive transfer 
of JAM-A deficient BM 
DCs, in vitro transwell 
assays 
JAM-A deficiency 
increases DC migration 
to LN and CHS responses 





Table 1.4: Adhesion molecules involved in leukocyte trafficking through lymphatic vessels.   
75 
 
Additionally, monoclonal blocking antibodies (mAbs) for ICAM-1 and VCAM-1, which 
blocked their binding to their corresponding integrin ligands, LFA-1/MAC-1 (αLβ2) and 
VLA-4 (α4β1), respectively, were found to inhibit adhesion of DCs to TNF-stimulated 
LECs, as well as block DC transmigration across the cultured lymphatic endothelium 
(Johnson et al., 2006). These molecules were also shown to be involved in DC migration 
to dLNs in vivo (Johnson et al., 2006). In support of this, blockade of DC-expressed LFA-
1 has been shown to reduce DC migration to dLNs from inflamed skin in vivo (Teijeira 
et al., 2013). Thus, ICAM-1 and VCAM-1 mediate leukocyte adhesion steps that are 
required for inflammation-induced DC transmigration, similar to the adhesion molecule-
mediated firm adhesion that occurs before leukocyte transmigration across the vascular 
endothelium in the leukocyte adhesion cascade (Ley et al., 2007). Interestingly, DCs have 
been found to express JAM-A, a junctional molecule also expressed on the blood and 
lymphatic vascular endothelium (Cera et al., 2004; Del Maschio et al., 1999). The use of 
JAM-A KO mice along with adoptive transfer experiments showed that whilst JAM-A-
deficient DCs exhibited enhanced migration across the lymphatic endothelium both in 
vivo and in vitro in FITC painting and transwell experiments; this was not observed in 
JAM-A-deficient LECs (Cera et al., 2004). An accumulation of DCs within dLNs was 
also found in mice with JAM-A deficient DCs but not with JAM-A-deficient LECs (Cera 
et al., 2004). Despite this, the mechanism involved in LEC-independent promotion of DC 
trafficking to lymph nodes in JAM-A KO mice remains to be fully elucidated. 
Collectively, the results show that DC-expressed JAM-A, CX3CR1, CCR7, MAC-1 and 
LFA-1, along with LEC-expressed D6, CX3CL1, CCL21, ICAM-1 and VCAM-1, are 
involved in the mechanisms of DC entry into lymphatic vessels (Figure 1.10), and are 






Figure 1.10: Key molecules involved in DC adhesion and transmigration across the lymphatic 
endothelium. At resting state, the lymphatic endothelium constitutively expresses the adhesion 
molecules ICAM-1 and ICAM-2, the ACKR D6, and the lymphatic chemokine CCL21 – all of 
which play important roles in DC migration across the lymphatic endothelium. The presence of 
pro-inflammatory cytokines results in the upregulation of ICAM-1, ICAM-2 and VCAM-1 on the 
lymphatic endothelium. DCs express LFA-1/MAC-1 and VLA-4, which are corresponding 
integrin ligands to ICAM-1 and ICAM-2, and VCAM-1, respectively. The binding of these 
integrins with their corresponding receptors is important in DC migration across the lymphatic 
endothelium during inflammation. Additionally, the expression of the chemokines CCL21 and 
CX3CL1 are also upregulated by the activated lymphatic endothelium. The corresponding 
chemokine receptors CCR7 and CX3CR1 are expressed by DCs and their binding to CCL21 and 
CX3CL1, respectively, is required for DC migration across the activated lymphatic endothelium. 
Furthermore, LEC-expressed D6 scavanges pro-inflammatory chemokines within the tissue, and 
it is likely that this process plays a role in the trafficking of DCs across the activated lymphatic 
endothelium. Finally, inflammatory and DC-expressed JAM A are required for DC migration 
across the activated lymphatic endothelium although the mechanisms behind this process remains 
to be elucidated. 
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 Molecules involved in intraluminal crawling of leukocytes within 
initial lymphatic vessels 
The crawling of DC and other leukocytes within the lumen of lymphatic vessels towards 
dLNs, following their transmigration across the lymphatic endothelium, has generally 
been thought of as a passive transport process owing to lymph flow (Alvarez et al., 2008; 
Randolph et al., 2005). This hypothesis was supported by intravital microscopy (IVM) 
experiments observing collecting lymphatic vessels within the rat mesentery, where free 
flowing lymphocytes were shown to rapidly disseminate in a pulsatile fashion (Dixon et 
al., 2005; Galanzha et al., 2005). Interestingly, the peak velocities of lymph flow within 
collecting vessels were found to be comparable to blood flow velocities, whereas lymph 
flow velocities within initial vessels were found to be much lower in comparison (Akl et 
al., 2011; Dixon et al., 2006; Dixon et al., 2005). Thus, doubts were raised with regards 
as to whether the hydrodynamic forces found within initial lymphatic vessels are adequate 
to support the passive transport of flowing leukocytes. Indeed, other IVM experiments 
have since shown that most DCs actively migrate within initial lymphatics and appear to 
only be passively transported by lymph once reaching collecting vessels (Figure 1.11) 
(Nitschke et al., 2012; Sen et al., 2010; Tal et al., 2011).  
 
Figure 1.11: DC crawling and transport within lymphatic vessels. (1) Initial lymphatics 
exhibit adjacent oakleaf-shaped LECs, which partially overlap, thus creating open flaps (red 
dotted lines) where DCs are thought to migrate through. (2) DC crawling occurs within initial 
lymphatics. (3) DCs are transported by flow of lymph once reaching collecting lymphatics, 
eventually reaching dLNs where they present antigens to B and T cells. DCs are not found within 
efferent lymph and therefore must accumulate and die in the lymph node. FAS/FAS-ligand 
mediated DC apoptosis is a likely mechanism which has been shown in rodent and human DCs 




The first candidate signalling molecule identified as being involved in intralymphatic DC 
migration was the Rho-associated protein kinase (ROCK) (Nitschke et al., 2012). This 
molecule is required for actomyosin-mediated cellular contraction when leukocytes 
migrate through narrow pores, such as through the interstitial space or across the vascular 
endothelium (Nourshargh et al., 2010; Vicente-Manzanares et al., 2009). Additionally, 
ROCK was shown to aid leukocyte migration by mediating cellular de-adhesion of 
leukocyte-expressed integrins, LFA-1 and MAC-1, at the cellular rear from the 
endothelial-expressed integrin ligand, ICAM-1, during their crawling on vascular ECs 
(Smith et al., 2003; Vicente-Manzanares et al., 2009). It has been reported that 
pharmacological blockade of ROCK had little to no effect on reducing intralymphatic 
crawling at steady state. However, following CHS-induced inflammation, blockade of 
ROCK resulted in a considerable reduction in the velocity of DC crawling within 
lymphatic capillaries; this is likely due to ROCK inhibiting de-adhesion from 
inflammation-induced expression of ICAM-1 (Nitschke et al., 2012). To date, no other 
molecules have been shown to be involved in intralymphatic DC crawling. However, it 
is highly possible that molecules previously shown to be critical for DC migration across 
the lymphatic endothelium could also support DC crawling within initial lymphatics, thus 
further experiments will have to be carried out to provide evidence for this.  
 Identified mechanisms of neutrophil migration into the 
lymphatic system 
Two possible routes of neutrophil entry into dLNs exist – via specialised blood vessels 
known as high endothelial venules (HEVs) or via afferent lymphatics. 
 Neutrophil migration via HEVs 
The first route involves neutrophils exiting the circulation via high HEVs; this however 
remains controversial, as human neutrophils apart from those that have infiltrated tumours 
seem to lack surface expression of CCR7 (Beauvillain et al., 2011; Eruslanov et al., 2014), 
a receptor for the chemokine, CCL21, which is required for lymphocyte migration across 
HEVs (Forster et al., 2008). Nevertheless, in mice, a sub-population of neutrophils have 
been found to express CCR7 on the cell surface following stimulation, suggesting the 
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existence of a preformed stock that can be rapidly mobilised at the cell membrane in 
response to an inflammatory stimulus (Beauvillain et al., 2011). It has also been shown 
in a murine model of Complete Freund’s Adjuvant (CFA) and ovalbumin (OVA)-induced 
inflammation that neutrophil homing to dLNs via HEVs occurs and requires the 
neutrophil-expressed β2 integrins, MAC-1 and LFA-1, and chemokine receptor, CXCR4, 
as well as the EC-expressed adhesion molecules, L- and P-selectin (refer back to Figure 
1.4) (Gorlino et al., 2014). CFA is able to stimulate responses associated with adaptive 
immunity, and consists of a mixture of paraffin oil and surfactant with heat-killed 
Mycobacterium tuberculosis in which an aqueous antigen solution is emulsified (Coffman 
et al., 2010).  
The CXCR4 ligand, CXCL12, has also been shown to be expressed by cells in the medulla 
of LNs (Hargreaves et al., 2001); therefore, it is possible that this chemokine plays a role 
in neutrophil homing to these tissues. Additional chemokines and cytokines secreted by 
activated tissue-resident macrophages are likely to play roles in orchestrating the 
attraction of neutrophils into dLNs via HEVs; this has been shown to be the case in 
tumour-dLNs, where tumours subjected to photodynamic therapy to induce additional 
sterile inflammation, led to neutrophil recruitment to tumour-dLNs via HEVs in an IL 17-
dependent manner (Brackett et al., 2013). Similarly, macrophage-derived IL-1β and TNF 
were found to be required for neutrophil entry into dLNs following injections of bacteria 
and viruses (Kastenmuller et al., 2012; Sagoo et al., 2016). Collectively, this suggests that 
at least some of the molecules responsible for neutrophil homing to inflamed tissues also 
play roles in regulating neutrophil recruitment to LNs. 
 Migration via afferent lymphatics 
The second route of neutrophil migration to LNs involves their migration (a.k.a 
intravasation) into afferent lymphatics, presumably via initial lymphatics, where they are 
eventually carried to dLNs. Neutrophil migration into the lymphatic system and their 
influence on the orchestration of the adaptive immune response was discussed in section 
1.1.3.2. Here, presently known potential mechanisms of neutrophil migration across the 
lymphatic endothelium, an essential part of their journey towards the dLNs where 
adaptive immune responses are initiated are discussed. 
In steady state, DCs constitutively migrate to dLNs via afferent lymphatic vessels. 
Neutrophils, however, have only been observed to migrate via afferent lymphatics in the 
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context of acute inflammation or infection (Abadie et al., 2005; Beauvillain et al., 2011; 
Chtanova et al., 2008; Hampton et al., 2015). Following CFA+Ag-induced inflammation, 
OVA+ neutrophils were found to not only appear at the injection site, but they also 
represented the main OVA+ cells present within dLNs (Gorlino et al., 2014). These 
OVA+ neutrophils were found to localise in the subcapsular sinuses of dLNs, thus 
indicating that these neutrophils had reached the LNs via afferent lymphatics (Gorlino et 
al., 2014).  It has been reported only neutrophils primed with certain cytokines (i.e. GM-
CSF and IL-17), or microbial moieties (LPS) can migrate toward lymphatic chemokines 
(i.e. CCL19 and CCL21) in vitro (Beauvillain et al., 2011). Furthermore, activation of 
cultured LEC monolayers with inflammatory cytokines lead to the up-regulation of 
ICAM-1 and VCAM-1, as well as chemokines that are compulsory for an efficient 
migration of the neutrophils across these cell monolayers in vitro (Aebischer et al., 2014). 
Indeed, blockade of ICAM-1, VCAM-1 and their integrin-binding partners (β2 or α4 
integrins) resulted in reduced neutrophil migration across the lymphatic endothelium 
(Rigby et al., 2015). The involvement of the neutrophil-expressed β2 integrin subunit, 
CD11b (MAC-1), and its LEC-expressed ligand, ICAM-1, in neutrophil migration to the 
dLNs was also confirmed in vivo (Rigby et al., 2015). Other studies have also provided 
evidence to support the involvement of CD11b as blocking of this integrin subunit in vivo 
resulted in a reduction in the numbers of neutrophils infiltrating dLNs (Gorlino et al., 
2014; Hampton et al., 2015). However, the ligand or combination of ligands required for 
CD11b-dependent migration of neutrophils from inflamed tissues into LNs is still not 
known as CD11b has well over 40 known ligands (Podolnikova et al., 2015). 
DC migration via the afferent lymphatics route requires the chemokine receptors, CCR7 
and/or CXCR4 (Kabashima et al., 2007; Ohl et al., 2004). However, the role of CCR7 
during migration of neutrophils into the LNs is highly controversial. CCR7 was shown to 
be required for LN recruitment of neutrophils in response to adjuvant challenge 
(Beauvillain et al., 2011), but this was proved to not be the case following S. aureus 
challenge (Hampton et al., 2015). Thus, CCR7 seems to be dispensable for some modes 
of neutrophil recruitment to LNs. This could possibly be due to the theory that different 
waves of neutrophil recruitment are governed by diverse mechanisms since the 
downstream Gαi signalling of many chemokine receptors is not required for neutrophil 
migration into dLNs immediately after immunisation, but yet is essential for neutrophil 
recruitment into dLNs after 72 h (Yang and Unanue, 2013). On the other hand, the 
CXCL12:CXCR4 chemokine axis, as well as S1P have recently been implicated in 
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neutrophil migration across the lymphatic endothelium in vivo (Figure 1.12) (Gorlino et 
al., 2014; Hampton et al., 2015). In the context of infection-induced inflammation with 
S. aureus, neutrophils within the dLNs were found to express elevated levels of the 
chemokine CXCR4 (Hampton et al., 2015). Consequently, CXCR4 blockade with 
CXCR4-specific inhibitor, AMD3100, resulted in a significant reduction in the number 
of neutrophils found within dLNs (Gorlino et al., 2014; Hampton et al., 2015). More 
recently, LEC-expressed CXCL8, a ligand of the chemokine receptors CXCR1 and 
CXCR2, was found to be one of the main chemoattractants in driving human neutrophil 
transmigration across a cultured lymphatic endothelium in vitro. It is unclear if this 
response is valid in vivo too and the role of murine CXCL8 analogous proteins need to be 
tested (Table 1.1). However, in vivo neutralisation of CXCR2 demonstrated that this 
chemokine receptor is not required for neutrophil migration into the lymphatic system 
(Hampton et al., 2015).  
 
Figure 1.12: Chemokine:chemokine receptor axes potentially involved in neutrophil 
transmigration across lymphatic endothelium in vivo. Following inflammation, (A) 
chemotaxis of neutrophils towards inflamed LECs secreting CCL21 and CXCL12 is triggered, 
leading to CCL21:CCR7 and CXCL12:CXCR4 interactions. (B) Neutrophil migration across the 
inflamed endothelium occurs as a result of these chemokine:chemokine receptor interactions. S1P 
and S1PR interactions are also potentially important in this process. Neutrophils are depicted in 
purple; LECs in red/pink. 
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It is clear that DCs and neutrophils have differential requirements for chemokines and 
integrins during migration into the lymphatic system (Gorlino et al., 2014; Hampton et 
al., 2015). DC migration is highly CCR7-dependent and only becomes integrin-dependent 
following inflammation; DCs are also able to migrate to dLNs in a completely integrin-
independent manner, which could explain why DCs are capable of constitutively 
migrating across the lymphatic endothelium at resting state despite low levels of integrin 
ligands being present (Teijeira et al., 2014). It has recently been reported that upon 
CXCL8-dependent chemotaxis and integrin-mediated adhesion to LECs in vitro, 
neutrophils are able to induce the enzymatic degradation of LEC junctions, as well as 
LEC retraction, thereby creating large portals that enable rapid migration of neutrophils 
across the lymphatic endothelium (Figure 1.13) (Rigby et al., 2015). Strikingly, 
neutrophil migration across the lymphatic endothelium in vitro resulted in an increase in 
LEC monolayer permeability, as subsequent applications of neutrophils resulted in a 
much more accelerated rate of migration across the LECs, thus implying that these 
preformed gaps had served as hotspots for successive neutrophils (Rigby et al., 2015). 
The induction of retraction of LEC-LEC junctions and gap formation by neutrophils was 
shown to be associated with their secretion of MMP8 and MMP9, as well as lipoxygenase 
products, in particular, the arachidonic acid-derived chemorepellent, 12(S)-HETE 





Figure 1.13: Proposed model of neutrophil transmigration across lymphatic endothelium in 
vitro. (A) Neutrophil chemotaxis towards inflamed LECs secreting CXCL8 leads to binding of 
CXCR1/2 to the chemokine. (B) β2 integrin-mediated neutrophil adhesion to LECs and focal 
secretion of MMP8, 9 and 12(S)-HETE. (C) Proteolytic activity of MMPs and LEC retraction 
leads to disruption of LEC-LEC junctions, which is mediated by 12(S)-HETE-induced 
chemorepulsion. (D) Resulting gap in lymphatic endothelium acts as a hotspot for apical to 
basolateral neutrophil transmigration.  
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This is in contrast to neutrophil migration across the blood vascular endothelium during 
the inflammatory response, where EC junctions reportedly remain intact in vitro (Burns 
et al., 2000). Additionally, DC migration across the lymphatic endothelium has also been 
shown to not harm the integrity of LEC monolayers in vitro (Rigby et al., 2015). In vivo 
studies have shown that the perilymphatic basement membrane of initial lymphatic 
vessels is discontinuous, thus the presence of preformed portals facilitates the entry of 
DCs into these vessels (Pflicke and Sixt, 2009). All of these results suggest that this 
neutrophil-specific mechanism of generating openings within the lymphatic endothelium 
might be an explanation as to why neutrophils have the capacity to cross LEC barriers so 
rapidly. However, as these experiments were primarily done in vitro, more studies have 
to be carried out to validate these results in vivo. This is especially important since initial 
lymphatics are organised in a highly specialised manner, with button-like junctions 
present that are considered to be the main site of leukocyte entry into lymphatic vessels 
(discussed in section 1.3.1). These junctions are not present in vitro, which makes it 
difficult to assess whether this unique neutrophil migration process is indeed what occurs 
at the level of the lymphatic endothelium in vivo.  
It is worth mentioning that the handful of studies that investigated the mechanisms of 
neutrophil migration in vivo made use of very different inflammatory models, ranging 
from inflammation induced by injection of inactivated pathogens, pathogenic 
constituents, parasites, to live bacilli (Abadie et al., 2005; Chtanova et al., 2008; Gorlino 
et al., 2014; Hampton et al., 2015; Rigby et al., 2015). Therefore, it is possible that the 
molecular mechanisms involved may vary depending on the type of inflammatory stimuli 
or infectious challenge used; this is supported by a plethora of studies showing that the 




 Aims of this study 
Recently, neutrophils have also been found to play a role in regulating the adaptive 
immunity in vitro following their rapid migration to LNs (Abi Abdallah et al., 2011). 
Several studies have indeed shown their early presence in LNs of infected or immunised 
animals in vivo (Abadie et al., 2005; Gorlino et al., 2014; Hampton et al., 2015). However, 
their unique recruitment into the lymphatic structures has not been extensively studied so 
far, but evidence suggests their arrival into LNs from afferent lymphatics like DCs 
(Beauvillain et al., 2011; Gorlino et al., 2014; Maletto et al., 2006). Thus, it was 
hypothesised that neutrophils gain entry into lymphatic vessels to shape adaptive immune 
responses. The overall aim of this study was to investigate some of these regulatory 
mechanisms in vivo using a murine model of antigen challenge in the cremaster muscle 
by addressing the following key objectives: 
 Investigate the dynamics of neutrophil migration from the blood 
circulation into the lymphatic system during inflammation and 
the potential role of TNF in driving these responses in vivo 
To elucidate the mechanisms of neutrophil migration into lymphatic vessels, a model of 
antigen sensitisation of the mouse cremaster muscles will be established. Experiments 
will include: 
 Characterising neutrophil migration responses across blood vasculatures and into 
lymphatic vasculatures following TNF and CFA+Ag-induced inflammation at 
different time periods in vivo.  
 The use of mice genetically deficient in both TNF receptors (TNFRI and II) to 
investigate the importance of TNF signalling in mediating neutrophil migration 
into lymphatic vessels. 
 The use of chimeric mice to elucidate if TNF-induced migration is due to a direct 





 Investigate potential chemokines and receptors involved in 
neutrophil migration into initial lymphatics in vivo 
The potential involvement of several chemokine:chemokine receptor axes, namely, 
CXCL1:CXCR1/2, CXCL12:CXCR4, and CCL21:CCR7, will be investigated following 
TNF- or CFA+Ag-induced inflammation in vivo. Experiments will include: 
 The use of blocking mAbs to CXCL1, a specific inhibitor of CXCR4, or mice 
genetically deficient in CCR7, followed by immunostaining and confocal 
microscopy analysis. 
 Examine the regulation and distribution of the LEC glycocalyx 
and chemokines during inflammation in vivo 
As the modulation of the BEC glycocalyx plays a role in neutrophil extravasation across 
the blood vessel wall, the regulation and redistribution of components of the LEC 
glycocalyx from cremaster lymphatic vessels upon inflammation will be investigated. 
Experiments will include: 
 Analysing changes in sugar residues on lymphatic vessels using lectin-binding 
 Analysing changes in HS and CCL21 (prototypical LEC chemokine) expression 
using fluorescent staining and confocal microscopy analysis.  
 Analyse interactions between neutrophils and the lymphatic 
endothelium post-migration into the vessels in vivo 
The interactions – and associated mechanisms- between neutrophils and the lymphatic 
endothelium following their entry into lymphatic vessels will be further investigated. 
Experiments will include: 
 The use of confocal IVM to visualise and quantify the intraluminal crawling of 
neutrophils in inflamed cremaster muscles of LysM-eGPF animals. 
 The use of blocking mAbs to study the role of TNF and adhesion molecules in 




 : Materials and methods 
 Animals 
All animal studies were performed according to the guidelines of the United Kingdom 
Home Office Animals (Scientific Procedures) Act (1986). 
 Strains 
All animals used weighed an average of 28 g and were between 8-12 weeks old. Where 





Male wild-type (WT) between the ages of 8-12 weeks were 
routinely used and purchased from Charles River Laboratories 
(Margate, UK).  
CCR7 knockout (CCR7KO) mice  
 These are mutant mice lacking the gene for the chemokine 
receptor CCR7, Ccr7tm1Rfor (Forster et al., 1999). They were 
generated by the insertion of a neomycin resistance cassette with 
a targeting vector designed to replace a fragment of the third 
exon of the targeted gene. Homozygous mice are viable and 
fertile and show delayed primary B or T cell immune responses. 
These mice are backcrossed 8 generations on a WT C57BL/6 
background and breeders were purchased from The Jackson 





CCR7KO LysM-eGFP mice 
 These are mutant mice lacking the gene for the chemokine 
receptor CCR7, Ccr7tm1Rfor, as well as expressing eGFP-labelled 
myelomonocytic cells with especially high fluorescence 
intensity in mature neutrophil granulocytes. CCR7KO mice were 
crossed with LysM-eGFP mice (Faust et al., 2000) to generate 
CCR7KO mice expressing Lysozyme M promoter-driven 
expression of enhanced green fluorescent protein in 
myelomonocytic cells 
LysM-eGFP mice These mice exhibit eGFP-labelled myelomonocytic cells and 
especially high fluorescence intensity is observed in mature 
neutrophil granulocytes. This mouse strain was generated as 
described by Faust et al. in 2000 and contains the mutated murine 
lysozyme M (lys) locus into which the coding sequence for eGFP 
(enhanced Green Fluorescent Protein) has been inserted (Faust 
et al., 2000). Homozygous mice are viable and fertile and show 
normal development. This strain was generated in a C57BL/6 
background and was obtained as a gift from Prof. Markus 
Sperandio (Walter Brendel Centre of Experimental Medicine, 
Ludwig-Maximillians-Universität, Munich, Germany). 
Heterozygous mice were used in all experiments. 
Tumour necrosis factor receptor double knockout (TNFRdbKO) mice 
 
These are double mutant mice lacking the genes for both TNF 
receptors, Tnfrsf1a (p55) and Tnfrsf1b (p75) (Peschon et al., 
1998). They were generated by intercrossing singly deficient 
mice whereupon the Tnfrsf1b mutation was transferred into the 
Tnfrsf1a background (C57BL/6). All mice are viable and fertile 




 Generation of chimeric mice 
To further investigate the mechanisms of neutrophil migration into lymphatic vessels in 
response to CFA+Ag-induced inflammation, chimeric mice were generated. Briefly, WT 
recipient mice were given acidified water (pH 2.6) for 1 week before bone marrow 
transfer. Bone marrow was isolated from the tibias of WT, TNFRdbKO and CCR7KO x 
LysM-eGFP mice under sterile conditions and suspended in sterile PBS at 5x106 cells/ml. 
WT recipient mice were irradiated with two doses of 5 Gy, 4 hours (h) apart using a 
RadSource-2000 irradiator. After the second irradiation, mice were given an intravenous 
(i.v.) injection of 1x106 bone marrow cells in 200 μl PBS. After irradiation and bone 
marrow transfer, animals were maintained in individually ventilated cages and given 
acidified (pH 2.6) water and Baytril for 4-6 weeks before use. 
Verification of chimera reconstitution by flow cytometry was carried out at the end of 
each experiment and is described further on in section 2.14. 
 
CCR7KO LysM-eGFP chimeric mice 
 These are C57BL/6 WT mice reconstituted with bone marrow 
from CCR7KO LysM-eGFP mice to generate WT mice with 
neutrophils lacking in the chemokine receptor CCR7. 
TNFRdbKO chimeric mice 
 These are C57BL/6 WT mice reconstituted with bone marrow 
from TNFRdbKO knockout mice to generate WT mice with 
neutrophils lacking in both TNF receptors, p55 and p75. 
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 Genotyping and phenotyping 
  Phenotyping of LysM-eGFP mice 
LysM-eGFP mice were phenotyped by fluorescence microscopy. For this purpose, mice 
were tail-bled before the whole blood was placed on glass slides for fluorescence 
microscopy to look for the presence of GFP positive leukocytes. Flow cytometry was also 
used to confirm GFP positive neutrophils were present. 
  Genotyping of TNFR double knockout mice 
TNFRdbKO mice were genotyped by polymerase chain reaction (PCR), which were 
performed by the laboratory manager, Dr Matthew Golding. 
  Genotyping of CCR7 knockout mice 
CCR7KO mice were genotyped by PCR. For this purpose, ear notch samples were taken, 
placed into a 1 ml eppendorf tube before digested in 500 μl lysis buffer containing 100 
μg/ml proteinase K overnight at 55 °C. The following day, tubes containing the digested 
samples were lightly vortexed and cooled to room temperature (RT) prior to DNA 
purification using isopropanol/ethanol precipitation. To precipitate the DNA, 500 μl 
isopropanol was added to each tube before they were inverted to mix. The mixtures were 
then centrifuged for 5 min at 20,000 g at RT and the resulting supernatents were 
discarded. The remaining pellets were washed with 1 ml of 70 % (v/v) ethanol before 
being centrifuged again for 5 min at 20,000 g at RT and the resulting supernatents 
discarded. All remaining traces of ethanol were carefully removed with a pipette and the 
pellets were air dried for approximately 10 min. The DNA was resuspended in 50 μl 
molecular biology grade water and stored at 4 °C or 20 °C for short- and long-term 






Detection of CCR7 (Ccr7tm1Rfor) knockout  
CCR7 knockout (CCR7KO) was detected using the protocol from Jackson Laboratory. 
Three primers were used to amplify both the WT and knockout allele at the same time 
(Table 2.1). PCR master mixes were prepared (Table 2.2), distributed into PCR tubes 
and 1 μl of purified DNA was added. Subsequently, DNA fragments were amplified in a 
PCR block (PTC-200 thermal cycler, MJ Research,) using the CCR7KO program (Table 
2.3). 
Primer Primer Sequence Melting 
temperature 
Primer type 
oIMR7074 5’-TAA GGG CAT CTT TGG 
CAT CT-3’ 
94 °C Common 
oIMR7075 5’-GCA TAC AAG AAA 
GGG TTG ACG-3’ 
50 °C WT reverse 
oIMR8162 5’-TGG ATG TGG AAT GTG 
TGC GAG-3’ 
72 °C Mutant reverse 










Primer 1: oIMR7074 100 mM 0.125 μl 0.5 uM 
Primer 2: oIMR7075 100 mM 0.125 μl 0.5 uM 
Primer 3: oIMR8162 100 mM 0.125 μl 0.5 uM 
dNTPs 10 mM 0.5 μl 0.2 mM 
MgCl2 50 mM 1 μl 2 mM 
NH4+ buffer 10 x 2.5 ul 1 x 
TAQ polymerase 5 U/μl 0.1 μl 0.05 U/μl 
DNA/RNA free water 







Total  25 μl  




Step Temperature and time No. of cycles 
Initial denaturation 94 for 2 min 1 





for 10 cycles 
Annealing 65 for 15 sec (-1.5 per cycle) 
68 for 10 sec 
Elongation of primer 1: 
oIMR7074 
94 for 15 sec  
Repeat 
elongation steps 
for 28 cycles 
Elongation of primer 2: 
oIMR7075 
50 for 15 sec 
Elongation of primer 3: 
oIMR8162 
72 for 10 sec 
Final elongation 72 for 2 min 1 
Table 2.3: PCR program for CCR7KO. 
 
Following amplification, 1 μl of 6 x agarose gel blue loading dye was added to 5 μl of 
each sample and 5 μl were run on a 2 % (w/v) agarose gel (in TAE buffer) with the 
addition of 0.5 μl/ml of GelRedTM. A 100 b.p DNA ladder was used as a marker. Gels 
were left running in an electrophoresis chamber (Mupid®-One) for approximately 35 min 
at 135 V. Pictures of gels were then taken under ultraviolet light on a UV White Darkroom 
BioImaging System (UVP, Cambridge, UK). 594 b.p PCR products corresponded to WT 
alleles, 200 b.p PCR products corresponded to knockout alleles and the presence of both 





Figure 2.1: Example gel of expected bands for WT and CCR7KO samples. 
  Genotyping of CCR7 LysM-eGFP mice 
CCR7KO LysM-eGFP mice were genotyped by PCR to confirm CCR7 knockout as 
described in section 2.1.3.3. They were also phenotyped by fluorescent microscopy to 









Isoflurane IsoFlo®, Zoetis, Zaventem, Belgium; 
Ketamine Ketaset Injection, conc. = 100 mg/ml, Cat. #SH4405D, 
Pfizer Ltd, Kent, UK; 
Xylazine  Rompun 2%, conc. = 20 mg/ml, Cat. #8109987, Bayer Plc., 
Newbury, UK. 
 Antibodies 
 Primary antibodies 
αSMA Purified monoclonal mouse anti-mouse α-smooth muscle 
actin, clone 1A4, conc. = 1.3 mg/ml, used at 2.5 µg/ml Cat. 
#A2547, Sigma-Aldrich, Saint Louis, USA. This antibody 
was directly conjugated to Alexa-488 using an Alexa® 488 
antibody labelling kit (Invitrogen, Cat. #A-20181, Paisley, 
UK) according to the manufacturer’s protocol; 
CCL21 Purified polyclonal rabbit anti-mouse Exodus-2, conc. = 1 
mg/ml, used at 7.5 µg/ml, Cat. #500-P114, Peprotech, 
London, UK; 
CCR7 Biotin conjugated rat anti-mouse CD197 (CCR7), clone 
4B12, conc. = 0.5 mg/ml, used at 10 µg/ml, eBioscience, 
Hatfield, UK; 
CD45.2 PE-Cy7 conjugated anti-mouse CD45.2, clone 104, conc. = 




CD3ε APC conjugated anti-mouse CD3ε, clone 145-2C11, conc. = 
0.2 mg/ml, used at 0.2 µg/ml, Cat. #17-0031-81, 
eBioscience, Hatfield, UK; 
CD11c PE-Cy5 conjugated hamster anti-mouse CD11c, clone 
N418, conc. = 0.2 mg/ml, used at 0.2 µg/ml, Cat. #117316, 
BioLegend, London, UK; 
CXCR4 PE conjugated anti-mouse clone 2B11, conc. = 0.2 mg/ml, 
used at 0.5 µg/ml, at Cat. #146505, eBioscience, Hatfield, 
UK; 
Fc BlockTM Purified monoclonal rat anti-mouse CD16/CD32 (FCγIII/II 
receptor), clone 2.4G2, conc. = 0.5 mg/ml, used at 5 µg/ml, 
Cat #553141, BD Biosciences, Oxford, UK; 
ICAM-1 Alexa Fluor® 488 conjugated rat anti-mouse CD54, clone 
YN1/1.7.4, conc. = 0.2 mg/ml, used at 16.7 µg/ml, at Cat. 
#116111, BioLegend, London, UK; 
LYVE-1 Purified monoclonal rat anti-mouse LYVE-1, clone ALY7, 
conc. = 0.5 mg/ml, used at 2.5 µg/ml for ex vivo-fixed 
staining and 10 µg/ml for in vivo-live staining, Cat. #14-
0443, eBioscience, Hatfield, UK. This antibody was directly 
conjugated to Alexa-488, Alexa-532, and Alexa-555 using 
Alexa® 488, 532 or 555 antibody labelling kits (Invitrogen, 
Cat. #A-20181; A-20182; A20187, Paisley, UK) according 
to the manufacturer’s protocol; 
Ly6G Alexa Fluor® 647 conjugated anti-mouse Ly-6G, clone 
1A8, conc. =0.2 mg/ml, used at 0.2 µg/ml, Cat. #127609, 
BioLegend, London, UK; 
PECAM-1  Purified monoclonal rat anti-mouse CD31, clone 390, conc. 
= 1 mg/ml, used at 2.5 µg/ml, eBioscience, Hatfield, UK. 
This antibody was directly conjugated to Alexa-488, Alexa-
555 and Alexa-647 using the Alexa® 488, 555 or 647 
antibody labelling kit (Invitrogen, Cat. #A-20181; A20187; 
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A-20186, Paisley, UK) according to the manufacturer’s 
protocol; 
Heparan Sulfate (HS) Mouse anti-heparan sulfate (10E4 epitope), clone F58-10E4, 
conc. = 1 mg/ml, used at 70µg/ml. Cat. #370255-S, Amsbio, 
Abingdon, UK; 
MRP14 Purified monoclonal rat anti-mouse MRP14, clone 2B10, 
conc. = 1.4 mg/ml, used at 2.5 µg/ml, received as a gift from 
Prof. Nancy Hogg (Cancer Research, UK). This antibody 
was directly conjugated to Alexa-488 and Alexa-555 using 
the Alexa® 647 antibody labelling kit (Invitrogen, Cat. #A-
20186, Paisley, UK) according to the manufacturer’s 
protocol. MRP14 is an intracellular marker for neutrophils 
(Hobbs et al., 2003). 
MECA-79 Alexa Fluor® 488 conjugated rat anti-mouse/human High 
Endothelial Venule (HEV) mAb, clone MECA-79, conc. = 
0.5 mg/ml, used at 2.5 µg/ml, Cat. #AF-425-SP, 
eBioscience, Hatfield, UK; 
TNFRI (p55) Purified goat anti-mouse CD120a (TNFR Type I/p55) Ab, 
conc. = 0.5 mg/ml, used at 2 µg/ml, Cat. #113001, R&D 
Systems, Abingdon, UK; 
TNFRII (p75) Purified goat anti-mouse CD120b (TNFR Type II/p75) Ab, 
conc. = 0.5 mg/ml, used at 2 µg/ml, Cat. #AF-426-SP, R&D 
Systems, Abingdon, UK. 
VE-Cadherin Purified rat anti-mouse CD144 mAb, clone eBioBV13 
(BV13), conc. = 1 mg/ml, used at 2.5 µg/ml, eBioscience, 
Hatfield, UK. This antibody was directly conjugated to 
Alexa-555 using the Alexa® 555 antibody labelling kit 




 Secondary antibodies 
Anti-hamster-A488 Alexa Fluor® 488 goat anti-Hamster IgG (H+L) Cross-
Adsorbed Secondary Ab, conc. = 2 mg/ml, used at 5 µg/ml, 
Cat. #R37118, Invitrogen, Paisley, UK; 
Anti-rabbit-A488 Alexa Fluor® 488 conjugated donkey anti-rabbit IgG 
secondary Ab, conc. = 2 mg/ml, used at 5 µg/ml, Cat. 
#R37118, Invitrogen, Paisley, UK; 
Anti-mouse-A488 Purified Alexa Fluor® 488 conjugated goat anti-mouse IgG 
(H+L) secondary Ab, conc. = 2 mg/ml, used at 3.3 µg/ml, 
Cat.#A-11001, Invitrogen, Paisley, UK; 
Streptavidin-A488 Alexa Fluor® 488 conjugate, conc. = 2 mg/ml, used at 3.3 
µg/ml, Cat. #S11223, Invitrogen, Paisley, UK. 
 Blocking antibodies 
Anti-CXCL1 mAb Purified rat anti-mouse CXCL1/GROα/KC/CINC‑1 mAb, 
used at 30 µg/mouse, Cat. #MAB453, R&D Systems, 
Abingdon, UK; 
Anti-ICAM-1 mAb Purified rat anti-mouse ICAM-1 mAb, clone YN1/1.4.7, 
conc. = 0.5 mg/ml, used 10 µg/mouse, eBioscience, 
Hatfield, UK; 
Anti-MAC-1 mAb Purified rat anti–mouse MAC-1 mAb, clone M1/70, conc. = 
0.5 mg/ml, used at 10 µg/mouse, Cat. #101202, BioLegend, 
London, UK; 
Anti-TNF mAb LEAF™ Purified anti-mouse TNF Antibody, clone MP6-
XT22, conc. = 1 mg/ml, used 50 µg/mouse, Cat. #506310, 






 Isotype controls 
for CCL21 Purified normal goat IgG control antibody, conc. = 1 mg/ml, 
used at 7.5 µg/ml. Cat. #AB-108-C, R&D Systems, 
Abingdon, UK; 
for CCR7 Biotin conjugated rat IgG2a, κ isotype control, eBR2a, conc. 
= 0.5 mg/ml, used at 10 µg/ml, Cat. #13-4321-82, 
eBioscience, Hatfield, UK; 
for CD45.2 PE-Cy7 conjugated rat anti-mouse IgG2a, κ isotype control 
antibody, conc. = 0.5 mg/ml, used at 0.2 µg/ml, clone 
MOPC-173, Cat. #400231, BioLegend, London, UK;   
for CD3ε APC conjugated Armenian hamster anti-mouse IgG isotype 
control antibody, conc. = 0.5 mg/ml, used at 0.2 µg/ml, clone 
eBio299Arm, Cat. #17-4888-81, eBioscience, Hatfield, UK;   
for CD11c PE-Cy5 conjugated hamster IgG2 isotype control antibody, 
conc. = 0.2 mg/ml, used at 0.2 µg/ml, clone HTK888, Cat. 
#400909, BioLegend, London, UK; 
for CXCR4 PE conjugated rat IgG2B, κ isotype control, clone 
RTK2758, conc. = 0.2 mg/ml, used at 0.5 µg/ml, Cat. #17-
4321, eBioscience, Hatfield, UK; 
for ICAM-1 Alexa Fluor® 488 conjugated rat IgG2b, κ isotype control 
antibody, clone RTK4530, conc. = 0.2 mg/ml, used at 16.7 
μg/ml, Cat. #400625, BioLegend, London, UK; 
for Ly6G Alexa Fluor® 647 conjugated rat IgG2a, κ isotype control, 
clone eBR2a, conc. = 0.2 mg/ml, used at 0.2 µg/ml, Cat. 
#400526, BioLegend, London, UK; 
for HS LEAF™ purified mouse IgM, κ isotype control antibody, 
conc. = 1 mg/ml, used at 70 µg/ml, Cat. #401604,  




for TNFRI (p55) and TNFRII (p75) 
 Purified normal goat IgG control, conc. = 1 mg/ml, Cat. 
#AB-108-C, R&D Systems, Abingdon, UK; 
for anti-CXCL1  Purified monoclonal rat IgG2a, κ, clone eBR2a, conc. = 0.5 
mg/ml, used at 30 µg/ml. Cat. #53-4321, eBioscience, 
Hatfield, UK; 
for anti-ICAM-1/MAC-1 mAb 
 LEAFTM purified rat IgG2b, κ isotype control antibody, 
conc. = 1 mg/ml, used 10 µg/mouse, Cat. #400622, 
BioLegend, London, UK; 
for anti-TNF mAb LEAFTM purified rat IgG1, κ isotype control antibody, conc. 
= 1 mg/ml, used 50 µg/mouse, Cat. #400414, BioLegend, 
London, UK. 
 Chemokine receptor antagonists 
AMD3100 octahydrochloride hydrate (CXCR4 antagonist) 
 1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-
tetraazacyclotetradecane octahydrochloride, 5mg, used at 10 
mg/kg, Cat # A5602. Sigma-Aldrich, Saint Louis, USA.  
 Fluorescent nuclei marker (viability)  
DAPI 4’,6-Diamidino-2-phenylindole dihydrochloride, 1 mg, Cat. 
#D9542, Sigma-Aldrich, Saint Louis, USA. 
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 Lectins and inhibitory sugars 
Lectins 
All lectins were directly conjugated in-house to Alexa-647 using the Alexa® 647 
antibody labelling kit (Invitrogen, Cat. # A-20186, Paisley, UK) according to the 
manufacturer’s protocol. 
Griffonia (Bandeirafa) Simplicifolia Lectin I Isolectin B4 (IB4) 
 IB4, conc. = 1 mg/ml, Cat. #L-1104, Vector 
Laboratories, California, U.S.A; 
Lycopersicon Esculentum (Tomato) Lectin (LEL) 
 
LEL, conc. = 1 mg/ml, Cat. #L-1170, , Vector 
Laboratories, California, U.S.A; 
Maackia Amurensis Lectin (MAL-1) 
 
MAL-1, conc. = 1 mg/ml, Cat. #L-1310, Vector 
Laboratories, California, U.S.A; 
Sambucus Nigra (Elderberry) Bark Lectin (SNA) 
 
SNA, conc. = 1 mg/ml, Cat. #L-1300, Vector 
Laboratories, California, U.S.A. 
 
Inhibitory sugars 
of IB4 Galactose, conc. = 100 mg/ml, Cat. #S-9003, Vector 
Laboratories, California, U.S.A; 
of LEL  Chitin hydrolysate, 100 mg/ml, Cat. #0090, Vector 
Laboratories, California, U.S.A; 
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of MAL-1 and SNB Lactose. Conc. 1.4 mg/ml. Cat. #S-9004, Vector 
Laboratories, California, U.S.A. 
 Enzymes 
DNase I Deoxyribonuclease I from bovine pancreas, conc. = 
5 mg/ml, used at 50 µg/ml. Activity less than 2000 
Kunitz units/mg, Cat. # D5025, Sigma-Aldrich, 
Saint Louis, USA. 
LiberaseTM TL Research Grade  
 
Conc. = 2.5 mg/ml, Activity = 13 Wünsch/ml, used 
at 200 µg/ml, Cat. #05401020001, Sigma-Aldrich, 
Saint Louis, USA; 
Proteinase K Conc. = 10 mg/ml, used at 100 µg/ml, Cat. #BIO-
37037, Activity = bigger than sign 400 units/ml, 
Bioline, London, UK. 
 Inflammatory stimuli 
Complete Freund’s Adjuvant (CFA) 
 Conc. = 20 mg/ml, used 200 µg/mouse, Cat. #7024, 
Amsbio, Abingdon, UK;  
Ovalbumin (OVA) Albumin from chicken egg white, 250 mg, 
reconstituted in PBS to 1 mg/ml, used 200 µg/mouse, 
Cat. #A2512, Sigma-Aldrich, Saint Louis, USA; 
Tumour necrosis factor alpha (TNF) 
 Recombinant Mouse TNF, Cat. #410-MT-050/CF, 




ACK lysis buffer 150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA, pH 
7.3 in H20; 
FACS buffer 1 x PBS supplemented with 1% heat-inactivated fetal 
bovine serum; 
 
Cremaster homogenising buffer 
 1 x PBS supplemented with 1% Triton X-100 and 
1% protease inhibitor cocktail; 
TAE buffer UltraPureTM 10x TAE buffer, Cat. No. 15558-026, 
Invitrogen, Paisley, UK. 
 Other miscellaneous reagents and solutions 
DNA ladder SmartLadder SF (100 – 1,000 bp), Cat. No. MW-
1800-04, Eurogentec, Southampton, UK; 
DNA gel loading dye (6X) Cat. #R0611, ThemoFisher Scientific, Paisley, UK; 
DMSO Dimethyl sulfoxide, Cat. # W387520, Sigma-
Aldrich, Saint Louis, USA; 
EDTA Ethylenediaminetetraaceticacid disodium salt 
dehydrate, Cat #E5134, Sigma-Aldrich, Saint Louis, 
USA; 
Fetal bovine serum (FBS) Cat. #10270-106, Gibco, Paisley, UK; 
GelRed Cat. No. 41003, Biotium, via Cambridge 
BioScience, Cambridge, UK; 
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HaltTM Protease Inhibitor Cocktail (100X) 
 Cat. #87786, ThemoFisher Scientific, Paisley, UK; 
Heparin Heparin sodium salt from porcine intestinal mucosa, 
≥ 180 USP units/mg, Cat #H3149, Sigma-Aldrich, 
Saint Louis, USA; 
Molecular biology grade 
water 
UltraPureTM DNase/RNase-free distilled water, 
Cat. No. 10977-049, Invitrogen, Paisley, UK; 
Normal goat serum (NGS) Goat serum, Cat #G6767, Sigma-Aldrich, Saint 
Louis, USA; 
Nystatin Nystatin powder reconstituted in DMSO, 1 mg/ml, 
used at 50 µM, Cat. # N6261, Sigma-Aldrich, Saint 
Louis, USA; 
HaltTM Protease Inhibitor Cocktail (100X) 
 Halt protease and phosphatase inhibitor cocktail, 
Cat. #87786, ThemoFisher Scientific, Paisley, UK; 
Incomplete Freund’s Adjuvant (IFA) 
 Liquid Freund’s Adjuvant, Incomplete, Cat. # 
F5506, Sigma-Aldrich, Saint Louis, USA; 
4% Paraformaldehyde (PFA) 
 Paraformaldehyde powder reconstituted in dH2O, 
Cat #158127, Sigma-Aldrich, Saint Louis, USA; 
Phosphate buffered saline (PBS) 
 Dulbecco’s 1 x PBS, pH 7.2, Cat. #D8662, Sigma-
Aldrich, Dorset, UK; 
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TritonTM X-100 Laboratory grade, Cat. #X100, Sigma-Aldrich, Saint 
Louis, USA. 
Tyrode’s salt solution Cat. No. 127K8303, Sigma-Aldrich, Poole, Dorset, 
UK; 
  Kits 
Fixation/Permeabilisation Solution Kit 
 BD Cytofix/Cytoperm™, Cat. #554714, BD 
Biosciences, Oxford, UK; 
Mouse CXCL12/SDF-1α Quantikine ELISA kit 
 Cat. #MCX120, R&D Systems, Abingdon, UK; 
Mouse TNF ELISA Ready-SET-Go!® 
 Cat. #88-7324-22, eBioscience, Hatfield, UK; 
Mouse GM-CSF ELISA Ready-SET-Go!® 
 Cat. #88-7334-22, eBioscience, Hatfield, UK; 
Mouse IL-17A (homodimer) ELISA Ready-SET-Go!® 
 Cat. #88-7371-22, eBioscience, Hatfield, UK; 
PierceTM BCA Protein Assay Kit  




 Preparation of Complete Freund’s Adjuvant (CFA) 
emulsion for inducing inflammation in the cremaster 
muscle 
To induce inflammation in the cremaster muscle with CFA, an emulsion of CFA and 
antigen (CFA+Ag) containing equal volumes of CFA/incomplete Freund’s adjuvant 
(IFA) and antigen/PBS was prepared. 300 μl of this emulsion was injected into each 
mouse to induce an inflammatory response. To make the emulsion, the antigen ovalbumin 
(OVA, 200 µg) was first diluted in sterile PBS. The required amount of CFA (200 
µg/mouse) was then pipetted into a 1.5 ml screw-top tube and topped up with the required 
amount of IFA. An equal volume of antigen/PBS was then added to the tube before being 
placed in a high-throughput tissues homogeniser, Precellys® 24 (Precellys, Derbyshire, 
UK), for 1 cycle of 45 s homogenisation at 6500 r.p.m to combine the adjuvant and 
antigen and form an emulsion. A 1 ml silliconised syringe (Plastipak Luer Lock, BD, 
Oxford, UK) was used to draw up the emulsion before a 23 gauge needle was attached. 
 Inducing inflammation in murine tissues and analysis 
by immunofluorescence labelling and confocal 
microscopy 
All i.s. injections of TNF/lectins/antibodies were given in a total volume of 400 μl made 
up with PBS. All i.s. injections of CFA+Ag were given in a total volume of 300 μl made 
up with CFA and OVA (see section 2.3). 
 Inducing inflammatory reactions of murine cremaster muscles 
in vivo 
8-12 week old male mice (strain used dependent on experiments) were sedated using an 
isoflurane machine (IsoFlo®, Zoetis, Belgium) before their cremaster muscles were 
stimulated via intrascrotal (i.s) injection of TNF (300 ng/400 µl PBS) or CFA (200 
μg/mouse) alongside OVA (200 μg/mouse), hereafter known as CFA+Ag. Control mice 
received 400 μl of PBS via i.s. injection. Several time-points following TNF/CFA+Ag 
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stimulation were investigated over the course of 48 h. At the end of each time point, mice 
were sacrificed and their cremaster muscles and cremaster dLNs (Inguinal) were 
dissected away and fixed at 4 °C for 1 h and overnight, respectively. Tissues were then 
permeabilised for 4 h at room temperature, followed by immunofluorescence labelling 
and confocal microscopy analysis as described in the sections below. 
 Immunofluorescence labelling of whole-mounted murine 
cremaster muscles and cremaster draining lymph nodes 
To investigate neutrophil migration responses across post-capillary venules and 
intravasation into initial lymphatic vessels and into the dLNs, whole-mounted murine 
tissues such as the cremaster muscle and dLNs (namely inguinal) had to be 
immunostained with fluorescent conjugated antibodies following 
fixation/permeabilisation for confocal microscopy analysis. 
Mice were sacrificed via cervical dislocation before cremaster muscles and cremaster 
draining LNs (inguinal and lumbar) were dissected away. These tissues (unstimulated, 
respective controls or stimulated with inflammatory mediators described above in section 
2.4.1) were then subjected to a modified version of the immunostaining protocol 
previously described (Wang et al., 2005). Briefly, cremaster tissues were fixed in 4% PFA 
in PBS for 1 hour at 4 °C and dLNs were fixed overnight at 4 °C. LNs were cut in half 
longitudinally with a scalpel following fixation. Fixed tissues were blocked and 
permeabilised in PBS (containing 12.5% goat serum, 12.5% fetal bovine serum [FBS] 
and 0.5% Triton X-100) for 4 h at room temperature. Tissues were then 
immunofluorescently stained for ECs (0.25 μg/100 µl, anti-PECAM-1 mAb) and LECs 
(0.25 μg/100 µl, anti-LYVE-1 mAb), and/or for neutrophils (0.25 μg/100 µl anti-MRP14 
mAb), in PBS (with 10% FBS) overnight at 4°C. Draining LNs were immunostained for 
high endothelial venules (HEVs) instead of BECs with an anti-MECA-79 mAb (0.25 
μg/100 µl) in PBS (with 10% FBS) overnight at 4°C. Following a 3 h wash, the tissues 
were imaged with a Leica SP5 or SP8 confocal microscope (Leica Microsystems, Milton 
Keynes, UK) as described in the following sections (section 2.4.3 and 2.4.4) for 
cremasters and dLNs, respectively.  
108 
 
 Confocal analysis of neutrophil migration responses in 
immunostained whole-mounted murine cremaster muscles  
Following immunostaining, all cremaster muscles were imaged with a Leica SP8 confocal 
microscope at 20 to 24°C with the use of a 20× water-dipping objective (numerical 
aperture [NA]: 1.0). Images of postcapillary venules and lymphatic vessels (at least 6 
vessels per tissue) were acquired with the use of sequential scanning of different channels 
at every 0.52 µm of tissue depth at a resolution of 1024 × 470 and 1024 x 800 pixels in 
the x × y plane, corresponding to a voxel size of 0.24 × 0.24 × 0.5 µm in x × y × z planes. 
Postcapillary venules and lymphatic vessels were imaged at a zoom factor of ×1.9 and 
×1.2, respectively. Quantification of neutrophil transmigration and intravasation into 
lymphatic vessels were analysed with the 3D-reconstructing image processing software 
IMARIS (Bitplane, Switzerland). Transmigrated neutrophils were defined as the number 
of neutrophils present in the extravascular tissue across a 300 μm blood vessel segment 
and within 50 μm from each side of the venule of interest. Data was expressed as the 
number of neutrophils per volume of tissue. Intravasated neutrophils were defined as the 
number of neutrophils present inside the lymphatic vessels and data was expressed as the 
number of neutrophils per given volume of vessel. To get the volume of lymphatic 
vessels, an isosurface was created using the channel showing immunofluorescence 
labelling of LYVE-1 as a source to represent the lymphatic endothelium (Figure 2.2). 






Figure 2.2: Creating isosurface of lymphatic vessels using IMARIS software. A 
representative isosurface showing the lymphatic endothelium (B) is illustrated, which has been 




 Quantification of neutrophil recruitment in immunostained 
cremaster draining LNs via confocal microscopy 
Following immunostaining, the LNs were imaged with a Leica SP8 confocal microscope 
at 20 to 24°C with the use of a 10× water-dipping objective (NA: 0.25). Images (12 in 
total from each pair of LNs/mouse) were obtained with the use of sequential scanning of 
different channels at every 5.8 µm of tissue depth at a resolution of 1024 × 1024 pixels 
in the x × y plane, corresponding to a voxel size of 0.91 × 0.91 × 5.8 µm in x × y × z 
planes. Quantification of neutrophil recruitment into the inguinal and lumbar LNs were 
analysed with the 3D-reconstructing image processing software IMARIS (Bitplane, 
Switzerland). Recruited neutrophils were defined as the number of neutrophils present 
per volume of tissue, excluding (unless specified) the blood circulating neutrophils 
present in HEVs.   
 Characterising the LEC glycocalyx of murine 
cremaster muscles 
 Visualising sugar residues on lymphatic vessels  
In order to visualise carbohydrates of LEC glycocalyx in tissues, two methods of 
glycocalyx staining using lectins were tested. The first involved ex vivo-fixed staining as 
previously described (Section 2.4.2), whereas the second staining method involved in 
vivo-live (intrascrotal [i.s. injection]) staining. Both methods are described below. 
Different techniques were tested as fixation could impact the binding capacity of the 
lectins and possibly affect analysis, thus live labelling was also carried out. In vivo-live 
staining is rapid but potential phagocytosis of fluorescent lectins can lead to non-specific 
signals. In ex vivo-fixed staining, sugar epitopes are present intracellularly in tissues (as 
opposed to in vivo-live staining, where sugar epitopes are on the surface of cells). 
Therefore, this could be used as an indication as to whether lectin staining is intracellular. 
All commercially available lectins, namely IB4, MAL-1, LEL and SNA with specific 
sugar residue binding properties were labelled in-house with an Alexa Flour® 647 protein 
labelling kit (Invitrogen). 
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 Ex vivo-fixed staining  
Cremaster muscles were harvested from WT mice and immunostained for the lectins 
(0.25 µg/ 100 μl, Alexa 647-conjugated), BECs (0.25 μg/100 µl, anti-PECAM-1 mAb, 
Alexa 488-conjugated) and LECs (0.25 μg/100 µl, anti-LYVE-1 mAb, Alexa 555-
conjugated) as described in section 2.4.2. In some experiments, cremaster muscles of 
mice were subjected to TNF- or CFA+Ag-stimulation before tissues were harvested. 
Neutrophils (0.25 µg/100 μl, anti-MRP14 mAb, Alexa 488-conjugated) were also 
labelled in some experiments. 
 In vivo-live staining  
Sugars (lectin), BECs (PECAM-1) and LECs (LYVE-1) labelling was achieved by i.s. 
injection of the fluorescent-conjugated lectin/antibodies (1 μg/100 µl). After 2 hours, 
mice were sacrificed and the cremaster muscles were dissected away and whole-mounted 
for fixation in 4% PFA in PBS followed by imaging with a Leica SP8 confocal 
microscope. In some experiments, cremaster muscles of mice were subjected to TNF- or 
CFA+Ag-stimulation before tissues were harvested. 
 Analysis of sugar residues on lymphatic vessels and blood vessels 
Expression of sugars to which the lectins bind to on the surface of lymphatic vessels and 
blood vessels was assessed by determining the mean fluorescence intensity (MFI) of 
tissue vessel structures stained with the lectins using IMARIS software. To do this, an 
isosurface was created using the channel showing immunofluorescence labelling of 
LYVE-1/PECAM-1 as a source to represent the lymphatic endothelium/blood vascular 
endothelium. This parameter depicts the limitation of the volume of interest in which 
IMARIS determines the MFI of the channel showing fluorescent labelling of the lectins. 
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 Investigating heparan sulfate and chemokine 
expression by lymphatic vessels 
 CCL21 immunostaining of TNF- or CFA+Ag-stimulated murine 
cremaster muscles 
Expression of the prototypical lymphatic chemokine, CCL21, on the lymphatic 
vasculatures was investigated by immunostaining of the lymphatic endothelium via in 
vivo-live staining (i.e. both surface and intracellular expression). For in vivo-live staining, 
C57BL/6 WT mice were i.s. injected with TNF or an emulsion of CFA+Ag and the 
inflammatory response was allowed to develop for 16 h. Two hours before the end of the 
inflammation period, mice received an i.s. injection of anti-LYVE-1 mAb (1 μg/100 μl), 
anti-CCL21 mAb/rabbit IgG isotype control Ab (0.75 μg/100 μl) to label lymphatic 
vasculatures and CCL21, respectively. Intrascrotal injections were carried out using an 
isoflurane anaesthetic machine. At the end of the inflammation period, cremaster muscles 
were dissected away and immediately visualised using a Leica SP5 or SP8 confocal 
microscope.  
 Heparan sulfate immunostaining of TNF-stimulated murine 
cremaster muscles 
Expression of the GAG, heparan sulfate (HS), by lymphatic vessels was investigated by 
immunostaining of the lymphatic endothelium via ex vivo-fixed staining. For ex vivo-
fixed staining, C57BL/6 WT mice were i.s. injected with TNF (300 ng/mouse) and the 
inflammatory response was allowed to develop for 16 h. Following dissection of the 
cremaster muscles, tissues were whole-mounted and fixed in 4% PFA for 1 h before being 
blocked and permeabilised in PBS (containing 12.5% goat serum, 12.5% fetal bovine 
serum (FBS) and 0.5% Triton X-100) for 3 h at room temperature. Tissues were then 
immunostained with an anti-HS Ab or mouse IgM isotype control Ab (7 μg/100 µl, 
purified) and anti-LYVE-1 mAb (0.25 μg/100 μl PBS) to label HS and lymphatic 
vasculatures, respectively, in PBS (with 10% FBS) overnight at 4°C. The following day, 
tissues were washed for 3 h before being immunostained with an anti-mouse IgM 
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secondary Ab (0.5 μg/100 µl, Alexa 488-conjugated) in PBS (with 10% FBS) for 2 h at 
RT. Following a 3 h wash, the tissues were imaged with a Leica SP8 confocal microscope.  
 Investigating neutrophil migration responses following 
chemokine/chemokine receptor blockade 
To investigate the CXCL1:CXCR1/2 chemokine axis, C57BL/6 WT male mice (8-12 
weeks) received i.s. injection of CFA+Ag (200 μg/mouse) as per section 2.4.1. 
Unstimulated control mice received 400 μl of PBS via i.s. injection. 4 h post-i.s. injection, 
mice received i.s. injections of either an anti-CXCL1 or rat IgG2a isotype control Ab (30 
µg/mouse). Eight hours post-i.s. injection, mice were sacrificed and their cremaster 
muscles and cremaster dLNs were dissected away and whole-mounted for fixation in 4% 
PFA in PBS for 1 h followed by immunofluorescence labelling (as carried out in section 
2.4.2), confocal microscopy and IMARIS analysis (as carried out in sections 2.4.3 and 
2.4.4 for the cremaster muscles and dLNs, respectively). 
To investigate the CXCL12:CXCR4 chemokine axis, C57BL/6 WT male mice (8-12 
weeks) received i.s. injection of TNF (300 ng/mouse) or CFA+Ag (200 μg/mouse) as per 
section 2.4.1. Unstimulated control mice received 400 μl of PBS via i.s. injection. 4 h 
post-i.s. injection, mice received i.s. injections of either AMD3100 (10 mg/kg) (Liu et al., 
2014) or vehicle control (PBS). Sixteen hours post-i.s. injection, mice were sacrificed and 
their cremaster muscles and cremaster dLNs were dissected away and whole-mounted for 
fixation in 4% PFA in PBS for 1 h followed by immunofluorescence labelling (as carried 
out in section 2.4.2), confocal microscopy and IMARIS analysis (as carried out in sections 
2.4.3 and 2.4.4 for the cremaster muscles and dLNs, respectively). 
To investigate the CCL21/CCR7 chemokine axis, CCR7KO male mice (8-12 weeks) 
received i.s. injection of TNF (300 ng/mouse) or CFA+Ag (200 μg/mouse) as per section 
2.4.1. Control mice received 400 μl of PBS via i.s. injection. Different time-points such 
as 8 h and 16 h were investigated following which the mice were sacrificed and their 
cremaster muscles and cremaster dLNs were dissected away and whole-mounted for 
fixation in 4% PFA in PBS for 1 h followed by immunofluorescence labelling (as carried 
out in section 2.4.2), confocal microscopy and IMARIS analysis (as carried out in sections 
2.4.3 and 2.4.4 for the cremaster muscles and dLNs, respectively). In some experiments, 
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chimeric mice exhibiting CCR7KO neutrophils in a WT environment were used. In other 
experiments, CCR7KO mice were given i.s. injections of the CXCR4-specific inhibitor, 
AMD3100, 4 h post-i.s. injection. At the end of the inflammatory period, cremaster 
muscles were dissected away and subjected to the same staining protocol as above, before 
being analysed by confocal microscopy and IMARIS software.  
 Analysis of heparan sulfate and chemokine staining on lymphatic 
vessels 
Expression of HS and CCL21 by lymphatic vessels was assessed by determining the mean 
fluorescence intensity (MFI) of tissue vessel structures stained with HS and CCL21 using 
IMARIS software. To do this, an isosurface was created using the channel showing 
immunofluorescence labelling of LYVE-1 as a source to represent the lymphatic 
endothelium. This parameter depicts the limitation of the volume of interest in which 
IMARIS determines the MFI of the channel showing fluorescent labelling of HS and 
CCL21. Intensity profiles for CCL21 expression along a certain distance (10 µm away 
from lymphatic vessels) were performed using Image J. 
 Investigating the role of TNF in neutrophil migration 
responses during antigen sensitisation 
To investigate the role of TNF signalling in neutrophil migration into lymphatic vessels, 
TNFRdbKO male mice (8-12 weeks) were given i.s. injection of CFA+Ag (200 
μg/mouse) as per section 2.4.1. Control mice received 400 μl of PBS via i.s. injection. 
Different time-points such as 8 h and 16 h were investigated following which the mice 
were sacrificed and their cremaster muscles and cremaster dLNs were dissected away and 
whole-mounted for fixation in 4% PFA in PBS for 1 h followed by immunofluorescence 
labelling (as carried out in section 2.4.2), confocal microscopy and IMARIS analysis (as 
carried out in sections 2.4.3 and 2.4.4 for the cremaster muscles and dLNs, respectively). 
In some experiments, chimeric mice exhibiting TNFRdbKO neutrophils in a WT 
environment were used. 
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 ICAM-1 expression on lymphatic vasculatures 
 ICAM-1 immunostaining in TNF- or CFA+Ag-stimulated 
murine cremaster muscles with/without TNF signalling blockade 
Expression of the adhesion molecule, ICAM-1, on the lymphatic vasculatures was 
investigated by immunostaining of the lymphatic endothelium. Male WT mice were i.s. 
injected with TNF (300 ng/mouse) or CFA+Ag (200 μg/mouse) as per section 2.4.1 and 
the inflammatory response was allowed to develop for 8 h. In some experiments, 
CFA+Ag-stimulated animals were pre-treated with a local (i.s.) injection of the blocking 
anti-TNF or rat IgG1κ isotype control mAbs (50 μg/mouse). Two hours before mice were 
sacrificed and the cremaster tissues dissected away, non-blocking doses of an anti-LYVE-
1 mAb (1 μg/100 µl, Alexa 555-conjugated) and an anti-PECAM-1 mAb (1 μg/100 µl, 
Alexa 647-conjugated) was injected i.s. to immunolabel LECs and EC junctions to aid 
with visualisation of the lymphatic endothelium and endothelial cell layer, respectively. 
For i.s. injections, an isoflurane anaesthesia machine was used. Following dissection of 
the cremaster muscles, tissues were whole-mounted and fixed in 4% PFA for 1 h before 
being blocked and permeabilised in PBS (containing 12.5% goat serum, 12.5% fetal 
bovine serum (FBS) and 0.5% Triton X-100) for 3 h at room temperature. Tissues were 
then immunofluorescently stained with an anti-ICAM-1 mAb or the rat IgG2b,κ isotype 
control (2 μg/100 µl, Alexa 488-conjugated) in PBS (with 10% FBS) overnight at 4°C. 
Following a 3 h wash, the tissues were imaged with a Leica SP8 confocal microscope. 
 Analysis of ICAM-1 staining on lymphatic vessels 
Expression of ICAM-1 on lymphatic vessels was assessed by determining the MFI of 
tissue vessel structures labelled with ICAM-1 using IMARIS software. To do this, an 
isosurface was created using the channel showing immunofluorescence labelling of 
LYVE-1 as a source to represent the lymphatic endothelium. This parameter depicts the 
limitation of the volume of interest in which IMARIS determines the MFI of the channel 
showing fluorescent labelling of ICAM-1. 
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  Confocal Intravital Microscopy 
Confocal intravital microscopy (IVM) was used to observe neutrophil responses within 
lymphatic vessels of the cremaster muscle upon TNF- or CFA+Ag-stimulation with or 
without TNF/ICAM-1/MAC-1-blockade in real-time in 4D. Appropriate techniques were 
adapted from confocal IVM of postcapillary venules carried out by previous members of 
the group (Woodfin et al., 2011), and developed to investigate neutrophil interactions 
with LECs in vivo (Arokiasamy et al., 2017), as described in the following sections. 
  Investigation of neutrophil migration responses in TNF- or 
CFA+Ag-stimulated murine cremaster muscles 
To investigate neutrophil migration across lymphatic vessels during inflammation in vivo, 
the cremaster muscles of male LysM-eGFP mice were stimulated by i.s. injection of TNF 
(300 ng/ml) or CFA+Ag (200 μg/mouse) and the inflammatory response was allowed to 
develop for 4 (TNF) to 6 h (CFA+Ag) before visualisation of the response by IVM. Two 
hours before surgery, non-blocking doses of an anti-LYVE-1 mAb (2.5 μg in 250 µl, 
Alexa 555-conjugated) and an anti-PECAM-1 mAb (2.5 μg in 250 µl, Alexa 647-
conjugated) was injected i.s. to immunolabel LECs and EC junctions to aid with 
visualisation of the lymphatic endothelium and endothelial cell layer, respectively. For 
i.s. injections, an isoflurane anaesthesia machine was used. Thirty minutes before surgery, 
mice were anaesthetised by i.p. injection of ketamine (100 mg/kg) and xylazine (10 
mg/kg) and maintained at 37 °C in an incubator (MediHeatTM, Ascon Tecnologic, Pavia, 
Italy). Surgery to exteriorise the cremaster muscle was carried out on a custom-built 
heated microscope stage, where the tissue was pinned out flat over the optical window of 
the stage and superfused with Tyrode’s solution (Figure 2.3A-B). Z-stack images of a 
lymphatic vessel were captured every 1 min for 90 min using a Leica SP5 confocal 
microscope. Z-stacks were captured at every 0.7 μm of tissue depth at a resolution of 
1045 × 600 in the x × y plane. 4D confocal image sequences acquired were then analysed 
using IMARIS software, enabling the dynamic interaction of neutrophils with lymphatic 
vessels to be observed, tracked and quantified as previously described for blood vessels 




Figure 2.3: Surgical exteriorisation and preparation of the cremaster muscle for confocal 
intravital microscopy. (A) The cremaster muscle of a mouse was exteriorised before being 
pinned out flat over the optical window of a heated microscope stage. (B) Following this, it was 
positioned under the microscope and superfused with Tyrode’s solution before being imaged. 
  Investigation of neutrophil migration and intraluminal crawling 
responses with TNF and ICAM-1/MAC-1 blockade 
To investigate neutrophil migration across lymphatic vessels and changes in intraluminal 
crawling within the lymphatic endothelium during inflammation in vivo, the cremaster 
muscles of male WT mice were stimulated by i.s. injection of CFA+Ag (200 μg/mouse) 
and the inflammatory response was allowed to develop for 6 h (CFA+Ag) before 
visualisation of the response by IVM. Mice were pre-treated with a local (i.s.) injection 
of the following blocking antibodies 90 to 120 min before surgery: anti-TNF or rat IgG1κ 
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isotype control mAbs (50μg/mouse), anti-ICAM-1/anti-MAC-1 mAbs or rat IgG2b 
isotype control mAbs (10μg/mouse) along with non-blocking doses of anti-LYVE-1 mAb 
(2.5 μg in 250 µl, Alexa 555-conjugated) and an anti-PECAM-1 mAb (2.5 μg in 250 µl, 
Alexa 647-conjugated) to immunolabel LECs and EC junctions to aid with visualisation 
of the lymphatic endothelium and endothelial cell layer, respectively. For i.s. injections, 
an isoflurane anaesthesia was used. Thirty minutes before surgery, mice were 
anaesthetised by i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) and 
maintained at 37 °C in an incubator (MediHeatTM, Ascon Tecnologic, Pavia, Italy). 
Surgery to exteriorise the cremaster muscle was carried out on a custom-built heated 
microscope stage, where the tissue was pinned out flat over the optical window of the 
stage and superfused with Tyrode’s solution (Figure 2.3B). Z-stack images of a 
lymphatic vessel were captured every 1 min for 90 min using a Leica SP5 confocal 
microscope. Z-stacks were captured at every 0.7 μm of tissue depth at a resolution of 
1045 × 600 in the x × y plane. 4D confocal image sequences acquired were analysed using 
IMARIS software. 
 Investigating cytokine expression profile of cremaster 
muscles following inflammation 
To determine whether the cytokines TNF, GM-CSF and IL-17A were produced following 
CFA+Ag-induced inflammation in the cremaster muscle, ELISAs were carried out to 
quantify cytokine release using supernatents obtained from homogenisation of inflamed 
cremaster tissues. BCA protein assays were carried out on the same samples in order to 
normalise the ELISA measurements by total protein concentration. 
 Inducing inflammation in the cremaster and tissue preparation 
Inflammation was induced in the cremaster muscles of WT C57BL/6 with CFA+Ag (as 
per section 2.4.1). After 16 h of CFA+Ag stimulation, mice were sacrificed and their 
cremaster muscles were dissected away, placed in 1.5 ml eppendorf tubes before being 
immediately snap-frozen in liquid nitrogen. Tissues were transferred into screw-top tubes 
containing homogenising beads along with 500 µl homogenising buffer (1% Triton™ X-
100, 1% protease inhibitor, PBS) prior to being placed in a high-throughput tissue 
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homogeniser, Precellys® 24 (Precellys, Derbyshire, UK), for 3 cycles of 20 s 
homogenisation at 6500 r.p.m with 40 s rest between each cycle. Homogenised samples 
were then frozen at -80 °C for 1 h before being thawed and centrifuged for 5 min at 10 
000 g using a tabletop centrifuge.  The supernatent was taken and used to quantify the 
release of the cytokines TNF, GM-CSF and IL-17A, and total protein concentration by 
Enzyme-Linked Immunosorbent Assay (ELISA) and Bicinchoninic Acid (BCA) protein 
assay, respectively. 
 ELISAs 
The production of the cytokines TNF, GM-CSF, IL-17A and the chemokine CXCL12 
following stimulation with CFA+Ag were investigated. For this purpose, different kits 
were used and brief descriptions of the methods used for the ELISAs are detailed in the 
sections below. 
  Cytokine ELISAs 
To determine the expression of the cytokines TNF, GM-CSF and IL-17A in the cremaster 
muscle following inflammation, ELISAs were carried out. Before doing this, animals 
were subjected to CFA+Ag-induced inflammation of the cremaster muscles. Control mice 
received an injection of PBS (300 µl). Tissues were prepared (as described above in 
section 2.11.1). Mouse ELISA Ready-SET-Go® kits (eBioscience, Hatfield, UK) for all 
3 cytokines were used according to the manufacturer's protocol. Briefly, flat-bottom 96 
well ELISA plates (NUNC MaxiSorp®, eBioscience, Hatfield, UK) were coated with 100 
μl/well of capture antibody (pre-titrated, 48 μl diluted in 12 ml 1× coating buffer), sealed 
and incubated at 4 °C overnight. The next day, wells were aspirated and washed 3 times 
with 250 µl/well of wash buffer (1× PBS and 0.05% Tween-20). Following this, 200 
µl/well of 1× ELISA diluent was used to block the wells at room temperature for 1 h after 
which wells were aspirated and washed at least once with wash buffer. Standards were 
then diluted with 1× ELISA diluent according to the manufacturer's instructions to 
prepare the top concentration of the standard. 100 µl of the top standard concentration 
was added to the appropriate wells in duplicates and 2-fold serial dilutions were 
performed to make the standard curve for a total of 8 points. 100 µl/well of homogenised 
tissue samples was added to the appropriate wells in triplicates before the plate was sealed 
and incubated at room temperature for 2 h. Wells were aspirated and washed for a total 
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of 5 washes before 100 µl/well of detection antibody (pre-titrated, 48 μl diluted in 12 ml 
1× ELISA diluent) was added to the plate and incubated for 1 h after being sealed. Wells 
were aspirated and washed again for a total of 5 washes. 100 µl/well of Avidin-HRP (pre-
titrated, 48 μl diluted in 12 ml 1× ELISA diluent) was added to the plate before it was 
sealed and incubated at room temperature for 30 min. Wells were aspirated and washed 
as before with the addition of soaking wells in wash buffer for 1 to 2 min prior to 
aspiration between each wash. 100 µl/well of 1× 3,3',5,5'-Tetramethylbenzidine (TMB) 
solution diluted in 1× ELISA diluent was added to the plate and incubated at room 
temperature for 15 min after being sealed. Wells were aspirated and washed again for a 
total of 5 washes. 50 µl/well of stop solution (2mM sulfuric acid [H2SO4]) was added to 
the plate before it was read on a plate reader (Spectra MR, Dynex Technologies Ltd, West 
Sussex, UK) at a wavelength of 450nm. Sample concentrations were calculated using the 
standard curve. A BCA protein assay was carried out (as per section 2.11.3) on the same 
samples in order to normalise the ELISA measurements by total protein concentration 
(ng/ml). 
  Chemokine ELISA 
To assess differences in the levels of the chemokine CXCL12 in the cremaster draining 
LNs of WT and CCR7KO mice, ELISAs were carried out to quantify CXCL12 levels 
using supernatents obtained from homogenisation of dLNs from unstimulated mice. 
Tissues were prepared as described in section 2.11.1. A mouse CXCL12/SDF-1α 
Quantikine ELISA kit (R&D Systems, Abingdon, UK) was used according to the 
manufacturer's protocol. Briefly, reagents were reconstituted and standards were diluted 
with Calibrator Diluent RD6Q according to the manufacturer’s instructions. As the plate 
comes pre-coated with the CXCL12 capture antibody, 50 µl of Assay Diluent RD1-55 
was directly added to each well along with 50 µl of Standard, Control or sample (1:2 
dilution) per well. The plate was sealed with the adhesive strip provided and incubated 
for 2 h at RT on a horizontal plate shaker (LSE™ Vortex Mixer, Corning, UK) at a low 
speed setting. Wells were aspirated and washed for a total of 5 washes before 100 µl/well 
of Mouse SDF-1α Conjugate was added to the plate and incubated for 2 h at RT on a 
shaker after being sealed. Wells were aspirated and washed again for a total of 5 washes. 
200 µl/well of Substrate Solution was added to the plate and incubated for 30 mins at RT, 
protected from light. Following this, 50 µl of Stop Solution was added to each well before 
the plate was read on a microplate reader at a wavelength of 450nm and the sample 
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concentrations were calculated from the standard curve. A BCA protein assay was carried 
out (as per section 2.11.3) on the same samples in order to normalise the ELISA 
measurements by total protein concentration (ng/ml). 
 BCA Protein Assay 
To determine the total protein concentration of each inflamed cremaster muscle in order 
to normalise the ELISA measurements by total protein concentration, BCA protein assays 
were carried out. Before doing this, animals were subjected to inflammation of the 
cremaster muscle and tissue samples were prepared (as described above in 2.11.1). 
Following this, a Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, Paisley, 
UK) was used according to the manufacturer’s protocol. The assay was performed in a 
96-well plate. Briefly, diluted protein standards were prepared using 1× PBS and the 
contents of one bovine serum albumin (BSA) ampule provided in the kit. Next, 25 µl of 
each standard or unknown sample was incubated with 200 µl of BCA working reagent 
(50:1, Reagent A:B). The plate was incubated at 37 °C for 30 mins and after leaving to 
cool to RT, the absorbance was measured at 570 nm on a plate reader (Spectra MR, Dynex 
Technologies Ltd, West Sussex, UK). The protein concentration in each sample was 
calculated using the BSA standard curve. 
 Investigating the expression of CXCL12 by cremaster 
draining lymph nodes  
To assess differences in the levels of the chemokine CXCL12 in the cremaster draining 
LNs of WT and CCR7KO mice, ELISAs were carried out (as per section 2.11.2) to 
quantify CXCL12 levels using supernatents obtained from homogenisation of dLNs from 
unstimulated mice. Tissues were prepared as described in section 2.11.1. A mouse 
CXCL12/SDF-1α Quantikine ELISA kit (R&D Systems, Abingdon, UK) was used 
according to the manufacturer's protocol. Briefly, reagents were reconstituted and 
standards were diluted with Calibrator Diluent RD6Q according to the manufacturer’s 
instructions. As the plate comes pre-coated with the CXCL12 capture antibody, 50 µl of 
Assay Diluent RD1-55 was directly added to each well along with 50 µl of Standard, 
Control or sample (1:2 dilution) per well. The plate was sealed with the adhesive strip 
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provided and incubated for 2 h at RT on a horizontal plate shaker (LSE™ Vortex Mixer, 
Corning, UK) at a low speed setting. Wells were aspirated and washed for a total of 5 
washes before 100 µl/well of Mouse SDF-1α Conjugate was added to the plate and 
incubated for 2 h at RT on a shaker after being sealed. Wells were aspirated and washed 
again for a total of 5 washes. 200 µl/well of Substrate Solution was added to the plate and 
incubated for 30 mins at RT, protected from light. Following this, 50 µl of Stop Solution 
was added to each well before the plate was read on a microplate reader at a wavelength 
of 450nm and the sample concentrations were calculated from the standard curve. A BCA 
protein assay was carried out (as per section 2.11.3) on the same samples in order to 
normalise the ELISA measurements by total protein concentration. 
 Investigating neutrophil expression of chemokine 
receptors following TNF stimulation 
   Isolation and TNF stimulation of leukocytes 
To examine the expression of the chemokine receptors: CCR7 and CXCR4 on neutrophils 
in naïve and inflamed conditions, flow cytometry was used as a tool. Certain experiments 
investigating intracellular and extracellular expression of CCR7 by neutrophils from 
digested cremaster muscles and dLNs were previously done by Dr. Christian Zakian and 
will be specified in the results section where appropriate.  
For experiments looking at extracellular expression of CCR7 and CXCR4 on neutrophils, 
whole blood was recovered from WT and CCR7KO mice by cardiac puncture using a 27 
gauge needle and 1 ml syringe filled with 20 µl heparin sodium. 0.5 – 1 ml of blood was 
obtained per mouse. Circulating cells were lysed with ACK lysis buffer as required 
(150mM NH4Cl, 1mM KHCO3, 0.1mM EDTA) before being passed through a 40 μm cell 
strainer for a single-cell suspension. Blood samples were then centrifuged at 300 g for 5 
mins at 4 °C and serum supernatant discarded. All samples were then washed twice with 
FACS buffer (1× PBS supplemented with 10% FBS) by centrifugation before being 
resuspended in the same buffer.  
Following isolation of leukocytes as above, TNF (1, 10 or 100 ng/ml) or PBS was added 
to stimulated or unstimulated groups, respectively, and left in an incubator (10% C02) at 
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37 °C in RPMI (supplemented with 10% FBS and 2mM of L-Glutamin) for 4 h before 
being fluorescently labelled for flow cytometry as detailed in section 2.13.3.   
   Inhibiting caveolae-dependent endocytic pathways 
In some experiments investigating CCR7 extracellular expression on neutrophils, the 
caveolae-dependent inhibitor, nystatin (50 µM), was used. Inhibitors were either added 
alongside TNF and used throughout the rest of the experiment or added 30 min prior to 
immunofluorescence staining with conjugated antibodies against CCR7 or the 
appropriate isotype control antibodies (0.2–2 μg/ml, various fluorochromes) and DAPI 
(for viability). 
   Immunofluorescence labelling of leukocytes and flow cytometry 
Cells were fluorescently labelled with mAbs against CD45.2, Ly6G, CD3ε, CD11c, 
CCR7, CXCR4 or the appropriate isotype control Abs (0.2–2 μg/ml, various 
fluorochromes) and DAPI (for viability) for at least 1 h at 4 °C  along with 0.5 μg FcγIII/II 
receptor blocking antibody (Fc-block™) to prevent unspecific Fc-receptor binding. 
CCR7-intracellular expression was performed using the Cytofix/Cytoperm kit (BD 
Biosciences) according to the manufacturer’s recommendations. 
Antibody-labelled cells were washed twice with FACS buffer by centrifugation at 300 g 
for 5 mins at 4 °C before being resuspended in 200 µl cold FACS buffer to achieve a 
single cell suspension. Following this, all samples were kept on ice. DAPI (1 μg/ml), a 
fluorescent dead cell nuclear marker, was added prior to analysis by flow cytometry. 
Samples were run on a BD LSR-Fortessa flow cytometer (BD Biosciences) using 
FACSDIVA software. Multi-colour fluorescence overlap was compensated for by using 
single-stained cells. At least 20,000 events were acquired per sample. 
Leukocytes were identified by FSC and SSC characteristics, CD45.2 positive staining and 
DAPI negative staining. Neutrophils were identified based on Ly6G high staining. T cells 
were identified based on CD3ε-high staining (Figure 2.4). The chemokine receptor 
CXCR4 was identified by CXCR4-high staining. CCR7 was labelled with a biotin-
conjugated Ab followed by streptavidin A488-conjugated secondary Ab and positive 
neutrophils were gated after determining the level of background fluorescence in the 
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CCR7KO or isotype control stained samples using 495/519 nm excitation/emission. Data 
were analysed with FlowJo analysis software (Treestar).  
 
Figure 2.4: Leukocyte subset gating strategies for cells of interest. 
 Verification of chimera reconstitution 
Alongside each experiment, whole blood was taken from each mouse via cardiac puncture 
and processed as described in section 2.13.1, to check reconstitution levels of chimerism 
by flow cytometry analysis.  
 CCR7KO LysM-eGFP/TNFRdbKO chimera verification 
Blood leukocytes from LysM-eGFP/TNRdbKO or chimeric animals were 
immunostained for neutrophil specific markers, CD45.2 and Ly6G, and TNFRs (p55 and 
p75). Neutrophil expression of GFP/TNFRs were analysed by flow cytometry to 
determine levels of chimerism.  
 Statistical Analysis 
Analysis of data was carried out using GraphPad Prism 6 software (San Diego, CA). 
Significant differences between groups were assessed by one-way analysis of variance 
(ANOVA) followed by Newman-Keuls multiple comparison test or unpaired two-tailed 
Student’s T-test. Data is expressed as means ± standard error of mean (SEM).  In all cases, 
a P value ≤ 0.05 was considered significant.          
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 : Investigating the dynamics of neutrophil migration 
during inflammation and the importance of TNF in 
driving these responses in vivo 
 Introduction 
The lymphatic system is composed of a hierarchical network of two basic vessels: 
lymphatic capillaries (or initial lymphatics) and collecting vessels, both of which have 
specific features serving their unique functions. Blind-ended initial lymphatics are 
comprised of oak-leaf shaped LECs with specialised flaps and buttons that regulate the 
drainage of interstitial fluid and the formation of lymph (Baluk et al., 2007). Once the 
lymph is formed, it is transported through a network of collecting lymphatic vessels back 
into the circulatory system (Bazigou et al., 2014). Although the structure of lymphatic 
vessels have been well-characterised in other tissues, those in the cremaster muscle have 
yet to be characterised. 
To date, neutrophil migration into the lymphatic system has been poorly studied. This 
process has been described in several models of infections and immunisation sensitisation 
(Abadie et al., 2005; Beauvillain et al., 2011; Chtanova et al., 2009; Maletto et al., 2006). 
However, the majority of these earlier studies did not study the cellular mechanisms 
regulating neutrophil entry into lymphatic vessels but were mostly looking at the 
regulation of downstream entry into the lymph nodes.  
In this chapter, the dynamics of neutrophil migration into the lymphatic vessels within 
cremaster muscles following inflammatory insult was investigated to further develop our 
understanding in order to progress towards the main goal of elucidating the mechanisms 
of neutrophil migration into lymphatic system. The murine cremaster muscle was chosen 
because it is a gold standard for both in vivo- and ex vivo-fluorescence staining for 
confocal microscopy analysis. The pro-inflammatory cytokine, TNF, and an emulsion of 
an antigen in CFA (CFA+Ag) were used as inflammatory mediators. TNF was chosen for 
its potency in mediating inflammation as well as its ability to prime neutrophils and 
trigger their mobilisation to sites of infection or inflammation (Hallett and Lloyds, 1995). 
CFA+Ag is able to stimulate responses associated with adaptive immunity and consists 
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of a mixture of paraffin oil and surfactant with heat-killed Mycobacterium tuberculosis 
in which an aqueous antigen solution, in the case of this study ovalbumin (OVA), is 
emulsified (Coffman et al., 2010). Recent evidence suggests neutrophils not only play 
roles in resolving acute inflammation but are also involved in shaping adaptive immune 
responses through their migration into lymphatic vessels and into lymph nodes (LNs) 
where adaptive responses take place (Hampton et al., 2015; Teijeira et al., 2013). Using 
an emulsion of CFA+Ag is a way for us to model antigen sensitisation that is achieved 
using the classical immunisation protocol to mimic the initiation of an adaptive immune 
response. 
Despite the role of TNF in priming neutrophils for numerous immune functions, such as 
triggering the production of microbicides and oxidants to fight invading pathogens 
(Kowanko et al., 1996; She et al., 1989), its role in the process of neutrophil migration 
into lymphatic vessels in vivo remains unknown. This chapter therefore aimed to further 
explore this avenue.  
 Aims 
The structure of lymphatic vessels has previously been reported in the mouse trachea and 
various other organs (Baluk et al., 2007), but not in the cremaster muscle. Thus, it is 
important to first characterise these in the current model used in this study. Furthermore, 
despite previous investigations into the effect of TNF and CFA+Ag on the inflammatory 
response in the lymphatic system, many if not all have focused on neutrophil trafficking 
into lymph node (LNs) and not on the mechanisms of their entry via lymphatic vessels 
(Abadie et al., 2005; Beauvillain et al., 2011; Hampton et al., 2015; Maletto et al., 2006). 
Therefore, further investigations into the migratory responses of leukocytes, specifically 
neutrophils, into lymphatic vessels are required to understand this phenomenon. This 
chapter therefore aimed to characterise the structure of lymphatic vessels found in the 
cremaster muscle and to investigate the effects of the inflammatory mediators, TNF and 
CFA+Ag, on neutrophil migration into lymphatic vessels in vivo using a mouse model of 
cremaster muscle inflammation. The effects of TNF and CFA+Ag were characterised 
over time in the cremaster muscle to explore the dynamics of neutrophil migration into 
the lymphatic system as observed by immunostaining and confocal microscopy. 
Furthermore, neutrophil-lymphatic vessel interactions following TNF-stimulation and 
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antigen sensitisation through the use of an emulsion of CFA+Ag were observed in real-
time via intravital confocal microscopy (IVM), allowing the direct visualisation of cell-
cell interactions in high-resolution. IVM is a powerful technique for real-time in vivo 
investigation of leukocyte/vessel wall interactions in inflammatory reactions and our 
group has developed immunofluorescence in vivo labelling to be able to visualise 
different components of the vessel wall for confocal IVM. 
Subsequently, the effect of endogenous TNF release during antigen sensitisation 
(CFA+Ag) was investigated ex vivo by carrying out ELISAs on tissue homogenates, and 
in vivo through the use of transgenic mice, immunostaining and confocal microscopy.  
The specific aims were to: 
 Investigate the structure of lymphatic vessels in the cremaster muscles of mice. 
 Investigate the effects of the pro-inflammatory cytokine TNF and antigen 
sensitisation with the use of an emulsion of an antigen in CFA (CFA+Ag) on 
neutrophil migration into lymphatic vessels through the use of ex vivo 
immunofluorescence staining and confocal microscopy analysis.  
 Use neutrophil reporter LysM-eGFP mice to track GFPhigh neutrophils at the 
site of inflammation using IVM to observe TNF- or CFA+Ag-induced 
migration into lymphatic vessels in vivo. 
 Investigate TNF release in the cremaster muscle following antigen sensitisation 
by carrying out ELISAs. 
 Investigate the role of TNF in neutrophil migration into lymphatic vessels by 
using TNFRdbKO mice as a means of abolishing TNF signalling. 
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 Results  
 Structure of lymphatic vasculature in the murine cremaster 
muscle 
To determine the structure of lymphatic vessels in the cremaster muscle of mice, whole-
mount cremaster tissues of naïve WT C57BL/6 mice were immunostained for LYVE-1 
and PECAM-1/VE-Cadherin. This showed the presence of a unidirectional network of 
lymphatic vessels (LYVE-1, red channel) with characteristic blind-ended lymphatic 
capillaries (orange arrows) (Figure 3.1A). LYVE-1 was also found to be expressed all 
over these lymphatic vessels (Figure 3.1A). Further analysis of the expression of the 
adhesion molecules, PECAM-1 and VE-Cadherin, on initial lymphatic vessels showed 
the presence of VE-Cadherin-rich buttons (red channel) and PECAM-1-rich flaps (blue 
channel). Lymphatic endothelial cells (LECs) also exhibited an oak-leaf shaped 
morphology (Figure 3.1B). 
 
Figure 3.1: Lymphatic architecture of the murine cremaster muscle. 
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(A) Representative 3D confocal image of a whole-mount fixed cremaster muscle of a WT 
mouse, immunostained with an antibody against LYVE-1 (red, Alexa555-conjugated) and 
PECAM-1 (blue, Alexa647-conjugated) to visualise lymphatic and blood vasculatures, 
respectively. Orange arrows indicate the blind-ended capillaries of the initial lymphatic 
vessels. Bar: 50 μm. (B) Representative confocal image (kindly provided by Dr Mathieu-
Benoit Voisin) of a fixed cremasteric lymphatic vessel immunostained for VE-Cadherin 
(Alexa555-conjugated, red) and PECAM-1 (Alexa647-conjugated, blue). The inserts on 
the right area show a magnified view of the heterogeneous distribution of the adhesion 
molecules (with VE-cadherin-rich buttons and PECAM-1-rich flaps) expressed by the 
endothelial cells of the cremasteric lymphatic vessels and exhibiting an oak-leaf shape 
morphology. Bar: 20 µm. 
 Time-course of TNF- or CFA+Ag-induced neutrophil migration 
across postcapillary venules and their migration into the 
lymphatic vessels and dLNs in the murine cremaster muscle 
In order to characterise the effects of TNF and CFA+Ag in the cremaster muscle on 
neutrophil trafficking from blood vessels into the lymphatic system, time-courses of the 
responses elicited by these inflammatory mediators were investigated. The dose 
employed for both TNF and CFA+Ag were those known to elicit significant leukocyte 
transmigration in this model based on previous findings from our group (Woodfin et al., 
2009). For this purpose, WT mice were given intrascrotal (i.s.) injections of either 300ng 
TNF (in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl total volume) and their 
cremaster muscles and draining lymph nodes (dLNs) were dissected away at different 
time-points, fixed and used whole-mounted for immunofluorescence staining and 
confocal analysis. The cremaster muscles were immunostained with anti-PECAM-1, anti-
LYVE-1 and anti-MRP14 mAbs to label the blood vasculatures, lymphatic vasculatures 
and neutrophils, respectively. The dLNs were immunostained with anti-HEV, anti-
LYVE-1 and anti-MRP14 mAbs to label blood vasculatures, lymphatic vasculatures and 
neutrophils, respectively. The timecourse for CFA+Ag-induced inflammation was carried 
out in collaboration with a previous member of the group, Dr Christian Zakian, and 
neutrophil migration responses into the draining LNs were analysed via flow cytometry. 
Draining LNs (dLNs) of the cremaster muscle were previously determined by Dr 
Mathieu-Benoit Voisin with the use of i.s. injections of Evans blue. 
Following TNF stimulation, 3D-reconstructed confocal images showed that a 
significantly higher number of neutrophils were present within the interstitial tissue 
130 
 
surrounding postcapillary venules (PCVs) at the 16 h time-point (Figure 3.2A, right) as 
compared to the unstimulated controls (Figure 3.2A, left). Quantification of these images 
using IMARIS software showed that neutrophil migration across PCVs into the inflamed 
interstitial tissue upon local injection of exogenous TNF occurred in a time-dependent 
manner (Error! Reference source not found.C). After 2 h TNF stimulation, neutrophil 
ransmigration could be detected and this was further increased at the 4–8 h timepoint 
before peaking at the 16 h time point and returning to basal levels after 48 h. This 
extravasation response observed in PCVs was associated with neutrophil migration into 
lymphatic vessels. 3D-reconstructed confocal images showed that a higher number of 
neutrophils were seen within lymphatic vessels at the 8h time point (Figure 3.2B, right) 
as compared to the unstimulated controls (Figure 3.2B, left). Quantification of these 
images using IMARIS software revealed a rapid but transient migration of neutrophils 
into lymphatic vessels at 8 h post-i.s. injection before returning to basal levels at the 48 h 




Figure 3.2: Neutrophil transmigration across postcapillary venules and into lymphatic 
vessels following TNF-induced inflammation in the cremaster muscle. TNF was injected i.s. 
into WT C57BL/6 mice and cremaster muscles were dissected at different time-points after 
stimulation, fixed, immunostained for PECAM-1 (blue), LYVE-1 (red) and MRP14 (green) and 
analysed by confocal microscopy and IMARIS software. (A) Representative 3D reconstructed 
confocal images from unstimulated (left) and TNF- stimulated (right) postcapillary venules 
illustrating neutrophil transmigration responses obtained at the 16 h time point. Bar: 50 µm. (B) 
Representative 3D reconstructed confocal transverse-section images of a unstimulated (left) and 
TNF- stimulated (right) lymphatic vessels at 8 h showing selected neutrophils within the lumen 
of the vessel. Bar: 50 µm. (C) Time course of transmigrated neutrophils per mm3 of tissue. (D) 
Time course of neutrophil migration into lymphatic vessels per mm3 of vessel. Data are expressed 
as mean ± SEM from at least 8-10 vessels/animals, with 5-12 animals per group (at least 5 
independent experiments). Statistically significant differences between stimulated and 
unstimulated treatment groups are indicated by asterisks: *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001. Significant differences between responses at different time points are indicated 




3D-reconstructed confocal images also showed that considerably more neutrophils can 
be seen within the dLNs (inguinal) at 24 h post-i.s. injection (Figure 3.3A, right) as 
compared to unstimulated controls (Figure 3.3A, left). Quantification of these images 
indicated the same time-dependent neutrophil response was occuring in cremaster muscle 
dLNs (inguinal) (Figure 3.3B), with neutrophil infiltration peaking at a delayed time-
point of 24 h before returning to basal levels after 48 h.  
 
Figure 3.3: Neutrophil migration into dLNs following TNF-induced inflammation of the 
cremaster muscle. PBS (unstimulated control) or TNF was injected i.s. into WT C57BL/6 mice 
and inguinal dLNs were dissected away 24 h after stimulation, fixed, immunostained for LYVE-
1 (red), MRP14 (green) and analysed by confocal microscopy. Representative images from 
unstimulated (left) and TNF-stimulated (right) dLNs illustrating neutrophil infiltration responses 
obtained at the 24 h time point. Bars: 100 µm. (B) Time course of the total neutrophil infiltration 
per mm3 of dLNs. Data are expressed as mean ± SEM from at least 8-10 vessels/animals, with 5-
12 animals per group (at least 5 independent experiments). Statistically significant differences 
between stimulated and unstimulated treatment groups are indicated by asterisks: *, P < 0.05; **, 
P < 0.01; ***, P < 0.001; ****, P < 0.0001. Significant differences between responses at different 
time points are indicated by hash symbols: #, P < 0.05; ####, P < 0.0001. Statistical significance 




Next, the inflammatory responses elicited by i.s. injection of an emulsion of CFA+Ag 
was looked at. 3D-reconstructed confocal images showed that at 8 h post-i.s. injection, 
neutrophils could still be seen in the process of migrating into lymphatic vessels (Figure 
3.4, top and middle) but most were within lymphatic vessels by 8 h post-i.s. injection 
(Figure 3.4, bottom). Quantification of these images also showed that CFA+Ag-induced 
transmigration through PCVs and into lymphatic vasculatures exhibited a time-dependent 
increase in the number of neutrophils, with detection of neutrophils within the inflamed 
tissues at 2 h post-i.s. injection and migration across PCVs peaking at 16 h post-i.s. 
injection (Figure 3.5A). Neutrophil migration into lymphatic vessels peaked at 8 h 
(Figure 3.5B) post-i.s. injection.  
The responses seen in the cremaster muscle were associated with an increase in neutrophil 
infiltration of the tissue dLNs (inguinal) but not in non-dLNs (axillary) as quantified by 
flow cytometry (Figure 3.5C). This response peaked at 8 h post-i.s. injection before 
gradually returning to basal levels after 24 h. Confocal microscopy analysis also 
confirmed this response and a significantly higher number of neutrophils was observed 
within the dLNs at 8 h post-i.s. injection (Figure 3.6, right) as compared to the 





Figure 3.4: CFA+Ag-induced migration of neutrophils into lymphatic vessels. These are 3D-
reconstructed confocal images showing neutrophils labelled with an anti-MRP-14 mAb within 
the lumen of a lymphatic vessel labelled with an anti-LYVE-1 mAb (as indicated by yellow 
arrows in top and bottom images). The top image depicts a lymphatic vessel surrounded by 
neutrophils. The middle image (insert from top image in orange box) shows a neutrophil mid-
migration at 8 h post-i.s. injection with CFA+Ag. The bottom image is a transverse section of 
another lymphatic vessel showing neutrophils within the lumen (yellow arrows) at 8 h post-i.s. 




Figure 3.5: Time course of neutrophil migration into the lymphatic system following 
CFA+Ag-induced inflammation in the murine cremaster muscle. WT C57BL/6 mice received 
i.s. injections of CFA+Ag (200 µg of each in 300 µl total volume) and were left for several in 
vivo test periods. Control mice received i.s. of PBS (300 µl). Neutrophil migration into the 
lymphatic system of WT C57BL/6 mice cremaster muscles was visualised by confocal 
microscope following dissection, fixation and permeabilisation of the tissues at the end of each 
time point. (A) Time course of transmigrated neutrophils per mm3 of tissue. (B) Time course of 
neutrophil migration into lymphatic vessels per mm3 of vessel. (C) Time course of neutrophil 
migration into draining LNs (inguinal) or non-draining LNs (axillary) of mice injected 
intradermally with CFA+Ag and as analysed by flow cytometry.  Data was obtained with Dr 
Mathieu-Benoit Voisin and Dr Christian Zakian. Data are expressed as mean ± SEM from at least 
8-10 vessels/animal (for confococal microscopy), with 5-12 animals per group (at least 5 
independent experiments). Statistically significant differences between stimulated and 
unstimulated treatment groups are indicated by asterisks: *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001. Significant differences between responses at different time-points are indicated 
by hash symbols: ##, P < 0.01; ####, P < 0.0001. Statistical significance was determined using 
one-way ANOVA 
 




Figure 3.6: Neutrophil migration into dLNs following CFA+Ag-induced inflammation of 
the cremaster muscle. PBS (unstimulated control) or CFA+Ag was injected i.s. into WT 
C57BL/6 mice and inguinal dLNs were dissected away at 8 h post-i.s. injection, fixed, 
immunostained for HEVs (green), LYVE-1 (red), MRP14 (blue) and analysed by confocal 
microscopy. Representative images from unstimulated (left) and CFA+Ag-stimulated (right) 
dLNs illustrating neutrophil infiltration responses obtained at the 8 h time point. Bars: 100 µm. 
 
Due to the low incidence of neutrophils present in the dLNs (less than 1% of total LN-
infiltrated leukocytes as observed by flow cytometry) and to exclude the increase of 
circulating neutrophils due to CFA+Ag-induced neutrophilia (as observed by previous 
group members) from the current data analyses, a detailed investigation of whole-mount 
dLNs immunostained for HEVs (blood vasculatures), LYVE-1 (lymphatic vasculatures) 
and MRP14 (neutrophils) was carried out by confocal microscopy (Figure 3.7A-D). This 
showed that out of the total number of neutrophils (655 ± 180) in the dLNs of 
unstimulated mice (Figure 3.7A), 125 ± 32, 231 ± 57, 746 ± 228 neutrophils were within 
the HEVs, lymphatics and stroma, respectively (Figure 3.7B-D). At 8 h post-i.s. 
injection, the highest number of neutrophils (5684 ± 1236) were found within the 
lymphatic vessels, representing the majority of neutrophils of the total number found 
within dLNs at this time-point (9984 ± 2050). At 16 h post-i.s. injection, out of 4085 ± 
920 neutrophils, only 1173 ± 222 neutrophils were within lymphatic vessels, whilst 2002 
± 460 neutrophils were found in the LN stroma. This indicated that at 8 h post-i.s. 
injection, neutrophils were mainly within lymphatic vessels but by the 16 h timepoint, 
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they had moved on into the stroma. Overall, only a minority of the neutrophils were found 
within the HEVs at these time-points. 
 
Figure 3.7: Number of neutrophils within the stroma, HEVs and lymphatics of the 
cremaster dLNs. Neutrophil migration into the lymphatic system was induced in WT animals 
following antigen sensitisation with complete Freund’s adjuvant (CFA+Ag). (A) Quantification 
of total neutrophil numbers in the dLNs of mice stimulated with CFA+Ag (8 or 16 h) or with PBS 
(control). (B) Quantification of neutrophil localisation within HEVs in the dLNs of mice 
stimulated with CFA+Ag (8 or 16 h) or with PBS (control). (C) Quantification of neutrophil 
localisation within lymphatic vessels in the dLNs of mice stimulated with CFA+Ag (8 or 16 h) or 
with PBS (control). (D) Quantification of neutrophil localisation within the stroma in the dLNs 
of mice stimulated with CFA+Ag (8 or 16 h) or with PBS (control). Data are represented as 
absolute numbers of neutrophils present in the HEV, LYVE-1+ vessels and in the stroma of the 
LNs as analysed by confocal microscopy. Data are expressed as mean±SEM of N = 5-12 animals 
(~10 images per pair of dLNs for confocal microscopy) per group from at least 5-10 independent 
experiments. Statistically significant differences between unstimulated and stimulated mice are 
indicated by asterisks: ***, P < 0.001; ****, P < 0.0001. Significant differences between 
responses in CFA+Ag stimulated groups are indicated by hash signs: ##, P < 0.01; ###, P < 0.001; 
####, P < 0.0001. Statistical significance was determined using one-way ANOVA 
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 Confocal intravital microscopy to observe TNF- or CFA+Ag-
induced migration of neutrophils into lymphatic vasculatures in 
real-time in vivo  
As a next step, the dynamics of neutrophil-lymphatic vessel interactions in vivo was 
analysed in real-time in the cremaster muscle of neutrophil reporter LysM-eGFP mice 
upon TNF or CFA+Ag-stimulation. For this purpose, LysM-eGFP mice were given i.s. 
injections of either 300ng TNF (in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl 
total volume) for 4 h and 6 h, respectively. Following this, in vivo fluorescent-
immunostaining with a non-inhibitory dose of anti-LYVE-1 mAbs was applied to the 
tissues to visualise lymphatic vessels to allow the tracking of GFPhigh neutrophil migration 
responses into and within the lymphatic vasculature by confocal IVM. LysM-eGFP mice 
are currently the most widely used mouse line for intravital neutrophil imaging, in which 
neutrophils are very bright (GFPhigh) and reasonably well differentiated from other less 
bright (GFPlow) myeloid cells (Bruns et al., 2010; Faust et al., 2000; Proebstl et al., 2012; 
Woodfin et al., 2011). Mice were anaesthetised and cremaster muscles were exteriorised 
and pinned out flat over the optical window of a heated microscope stage. Z-stack images 
of a lymphatic vessel were captured every 1 min for 90 mins in order to capture 
neutrophils migrating across the lymphatic endothelium between the time frames of 4–
5.5 h (for TNF stimulation) or 6–7.5 h (for CFA+Ag-stimulation). These time frames 
were chosen in order to allow enough time for neutrophils to transmigrate into the 
interstitial tissue and allow migrating neutrophils to be tracked and captured before the 
peak of neutrophil migration into lymphatic vessels, which occurs at 8 h for both 
inflammatory mediators. Tyrode’s salt solution was used to constantly superfuse 
cremaster muscles during all experiments. 
Following stimulation with TNF, neutrophils were observed to migrate rapidly through 
LECs into the lumen of lymphatic vessels (Figure 3.9A & Video 1). The actual 
transmigration process of neutrophils from the abluminal side of the LECs into the lumen 
of lymphatic vessels took on average 4.5 ± 0.58 min (Figure 3.9B).  
Surprisingly, neutrophil migration into lymphatic vessels following CFA+Ag-induced 
inflammation at the time-points chosen was not able to be observed as the majority of 
neutrophils were already within the lumen of the lymphatic vessel during the timeframe 




Figure 3.8: Neutrophil breaching lymphatic endothelium during IVM of a TNF-stimulated 
cremaster muscle. Mice were subjected to TNF-induced inflammation of the cremaster muscle 
and the dynamics of neutrophil migration into the tissue and lymphatic vessels was analysed by 
intravital confocal microscopy. (A) Representative 3D-reconstructed still image of a live 
recording of a cremaster region including a lymphatic vessel of a LysM-eGFP mouse and 
immunostained in vivo with anti-LYVE-1 mAb (red, conjugated to Alexa555). The bottom panel 
images illustrate a time-lapse series of 2μm-thick cross-sections along the z-plane (dotted blue 
arrow) and shows the migration of a neutrophil into the lymphatic vessel. Bars: 50 µm. (B) Time 
taken for neutrophils to migrate into the lumen of lymphatic vessels from the LEC surface. Results 
are from analysis of 10 cells from n=8 mice, each mouse representing one independent 
experiment. T, time. 
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 The effect of TNF signalling on neutrophil migration into 
lymphatic vessels following CFA+Ag-induced inflammation 
To investigate the effect of endogenous TNF release during CFA+Ag-induced 
inflammation, ELISAs were carried out to determine the amount of TNF released 
following antigen sensitisation in WT mice. For this purpose, WT mice were given i.s. 
injections of CFA+Ag as before and their cremaster muscles were dissected away 
following different in vivo test periods, snap-frozen and homogenised for analysis by 
ELISA. Interestingly, stimulation of WT cremaster muscles with CFA+Ag induced a 
modest but rapid release of TNF in the tissue between 4-8 h with the maximal release 
(17.5 ± 4.4 pg/ml) occurring at 16 h post-i.s. injection (Figure 3.9). 
 
 
Figure 3.9: TNF release in murine cremaster muscles following antigen sensitisation 
(CFA+Ag) in vivo. Time course of TNF release in the cremaster muscles of WT C57BL/6 mice 
following intra-scrotal injection of CFA+Ag and as quantified by ELISA. Mice were stimulated 
intrascrotally with CFA+Ag for different in vivo test periods before being sacrificed by cervical 
dislocation and their cremaster muscles isolated, snap-frozen and homogenised for use in ELISAs. 
Data are expressed as mean±SEM of N = 6-21 animals per group from 7 independent experiments. 
Statistically significant differences between unstimulated and stimulated mice are indicated by 
asterisks: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Statistical significance was determined 




Next, the significance of TNF signalling during the migration of neutrophils into 
lymphatic vessels was investigated. In order to block TNF signalling, global knockout 
mice lacking both TNF receptors (p55 and p75) were used. Neutrophil migration 
responses at 16 h post-i.s. injection (this being the peak of TNF release) in these TNF 
receptor double knockout (TNFRdbkO) mice and WT mice were studied and compared 
by confocal microscopy following antigen sensitisation. For this purpose, WT and 
TNFRdbkO mice were given i.s. injections of CFA+Ag as before. Control mice were 
given i.s. injections of PBS (300 μl). Cremaster muscles were then dissected away 16 h 
post-i.s. injection, fixed and immunostained with anti-PECAM-1, anti-LYVE-1 and anti-
MRP14 mAbs to label the blood vasculatures, lymphatic vasculatures and neutrophils, 
respectively. Cremaster dLNs were also harvested for flow cytometry analysis. Cells from 
digested LNs were immunostained with anti-CD45.2 and anti-Ly6G Abs in order to gate 
for leukocytes and neutrophils. 
Quantification of confocal microscopy images demonstrated that neutrophil 
transmigration across PCVs of WT and TNFRdbKO mice were similar at 16 h post-i.s. 
injection (Figure 3.10A). Interestingly, neutrophil migration into lymphatic vessels 
showed approximately 75% reduction in KO animals as compared to WT animals (Figure 
3.10B). This response was also associated with a reduction of approximately 64% in the 
number of neutrophils that had infiltrated the dLNs of KO animals in comparison to WT 
animals (Figure 3.10C). This is presumably because neutrophils are unable to migrate 






Figure 3.10: Neutrophil migration responses of WT and TNFRdbKO mice following 
CFA+Ag-induced inflammation in the cremaster muscle. Neutrophil migration into the 
lymphatic system of the cremaster muscle following antigen sensitisation with complete Freund’s 
adjuvant (CFA+Ag) was induced in WT and TNFRdbKO mice. (A) Number of extravasated 
neutrophils in cremaster muscles of WT and TNFRdbKO mice at 16 h post-CFA+Ag-stimulation 
as quantified by confocal microscopy. (B) Number of neutrophils within cremaster lymphatic 
vessels of WT and TNFRdbKO mice at 16 h post-CFA+Ag-stimulation as quantified by confocal 
microscopy. (C) Percentage of neutrophils in dLNs of WT and TNFRdbKO mice at 16 h post-
CFA+Ag-stimulation as quantified by flow cytometry. Data are expressed as mean±SEM of N = 
5-12 animals (~10 images per cremasters for confocal microscopy) per group from at least 5-10 
experiments. Statistically significant differences between WT and TNFRdbKO mice are indicated 





TNFRdbKO chimeric mice 
In order to address whether neutrophils respond directly or indirectly to endogenous TNF 
released during inflammation, chimeric animals exhibiting either WT or TNFR-deficient 
neutrophils were generated. For this purpose, lethally irradiated WT mice were 
reconstituted with bone marrow hematopoietic cells from either WT or TNFRdbKO 
animals before being subjected to antigen sensitisation.  
Chimerism of reconstituted mice were also verified at the end of the inflammatory period 
for each experiment. Briefly, whole blood was taken from TNFRdbKO or chimeric 
animals via cardiac puncture before being lysed in preparation for immunostaining. Blood 
leukocytes were then immunostained for neutrophil specific markers (CD45+ Ly6G+) 
and their surface expression of TNFR p55 and p75 before being analysed by flow 
cytometry.  
Phenotypic analysis by flow cytometry confirmed that all chimeras were fully 
reconstituted with the intended bone marrow hematopoietic cells (Figure 3.11A). 
Leukocytes from WT mice reconstituted with cells from TNFRdbKO mice showed no 
changes in fluorescence intensity for the TNFRs, p55 and p75, as compared to leukocytes 
from TNFRdbKO controls (Figure 3.11A, left panel), thus indicating that TNFRdbKO 
chimeras had neutrophils deficient in both TNFRs. In contrast, leukocytes from WT mice 
reconstituted with cells from other WT mice showed an increase in fluorescence intensity 
for the TNFRs, p55 and p75, as compared to TNFRdbKO controls (Figure 3.11A, right 
panel), thus indicating that these WT chimeras possessed neutrophils with expression of 
both TNFRs. The percentage of circulating neutrophils was also looked at and this proved 






Figure 3.11: Phenotypic analysis of blood neutrophils from TNFRs chimeric mice. Blood 
leukocytes from TNFRdbKO or chimeric animals were immunostained for neutrophil specific 
markers (CD45+ Ly6G+) and their surface expression of TNFRs p55 and p75 were analysed by 
flow cytometry. (A) Representative histograms of the fluorescence intensity for p55 (top panel) 
and p75 (bottom panel) of blood neutrophils from lethally irradiated WT mice and reconstituted 
with TNFRdbKO (TNFRdbKOWT) or WT (WTWT) bone marrow hematopoietic cells 
(blue) and compared to the intensity of staining from neutrophils of TNFRdbKO animals (as 
control, red). (B) Percentage of circulating neutrophils in WTWT and TNFRdbKOWT 
chimeric mice. Data are expressed as mean±SEM of N = 6-8 animals per group from at least 4 
independent experiments. Statistical significance was determined using Student’s T-test. 
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Following this, neutrophil migration responses in these mice were investigated. Similarly 
to full TNFRdbKO mice, the neutrophil migration response into the lymphatic system 
was impaired in chimeric animals exhibiting WT vasculature and tissue-resident cells 
along with neutrophils deficient in TNFRs, with a decrease of 77.6% and ~85% in the 
number of neutrophils present within lymphatic vessels and dLNs, respectively, as 
compared to the control group (Figure 3.12A and B). Neutrophil transmigration across 
PCVs was significantly higher in TNFRdbKO chimeric mice as compared to WT 
chimeric mice (Figure 3.12C). 
Overall, these results demonstrate for the first time the direct involvement of TNF in 
triggering the migration of neutrophils into tissue-associated lymphatic vessels upon 





Figure 3.12: Neutrophil migration responses of WT and TNFRdbKO chimeric mice 
following CFA+Ag-induced inflammation in the cremaster muscle. Neutrophil migration into 
the lymphatic system of the cremaster muscle following antigen sensitisation with complete 
Freund’s adjuvant (CFA+Ag) was induced in chimeric animals exhibiting neutrophils deficient 
in both TNFRs. Neutrophil migration responses were visualised by confocal microscopy and 
analysed by IMARIS Software. (A) Number of neutrophils within cremaster lymphatic vessels at 
16 h post-CFA+Ag-stimulation from chimeric animals receiving bone marrow transplant of WT 
or TNFRdbKO donor mice and as quantified by confocal microscopy. (B) Number of neutrophils 
found in the dLNs of chimeric animals receiving bone marrow transplant of WT or TNFRdbKO 
donor mice as quantified by confocal microscopy 16 h post-CFA+Ag-stimulation. (C) Number of 
extravasated neutrophils in cremaster muscles at 16 h post-CFA+Ag-stimulation from chimeric 
animals receiving bone marrow transplant of WT or TNFRdbKO donor mice and as quantified 
by confocal microscopy. Data are expressed as mean±SEM of N = 6-7 animals (~10-12 images 
per pair of cremaster/dLNs for confocal microscopy) images per cremasters for confocal 
microscopy) per group from at least 5-10 experiments. Statistically significant differences 
between WT and TNFRdbKO mice are indicated by asterisks: *, P < 0.05; **, P < 0.01. Statistical 





In this chapter, the structure of lymphatic vessels in the murine cremaster muscle was 
lymphatic system during inflammation was also investigated. The link between TNF and 
CFA+Ag was then established by inducing inflammation in cremaster muscles using 
these inflammatory triggers. 
The recirculation of fluid (lymph) and cells within interstitial tissues through the 
lymphatic system is an important process that occurs in normal tissue homeostasis, 
inflammatory diseases, and cancer. However, cellular features responsible for the entry 
of lymph and leukocytes, specifically neutrophils, into lymphatic vessels is still poorly 
understood. Reports have shown the presence of discontinuous button-like junctions 
between endothelial cells (ECs) of initial lymphatics at likely sites of fluid entry, with 
continuous zipper-like junctions found on collecting vessels in the mouse trachea and 
several other organs, including  the diaphragm, urinary bladder, and skin of ear and tails 
(Baluk et al., 2007; Dejana et al., 2009). The reports also showed initial lymphatics had 
distinctive oak-leaf shaped LECs and immunostaining for the lymphatic endothelial cell 
marker, LYVE-1, was concentrated at the top of scalloped edges (flaps) of oak leaf-
shaped cells. In the opening results chapter, investigations into the structure of initial 
lymphatic vessels found in the chosen inflammatory model were carried out, where the 
cremaster muscle was used. Whole-mount cremaster muscles immunostained for the 
lymphatic endothelial cell marker, LYVE-1, and the endothelial cell markers, PECAM-
1/VE-Cadherin showed the presence of a fully developed unidirectional network of 
lymphatic vessels with blind-ended lymphatic capillaries and initial vessels with button-
like junctions and oak-leaf shaped cells in accordance with what was found in initial 
lymphatics in Baluk et al.’s report. Despite previous findings indicating that LYVE-1 was 
mainly concentrated at flaps of initial lymphatics (Baluk et al., 2007; Dejana et al., 2009), 
this molecule was found to be expressed all over these vessels in the present study. These 
differences could be due to differences in the staining protocol and confocal settings. 
Collectively, these findings suggest that in the cremaster model for this study, majority 
of the lymphatic vessels that were looked at are initial lymphatics. 
Next, the dynamics of leukocyte migration from the circulation into the lymphatic system 
was investigated. The dynamics of leukocyte, specifically neutrophil, transmigration, 
through venular walls (Proebstl et al., 2012; Woodfin et al., 2009) and their downstream 
entry into LNs (Abadie et al., 2005; Maletto et al., 2006; Rigby et al., 2015) in response 
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to inflammatory stimuli in mice has been previously looked at in separate in vivo and in 
vitro studies. However, the overall dynamics of these events occurring successively has 
not been studied. Innate immunity comes into play when tissues become inflamed due to 
tissue injury or infection. Chemokines produced by resident patrolling macrophages then 
cause neutrophils from the circulation to transmigrate across PCVs to the site of 
inflammation (Ley et al., 2007). 
Studies have shown that neutrophils are detected in the interstitial tissue at the site of 
inflammation from as early as 45 min up to a period of 48 h (Frasch et al., 2013; Woodfin 
et al., 2009; Yadav et al., 2003). Neutrophil transmigration responses from the circulation 
across PCVs was investigated by carrying out a time-course experiment. Local injection 
of either TNF or an emulsion of CFA+Ag elicited neutrophil migration in a time-
dependent manner. Following TNF-stimulation, neutrophils are still present in the 
inflamed tissue at 48 h but at low numbers, close to basal levels, which is in accordance 
with a previous study using another inflammatory mediator, zymosan (Frasch et al., 
2013). The longest time-point looked at post CFA+Ag-stimulation was 24 h, and although 
neutrophils numbers are not quite back to basal levels, a decreasing trend can be seen. In 
accordance with the present study, an earlier study using CFA+Ag to induce peritonitis 
demonstrated that neutrophil migration recruitment into the peritoneal cavity also 
occurred in a time-dependent manner peaking at 6 h, and although neutrophil numbers 
were low at the 24 h time-point, numbers only fully returned to basal levels at the 48 h 
time-point (Klein et al., 1995). Additionally, in another model of intraperitoneal antigen 
(methylated BSA) challenge, neutrophil recruitment to the peritoneal cavity was also 
demonstrated to occur in a time-dependent manner with neutrophils being detected at the 
site of inflammation from 2 h, and neutrophil numbers peaking at 6 h before returning 
close to basal levels at 24 h post-i.s. injection (Vieira et al., 2009). Albeit the different 
peaks seen in the current model of antigen sensitisation, this is still in accordance with 
the time-course results. 
Following elicitation of the innate immune response, the induction of an adaptive immune 
response depends on the effective transport of antigens through afferent lymphatic 
vessels. These antigens are transported to lymphoid tissue by either being taken up by 
antigen-presenting cells (APCs), which then carry them to dLNs, or they get drained to 
the nodes as a soluble component of lymph fluid.  To date, most studies have focused on 
the ability of peripheral dendritic cells (DCs) to exert this function and studies looking at 
the ability of neutrophils to do this has been neglected. However, recent reports have 
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shown that these extravasated neutrophils play more than just a minor role in innate 
immunity. Once activated by an inflammatory stimulus, both mice and human neutrophils 
have been shown to express MHC-II and the co-stimulatory molecules CD80 and CD86, 
thus enabling them to function as APCs (Abi Abdallah et al., 2011; Culshaw et al., 2008; 
Lei et al., 2001). Rather than dying locally in the interstitial tissue, a sub-population of 
neutrophils can remain viable and migrate from tissues to dLNs via lymph where they 
then act as APCs. In particular, neutrophils bearing phagocytosed M.bovis BCG and 
Toxoplasma gondii have been found within the sinuses of draining lymph nodes in several 
models (Abadie et al., 2005; Chtanova et al., 2008; Maletto et al., 2006). This chapter 
sought to look at neutrophil migration into lymphatic vessels and their downstream entry 
into dLNs following TNF- or CFA+Ag-stimulation. As with neutrophil transmigration 
into interstitial tissues, this was both also found to occur in a time-dependent manner. The 
dynamics of neutrophil entry into lymphatic vessels has not been well characterised in 
the literature, but confocal IVM in the present study showed that neutrophils take ~4.5 
minutes to breach the lymphatic endothelium in a TNF-stimulated cremaster muscle, 
which is similar to the time it takes (~2–5 minutes) for leukocytes to migrate through the 
vascular EC barrier (Ley et al., 2007). In vitro, Rigby et al. showed that TNF stimulation 
causes neutrophils to transmigrate across a monolayer of primary human dermal 
lymphatic endothelial cells (HDLECs) in a time-dependent manner starting at ~18 mins 
and peaking at ~90 mins before plateauing and decreasing in number (Rigby et al., 2015). 
Direct comparisons of these results cannot be made to the current in vivo study but 
similarities can be inferred as a time-dependent response was seen in the current study. 
Rigby et al. also showed that TNF stimulation triggers the secretion of neutrophil specific 
chemokines, CXCL2, CXCL5 and CXCL8, with the latter being particularly important in 
directing neutrophil transmigration across the lymphatic endothelium (Rigby et al., 2015). 
Other molecules involved in neutrophil migration through initial lymphatic vessels along 
with other cellular aspects that could account for the striking kinetics of this process, are 
only now starting to be elucidated but these will be further discussed in chapter 4 and 6 
of this thesis. In particular, the roles of chemokines in this process will be investigated 
and discussed in further detail in chapter 4 of this thesis. Studies looking at the ability of 
neutrophils to migrate across the lymphatic endothelium following antigen sensitisation 
in vivo have been neglected. 
Following this, the dynamics of neutrophil migration into dLNs following TNF- or 
CFA+Ag-induced inflammation was investigated. As mentioned before, such studies to 
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date have mainly involved looking at DC migration. DC migration from the interstitial 
tissue to dLNs is a slow process that typically peaks a couple of days after elicitation of 
the inflammatory response (Kissenpfennig et al., 2005; Shklovskaya et al., 2008). Rigby 
et al. demonstrated that DCs displayed a characteristic lag of 4–6 h before migrating 
across the lymphatic endothelium in vitro, whereas neutrophils initiated transmigration 
almost immediately (Rigby et al., 2015). Interestingly, there have been several recent 
studies that have shown neutrophils to be the first lymph-borne cell type transporting 
antigen to dLNs in different models of infection (Abadie et al., 2005; Beauvillain et al., 
2011; Hampton et al., 2015).  
These investigations not only demonstrated that neutrophil infiltration in dLNs was 
detected as early as 4–6 h after administration of inflammatory stimuli (Beauvillain et al., 
2011; Hampton et al., 2015), but emerging data suggests that this early influx of 
neutrophils may perhaps impact the developing immune response (Hampton et al., 2015; 
Mocsai, 2013). Several other studies reported similar observations in vaccinal (using 
antigens and CFA) and parasitic infection models (Chtanova et al., 2008; Maletto et al., 
2006; Yang et al., 2010). In these works, migration of neutrophils into dLNs was observed 
from as early as 15–30 min, with neutrophils still being detected at 24–48 h post 
immunisation/infection. Comparing this to the results from the present study, neutrophils 
were detected within dLNs of mice from as early as 2 h after stimulation with both TNF 
and CFA+Ag, with neutrophil infiltration continuing to increase until reaching a peak at 
24 h and 8 h, respectively. Moreover, neutrophils were still detected after 24 h and 48 h 
of CFA+Ag- or TNF-stimulation, respectively, all of which is in accordance to previous 
observations. Furthermore, examination of the localisation of neutrophils within dLNs of 
the cremaster muscle showed that at 8 h post-CFA+Ag inflammation, a much higher 
number of neutrophils were found within lymphatic vessels in the dLNs at 16 h post-
stimulation with CFA+Ag as compared to the 8 h timepoint. Additionally, majority of 
neutrophils were found in the stroma at this time point with only a minority found within 
HEVs. This all suggests that the early and rapid migration of neutrophils into dLNs may 
occur via afferent lymphatics and further strengthens previous findings from other models 
that neutrophils play a role in adaptive immune responses. It is worth mentioning that 
neutrophils can also enter LNs through an alternative route by migrating from the 
circulation across HEVs, as has been observed following intradermal injection of S. 
aureus and CFA (Gorlino et al., 2014; Kamenyeva et al., 2015). Thus, some of the 
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neutrophils present within dLNs at the early time-points could potentially have migrated 
via this route. 
In the present study, either TNF or an emulsion of CFA+Ag were used as inflammatory 
mediators. Having observed both the efficacy of CFA+Ag and exogenous TNF in 
inducing neutrophil migration into lymphatic vessels, the potential role of endogenous 
TNF in this response in a model of antigen sensitisation was next investigated. 
Interestingly, CFA+Ag-stimulation of cremaster muscles induced a rapid release of TNF 
in the tissues. Owing to the fact that TNF can prime neutrophils and trigger their 
mobilisation to sites of infection or inflammation (Hallett and Lloyds, 1995), the 
functional role of endogenous TNF during CFA+Ag-induced inflammation at the 16 h 
time-point was investigated. TNF signalling was blocked using TNFRdbKO mice 
deficient in both TNF receptors, p55 and p75. Results showed that neutrophil migration 
into lymphatic vessels was impaired in these mice. Strikingly, TNF did not appear to have 
any effect on neutrophil transmigration across venular endothelial cells into interstitial 
tissues, signifying a distinct role for TNF in driving neutrophil migration into lymphatic 
vessels but not through blood vessels. This was also found to be the case at an earlier time 
point of 8 h (Appendix 1), thus confirming that the lower number of neutrophils seen at 
the 16 h timepoint is not due to faster efflux of neutrophils from lymphatic vessels. 
Furthermore, the use of chimeric animals showed that TNF is able to directly act on 
leukocytes to induce this neutrophil migration response as neutrophils deficient in both 
TNFRs showed impaired neutrophil migration into lymphatic vessels.  
In contrast with pure TNFRdbKO mice, a significant increase was seen in extravasation 
of TNFRdbKO chimeric mice as compared to WT chimeric mice. Other studies have 
showed results similar to this study regarding neutrophil recruitment to sites of 
inflammation in the absence of TNF signalling (Peschon et al., 1998; Woodfin et al., 
2009).  In accordance with the results found in TNFRdbKO mice used in this study, 
Woodfin et al. showed in vivo in a model of cremaster inflammation that at 4 h post-
stimulation with IL-1β, no differences in neutrophil extravasation were seen between WT 
and TNFRdbKO mice (Woodfin et al., 2009). Peschon et al. also demonstrated in an in 
vivo model of LPS-induced peritonitis that neutrophil recruitment to the peritoneum is the 
same in both WT and TNFRdbKO mice. This suggests an accumulation of neutrophils is 
occurring within the inflamed tissue of TNFRdbKO chimeric mice for unidentified 
reasons. The percentage of circulating neutrophils between both WT and TNFRdbKO 
chimeras was the same, therefore this could be disregarded as an explanation as to why a 
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higher number of neutrophils were seen in the inflamed tissue. Another explanation could 
be the presence of higher concentrations of neutrophil chemoattractants in the inflamed 
tissue of TNFRdbKO chimeric mice. In order to generate these chimeric mice, WT mice 
had to be subjected to two low doses (5 Gy) of irradiation before reconstitution of either 
WT or TNFRdbKO bone marrow hematopoietic cells. A study looking at the effect of 
low-dose irradiation (8 Gy) on chemokine expression in mice liver demonstrated an 
upregulation of gene expression of several chemokines in the parenchyma, including the 
chemoattractants implicated in neutrophil recruitment - CXCL1, CXCL2 and CXCL8 
(Malik et al., 2010). However, this study only looked at several timepoints up to 48 h 
after irradiation. Another study in humans showed that TNF induces a stop signal that 
promotes firm neutrophil adhesion and inhibits polarisation and chemotaxis of 
neutrophils to chemoattractants including IL-8 and C5a, thus promoting the retention of 
neutrophils within blood vessels (Lokuta and Huttenlocher, 2005). Although these 
findings were found in a different tissue to the cremaster muscle and in humans, an 
upregulation in the expression of these chemokines in the interstitial tissues along with 
dysfunctional leukocyte TNF signalling, could be an explanation as to why TNFRdbKO 
chimeric mice exhibit higher neutrophil numbers within the interstitial tissue. There have 
been few reports of the direct effect of blocking TNF signalling on neutrophils with the 
use of anti-TNF agents (den Broeder et al., 2003; Taylor et al., 2000). However, these 
drugs have been shown to significantly reduce migration of neutrophils from peripheral 
blood into chronically inflamed joints, in the case of rheumatoid arthritis (den Broeder et 
al., 2003; Taylor et al., 2000). Its effect on neutrophil migration into lymphatic vessels is 
still unknown, although findings in the present study have implicated a role for TNF in 
this process. 
Collectively, the findings in this chapter indicate that lymphatic vessels of the cremaster 
muscle analysed via confocal microscopy are mainly initial lymphatics and also highlight 
the dynamic responses of neutrophil migration from blood vasculatures into the lymphatic 
system during TNF and CFA+Ag-induced inflammation. Furthermore, findings here 
demonstrate for the first time the involvement of TNF in triggering the migration of 
neutrophils into tissue-associated lymphatic vessels upon antigen challenge in vivo. This 






Limitations of the study 
As with most studies, there are certain limitations to the model used in this study. The 
obvious being the use of mice in the in vivo inflammatory models, which renders it less 
relevant to humans. However, due to ethical reasons, the mouse model is the best 
alternative as it allows the visualisation of neutrophil migration responses at any chosen 
time-point of the inflammation at the cellular and molecular level in structures (blood and 
lymphatic vessels, LNs etc.) that are not easily accessible in humans. Furthermore, it also 
allows the visualisation of these responses within lymphatic vessels in real-time using 
confocal IVM, a technique that is not currently applicable to human studies. Another 
caveat is the fact that the model of inflammation used in this study makes use of the mouse 
cremaster muscle, which might not be relevant to the female population as it has been 
shown that there are sex differences in immune responses (Klein and Flanagan, 2016). To 
overcome this, another vascular bed such as the ear or mesentery can be used to confirm 
these results in female mice. Finally, the use of CFA is not relevant to humans as the use 
of this adjuvant is prohibited due to its toxicity. However, it is widely used in animal 
models to mimic the classical immunisation protocols used in humans, which makes it 




 : Investigating the chemokine:chemokine receptor 
axes responsible for TNF-dependent migration of 
neutrophils into lymphatic vessels in vivo  
 Introduction 
Neutrophil migration into the lymphatic system has been described in models of 
infections and immunisation sensitisation (Abadie et al., 2005; Beauvillain et al., 2011; 
Chtanova et al., 2009; Maletto et al., 2006), but the mechanisms associated with this 
response are not fully understood. As supported by the literature, Chapter 3 presented 
results indicating initial lymphatics form blind-ended structures, with the presence of 
discontinuous endothelial junctions with distinctive PECAM-1-rich flaps and VE-
Cadherin-rich buttons. These flaps have been shown to serve as entry portals for 
leukocytes, such as DCs, which are reported to migrate at steady-state into initial 
lymphatics via integrin-independent mechanisms that are largely controlled by 
CCL21/CCR7-mediated chemotaxis (Pflicke and Sixt, 2009).  
To date, there is controversy surrounding the involvement of chemotactic stimuli in 
neutrophil migration into draining lymph nodes via lymphatic vessels. The first study 
reported that CCR7 is key for this process (Beauvillain et al., 2011), whereas a following 
study provided evidence to show that CCR7 is entirely dispensable (Hampton et al., 
2015). Additionally, the chemokine axis, CXCR4:CXCL12, and Sphingosine-1-
Phosphate (Gorlino et al., 2014; Hampton et al., 2015) have recently been implicated in 
neutrophil trafficking into LNs. Additionally, the chemokine CXCL8, a ligand of 
chemokine receptors CXCR1 and CXCR2, has been found to be expressed by human 
LECs and identified as the main chemotactic driver in the transmigration of neutrophils 
across a monolayer of LECs in vitro (Rigby et al., 2015). Conversely, CXCR2 has been 
shown to not have a role in neutrophil trafficking to draining lymph nodes (Gorlino et al., 
2014). In light of this, it has to be mentioned that all these studies made use of very 
different inflammatory models, ranging from inflammation induced by injection of 
inactivated pathogens, immune complexes in CFA to live bacilli, with some of these 
chemokine axes being implicated in neutrophil trafficking to LNs via HEVs as opposed 
to via lymphatic vessels (Beauvillain et al., 2011; Gorlino et al., 2014; Hampton et al., 
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2015). The involvement of chemokine:chemokine receptor axes may possibly vary with 
the type of inflammatory model used, especially since the up-regulation of chemokines 
in LECs has been widely shown to be highly stimulus specific (Aebischer et al., 2014). 
With relevance to this, it has been demonstrated that TNF is likely to be a master regulator 
of the signals responsible for directing cells to the site of infection, with TNF influencing 
appropriate chemokine expression by infected macrophages to orchestrate neutrophil 
recruitment to sites of inflammation (Algood et al., 2005; Vieira et al., 2009). The 
chemokines IL-8 (CXCL8), MIP-2 (CXCL2) and KC (CXCL1) have been shown to be 
the most critical for neutrophil recruitment to these sites (De Filippo et al., 2008; Shen et 
al., 2004). A study by Ihenetu et al. showed in vitro in an epithelial cell line that IL-8 
release was time-dependent following stimulation with TNF (Ihenetu et al., 2003). 
Another study by Lo et al. demonstrated in vitro using HUVECs that TNF stimulation 
induces the release of CXCL1 and its mRNA expression in a time-dependent manner (Lo 
et al., 2014). In the context of LECs, TNF stimulation has been demonstrated to induce a 
dramatic increase in CX3CL1, which has been implicated in DC cell migration across the 
lymphatic endothelium both in vivo and in vitro (Johnson and Jackson, 2013). TNF has 
also been shown to upregulate CCL21 expression by lymphatic vessels, which leads to 
DC migration across LECs via a β2-integrin-mediated mechanism in vitro (Johnson and 
Jackson, 2010). 
As the specific mechanisms by which neutrophils migrate into lymphatic vessels remains 
largely unknown, the present study set out to decipher further molecular mechanisms 
involved in neutrophil migration into lymphatic vessels, and more specifically, which 
chemokine:chemokine receptor axes are associated with this response under 






Neutrophils are the first immune cells to be recruited from the circulating blood to sites 
of infection or diseased tissues. CXC chemokines including IL-8 (CXCL8 – human 
equivalent of murine CXCL1/2), MIP-2 (CXCL2) and KC (CXCL1) have been widely 
demonstrated to be the most critical for such recruitment (Kobayashi, 2008). In the 
context of leukocyte migration across the lymphatic endothelium, the CCL21:CCR7, 
CXCL12:CXCR4, and CX3CL1:CX3CR1 chemokine axes have all been implicated in 
DC migration into the lymphatic system. In contrast, the chemokine:chemokine receptor 
axes involved in neutrophil trafficking into lymphatic vessels are still relatively unknown. 
Having previously identified a role for endogenous TNF in controlling the entry of 
neutrophils into lymphatic vessels in the previous chapter, this chapter aimed to elucidate 
chemokine:chemokine receptor axes responsible for promoting this response. The 
specific aims of this chapter were to: 
 Investigate the role of the CXCL1:CXCR1/2 and CXCL12:CXCR4 chemokine 
axes in neutrophil migration into lymphatic vessels of WT mice using anti-
CXCL1 blocking mAbs and AMD3100 (CXCR4 inhibitor) following CFA+Ag-
stimulation. Ex vivo immunofluorescence staining and confocal microscopy 
analysis will be carried out. 
 Investigate neutrophil expression of CCR7 following TNF- or CFA+Ag-
stimulation both in vivo and in vitro through the use of flow cytometric analysis. 
 Investigate the role of the CCL21:CCR7 chemokine axis in neutrophil migration 
into lymphatic vessels by confocal microscopy following TNF- or CFA+Ag-
stimulation through the use of CCR7KO mice as a means of abolishing CCR7 
signalling.  
 Investigate the importance of CXCR4 in neutrophil recruitment into the lymphatic 
system via confocal microscopy, in the absence of the CCR7 signalling with the 
use of CCR7KO mice. 
 Further investigate the role of CCR7 on neutrophils in a WT environment by 
generating chimeric mice exhibiting CCR7KO-deficient neutrophils and 






 Effects of the CXCL1:CXCR1/2 chemokine axis on neutrophil 
migration during CFA+Ag-induced inflammation of the 
cremaster muscle 
The role of the CXCL1:CXCR1/2 chemokine axis was first investigated in neutrophil 
trafficking into the lymphatic system during antigen sensitisation in vivo, as the human 
equivalent of murine CXCL1, CXCL8, has recently been shown to promote neutrophil 
migration through a monolayer of LECs in vitro (Rigby et al., 2015). Furthermore, 
CXCL1 has been demonstrated to be upregulated in lymphatic vessels of mice ears 
following CHS-induced inflammation in vivo (Vigl et al., 2011). 
For this purpose, neutrophil migration responses were looked at following 8 h (peak of 
neutrophil migration into lymphatic vessels) CFA+Ag-induced inflammation of the 
cremaster muscle of WT mice. Briefly, WT mice were given i.s injections of an emulsion 
of CFA+Ag (200 µg of each in 300 µl total volume) and were i.s injected with 30 µg of 
anti-CXCL1 blocking/isotope control antibody 4 h post-i.s. injection. This dosage was 
chosen as it has been demonstrated to inhibit neutrophil migration across blood vessels 
by other members of the group (unpublished data). Unstimulated control mice were given 
i.s injections of PBS. Eight hours post-i.s. injection, mice cremaster muscles and dLNs 
were dissected away, fixed and whole-mounted for immunofluorescence staining and 
confocal analysis. Cremaster muscles were immunostained with anti-PECAM-1, anti-
LYVE-1 and anti-MRP14 mAbs to label blood vasculatures, lymphatic vasculatures and 
neutrophils, respectively. Draining LNs were immunostained with anti-MECA-79, anti-
LYVE-1 and anti-mRP14 mAbs to label HEVs, lymphatic vasculatures and neutrophils, 
respectively. Images obtained from confocal microscopy were analysed using IMARIS 
software.  
No significant differences were seen via confocal microscopy in the interstitial tissue 
surrounding postcapillary venules at 8 h post-i.s. injection in mice treated with anti-
CXCL1 blocking antibody (Figure 4.1A, right panels) as compared to isotype controls 
(Figure 4.1A, left panels). Quantification of confocal images showed that a delayed local 
delivery of anti-CXCL1 blocking antibody did not affect the migration of neutrophils 
across postcapillary venules (Figure 4.1B). Additionally, 3D-reconstructed images from 
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confocal microscopy showed no differences in neutrophil numbers within lymphatic 
vessels of mice treated with anti-CXCL1 blocking antibody (Figure 4.2A, right panels) 
as compared to isotope controls (Figure 4.2A, left panels). Quantification of these 
images showed that treatment with anti-CXCL1 blocking antibody had no significant 
effect on neutrophil migration into lymphatic vessels (Figure 4.2B). Finally, 3D-
reconstructed images from confocal microscopy showed no differences in number of 
neutrophils seen within dLNs of mice treated with anti-CXCL1 blocking antibody 
(Figure 4.3A, right panels) as compared to those that received i.s. injections of isotype 
control antibody (Figure 4.3A, left panels). Quantification of confocal images showed 
that treatment with anti-CXCL1 blocking antibody demonstrated no significant effect on 
neutrophil infiltration in dLNs (Figure 4.3B). 
Collectively, the results in this section suggests that the CXCL1:CXCR1/2 chemokine 
axis does not play any significant role in neutrophil recruitment into lymphatic vessels 




Figure 4.1: Neutrophil transmigration responses across postcapillary venules of WT mice 
following in vivo blockade of the chemokine CXCL1 in unstimulated and CFA+Ag-
stimulated cremasters. WT C57BL/6 mice were subjected to CFA+Ag-induced cremaster 
inflammation. Four hours later, an anti-CXCL1 blocking mAb (30µg/mouse) or and an 
isotype control mAb was given i.s. to all mice. This dose was selected for its capacity to 
block neutrophil extravasation following cytokine-induced inflammation (data not 
shown). Eight hours post-stimulation, cremaster muscles were dissected away, fixed and 
immunostained for αSMA (red) and MRP14 (blue) to visualise the blood vasculatures 
and neutrophils, respectively. Neutrophil migration responses were visualised by 
confocal microscopy and analysed by IMARIS Software. (A) Representative 3D-confocal 
images of neutrophil extravasation from postcapillary venules in the cremaster muscles 
of CFA+Ag-stimulated WT mice treated with isotype control Ab (left) or anti-CXCL1 
blocking mAb (right). (B) Number of extravasated neutrophils in inflamed cremaster 
muscles. Data are expressed as mean ± SEM of n=5-7 animals per group (~10-12 images 
per pair of dLNs for confocal microscopy). Statistically significant differences between 
stimulated and unstimulated treatment groups are indicated by asterisks: *, P < 0.05; **, 





Figure 4.2: Neutrophil migration responses into lymphatic vessels of WT mice following in 
vivo blockade of the chemokine CXCL1 in unstimulated and CFA+Ag-stimulated 
cremasters. WT C57BL/6 mice were subjected to CFA+Ag-induced cremaster inflammation. 
Four hours later, an anti-CXCL1 blocking mAb (30µg/mouse) or and an isotype control mAb was 
given i.s. to all mice. This dose was selected for its capacity to block neutrophil extravasation 
following cytokine-induced inflammation (data not shown). Eight hours post-stimulation, 
cremaster muscles were dissected away, fixed and immunostained for LYVE-1 (green) and 
MRP14 (blue) to visualise the lymphatic vasculatures and neutrophils, respectively. Neutrophil 
migration responses were visualised by confocal microscopy and analysed by IMARIS Software. 
(A) Representative 3D-confocal images of neutrophils within lymphatic vessels in the cremaster 
muscles of CFA+Ag-stimulated WT mice treated with isotype control Ab (left) or anti-CXCL1 
blocking mAb (right). The top panels show all neutrophils present in the field of view. The bottom 
panels show neutrophils present only within the lymphatic vessels. Bars: 50 μm. (B) Number of 
neutrophils within the cremaster lymphatic vessels. Data are expressed as mean ± SEM of n=5-7 
animals per group (~10-12 images per pair of dLNs for confocal microscopy). Statistically 
significant differences between stimulated and unstimulated treatment groups are indicated by 





Figure 4.3: Neutrophil migration responses into dLNs of WT mice following in vivo blockade 
of the chemokine CXCL1 in unstimulated and CFA+Ag-stimulated cremasters. WT 
C57BL/6 mice were subjected to CFA+Ag-induced cremaster inflammation. Four hours later, an 
anti-CXCL1 blocking mAb (30µg/mouse) or an isotype control mAb was given i.s. to all mice. 
This dose was selected for its capacity to block neutrophil extravasation following cytokine-
induced inflammation (data not shown). Eight hours post-stimulation, dLNs (inguinal) were 
dissected away, fixed and halved before being immunostained for LYVE-1 (red), HEVs (green) 
and MRP14 (blue) before being analysed by confocal microscopy and IMARIS software. (A) The 
figure shows representative 3D-confocal images of neutrophil infiltration into the dLNs of mice 
that received i.s injection of isotope control Ab (left) or treatment of anti-CXCL1 blocking mAb 
(right) Bars: 50 μm. (B) Number of neutrophils found in the dLNs. Data are expressed as mean ± 
SEM of n=5-7 animals per group (~10-12 images per pair of dLNs for confocal microscopy). 
Statistically significant differences between stimulated and unstimulated treatment groups are 
indicated by asterisks: *, P < 0.05; **, P < 0.01. Statistical significance was determined using 
one-way ANOVA.  
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 Effects of the CXCL12:CXCR4 chemokine axis on neutrophil 
migration during CFA+Ag-induced inflammation of the 
cremaster muscle 
The role of the CXCL12:CXCR4 chemokine axis was next investigated on neutrophil 
trafficking into the lymphatic system during antigen sensitisation. For this purpose, a 
CXCR4 specific inhibitor, AMD3100, was used. As before, neutrophil migration 
responses were looked at following 16 h (peak of neutrophil migration into lymphatic 
vessels) of CFA+Ag-induced inflammation in the cremaster muscle of WT mice. Briefly, 
WT mice were given i.s injections of 200 μg of an emulsion of CFA+Ag (200 µg of each 
in 300 µl total volume) and were i.s injected with AMD3100/vehicle control (PBS) 4 h 
post-i.s. injection. Unstimulated control mice were given i.s injections of PBS. Sixteen 
hours post-i.s. injection, cremaster muscles and dLNs were dissected away, fixed and 
whole-mounted for immunofluorescence staining and confocal analysis. Cremaster 
muscles were immunostained with anti-PECAM-1, anti-LYVE-1 and anti-MRP14 mAbs 
to label blood vasculatures, lymphatic vasculatures and neutrophils, respectively. 
Draining LNs were immunostained with anti-MECA-79, anti-LYVE-1 and anti-MRP14 
mAbs to label HEVs, lymphatic vasculatures and neutrophils, respectively. Images 
obtained from confocal microscopy were analysed using IMARIS software.  
Similarly to CXCL1-blockade, quantification of 3D-reconstructed confocal images 
showed that local delivery of AMD3100 did not significantly affect the migration of 
neutrophils across postcapillary venules at 16 h post-i.s. injection although there was an 
increased tendency towards there being more neutrophils in the interstitial tissue of 
AMD3100 treated mice as compared to vehicle controls (Figure 4.4A). Furthermore, 
quantification of confocal images showed that treatment with AMD3100 had no 
significant effect on neutrophil migration into lymphatic vessels (Figure 4.4B). Finally, 
quantification of confocal images showed that treatment with AMD3100 demonstrated 




Figure 4.4: Neutrophil migration responses of WT mice following in vivo blockade of the 
chemokine receptor CXCR4 in unstimulated and CFA+Ag-stimulated cremasters. WT 
C57BL/6 mice were subjected to CFA+Ag-induced inflammation of the cremaster muscles. Four 
hours later, mice received an i.s. injection of the CXCR4 specific inhibitor AMD3100 (10mg/kg) 
or PBS vehicle as control. Sixteen hours post-stimulation, cremaster muscles were dissected 
away, fixed and immunostained for αSMA/MECA-79, LYVE-1 and MRP14 to visualise the 
blood vasculatures, lymphatics and neutrophils, respectively. Neutrophil migration responses 
were visualised by confocal microscopy and analysed by IMARIS Software. (A) Number of 
extravasated neutrophils in unstimulated and CFA+Ag-stimulated mice treated with AMD3100 
or vehicle control. (B) Number of neutrophils within the cremaster lymphatic vessels of 
unstimulated and CFA+Ag-stimulated mice treated with AMD3100 or vehicle control. (C) 
Number of neutrophils found in the dLNs of unstimulated and CFA+Ag-stimulated mice treated 
with AMD3100 or vehicle control. Data are expressed as mean±SEM of n = 5-12 animals (~10-
12 images per pair of cremaster/dLNs for confocal microscopy) per group from at least 5 
independent experiments. Statistically significant differences between unstimulated and 





The blockade of CXCR4 by AMD3100 has been previously been reported to result in a 
rapid increase in circulating neutrophils as a result of egress from the BM (Liu et al., 
2014; Ma et al., 1999; Martin et al., 2003). To ensure AMD3100 treatment was not 
affecting other aspects of neutrophil migration such as causing an increase in neutrophil 
numbers within the circulation, the percentage of circulating neutrophils within 
AMD3100/vehicle control treated mice were assessed by flow cytometry. The expression 
of the chemokine receptor, CXCR4, was also investigated in these mice. For this purpose, 
whole blood was taken from mice via cardiac puncture. Red blood cells were lysed in 
preparation for immunostaining. Blood leukocytes were immunostained for neutrophil 
specific markers (CD45+ Ly6G+) before the percentage of circulating neutrophils and 
their surface expression of CXCR4 were analysed by flow cytometry.  
Although a significant increase was found in the percentage of circulating neutrophils 
between unstimulated and CFA+Ag stimulated mice, no significant difference was 
established between CFA+Ag-stimulated mice treated with either AMD3100 or vehicle 
control (Figure 4.5A). Similarly, no difference in the surface expression of CXCR4 was 
established between CFA+Ag-stimulated mice treated with either AMD3100 or vehicle 
control (Figure 4.5B). Interestingly, a down-regulation of CXCR4 expression was found 
between unstimulated and CFA+Ag-stimulated mice (Figure 4.5B). 
Collectively, the results in this section suggests that the CXCL12:CXCR4 chemokine axis 
does not play any significant role in neutrophil recruitment into lymphatic vessels during 





Figure 4.5: Percentage of circulating neutrophils and their CXCR4 expression in CFA+Ag-
stimulated and AMD3100-treated mice compared to unstimulated/vehicle controls. WT 
C57BL/6 mice were subjected to CFA+Ag-induced inflammation of the cremaster muscles. Four 
hours later, mice received an i.s. injection of the CXCR4 specific inhibitor AMD3100 (or PBS 
vehicle as control). After 16 hours, whole blood was taken from each mouse via cardiac puncture 
and cells were immunostained for CD45.2, Ly6G, CD3ε and CXCR4 for flow cytometry analysis. 
(A) Percentage of neutrophils into the blood circulation as assessed by flow cytometry. (B) 
Surface expression of CXCR4 (RFI) on blood circulating neutrophils as assessed by flow 
cytometry. Data are expressed as mean ± SEM of n=5-7 animals per group. Statistically 
significant differences between stimulated and unstimulated treatment groups are indicated by 






 Expression profile of CCR7 by circulating neutrophils 
Before investigating the potential involvement of the CCL21/CCR7 axis that has been 
widely linked with DC/T-cell migration into the lymphatic system (Johnson and Jackson, 
2008), the expression of CCR7 on blood-borne, cremaster tissue-infiltrating and dLN-
infiltrating neutrophils were first examined by flow cytometry post CFA+Ag-induced 
inflammation (Figure 4.6). Experiments investigating CCR7 expression on different 
tissues were carried out by Dr. Mathieu-Benoit Voisin. For this purpose, WT and 
CCR7KO mice were used, with the latter used as negative controls. 16 h post CFA+Ag-
stimulation, cremaster and dLNs tissues were dissected away and digested in preparation 
for immunostaining. Whole blood was also taken from these mice via cardiac puncture 
before red blood cells were lysed in preparation for immunostaining. Leukocytes were 
fixed in some cases to examine intracellular expression of CCR7. Leukocytes were 
immunostained for neutrophil specific markers (CD45+ Ly6G+) and their surface 
expression of CCR7 was analysed by flow cytometry (Figure 4.6). Whilst WT blood 
neutrophils did not express CCR7 on their surface, intracellular stores of the molecule 
were detected. Interestingly, neutrophils isolated from CFA+Ag-stimulated cremaster 
muscles showed a small but significant expression of CCR7 on their cell surface 





Figure 4.6: Neutrophil migration responses following 16 h CFA+Ag-induced inflammation. 
WT and CCR7KO mice were stimulated with CFA+Ag for 16 h before leukocytes from blood 
circulation, cremaster muscle and dLNs were isolated. Blood leukocytes from WT or CCR7KO 
animals were immunostained with an anti-CCR7 mAb or an isotype control mAb before being 
analysed by flow cytometry. Data are expressed as mean ± SEM of n=7-12 animals per group. 
Statistically significant differences between stimulated and unstimulated treatment groups are 
indicated by asterisks: **, P < 0.01. Significant differences between responses in WT vs. 
CCR7KO animals (or between different tissues) are indicated by hash signs: #, P < 0.05; ##, P < 
0.01. Statistical significance was determined using one-way ANOVA. Data was acquired with 
Jessica Dilliway and Dr Mathieu-Benoit Voisin. 
 
Next, CCR7 up-regulation following TNF stimulation was investigated. Due to the 
previous experiment demonstrating that WT blood neutrophils do not express CCR7 on 
the surface after CFA+Ag-induced inflammation (Figure 4.6), and a previous study also 
reporting that both murine and human neutrophils contain intracellular stores of CCR7, 
which are rapidly mobilised to the cell surface following activation (Beauvillain et al., 
2011), it was hypothesised that CCR7 was being rapidly internalised and recycled through 
endocytosis. Therefore, the possibility of this occurrence was next examined with the use 
of a caveolae-dependent endocytosis inhibitor, nystatin, during stimulation with different 
doses of TNF (Figure 4.7). For this purpose, blood leukocytes were stimulated in vitro. 
Briefly, whole blood was taken from WT mice via cardiac puncture and blood cells were 
lysed. Blood leukocytes were then stimulated with TNF for 4 h in dose-response 
experiments along with simultaneous treatments of nystatin. TNF was used as the 
inflammatory stimuli in this case as in vitro stimulation of cells with an emulsion of 
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CFA+Ag is not possible, and TNF was previously shown in Chapter 3 to be released in 
response to CFA+Ag-stimulation. Leukocytes were immunostained for neutrophil 
specific markers (CD45+ Ly6G+) and their surface expression of CCR7 was analysed by 
flow cytometry. Blood neutrophils’ surface expression of CCR7 was demonstrated to 
decrease in a TNF dose-dependent manner. The lowest dose of TNF (1 ng/ml) resulted in 
a small but significant expression of cell surface CCR7. This surface expression of CCR7 
decreased with increasing doses of TNF, with 10 ng/ml TNF still resulting in a smaller 
but still significant surface expression and 100 ng/ml TNF resulting in insignificant 
surface expression. 
Overall, the results from this section suggests that neutrophils are primed post-stimulation 
in order to induce cell surface expression of CCR7. CCR7 on neutrophils also seems to 
be internalised via caveolae-dependent endocytic pathways and this expression is 
inversely correlated to increasing doses of TNF (i.e. low doses of TNF can induce the 
surface expression of CCR7 on neutrophils).  
 
Figure 4.7: CCR7 expression on surface of TNF-stimulated neutrophils following 
treatment with caveolae-dependent endocytosis inhibitor, nystatin. Whole blood was 
taken from WT mice via cardiac puncture, the red blood cells were lysed, and the 
leukocytes were cultured with various doses of TNF for 4 h. Leukocytes were then 
immunostained for neutrophil specific markers (CD45+ Ly6G+) and the expression of 
CCR7 on blood neutrophils was analysed by flow cytometry. Data are from n = 6-17 mice 
from 16 independent experiments. Statistically significant differences between stimulated 
and unstimulated treatment groups are indicated by asterisks: *, P < 0.05; **, P < 0.01. 
Significant differences between stimulated groups are indicated by hash signs: #, P < 0.05. 
Statistical significance was determined using one-way ANOVA.  
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 Effects of the CCL21:CCR7 chemokine axis on neutrophil 
migration during TNF- or CFA+Ag-induced inflammation of the 
cremaster muscle 
Having discovered that tissue-infiltrated neutrophils up-regulate CCR7 on their cell 
surface, it was hypothesised that this chemokine receptor may mediate the migration of 
neutrophils through lymphatic vessels of the cremaster muscles. To address the potential 
involvement of the CCL21:CCR7 axis, neutrophil migration responses at 16 h-post 
inflammation in WT and CCR7KO mice were examined and compared by confocal 
microscopy analysis following TNF- or CFA+Ag-stimulation. The other CCR7 ligand, 
CCL19, will not be looked at in this study as it has been shown to not be constitutively 
expressed at steady-state or in inflamed tissue-associated LECs (Russo et al., 2013; Vigl 
et al., 2011). For this purpose, WT and CCR7KO mice were given i.s injections of TNF 
or an emulsion of CFA+Ag as before. Control mice received i.s injections of PBS. Sixteen 
hours later, cremaster muscles were dissected away, fixed and immunostained with anti-
PECAM-1, anti-LYVE-1 and anti-MRP14 mAbs to label blood vasculatures, lymphatic 
vasculatures and neutrophils, respectively. DLNs were immunostained with anti-MECA-
79, anti-LYVE-1 and anti-MRP14 mAbs to label HEVs, lymphatic vasculatures and 
neutrophils, respectively. Images obtained from confocal microscopy were analysed on 
IMARIS software. 
Following TNF-stimulation, 3D-reconstructed confocal images showed no difference in 
the neutrophil numbers within the interstitial surrounding postcapillary venules at 16 h 
post-i.s. injection in CCR7KO mice (Figure 4.8A, right) as compared to WT mice 
(Figure 4.8A, left). Quantification of these confocal microscopy images demonstrated 
that neutrophil transmigration across postcapillary venules was unaffected in CCR7KO 
mice 16 h post-i.s. injection (Figure 4.8B). Strikingly, 3D-reconstructed confocal images 
showed neutrophil migration into the lymphatic vessels of CCR7KO mice was almost 
completely absent (Figure 4.9A, right) as compared to WT mice (Figure 4.9A, left). 
Quantification of these confocal images showed that trafficking of neutrophils into 
cremaster lymphatic vessels was completely inhibited (~97% suppression) in CCR7KO 
animals as compared to WT animals (Figure 4.9B). Furthermore, and in contrast to WT 
animals, the level of dLN-infiltrated neutrophils was not increased in CCR7KO mice after 
stimulation with TNF, as observed by confocal microscopy (Figure 4.10A, bottom). 
Quantification of 3D-reconstructed confocal images showed that TNF induced an 
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increase of neutrophils in WT mice as compared to WT control group (Figure 4.10B). 
However, neutrophil numbers within dLNs of TNF-stimulated CCR7KO mice was 
comparable to neutrophil infiltration exhibited by the unstimulated control group (Figure 
4.10B). 
 
Figure 4.8: Neutrophil migration responses across postcapillary venules of WT and 
CCR7KO mice in unstimulated and TNF-stimulated cremaster muscles. WT C57BL/6 and 
CCR7KO mice were subjected to TNF-induced inflammation of the cremaster muscles. Control 
mice received i.s injection of PBS. Sixteen hours later, cremaster muscles were dissected away, 
fixed and immunostained for αSMA (red) and MRP14 (blue) to label blood vasculatures and 
neutrophils, respectively, before being analysed by confocal microscopy and IMARIS. (A) 
Representative 3D-confocal images of neutrophil extravasation from postcapillary venules 
following TNF-stimulation of the cremaster muscles of WT (left) and CCR7KO (right) mice. Bar: 
50 μm. (B) Number of extravasated neutrophils in inflamed cremaster muscles of unstimulated 
and TNF-stimulated WT and CCR7KO mice. Data are expressed as mean ± SEM from at least 4 
independent experiments with n = 5-12 animals per group (~10-12 images per pair of cremasters 
for confocal microscopy). Statistically significant difference between stimulated and unstimulated 
animals are indicated by asterisks: *, P< 0.05; **, P< 0.01; ***, P < 0.001; ****, P < 0.0001. 
Statistical significance was determined using one-way ANOVA. Statistical significance was 




Figure 4.9: Neutrophil migration responses into lymphatic vessels of WT and CCR7KO 
mice in unstimulated and TNF-stimulated cremaster muscles. WT C57BL/6 and CCR7KO 
mice were subjected to TNF-induced inflammation of the cremaster muscles. Control mice 
received i.s injection of PBS. Sixteen hours later, cremaster muscles were dissected away, fixed 
and immunostained for LYVE-1 (green) and MRP14 (blue) to visualise the lymphatic 
vasculatures and neutrophils, respectively, before being analysed by confocal microscopy and 
IMARIS. Neutrophil migration responses were visualised by confocal microscopy and analysed 
by IMARIS Software. (A) Representative 3D-confocal images of neutrophils within lymphatic 
vessels following TNF-stimulation of the cremaster muscles of WT (left panels) and CCR7KO 
(right panels) mice. The top panels show all neutrophils present in the field of view. The bottom 
panels show neutrophils present only within the lymphatic vessels. Bars: 50 μm. (B) Number of 
neutrophils within the cremaster lymphatic vessels of unstimulated and TNF-stimulated WT and 
CCR7KO mice. Data are expressed as mean ± SEM from at least 4 independent experiments with 
n = 5-12 animals per group (~10-12 images per pair of cremasters for confocal microscopy). 
Statistically significant differences between stimulated and unstimulated animals are indicated by 
asterisks: ****, P < 0.0001. Statistically significant differences between WT and CCR7KO mice 
are indicated by hash signs: ###. P < 0.001. Statistically significant differences between WT and 
CCR7KO mice are indicated by hash signs: ###. P < 0.001. Statistical significance was 




Figure 4.10: Neutrophil migration responses into dLNs of WT and CCR7KO mice in 
unstimulated and TNF-stimulated cremaster muscles. WT C57BL/6 and CCR7KO mice were 
subjected to TNF-induced inflammation of the cremaster muscles. Control mice received i.s 
injection of PBS. Sixteen hours later, cremaster dLNs were dissected away and immunostained 
for LYVE-1, HEVs and MRP14. Neutrophil migration responses were visualised by confocal 
microscopy and analysed by IMARIS Software. (A) The figure shows representative 3D-confocal 
images of neutrophil infiltration into the dLNs of unstimulated (left panel) and TNF-stimulated 
(right panel) of WT (top panel) and CCR7KO (bottom panel) mice. Bars: 50 μm. (B) Number of 
neutrophils within the cremaster dLNs of unstimulated and TNF-stimulated WT and CCR7KO 
mice. Data are expressed as mean ± SEM from at least 4 independent experiments with n = 5-12 
animals per group (~10-12 images per pair of dLNs for confocal microscopy). Statistically 
significant difference between stimulated and unstimulated animals are indicated by asterisks: 
***, P < 0.001. Statistically significant differences between WT and CCR7KO mice are indicated 
by hash signs: ##. P < 0.01. Statistical significance was determined using one-way ANOVA. 
Statistical significance was determined using one-way ANOVA. 
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Similarly, quantification of 3D-reconstructed confocal images showed that CFA+Ag-
stimulation of both WT and CCR7KO mice resulted in no differences in neutrophil 
extravasation between both groups (Figure 4.11A). However, unlike TNF-stimulation, 
quantification of confocal images showed that neutrophil migration into lymphatic 
vessels was suppressed by ~75% in CCR7KO mice as compared to WT mice in response 
to CFA+Ag-induced inflammation (Figure 4.11B). Furthermore, comparable to TNF-
stimulation, quantification of confocal images proved that neutrophil infiltration into 
dLNs following CFA+Ag stimulation was not increased in CCR7KO mice (Figure 
4.11C). In particular, CCR7KO animals exhibited ~25 times more LN-infiltrated 





Figure 4.11: Neutrophil migration responses of WT and CCR7KO mice in unstimulated and 
CFA+Ag-stimulated cremaster muscles. WT C57BL/6 and CCR7KO mice were subjected to 
CFA+Ag-induced inflammation of the cremaster muscles. Control mice received i.s injection of 
PBS. Sixteen hours later, cremaster muscles and dLNs were dissected away, fixed and 
immunostained for αSMA/MECA-79, LYVE-1 and MRP14 to visualise the blood vasculatures, 
lymphatics and neutrophils, respectively. Neutrophil migration responses were visualised by 
confocal microscopy and analysed by IMARIS Software. (A) Number of extravasated neutrophils 
in unstimulated and CFA+Ag-stimulated WT and CCR7KO mice. (B) Number of neutrophils 
within the cremaster lymphatic vessels of unstimulated and CFA+Ag-stimulated WT and 
CCR7KO mice. (C) Number of neutrophils found in the dLNs of unstimulated and CFA+Ag-
stimulated WT and CCR7KO mice. Data are expressed as mean±SEM of n = 5-12 animals (~10-
12 images per pair of cremaster/dLNs for confocal microscopy) per group from at least 4 
independent experiments. Statistically significant difference between stimulated and unstimulated 
animals are indicated by asterisks: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Statistically 
significant differences between WT and CCR7KO mice are indicated by hash signs: ##, P < 0.01; 
#### < 0.0001. Statistical significance was determined using one-way ANOVA. Statistical 




CCR7KO chimeric mice 
To overcome the abnormal architecture of dLNs in CCR7KO mice, chimeric animals 
were generated by injecting lethally irradiated WT mice with bone marrow hematopoietic 
cells from either WT or LysM-eGFP-CCR7KO animals. These mice were then subjected 
to 16 h CFA+Ag-stimulation.  
Chimerism of reconstituted mice were also checked alongside each experiment. Briefly, 
whole blood was taken from LysM-eGFP mice (used as positive controls) or chimeric 
mice via cardiac puncture before being lysed in preparation for immunostaining. Blood 
leukocytes were immunostained for neutrophil specific markers (CD45+ Ly6G+) and 
their expression of GFP was analysed by flow cytometry. Since bone marrow cells from 
CCR7KO animals exhibiting GFP+ neutrophils were used for reconstitution of chimeras, 
GFP+ neutrophils would indicate the level of chimerism. Comparisons in the percentage 
of circulating neutrophils in WT and CCCR7KO chimeras proved to be the same (~30%) 
(Figure 4.12A). Phenotypic analysis also confirmed all CCR7KO chimeras were fully 
reconstituted with the intended bone marrow hematopoetic cells as shown by the presence 
of ~98% of GFP+ neutrophils within the circulation (Figure 4.12B).  
 
 
Figure 4.12: Phenotypic analysis of blood neutrophils from WT and CCR7KO chimeric 
mice. Blood leukocytes from LysM-eGFP or chimeric animals were immunostained for 
neutrophils specific markers (CD45+ Ly6G+) and their expression of GFP was analysed by flow 
cytometry. (A) Percentage of circulating neutrophils in WTWT and CCR7KOWT chimeric 
mice. (B) Percentage of GFP+ neutrophils in WTWT and CCR7KOWT chimeric mice. 
CCR7KO-LysM-eGFP Data are expressed as mean±SEM of N = 4-6 animals per group from at 
least 4 independent experiments. Statistically significant difference between stimulated and 
unstimulated animals are indicated by asterisks: ****, P < 0.0001. Statistical significance was 
determined using Student’s t-test. 
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Following this, neutrophil migration responses in these chimeras were investigated 16 h 
post-antigen sensitisation. Similar to a full KO, chimeric mice exhibiting CCR7KO 
neutrophils showed no difference in neutrophil extravasation across blood vasculatures 
post-i.s. injection, although there was an increased tendency towards there being more 
neutrophils in the interstitial tissue of CCR7KO chimeras as compared to WT chimeras 
(Figure 4.13A). Also reminiscent to full CCR7KO mice, CCR7KO chimeric mice 
showed a reduced migration of these leukocytes (~76% less) into lymphatic vessels as 
compared to WT chimeric mice (Figure 4.13B). Interestingly, unlike full KO mice, 
CCR7KO chimeras showed a reduced number of neutrophils infiltrating the dLNs (~62% 
less) as compared to control littermates (Figure 4.13C). This suggests that neutrophils 





Figure 4.13: Neutrophil migration responses of WT and CCR7KO chimeric mice following 
CFA+Ag-induced inflammation in the cremaster muscle. Neutrophil migration into the 
lymphatic system of the cremaster muscle following antigen sensitisation with complete Freund’s 
adjuvant (CFA+Ag) was induced in chimeric animals exhibiting neutrophils deficient in CCR7. 
Neutrophil migration responses were visualised by confocal microscopy and analysed by 
IMARIS Software.  (A) Number of extravasated neutrophils in cremaster muscles at 16 h post-
CFA+Ag-stimulation from chimeric animals receiving bone marrow transplant of WT or 
CCR7KO donor mice and as quantified by confocal microscopy. (B) Number of neutrophils 
within cremaster lymphatic vessels at 16 h post-CFA+Ag-stimulation from chimeric animals 
receiving bone marrow transplant of WT or CCR7KO donor mice and as quantified by confocal 
microscopy. (C) Number of neutrophils found in the dLNs of chimeric animals receiving bone 
marrow transplant of WT or CCR7KO donor mice as quantified by confocal microscopy 16 h 
post-CFA+Ag-stimulation. Data are expressed as mean±SEM of N = 6-7 animals (~10-12 images 
per pair of cremaster/dLNs for confocal microscopy) images per cremaster for confocal 
microscopy) per group from at least 5-10 experiments. Statistically significant differences 
between WT and CCR7KO chimeric mice are indicated by asterisks: **, P < 0.01. Statistical 




 Investigating the cause of abnormal neutrophil trafficking into dLNs 
of CCR7KO mice 
Due to the previous observation that CCR7KO mice had an increase in neutrophil 
numbers within dLNs in steady state conditions (Figure 4.10 & Figure 4.11), the possible 
cause of this abnormal trafficking of neutrophils in these mice was explored. As CXCR4 
has previously been shown to be a key regulator of neutrophil release from the bone 
marrow (Eash et al., 2010), the potential role of the CXCL12:CXCR4 chemokine axis in 
abnormal trafficking of neutrophils into dLNs of full CCR7KO mice was investigated. 
For this purpose, neutrophil migration responses at 16 h-post inflammation in CCR7KO 
mice were examined by confocal microscopy analysis following CFA+Ag-stimulation. 
Briefly, CCR7KO mice were given i.s injections of TNF or an emulsion of CFA+Ag as 
before. Unstimulated control mice received i.s injections of PBS. Four hours post-i.s. 
injection, i.s. of the CXCR4-specific inhibitor, AMD3100, or vehicle control (PBS) was 
carried out. Sixteen hours post-i.s. injection, cremaster muscles were dissected away, 
fixed and immunostained as described in the previous sections. Images obtained from 
confocal microscopy were analysed on IMARIS software. 
Following CFA+Ag-stimulation, 3D-reconstructed confocal images showed much higher 
neutrophil numbers within the interstitial surrounding postcapillary venules at 16 h post-
i.s. injection in AMD3100-treated CCR7KO mice (Figure 4.14A, right) as compared to 
vehicle controls (Figure 4.14A, left). Quantification of confocal microscopy images 
demonstrated that neutrophil transmigration across postcapillary venules was 
significantly increased (~100% more) in AMD3100-treated CCR7KO mice at 16 h post-
i.s. injection as compared to vehicle controls (Figure 4.14B). Interestingly, 3D-
reconstructed confocal images showed similar numbers of neutrophils within lymphatic 
vessels of AMD3100-treated CCR7KO mice (Figure 4.15A, right) as compared to the 
vehicle control-treated mice (Figure 4.15A, left). Quantification of these confocal images 
demonstrated that trafficking of neutrophils into cremaster lymphatic vessels remained 
unchanged in AMD3100-treated CCR7KO animals as compared to the vehicle control-
treated mice (Figure 4.15B). Strikingly, 3D-reconstructed confocal images showed that 
neutrophil migration into the dLNs of AMD3100-treated CCR7KO mice (Figure 4.16A, 
right) was lower as compared to vehicle control-treated mice (Figure 4.16A, left). 
Quantification of these confocal images proved that treatment with the CXCR4 antagonist 
resulted in a significant reduction (~63% less) in the number of neutrophils infiltrating 




Figure 4.14: Neutrophil migration responses across postcapillary venules of CCR7KO mice 
following in vivo blockade of the chemokine receptor CXCR4 in CFA+Ag-stimulated 
cremasters. CCR7KO mice were subjected to CFA+Ag-induced inflammation of the cremaster 
muscles. Four hours later, mice received an i.s. injection of the CXCR4 specific inhibitor 
AMD3100 (10mg/kg) or PBS vehicle as control. Sixteen hours post-stimulation, cremaster 
muscles were dissected away, fixed and immunostained for αSMA (red) and MRP14 (blue) to 
visualise the blood vasculatures and neutrophils, respectively. Neutrophil migration responses 
were visualised by confocal microscopy and analysed by IMARIS Software. (A) Representative 
3D-confocal images of neutrophil extravasation from postcapillary venules in the cremaster 
muscles of CFA+Ag-stimulated CCR7KO mice injected i.s with vehicle control (left) or treated 
with AMD3100 (right). Bars: 50 μm. (B) Number of extravasated neutrophils in inflamed 
cremaster muscles. Data are expressed as mean ± SEM from at least 4 independent experiments 
with n = 5-12 animals per group (~10-12 images per pair of cremasters for confocal microscopy). 
Statistically significant differences between stimulated and unstimulated animals are indicated by 
asterisks: **, P< 0.01; ****, P < 0.0001. Statistically significant differences between vehicle 
control and AMD3100 treated groups are indicated by hash signs: ##, P < 0.01. Statistical 






Figure 4.15: Neutrophil migration responses into lymphatic vessels of CCR7KO mice 
following in vivo blockade of the chemokine receptor CXCR4 in CFA+Ag-stimulated 
cremasters. WT C57BL/6 mice were subjected to CFA+Ag-induced inflammation of the 
cremaster muscles. Four hours later, mice received an i.s. injection of the CXCR4 specific 
inhibitor AMD3100 (10mg/kg) or PBS vehicle as control. Sixteen hours post-i.s. injection, 
cremaster muscles were dissected away, fixed and immunostained for LYVE-1 (green) and 
MRP14 (blue) before being analysed by confocal microscopy and IMARIS. (A) Representative 
3D-confocal images of neutrophils within lymphatic vessels in the cremaster muscles of 
CFA+Ag-stimulated CCR7KO mice injected i.s with vehicle control (left) or treated with 
AMD3100 (right). The top panels show all neutrophils present in the field of view. The bottom 
panels show neutrophils present only within the lymphatic vessels. Bars: 50 μm. (B) Number of 
neutrophils within the cremaster lymphatic vessels of unstimulated and CFA+Ag-stimulated mice 
treated with AMD3100 or vehicle control. Data are expressed as mean ± SEM from at least 4 
independent experiments with n = 5-12 animals per group (~10-12 images per pair of cremasters 
for confocal microscopy). Statistically significant differences between stimulated and 
unstimulated animals are indicated by asterisks: *, P< 0.05; **, P< 0.01. Statistical significance 




Figure 4.16: Neutrophil migration responses into dLNs of CCR7KO mice following in vivo 
blockade of the chemokine receptor CXCR4 in CFA+Ag-stimulated cremasters. CCR7KO 
mice were subjected to CFA+Ag-induced inflammation of the cremaster muscles. Four hours 
later, mice received an i.s. injection of the CXCR4 specific inhibitor AMD3100 (10mg/kg) or 
PBS vehicle as control. Sixteen hours post-stimulation, dLNs (inguinal) were dissected away, 
fixed and halved before being immunostained for LYVE-1 (red), HEVs (green) and MRP14 
(blue) before being analysed by confocal microscopy and IMARIS software. (A) The figure 
shows representative 3D-confocal images of neutrophil infiltration into the dLNs of CCR7KO 
mice that received i.s injection of vehicle control Ab (left) or treatment of AMD3100 (right) Bars: 
50 μm. (B) Number of neutrophils found in the dLNs. Data are expressed as mean±SEM from at 
least 4 independent experiments with n = 5-12 animals per group (~10-12 images per pair of dLNs 
for confocal microscopy). Statistically significant differences between vehicle control and 
AMD3100 treated groups are indicated by hash signs: #, P < 0.05. Statistical significance was 
determined using one-way ANOVA. 
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Subsequently, investigations were carried out to determine differences in the phenotype 
of neutrophils relating to CXCR4 between WT and CCR7KO animals under basal 
conditions. For this purpose, whole blood was taken from mice via cardiac puncture and 
lysed. Blood leukocytes were immunostained for neutrophil specific markers (CD45+ 
Ly6G+) and their surface expression of CXCR4 was analysed by flow cytometry. 
Draining LNs of WT and CCR7KO mice were also dissected away, snap-frozen and 
homogenised for analysis of CXCL12 expression levels by ELISAs. Flow cytometry 
analysis showed no differences in the percentage of circulating neutrophils (Figure 
4.17A) and expression levels of CXCR4 (Figure 4.17B) between WT and CCR7KO 
mice. Interestingly, CXCL12 generation at basal levels was significantly increased in 
dLNs of CCR7KO mice as compared to dLNs of WT mice (Figure 4.17C). This response 
could be related to ~25 times more neutrophil infiltration seen in dLNs of CCR7KO mice 
as compared to WT mice in unstimulated conditions, discovered previously (Figure 
4.10B). This supports the hypothesis that CXCR4 signalling contributes to neutrophil 
homing to LNs through HEVs (Gorlino et al., 2014). 
Overall, these results implicate the CCL21:CCR7 chemokine axis in promoting 
neutrophil migration into lymphatic vessels. TNF was also shown to be particularly 
important in promoting neutrophil migration into lymphatic vessels in a CCR7-dependent 
manner as complete inhibition of this process occurred following TNF-stimulation, with 
only partial inhibition seen following antigen sensitisation. Additionally, the 
CXCL12:CXCR4 chemokine axis was shown to be responsible for the high number of 






Figure 4.17: CXCR4 expression on neutrophils and CXCL12 generation in dLNs of naïve 
WT and CCR7KO mice. Blood leukocytes from WT or CCR7KO animals were immunostained 
for neutrophils specific markers (CD45+ Ly6G+) and their expression of CXCR4 on blood 
neutrophils was analysed by flow cytometry. Draining LNs were dissected away from naïve WT 
and CCR7KO mice, snap-frozen and homogenised for quantification of CXCL12 generation by 
ELISA. (A) Percentage of circulating neutrophils in naive WT and CCR7KO mice. (B) Relative 
fluorescence intensity (RFI) of CXCR4 expression on blood circulating neutrophils. (C) CXCL12 
release as quantified by ELISA. Data are expressed as mean ± SEM of N = 4-6 animals per group 
from at least 4 independent experiments. Statistically significant difference between WT and 
CC7KO animals are indicated by asterisks: *, P < 0.05. Statistical significance was determined 







It is now well established that neutrophils contribute to the shaping of the adaptive 
immune response against a huge repertoire of foreign antigens or infectious agents 
following their rapid migration into the lymphatic system (Gorlino et al., 2014; Hampton 
et al., 2015; Lynskey et al., 2015). However, unlike neutrophil transmigration across 
blood vessel walls, the mechanisms of this migratory response is massively understudied. 
The results from this chapter demonstrated that neither CXCL1:CXCR1/2 nor 
CXCL12:CXCR4 chemokine axes were found to play significant roles in neutrophil 
migration across the lymphatic endothelium during antigen sensitisation at the time-
points analysed (8 and 16 h). However, the CCL21:CCR7 chemokine axis was implicated 
in promoting neutrophil migration into lymphatic vessels. Additionally, neutrophils were 
shown to be primed to upregulate CCR7 surface expression post-stimulation with 
CFA+Ag in vivo and this response was associated with an inverse relationship to 
increasing doses of TNF-stimulation in vitro. Finally, the CXCL12:CXCR4 chemokine 
axis was shown to be responsible for the high number of neutrophils found within dLNs 
of CCR7KO mice under steady state conditions. In general, the main finding within this 
chapter is the discovery of a previously unknown role for endogenous TNF in 
orchestrating neutrophil trafficking into lymphatic vessels of inflamed tissues in a strictly 
CCR7-dependent manner in vivo.  
It was demonstrated earlier on in Chapter 3 of this thesis that TNF could induce the rapid 
migration of neutrophils from inflamed tissues into lymphatic vessels. These studies were 
then extended to a model of antigen sensitisation characterised by the generation of 
endogenous TNF. CFA+Ag-stimulation was also associated with rapid neutrophil 
migration into lymphatic vessels, a response that was impaired in mice deficient in both 
TNF receptors, p55 and p75. Furthermore, the use of chimeric animals demonstrated that 
TNF acts directly on leukocytes to induce this neutrophil migration response. 
In the present study, TNF was demonstrated to trigger migration of neutrophils into 
lymphatic vessels in a strictly CCR7-dependent, with complete inhibition of neutrophil 
migration into lymphatic vessels seen following TNF-induced inflammation in CCR7KO 
mice. The role of CCR7 in neutrophil recruitment into the lymphatic system was first 
demonstrated by Beauvillain et al. in a model of intradermal immunisation (Beauvillain 
et al., 2011). In accordance with their study, intracellular stores of CCR7 were detected 
in murine blood neutrophils. However, in the present study, a significant up-regulation of 
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CCR7 on the cell surface was found on neutrophils recruited into inflamed tissues 
following antigen sensitisation as compared to blood neutrophils within the circulation. 
Since Eruslanov et al. recently showed a similar up-regulation of CCR7 on human 
neutrophils in a tumour model (Eruslanov et al., 2014), data from the present study 
suggests that neutrophils are being primed for enhanced chemokine receptor expression. 
Two of the key activators of neutrophils, GM-CSF and IL-17, have both been shown to 
prime neutrophils for potent migration towards CCL21 and CCL19 in vitro (Beauvillain 
et al., 2011). However, unlike the release of TNF demonstrated in Chapter 3, the 
generation of these cytokines in inflamed cremaster muscles could not be detected at any 
of the time-points analysed in vivo (Appendix 2), thus suggesting the predominant role 
of TNF in this response in vivo. An up-regulation found in CCR7 expression on the 
surface of neutrophils following TNF-stimulation in vitro provides further evidence of 
neutrophil priming by TNF. Differences in the extent of CCR7 up-regulation on primed 
neutrophils were seen between in vitro and in vivo experimental setups. Although similar 
levels of CCR7 was found on the surface of blood neutrophils for both setups, CCR7 
upregulation was found on the surface of neutrophils isolated from cremaster muscles in 
the in vivo setup. This could be due to differences in the techniques used, where 
leukocytes were primed within the animals (i.s. injection of CFA+Ag) before being 
isolated for CCR7 staining in the in vivo setup, whilst leukocytes were isolated from blood 
and stimulated in culture before staining in the in vitro setup. This suggests that the 
microenvironment is important for the appropriate priming of neutrophils. Additionally, 
the inflammatory stimulus (and timepoints) used in both setups were different. CFA+Ag 
(16 h) was used in the in vivo setup whilst TNF (4 h) was used for the in vitro setup. The 
use of CFA+Ag in vivo results in a multifactorial response, where pro-inflammatory 
cytokines such as Tyrode’s salt solution was used to constantly superfuse cremaster 
muscles during all experiments. 
IL-1β, IFNγ and TNF are produced (Awate et al., 2013). Additionally, other cells within 
the microenvironment could also be activated leading to the production of other factors 
leading to more efficient priming of neutrophils. The use of only TNF in the in vitro setup 
may not be as potent as CFA+Ag at priming neutrophils thus could be a reason for why 
CCR7 is up-regulated more in the in vivo setup. To confirm this, further experiments 




Interestingly, high basal levels of neutrophils within dLNs of naïve CCR7O mice was 
observed as compared to naïve WT mice, with inflammation of the cremaster muscles 
with TNF or CFA+Ag not further increasing the number of neutrophils found in the LNs. 
This abnormal trafficking was seen despite there being no difference in the percentage of 
circulating neutrophils between WT and CCR7KO mice. An explanation for this could 
be due to the 2.5-fold increase in generation of CXCL12 in the dLNs of naïve CCR7KO 
mice as compared to WT mice, thus causing more neutrophil homing to occur in the 
former. Spontaneous autoimmunity in CCR7KO mice could also be driving this 
phenotype although this will have to be further investigated. This study has demonstrated 
for the first time that high levels of CXCL12 within dLNs contributes to neutrophil 
migration via HEVs in steady-state. 
Whilst the expression of the chemokine receptor for CXCL12, CXCR4, was similar in 
both WT and CCR7KO mice, treatment with the CXCR4 antagonist, AMD3100, resulted 
in a significant reduction in the number of neutrophils infiltrating the dLNs of CCR7KO 
mice; this was not found to be the case for neutrophil migration into lymphatic vessels 
upon CFA+Ag inflammation. This is in accordance with previous studies that 
demonstrated the importance of CXCR4 in the homing of neutrophils from inflamed skin 
to LNs via HEVs (Gorlino et al., 2014; Hampton et al., 2015). Chimeric mice generated 
to overcome this abnormal trafficking of neutrophils into dLNs further confirmed that 
CCR7KO neutrophils were unable to migrate into lymphatic vessels in a WT 
environment, although further experiments will have to be carried out to determine if 
CXCL12 levels are normal in these mice. 
Since the role of CCR7 in neutrophil trafficking into the lymphatic system has proven to 
be controversial, other chemokine:chemokine receptor axes were investigated. The 
CXCL12:CXCR4 chemokine axis was recently demonstrated to be involved in neutrophil 
trafficking to the lymphatic system in a model of bacterial infection with S. aureus 
(Hampton et al., 2015). The current study provided evidence that CXCR4 blockade did 
not significantly inhibit neutrophil migration into cremaster lymphatic vessels and dLNs 
upon CFA+Ag-stimulation, thus highlighting potential differences between models. 
Regarding the higher numbers of neutrophils seen within the inflamed tissues of 
AMD3100-treated mice, evidence has shown that humans and mice treated with this 
CXCR4 antagonist or CXCR4-blocking antibodies exhibit a rapid mobilisation of 
neutrophils into the blood (Broxmeyer et al., 2005; Liles et al., 2003), which in turn 
potentially leads to more neutrophil transmigration across venular walls. 
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The potent neutrophil-chemoattractant, CXCL8, has recently been shown to be up-
regulated in TNF-stimulated human dermal endothelial cells in vitro; and promote human 
neutrophil migration through a monolayer of LECs (Rigby et al., 2015). In mice, LECs 
isolated from mouse skin showed an up-regulation of CXCL1 gene expression upon 
inflammation induced by contact hypersensitivity (Vigl et al., 2011). However, the in vivo 
model in the current study provided clear evidence of the predominant role of CCR7 in 
neutrophil trafficking into lymphatic vessels following TNF-stimulation. Moreover, local 
treatment with an anti-CXCL1 blocking mAb did not affect the capacity of neutrophils to 
enter the lymphatic system upon inflammation in vivo. Data from previproteous studies 
along with the current one highlights differences between in vivo and in vitro models.  
This chapter has shown that chemokine:chemokine receptor axis, CCL21:CCR7, is 
important for neutrophil migration into lymphatic vessels in both CFA+Ag- or TNF-
induced inflammation; the latter signalling of which is crucial for this phenomenon. It is 
also worth mentioning that at 8 h post-i.s. injection with CFA+Ag, the same partial 
impairment in neutrophil migration into lymphatic vessels was seen in CCR7KO mice, 
thus indicating that the decreased number of neutrophils seen within lymphatic vessels at 
16 h post-i.s. injection was not due to a time-dependent efflux of neutrophils out of 
lymphatic vessels to dLNs (Appendix 1). This chapter has also shown that the 
chemokine:chemokine receptor axes, CXCL1:CXCR1/2 and CXCL12:CXCR4, are not 
involved in neutrophil migration into lymphatic vessels following CFA+Ag-induced 
inflammation. Collectively, the results in this chapter provide evidence that TNF 
signalling triggers neutrophil migration into lymphatic vessels in a strictly CCR7-
dependent manner. This work has recently been published in Nature Scientific Reports 
(Arokiasamy et al., 2017). 
Limitations of the study 
In addition to the other limitations discussed at the end of Chapter 3, the fluorescently 
conjugated CCR7 antibodies used to analyse this chemokine receptor expression on 
neutrophils both in vivo and in vitro did not work under normal staining conditions of 
either room temperature or 4 °C. This is in accordance with the data sheet and published 
literature (Ohl, 2004). Due to this, cells had to be incubated with the antibody at 37 °C 
before the fluorescence was able to successfully be detected by flow cytometry at low 
levels. Staining at this high temperature could have resulted in the modulation and 
internalisation of these surface receptors, leading to a loss of fluorescence intensity. Thus, 
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this may be why such low fluorescence intensities were detected in these experiments. 
The generation of more efficient CCR7 antibodies or the use of labelled chemokines could 




 : Glycocalyx and chemokine regulation on lymphatic 
vessels during inflammation in vivo 
  Introduction 
The glycocalyx is a carbohydrate-enriched layer, which coats all healthy mammalian 
cells. In vivo studies have revealed the glycocalyx of blood capillaries to be a layer of 
about 0.5 µm thick (Vink and Duling, 1996), with this thickness increasing with vascular 
diameter, ranging from 2 to 3 µm in small arteries and 4.5 µm in carotid arteries (Megens 
et al., 2007; van Haaren et al., 2003). The glycocalyx is composed of sugar residues from 
cell surface membrane glycoproteins, sulphated proteoglycans, alongside their associated 
GAG side chains. Sugar residues can be specifically characterised by their binding to 
carbohydrate-binding proteins called lectins. Glycoproteins are also a component of the 
glycocalyx and include adhesion molecules, selectins and integrins (Reitsma et al., 2007). 
Proteoglycans are considered to be the “backbone” molecules of the glycocalyx, and 
consist of a core protein (Reitsma et al., 2007). The core protein is either anchored to the 
cell membrane (syndecans, glypicans) or secreted into the glycocalyx structure 
(mimecans, perlecans and biglycans). GAG side chains are bound to these proteoglycans 
and are comprised of heparan sulfate (HS), chondroitin sulfate (CS), and hyaluronan 
(HA), with HS being the most abundant in the endothelial glycocalyx (Oohira et al., 
1983). GAGs play significant roles by interacting with a variety of proteins within the 
lumen of blood vessels and are involved in the mediation of numerous physiological and 
pathological functions, including inflammation. The blood vascular EC (BEC) 
glycocalyx forms an integral part of the vascular barrier between flowing blood and the 
EC wall of blood vessels, and is involved in the regulation of leukocyte transmigration 
following inflammatory stimuli. In particular, HS is involved in the initial adhesion of 
leukocytes to the endothelium following inflammation by interacting with leukocyte-
expressed L-selectin during neutrophil rolling (Wang et al., 2005). Additionally, HS has 
been shown to be a key controller of chemokine presentation during the recruitment 
process of lymphocytes and DCs to lymph nodes (Bao et al., 2010). Bao et al. 
demonstrated in vivo that CCL21 chemokine presentation in ECs of lymph node HEVs 
was diminished in transgenic mice exhibiting impairments in HS synthesis, thus reducing 
immune cell trafficking into dLNs (Bao et al., 2010).  
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The BEC glycocalyx plays a critical role in many physiological processes, including 
regulation of vascular permeability, regulation of leukocyte adhesion during TEM, as 
well as the modulation of inflammatory processes (Kolarova et al., 2014; Reitsma et al., 
2007; Tarbell et al., 2005; Wang, 2007). In contrast, the presence of a glycocalyx on 
lymphatic vasculatures has not really been investigated, thus the role it plays in the 
context of the lymphatics is poorly understood. Nevertheless, recent emerging evidence 
has demonstrated that the LEC glycocalyx is present within the luminal side of rat 
mesenteric collecting lymphatic vessels and is an important element of lymphatic 
transport (Zolla et al., 2015). Components of the LEC glycocalyx in collecting lymphatic 
vessels has also been demonstrated to be similar to that of the BEC glycocalyx, thus one 
would expect the functions of both to be comparable (Zolla et al., 2015). In the context 
of lymphatic vasculatures, the LEC glycocalyx is thought to maintain permeability, aid 
lymphocyte rolling, generate a cytokine/chemokine gradient, as well as balance 
exchanges between lymphatic vessels and the surrounding interstitium (Levick and 
Michel, 2010; Reitsma et al., 2007; Zolla et al., 2015). It has been reported that collecting 
lymphatic vessels of aged rats (24 months old) exhibits reduced glycocalyx thickness as 
compared to those of adult rats (9 months old) (Zolla et al., 2015). This is associated with 
an increase in the permeability of aged lymphatic vessels, which results in increased 
extravasation of bacteria and fungi, and a reduced ability to maintain fluid transport (Zolla 
et al., 2015). This increased capacity of pathogens to escape aged lymphatic vessels could 
potentially contribute to the decreased ability of the immune system to control infections 
in aging. This is likely due to pathogens causing more infection and inflammation within 
the interstitium, as well as not being transported to dLNs, thus resulting in the host being 
unable to elicit an efficient adaptive immune response.  
Owing to a considerable lack of literature available regarding the composition of the 
glycocalyx on lymphatic vessels, especially in tissue-capillary lymphatics, this chapter 
aims to contribute to this sparsely studied field by characterising components of the LEC 





The LEC glycocalyx is vastly under-studied as compared to the BEC glycocalyx. 
Whether or not initial lymphatic vessels possess a glycocalyx is, as yet, unknown. This 
chapter therefore aimed to characterise the LEC glycocalyx by probing for the presence 
of several endothelial glycocalyx components and if successful, investigate the effects of 
inflammation on their expression. As HS is the most abundant GAG within the 
endothelial glycocalyx, its expression will be examined in lymphatic vessels. To tie in 
with investigations in the previous chapter looking at roles of chemokine:chemokine 
receptor axes in neutrophil migration into lymphatic vasculatures, particular due to CCR7 
being shown to have a key role in TNF-dependent neutrophil migration into lymphatic 
vessels, CCL21 expression on lymphatic vessels will also be examined. Therefore, the 
specific aims were to: 
 Characterise the composition and distribution of sugar residues on the LEC 
glycocalyx and compare this with the BEC glycocalyx. This was looked at in 
naïve mouse cremaster muscles. 
 Visualise and investigate the expression of HS and several sugar residues (with 
the use of the selected lectins) within the LEC glycocalyx following 
inflammation (i.e. TNF or CFA+Ag) in vivo. This was done through the use of 
several different fluorescent staining methods and confocal microscopy 
analysis. 
 Investigate the expression of the prototypical lymphatic chemokine, CCL21, on 
lymphatic vessels in relation to the LEC glycocalyx following TNF- or 
CFA+Ag-induced inflammation in vivo, through the use of immunostaining and 





 Assessment of lectin staining on lymphatic vessels under naïve 
conditions and comparison with blood vessels 
To visualise components of the glycocalyx present on the surface of and within lymphatic 
vessels in WT cremaster muscles, 2 different methods of staining were tested for specific 
sugar chains with the use of different lectins: ex vivo-fixed and in vivo-live staining (as 
detailed in sections 2.5.2 & 2.5.3, respectively). Briefly, ex vivo-fixed staining involved 
staining with lectins and other antibodies at 4 °C overnight after fixation and 
permeabilisation of tissues. In vivo-live staining involved i.s. injection of lectins and other 
antibodies for 2 h before harvesting tissues for immediate confocal analysis. Four 
different lectins were originally tested (Table 5.1) but only IB4 (specific to α-D-
Galactosyl moieties) and MAL-1 (specific for α2,3-sialylated glycans) positively stained 
lymphatic vessels. LEL and SNA failed to stain lymphatic vessels (Appendix 3), thus 
were dropped from any further analyses. Binding specificity of lectins were confirmed 
using competitive sugar binding assays with the use of their inhibitory sugars (Table 5.1) 
to show their staining on lymphatic vessels was specific (Appendix 4).  
 
Table 5.1: Plant lectins used to assess sugar expression of the glycocalyx present on the lymphatic 
endothelium, their sugar binding preferences, and their inhibiting sugars. Lectins were chosen for 
their ability to bind to specific sugar residues on BECs. 
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Under naïve conditions, 3D-reconstructed confocal images of lymphatic vessels stained 
with IB4 using both methods showed that different expression patterns occurred, with in 
vivo-live staining (Figure 5.1A) resulting in a more diffused staining pattern than ex vivo-
fixed staining (Figure 5.1B). However, quantification of confocal images showed no 
differences in IB4 staining (α-D-Galactosyl moiety expression) between both methods 
(Figure 5.2).  Interestingly, ex vivo-fixed staining of IB4 seemed to result in punctuate 
(dotted) staining, indicating the presence of intracellular stores (Figure 5.1B).  
 
Figure 5.1: Representative binding of IB4 to LECs of mouse cremaster muscles. Cremaster 
muscles from naïve C57BL/6 WT mice were labelled with anti-PECAM-1 (green), anti-LYVE-1 
(red) and IB4 lectin (blue) via both methods. Tissues were analysed on a confocal microscope 
and IMARIS software. (A-B) Orange boxes on images (left) indicate the region of vessel which 
is depicted on the zoomed-in images (right). Top right images show LYVE-1 and IB4 staining, 
and bottom right boxes show just IB4 staining.  (A) In vivo-live staining via intrascrotal injection 




Figure 5.2: MFI of IB4 binding to glycocalyx present on lymphatic vessels under naïve 
conditions. Quantification of the MFI of IB4 (specific for α D-Galactosyl moieties) binding to 
the surface of lymphatic vessels using 2 different staining methods – ex vivo-fixed and in vivo-
live. This also represents expression of α D-Galactosyl moieties on the surface of lymphatic 
vessels. For ex vivo-fixed staining, cremaster muscles from naïve WT C57BL/6 mice were 
dissected away before being labelled post-fixation/permeabilisation with IB4 and LYVE-1 
overnight for confocal analysis, respectively. For in vivo-live staining, i.s. injections of IB4 and 
anti-LYVE-mAb were given to naïve WT C57BL/6 mice before cremaster muscles were 
dissected away and fixed for confocal analysis. IB4 binding was quantified by creating isosurfaces 
on lymphatic vessels to determine the MFI of lectin binding on vessels. Data are expressed as 
mean ± SEM from at least 8-10 vessels/animals, with at least 3 animals per group from 4 





3D-reconstructed confocal images of lymphatic vessels stained with MAL-1 using both 
methods showed that ex vivo-fixed staining (Figure 5.3A) and in vivo-live staining 
(Figure 5.3B) resulted in similar distribution of these lectins under naïve conditions. 
Quantification of these confocal images confirmed that staining of MAL-1 (N-linked 
α2,3-sialylated glycans expression) using ex vivo-fixed and in vivo-live staining methods 
were both at similar levels (Figure 5.4).  
 
Figure 5.3: Representative binding of MAL-1 to LECs of mouse cremaster muscles. 
Cremaster muscles from naïve C57BL/6 WT mice were labelled with anti-PECAM-1 (green), 
anti-LYVE-1 (red) and MAL-1 lectin (blue) via 3 different methods. Tissues were analysed on a 
confocal microscope and IMARIS software. (A-B) Orange boxes on images (left) indicate the 
region of vessel which is depicted on the zoomed-in images (right). Top right images show 
LYVE-1 and MAL-1 staining, and bottom right boxes show just MAL-1 staining. (A) Ex vivo-
fixed staining (Post-fixation/perm-block) of MAL-1. (B) In vivo-live staining via intrascrotal 




Figure 5.4: MFI of MAL-1 binding to glycocalyx present on lymphatic vessels under naïve 
conditions. Quantification of the MFI of MAL-1 (specific for α2,3-sialylated glycans) binding to 
the surface of lymphatic vessels using 2 different staining methods – ex vivo-fixed and in vivo-
live. This also represents expression of α2,3-sialylated glycans on the surface of lymphatic 
vessels. For ex vivo-fixed staining, cremaster muscles from naïve WT C57BL/6 mice were 
dissected away before being labelled post-fixation/permeabilisation with MAL-1 and LYVE-1 
overnight for confocal analysis, respectively. For in vivo-live staining, i.s. injections of MAL-1 
and anti-LYVE-mAb were given to naïve WT C57BL/6 mice for 2 h before cremaster muscles 
were dissected away and fixed for confocal analysis. MAL-1 binding was quantified by creating 
isosurfaces on lymphatic vessels to determine the MFI of lectin binding on vessels. Data are 
expressed as mean ± SEM from at least 8-10 vessels/animals, with 3 animals per group from 3 
independent experiments. Significant differences groups are indicated by asterisks: **, P < 0.01; 
****. Statistical significance was determined using one-way ANOVA.  
 
Finally, 3D-reconstructed images of IB4 staining on blood vessels using the ex vivo-fixed 
staining method showed that α D-Galactosyl moieties were distributed homogeneously 
on blood vessels (Figure 5.5A). 3D-reconstructed images also showed that MAL-1 
staining (α2,3-sialylated glycans expression) on blood vessels was more patchy and 
heterogeneous as compared to IB4 (Figure 5.5B). Quantification of these images using 
IMARIS software, and comparisons with the previous results of lectin staining on 
lymphatic vessels revealed that IB4 staining on blood vessels was significantly higher (~3 
fold) than on lymphatic vessels. In contrast, MAL-1 staining was significantly higher 
(~1.5 fold) on lymphatic vessels, as compared to blood vessels (Figure 5.6). 
Overall, this section has demonstrated the presence of 2 types of sugars in the glycocalyx 
present on/within the lymphatic endothelium, namely α-D-Galactosyl moieties and 
sialylated N-linked glycans, by fluorescent staining with lectins in vivo and ex vivo. 
Furthermore, it has provided evidence of differences in the distribution and localisation 
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of different sugar chains on lymphatic vessels; MAL-1 staining of the N-linked α2,3-
sialylated glycans was shown to be more homogenous on/within LECs as compared to 
IB4 staining of α-D-Galactosyl moieties. Finally, it has also highlighted differences in the 
specific organisation of sugars on both blood and lymphatic vasculatures. 
 
Figure 5.5: Representative confocal images of IB4 and MAL-1 binding to glycocalyx present 
on blood vessels under naïve conditions. Representative 3D-reconstructed confocal images of 
(A) IB4 (specific for α-D-Galactosyl moieties) and (B) MAL-1 (specific for α2,3-sialylated 
glycans) binding to the surface of blood vessels using ex vivo-fixed staining. For ex vivo-fixed 
staining, cremaster muscles from naïve WT C57BL/6 mice were dissected away before being 
labelled post-fixation/permeabilisation with IB4/MAL-1, and for PECAM-1and LYVE-1 





Figure 5.6: MFI of IB4 and MAL-1 binding to glycocalyx present on blood vessels under 
naïve conditions. Quantification of the MFI of IB4 (specific for α-D-Galactosyl moieties) and 
MAL-1 (specific for α2,3-sialylated glycans) binding to the surface of blood vessels using ex vivo-
fixed staining. IB4/MAL-1 binding was quantified by creating isosurfaces on blood vessels to 
determine the MFI of lectin binding on vessels. Data are expressed as mean ± SEM from at least 
8-10 vessels/animals, with 3 animals per group from 3 independent experiments. Significant 
differences groups are indicated by asterisks: *, P < 0.05. Statistical significance was determined 





 Effects of TNF- or CFA+Ag-induced inflammation on sugar 
residues and HS expression levels on lymphatic vessels in the 
cremaster muscle 
To characterise the effects of TNF or CFA+Ag in the cremaster muscle in terms of 
glycocalyx regulation, lectin binding and HS expression on/within the lymphatic 
endothelium under basal and inflamed conditions were investigated via ex vivo-fixed and 
in vivo-live staining methods. For this purpose, WT mice were given i.s injections of 300 
ng TNF (in 400 µl PBS) or 200 μg of an emulsion of CFA+Ag (200 µg of each in 300 µl 
total volume) and the inflammation allowed to develop for 16 h. Unstimulated control 
mice were given i.s injections of PBS. Tissues were subjected to either ex vivo-fixed or 
in vivo-live staining of lectins (IB4/MAL-1) and anti-LYVE-1 to label sugars and 
lymphatic vasculatures, respectively, for confocal analysis. In some experiments, an anti-
MRP14 mAb was used to label neutrophils. Images obtained from confocal microscopy 
were analysed using IMARIS software. 
Following TNF- or CFA+Ag-induced stimulation of mice cremaster muscles, 3D-
reconstructed confocal images from both in vivo-live staining (not shown) and ex vivo-
fixed staining (Figure 5.7) showed that IB4 staining (α-D-Galactosyl residue expression) 
on lymphatic vessels seemed to be lower in both TNF (Figure 5.7, middle panel) and 
CFA+Ag (Figure 5.7, bottom panel) stimulated tissues, as compared to unstimulated 
controls (Figure 5.7, top panel). Quantification of these confocal images confirmed that 
ex vivo-fixed staining resulted in significantly lower (~ 3 fold decrease) IB4 staining (α-
D-Galactosyl residue expression) in TNF- or CFA+Ag-stimulated tissues; levels of 
expression were similar with both inflammatory mediators (Figure 5.8A). Although not 
significant, a similar decreasing trend was seen with in vivo-live staining (Figure 5.8B). 
These results suggest that α-D-Galactosyl moieties are being cleaved on lymphatic 
vessels following inflammation, thus resulting in a decrease of IB4 binding. Interestingly, 
when the relationship between the number of neutrophils found within lymphatic vessels 
and staining of IB4 was investigated in inflamed cremaster muscles, a negative correlation 
between IB4 staining and number of neutrophils present within lymphatic vessels was 
found, suggesting a possible contribution of α-D-Galactosyl cleavage in mediating 





Figure 5.7: IB4 staining (α D-Galactose expression) on lymphatic vessels following TNF and 
CFA+Ag-induced inflammation of the cremaster muscle. WT C57BL/6 mice were given i.s 
injections of PBS (400 µl), TNF (300 ng in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl 
total volume) and inflammation was allowed to be induced for 16 h before the mice were 
sacrificed by cervical dislocation and their cremaster muscles dissected away, fixed, 
permeabilised and stained (IB4 [blue] and LYVE-1 [red] staining) for confocal analysis. The left 
panels shows IB4 binding (or α D-Galactose expression, blue) on lymphatic vessels (red) 
following i.s injection of PBS, TNF and CFA+Ag, from top to bottom, respectively. The right 







Figure 5.8: MFI of IB4 staining on lymphatic vessels following (A) ex vivo-fixed and (B) in 
vivo-live staining of cremaster muscles from unstimulated, TNF and CFA+Ag stimulated 
WT C57BL/6 mice. WT C57BL/6 mice were intrascrotally stimulated with TNF or CFA+Ag for 
16 h before they were sacrificed via cervical dislocation and their cremaster muscles dissected 
away and either directly stained (in vivo-live) or fixed and permeabilised before being stained (ex 
vivo-fixed) with IB4 (binds to α D-Galactose) and labelled for LYVE-1. Control mice received 
i.s. injection of PBS. IB4 binding was quantified by creating isosurfaces on lymphatic vessels to 
determine the MFI of lectin binding on vessels. (A) MFI of IB4 staining following ex vivo-fixed 
staining. (B) MFI of IB4 staining following in vivo-live staining. Results are from n = 8-12 vessels 
per mouse with 3-6 animals per group from 14 independent experiments. Statistically significant 
differences between stimulated and unstimulated treatment groups are indicated by asterisks: ***, 
P < 0.001; ****, P < 0.0001. As the imaging techniques are different, it is not possible to compare 




Figure 5.9: Correlation between IB4 (α-D-galactose expression) and neutrophil migration 
into lymphatic vessels of inflamed cremaster tissues of WT mice. Graph showing correlation 
between MFI of ICAM-1 expression (y-axis) and number of neutrophils within combined 
lymphatic vessels (x-axis) of TNF- or CFA+Ag-stimulated WT mice as analysed by IMARIS 
software. Data are expressed as mean±SEM of n = 53 vessels (8-12 vessels/animals from 6 
animals, 6 independent experiments). Statistical significance was determined using linear 
regression analysis: **, P < 0.01. 
 
Due to in vivo-live staining resulting in similar binding of IB4 to lymphatic vessels as 
compared with ex vivo-fixed staining, changes in MAL-1 staining was examined with the 
latter technique. 3D-reconstructed images of MAL-1 staining with ex vivo-fixed staining 
(Figure 5.10) showed little difference in MAL-1 binding (α2,3-sialylated glycans 
expression) to lymphatic vessels following TNF (Figure 5.10, middle panel) and 
CFA+Ag (Figure 5.10, bottom panel), as compared to unstimulated controls (Figure 
5.10, top panel). MAL-1 binding (α2,3-sialylated glycans expression) to lymphatic 
vessels remained heterogeneous following stimulation with both inflammatory mediators. 
Quantification of these images showed no change in MAL-1 binding (α2,3-sialylated 
glycans expression) to lymphatic vessels following TNF- or CFA+Ag- stimulation, as 




Figure 5.10: α2,3-sialylated glycans expression on lymphatic vessels following TNF and 
CFA+Ag-induced inflammation of the cremaster muscle. WT C57BL/6 mice were given i.s 
injections of PBS (400 µl), TNF (300 ng in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl 
total volume) and inflammatory response was allowed to develop for 16 h before the mice were 
sacrificed by cervical dislocation and their cremaster muscles dissected away, fixed, 
permeabilised and stained for MAL-1 (blue) and immunostained with anti-LYVE-1 mAb (red) 
for confocal analysis. The left panels show MAL-1 binding (or α2,3-sialylated glycans 
expression, blue) on lymphatic vessels (red) following i.s injection of PBS, TNF and CFA+Ag, 






Figure 5.11: MFI of MAL-1 staining on lymphatic vessels following ex vivo-fixed staining of 
cremaster muscles from unstimulated, TNF and CFA+Ag-stimulated WT C57BL/6 mice. 
WT C57BL/6 mice were i.s. stimulated with TNF or CFA+Ag for 16 h before they were sacrificed 
via cervical dislocation and their cremaster muscles dissected away, fixed and permeabilised 
before being stained with MAL-1 (α2,3-sialylated glycans) and labelled for LYVE-1. Control 
mice received i.s. injection of PBS. MAL-1 binding was quantified by creating isosurfaces on 
lymphatic vessels to determine the MFI of lectin binding on vessels. Results are from n = 8-12 
vessels per mouse with 3-10 animals per group from 6 independent experiments. Statistical 
significance was determined using one-way ANOVA. 
 
Next, changes in the expression of one of the major GAGs in the glycocalyx, HS, were 
investigated following inflammation. HS was investigated as it has been demonstrated to 
be critically required for chemokine immobilisation and functional presentation on the 
cell surface of both HEV cells and LECs, during the process of lymphocyte and DC 
homing to dLNs (Bao et al., 2010). For this purpose, WT mice were given i.s injections 
of 300 ng TNF (in 400 µl PBS) and the inflammation allowed to develop for 16 h. Due 
to CFA+Ag-stimulation resulting in similar changes to glycocalyx sugar chains as 
demonstrated in the previous section, and in the interest of time, this inflammatory 
mediator was not used. Unstimulated control mice were given i.s injections of PBS. At 
the end of the inflammation period, tissues were fixed, permeabilised and immunostained 
with an anti-HS/isotype control Ab and anti-LYVE-1 mAb to label HS and lymphatic 
vasculatures, respectively, for confocal analysis. Images obtained from confocal 
microscopy were analysed on IMARIS software. 3D-reconstructed confocal images 
showed that a change in the distribution of HS on lymphatic vessels seemed to occur 
following TNF-stimulation, with this expression being more diffused and homogeneous 
on vessels as compared to patchy and heterogeneous expression seen in unstimulated 
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tissues (Figure 5.12). Quantification of confocal images showed that although 
redistribution of HS was seen following inflammation, there were no changes in total HS 
expression on lymphatic vessels in both unstimulated and TNF-stimulated tissues (Figure 
5.13). 
Overall, this section has demonstrated that IB4 binding (specific to α-D-Galactosyl 
moieties) to lymphatic vessels significantly decreases following TNF- or CFA+Ag-
stimulation, whilst MAL-1 binding (specific for α2,3-sialylated glycans) remains 
unchanged. This suggests that cleaving of α-D-Galactosyl moieties on lymphatic vessels 
is occurring following inflammation. Furthermore, no changes in expression of heparan 
sulfate was found on lymphatic vessels following TNF-stimulation, suggesting that 
redistribution of this GAG on lymphatic vessels could be instrumental in the formation 





Figure 5.12: Representative HS expression in unstimulated and TNF-stimulated murine 
cremaster muscles. C57BL/6 WT mice were given i.s injections of TNF (300 ng in 400 µl PBS) 
and the inflammatory response was allowed to develop for 16 h before the mice were sacrificed 
by cervical dislocation and their cremaster muscles dissected away, fixed, permeabilised and 
immunostained for HS (green) and LYVE-1 (red) to label the lymphatic vasculatures. 
Unstimulated controls received i.s injection of PBS. The images show representative 3D-
reconstructed confocal images of HS and LYVE-1 seen with the ex vivo-fixed (post-
fixation/perm-block) staining method. The orange box in the top images of unstimulated and 
TNF-tissues shows the selected region of lymphatic vessel depicted in the magnified images 
below, where heparan sulfate expression on the lymphatic vessel (left) and HS expression alone 





Figure 5.13: MFI of HS expression by lymphatic vessels following ex vivo-fixed staining of 
cremaster muscles from unstimulated and TNF-stimulated WT C57BL/6 mice. WT 
C57BL/6 mice were i.s. stimulated with TNF for 16 h before they were sacrificed via cervical 
dislocation and their cremaster muscles dissected away, fixed and permeabilised before being 
immunostained for isotype control/HS and LYVE-1. Control mice received i.s. injection of PBS. 
HS expression was quantified by creating isosurfaces on lymphatic vessels to determine the MFI 
of HS staining on vessels. Results are from n = 8-12 vessels per mouse with 2-4 animals per group 






 Expression of chemokine CCL21 on lymphatic vessels in TNF- 
or CFA+Ag-stimulated cremaster muscles 
Changes in the expression of the chemokine, CCL21, by lymphatic vessels during 
inflammation were next investigated. Both CCL19 and CCL21 are prototypical lymphoid 
chemokines that are ligands for the chemokine receptor CCR7. However, constitutive 
expression of only CCL21 by the lymphatic endothelium has been found (Gunn et al., 
1998; Vigl et al., 2011). Personal communication with my supervisor, Dr Mathieu-Benoit 
Voisin, has also indicated the lack of CCL19 detection via ELISAs. Furthermore, as the 
previous chapter has shown that CCR7 is important for neutrophil trafficking into 
lymphatic vessels in a TNF-dependent manner, presumably through its interactions with 
CCL21, the expression of this chemokine by initial lymphatic vessels was explored. First 
ex vivo-fixed staining of CCL21 was carried out. For this purpose, WT mice were i.s. 
injected with 300 ng TNF (in 400 µl PBS) or an emulsion of CFA+Ag (200 µg of each in 
300 µl total volume) and the inflammation allowed to develop for 16 h. Unstimulated 
control mice were given i.s injections of PBS. At the end of the inflammatory period, 
cremaster muscles were dissected away and immunostained for CCL21 and LYVE-1 and 
labelled with IB4 for confocal analysis. Images obtained from confocal microscopy were 
analysed using IMARIS software. 
Interestingly, when ex vivo-fixed immunostaining of CCL21 was carried out, the 
characteristic punctuate staining observed with IB4 staining previously (Figure 5.7), was 
also detected (Figure 5.14). Co-immunostaining of IB4 and CCL21 was therefore carried 
out following 16 h TNF-stimulation of WT mice cremaster muscles to investigate their 
co-localisation. 3D-reconstructed confocal images showed that IB4 and CCL21 punctuate 
staining exhibited co-localisation in the middle of single LECs (Figure 5.14, bottom 
panel). As ex vivo-fixed staining requires tissues to be permeabilised, this suggests that 
these punctuate staining could be intracellular stores of CCL21 and α-D-Galactosyl 




Figure 5.14: Co-localisation of IB4 and CCL21 on the surface of lymphatic vessels with ex 
vivo-fixed staining following TNF-induced inflammation. C57BL/6 WT mice were given i.s 
injections of TNF (300 ng in 400 µl PBS). Sixteen hours post-i.s. injection, mice were sacrificed 
by cervical dislocation and their cremaster muscles dissected away, fixed and permeabilised, then 
stained with IB4 (blue) and immunostained with anti-LYVE-1mAb (red) and anti-CCL21 mAb 
(green). Tissues were then washed and analysed via confocal microscopy and IMARIS software. 
The figure shows representative 3D-reconstructed confocal images of co-localisation between 
CCL21 and IB4 dotted staining seen with the ex vivo-fixed (Post-fixation/perm-block) staining 
protocol. The orange box in the top panel shows the selected region of lymphatic vessel depicted 
in the magnified images on the bottom panel. The bottom left image shows LYVE-1, CCL21 and 
IB4 staining. The bottom right image shows just CCL21 and IB4 staining. Bar: 50 μm.  
 
Due to the potential detection of signal from intracellular stores, in vivo-live staining of 
CCL21 was carried out. For this purpose, WT mice were given i.s injections of 300 ng 
TNF (in 400 µl PBS) or an emulsion of CFA+Ag (200 µg of each in 300 µl total volume) 
and the inflammation allowed to develop for 16 h. Unstimulated control mice were given 
i.s injections of PBS. Two hours before the end of the inflammation period, mice received 
i.s. injections (in vivo-live immunostaining) of anti-LYVE-1 mAb and anti-
CCL21/isotype control mAb to label lymphatic vasculatures and CCL21, respectively, 
for confocal analysis. Images obtained from confocal microscopy were analysed using 
IMARIS software. Following TNF- or CFA+Ag-stimulation, a down-regulation and 
redistribution of CCL21 expression on lymphatic vessels was observed; expression of 
CCL21 was patchy and heterogeneous as compared to the more diffused and 
homogeneous expression observed in unstimulated tissue (Figure 5.15). Quantification 
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of confocal images provided evidence that expression of CCL21 by lymphatic vessels 
was significantly reduced (~0.5 fold lower) in TNF-stimulated tissues, whilst CFA+Ag-
stimulation resulted in an even more significant reduction (~3 fold lower) of CCL21 
expression (Figure 5.16A). Additionally, to ensure that lymphatic vessel size was not 
giving rise to differences in MFI, the volume of vessels in PBS, TNF or CFA+Ag-
stimulated tissues were quantified (Figure 5.16B). This showed no significant changes in 
lymphatic vessel size in TNF and CFA+Ag-stimulated tissues as compared to 
unstimulated tissues. This indicates that the differences in MFI of CCL21 staining on 
lymphatics following inflammation are not due to changes in vessel size. In order to 
determine whether CCL21 was being released into the interstitium, the concentration 
gradient of CCL21 from the abluminal side of the lymphatic endothelium up to 10 µm 
away from the lymphatic vessel was quantified. The results from CFA+Ag-stimulated 
cremaster muscles showed that there was a higher expression (~2.5 fold higher) of CCL21 
on lymphatic vessels, as compared to the interstitial tissue (Figure 5.17A). Additionally, 
the results from unstimulated and CFA+Ag-stimulated cremaster muscles demonstrated 
that CCL21 expression was generally highest closest to the abluminal side of the 
lymphatic endothelium, and exhibited a decreasing trend as quantification moved away 
from the lymphatic vessel, thus establishing a CCL21 gradient (Figure 5.17B). 
Additionally, CFA+Ag-stimulated cremaster muscles resulted in the formation of a 
steeper gradient, as compared to unstimulated controls. 
Overall, this section has demonstrated that the expression of CCL21 on lymphatic vessels 
is not only reduced in response to TNF- or CFA+Ag-stimulation, but a redistribution of 
this chemokine is also seen on the surface of LECs. Furthermore, a steeper gradient of 





Figure 5.15: CCL21 staining on lymphatic vessels in unstimulated, TNF- or CFA+Ag-
stimulated conditions. WT C57BL/6 mice were given i.s injections of PBS (400 µl), TNF (300 
ng in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl total volume) for 16 h and the 
inflammatory response allowed to develop for 16 h. Two hours before the end of the inflammation 
period, mice received an i.s. injection of anti-LYVE-1 mAb (red) and anti-CCL21 mAb/rabbit 
IgG isotype control (green) Ab. At the end of the inflammation period, cremaster muscles were 
dissected away and immediately analysed via confocal microscopy and IMARIS software. The 
images show representative 3D-reconstructed confocal images of CCL21 expression on 
lymphatic vessels following in vivo-live staining (no fixation/no permeabilisation) in unstimulated 





Figure 5.16: MFI of CCL21 expression and lymphatic vessel volume of unstimulated, TNF 
and CFA+Ag-stimulated cremaster muscles. C57BL/6 WT mice were given i.s injections of 
TNF (300 ng in 400 µl PBS) or CFA+Ag (200 µg of each in 300 µl total volume) and the 
inflammatory response allowed to develop for 16 h. Two hours before the end of the inflammation 
period, mice received an i.s. injection of anti-LYVE-1 mAb and anti-CCL21 mAb/rabbit IgG 
isotype control Ab. (A) CCL21 expression was quantified by creating isosurfaces on lymphatic 
vessels to determine the MFI of CCL21 staining on vessels. Results are from n = 8-12 vessels per 
mouse with 3-5 animals per group from 3 independent experiments. (B) Volume of lymphatic 
vessels were quantified by creating isosurfaces on lymphatic vessels. Statistically significant 
differences between isotype control Ab and CCL21 Ab groups are indicated by asterisks: *, P < 
0.05; **, P < 0.01; ***, P < 0.001. Statistically significant differences between stimulated and 
unstimulated treatment groups are indicated by hash signs: #, P < 0.05; ##, P < 0.01. Statistical 





Figure 5.17: CCL21 gradient in unstimulated (PBS) or CFA+Ag-stimulated cremaster 
muscles. C57BL/6 WT mice were given i.s injections of CFA+Ag (200 µg of each in 300 µl total 
volume) and the inflammatory response allowed to develop for 16 h. Two hours before the end 
of the inflammation period, mice received an i.s. injection of anti-LYVE-1 mAb and anti-CCL21 
mAb/rabbit IgG isotype control Ab. (A) IMARIS quantification showing levels of CCL21 
expression in the interstitial tissue vs. lymphatic vessels of CFA+Ag stimulated WT mice. (B) A 
line intensity profile was generated perpendicular to the direction of the vessel (10 lines/vessel) 
from the abluminal surface into the tissue (10 µm length) using ImageJ to look at the potential 
gradient of CCL21 guiding leukocytes toward lymphatic vessels. Data are presented as percentage 
change from the first pixel of the line. Results are from n = 8-12 vessels per mouse with 2-3 
animals per group from 3 independent experiments. Statistically significant differences between 
isotype control Ab and anti-CCL21 Ab groups are indicated by asterisks: **, P < 0.01; ****, P < 
0.0001. Statistically significant differences between the interstitial tissue vs. the lymphatic vessels 





In contrast to the BEC glycocalyx, the LEC glycocalyx is not very well studied. Thus, 
this chapter aimed to characterise the LEC glycocalyx with the use of several lectins and 
antibodies targeted to the most abundant proteoglycan, HS, and the prototypical 
lymphatic chemokine, CCL21, which is thought to be associated with HS (Weber et al., 
2013). The potential regulation and redistribution of these components of the LEC 
glycocalyx following TNF- or CFA+Ag-induced inflammation was also investigated. 
Initially, in an effort to characterise the glycocalyx present on lymphatic vessels, a panel 
of 4 lectins were utilised: IB4, MAL-1, SNA, and LEL. However, only IB4 and MAL-1 
successfully bound to lymphatic vessels. LEL binds to N-acetylglucosamine and has been 
used effectively to label the blood vascular endothelium in rodents (Robertson et al., 
2015), however this does not seem to be the case for the lymphatic endothelium. SNA 
binds to α2,6 SAs and has been shown to interact with the LEC marker, LYVE-1, but this 
was demonstrated in LYVE-1 transfected HEK 293T cells, and is therefore not a good 
indicator of the true binding capabilities of this lectin to lymphatic vessels (Nightingale 
et al., 2009). It is possible that there is competition of binding between SNA and the anti-
LYVE-1 Ab, thus preventing proper binding of this lectin to lymphatic vessels. It is 
perhaps also possible that α2,6 SAs are not present within the LEC glycocalyx, as the 
current study has shown this to be the case in lymphatic vessels. 
Using different staining methods, α-D-galactosyl moieties (bound by IB4) and N-linked 
α2,3-sialylated glycans (bound by MAL-1), were found to be present both intracellularly 
and on the surface of LECs. It was also found that the BEC glycocalyx had a far higher 
expression of α-D-galactosyl moieties, with this expression being more homogeneous 
than that of the LEC glycocalyx. Additionally, N-linked α2,3-sialylated glycans were 
found to be expressed more highly within the LEC glycocalyx, as compared to the BEC 
glycocalyx. IB4 has never been reported to bind to lymphatic vessels, but it has been 
demonstrated to specifically bind to terminal α-D-galactosyl residues expressed by 
various cell types, including BECs in mouse, rabbit, rat and human tissues (Brabec et al., 
1980; Goldstein and Winter, 1999; Laitinen, 1987; Peters and Goldstein, 1979). 
Consequently, it is now recognised as a blood vasculature marker that has been widely 
used in a variety of angiogenesis studies (Bryson et al., 2011; Ernst and Christie, 2006; 
Walchli et al., 2015). This is in accordance with results from the present study where a 
higher and more homogeneous staining of IB4 was observed on blood vessels. This study 
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has, however, shown for the first time, the presence of α-D-Galactosyl moieties as a 
component of the LEC glycocalyx. MAL-1 has been utilised in many studies to detect N-
linked α2,3-sialylated glycans (Khatua et al., 2013; Knibbs et al., 1991; Nicholls et al., 
2007; Wang and Cummings, 1988). The detection of sialic acids (SAs) on lymphatic 
vessels is particularly relevant as SAs are known to play important roles in several human 
viral infections. Pathogens such as influenza viruses, rotaviruses, polyoma viruses and 
adenoviruses, have been shown to use host-sialylated structures for binding to their target 
host cell (Cashman et al., 2004; Dugan et al., 2008; Isa et al., 2006; Skehel and Wiley, 
2000). SAs are thought to be a good target for these viruses as they are highly conserved 
and are found in abundance in all mammalian cells. Viral infections of LECs have been 
shown to induce increased LEC permeability (Gavrilovskaya et al., 2012, 2013), thus the 
binding of viruses to SAs on lymphatic vessels could potentially result in increased viral 
entry into the lymphatic system and their recirculation into the bloodstream, consequently 
leading to systemic viral infections. Alternatively, as previously observed with bacteria 
escaping aged lymphatic vessels exhibiting decreased glycocalyx coverage and increased 
permeability, this increased permeability caused by viral LEC infection could result in 
other pathogens being released back into the interstitium, thus disrupting host immune 
responses in controlling infections (Zolla et al., 2015). Furthermore, bacteria use host SAs 
in order to colonise, persist and cause disease in humans (Severi et al., 2007). The most 
abundant and best-studied SA in these studies in N-acetylneuraminic acid (Neu5Ac) 
(Severi et al., 2007). MAL-1 has been shown to react with greatest affinity with Neu5Ac 
(Knibbs et al., 1991), thus making the current study relevant to this field as MAL-1 
staining is abundantly present on lymphatic vessels. These results therefore implicate 
lymphatic vessels as having potentially causative roles in immune evasion by such 
microbes. 
This chapter next sought to characterise the effects of inflammation on LEC glycocalyx 
regulation and redistribution. TNF- or CFA+Ag-induced inflammation of the cremaster 
muscle resulted in a reduction of α-D-Galactosyl residues (IB4 staining) present in the 
LEC glycocalyx on lymphatic vessels. A reduction in α-D-Galactosyl residue expression 
by lymphatic vessels was associated with an increased number of neutrophils found 
within the lumen of these vessels, providing evidence that neutrophil migration across the 
lymphatic endothelium is associated with cleavage of α-D-Galactosyl residues. Under 
inflammatory conditions, activated immune cells, such as neutrophils, macrophages and 
mast cells degranulate enzymes, which can contribute to the degradation of the glycocalyx 
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(Henry and Duling, 2000; VanTeeffelen et al., 2007). In particular, activated neutrophils 
can induce glycocalyx damage through the production of ROS and proteases from their 
storage granules (van Golen et al., 2012), all of which supports the result observed in the 
present study. It has also been reported that the vascular glycocalyx is rapidly shed in 
response to inflammatory mediators, such as cytokines and chemokines, under various 
experimental models of inflammation (Becker et al., 2010; Chappell et al., 2009a). 
Glycocalyx shedding induced by TNF is particularly relevant to the current study 
(Chappell et al., 2009a). As adhesion molecules are harboured within the glycocalyx 
(Chappell et al., 2008), the release of inflammatory mediators, such as TNF, could 
increase the accessibility of leukocytes to adhesion molecules through the degradation of 
the enveloping glycocalyx (Chappell et al., 2009a). All of these factors could be an 
explanation as to why a reduction in α-D-Galactosyl residues results in a higher number 
of neutrophils being able to migrate into lymphatic vessels. 
In contrast, TNF- or CFA+Ag-induced inflammation did not result in a down-regulation 
of α2,3-sialylated glycans (MAL-1 staining). Despite the expression levels of both 
components remaining the same under both basal and inflamed conditions, a 
redistribution of their expression within the LEC glycocalyx occurred. Although this has 
not been demonstrated in the context of inflammation, SA redistribution has been shown 
to occur within the BEC glycocalyx during shear flow in vitro (Bai and Wang, 2014). It 
has been reported that shear stress results in the redistribution and relocalisation of SAs 
to the cell-cell junctions of human umbilican vein endothelial cells (HUVECs) (Bai and 
Wang, 2014). As discontinuities of tight junctions in intercellular clefts between adjacent 
ECs has been demonstrated to provide a leakage route for macromolecules (Adamson et 
al., 1993), this redistribution of the glycocalyx is important for permeability control. 
Therefore, the redistribution of SAs observed in the current study could potentially also 
play similar roles in the regulation of lymphatic vessel permeability and barrier function 
during inflammation.  
In the present study, HS expression remained unchanged following TNF stimulation. HS 
has been shown to be cleaved and shed in response to TNF, as well as in surgical diseases 
states (I/R injury) (Chappell et al., 2009a; Chappell et al., 2009b). Under physiological 
conditions, heparan sulfate proteoglycans (HSPGs) have been shown to inhibit neutrophil 
adhesion (Schmidt et al., 2012). However, in an experimental sepsis model of acute lung 
injury, the production of endogenous TNF was shown to activate ECs to produce the 
enzyme, heparanase, which catalyses the partial degradation of HS constituents of the 
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glycocalyx; this loss of HS resulted in a significant increase in neutrophil binding to 
vascular walls and inflammation (Schmidt et al., 2012). HS degradation not only exposes 
underlying adhesion molecules but could also release pro-inflammatory mediators (e.g. 
IL-8), which are typically sequestered within the BEC layer, thus facilitating neutrophil 
adhesion and their extravasation (Reitsma et al., 2007). In the current experimental model, 
a redistribution of HS on lymphatic vessels was observed, despite no changes in total 
expression levels being found. An explanation for this could be due to the fact that the 
present study has shown differences in the distribution of sugars on the BEC and LEC 
glycocalyx, thus what is observed on blood vessels does not necessarily translate to the 
same observation on lymphatic vessels. Additionally, it could be due to a matter of 
differences in time-points investigated. Previous studies looking at changes in the BEC 
glycocalyx looked at shedding after just 0-90 mins of TNF stimulation (Chappell et al., 
2009a; Schmidt et al., 2012), and 20 mins of I/R injury (Chappell et al., 2009b). These 
inflammatory time-points are far more acute than the timepoint investigated in the present 
study, where changes in the LEC glycocalyx were only looked at 16 h post-i.s. injection 
(appropriate time for neutrophil-LECs interactions). Furthermore, it has recently been 
demonstrated that whilst short-term (30 min) shear stress results in shedding of the BEC 
glycocalyx, long-term (24 h) exposure to shear stress results in glycocalyx components, 
such as HS expression, being increased on the cell surface, close to static levels (Zeng 
and Tarbell, 2014). As only 16 h post-i.s. injection was looked at in the present study, this 
could very well be happening at earlier time-points, but further experiments will have to 
be carried out to determine this. It is worth mentioning that the shear stress in lymphatic 
vessels is very low, therefore what occurs in blood vessels may not necessarily be 
mirrored in lymphatic vessels. All of these differences could contribute to the explanation 
as to why no changes in HS expression were observed. 
Besides having regulatory roles in cell adhesion as a component of the vascular EC 
glycocalyx, HS also promotes cell signalling by providing binding sites for growth factors 
and chemokines, which leads to the formation of ternary complexes with their receptors 
(Handel et al., 2005; Schlessinger et al., 2000). It has been reported that a chemotactic 
gradient of CXCL2 (MIP-2) sequestered on HS in the vascular EC glycocalyx induces 
the directional intraluminal crawling of neutrophils within blood vessels (Massena et al., 
2010). Additionally, the constitutively expressed LEC chemokine, CCL21, has also been 
shown to bind to HS within the vascular EC glycocalyx, which leads to its immobilisation 
and the formation of a chemotactic gradient that guides DCs within the interstitium 
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towards lymphatic vessels (Weber et al., 2013). A similar interaction is thought to occur 
in LNs, where HS expression by HEVs is thought to control CCL21 chemokine 
presentation to facilitate lymphocyte homing into peripheral lymphoid organs (Bao et al., 
2010; Tsuboi et al., 2013). Thus, the expression of CCL21 on lymphatic vessels following 
TNF- or CFA+Ag-induced inflammation was investigated in the present study. 
Interestingly, despite the expression levels of HS remaining the same following 
inflammation, a decrease in the expression levels of CCL21 was found on lymphatic 
vessels. Despite this difference in expression, a redistribution of CCL21 was observed via 
confocal microscopy, as was observed with HS, although further experiments have to be 
carried out to check if they do indeed co-localise. Furthermore, the characteristic 
punctuate staining of CCL21 observed in lymphatic vessels is in line with previous 
observations of intracellular stores of this chemokine within LECs (Johnson and Jackson, 
2010; Weber et al., 2013). Since a down-regulation in CCL21 expression by lymphatic 
vessels was observed, the possibility of CCL21 release into the interstitium was next 
investigated. Although this did not turn out to be the case, preliminary results showed that 
CFA+Ag-induced inflammation resulted in a higher concentration gradient forming 
within the interstitium as compared to unstimulated conditions, with the highest 
expression of CCL21 being found nearest to the abluminal side of the lymphatic vessel. 
The expression of CCL21 decreased along a line up to 10 µm away from the abluminal 
side of the lymphatic endothelium, appearing to form a concentration gradient, which 
may potentially guide neutrophils towards lymphatic vessels, as is presumed to be the 
case for DCs (Haessler et al., 2011). This is also akin to the ‘source and sink’ hypothesis 
as proposed for morphogen gradients, where the establishment of a chemoattractant 
gradient in principle would require a stable production of the molecule (source) and its 
subsequent diffusion and elimination (sink) (Crick, 1970). The ‘source’ of CCL21 in this 
case would be the LECs, and the ‘sink’ would be the interstitial tissue and CCR7 
expressed by neutrophils, thus leading to the formation of a CCL21 gradient. This could 
in turn lead to the polarisation of migrating neutrophils and their chemotaxis towards 
LECs. 
As results from the present study indicate CCL21 is not being released into the 
interstitium, it is likely CCL21 is being drained away via the initial lymphatics, as is 
indicated by recent quantifications by Dr Voisin, showing the presence of a CCL21 
gradient within initial lymphatic vessels (Appendix 5A). Furthermore, the total CCL21 
expression within the tissue is also not altered (Appendix 5B). Interestingly, in support 
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of this hypothesis, a recent report provided in vitro evidence that an intraluminal CCL21 
gradient is induced by lymph flow, thus guiding DCs migrating within capillaries in the 
downstream direction of collecting lymphatic vessels (Russo et al., 2016).  
Collectively, the results in this chapter have demonstrated for the first time the presence 
of α-D-Galactosyl moieties as a component of the LEC glycocalyx, in addition to N-
linked α2,3-sialylated glycans (SAs). These sugar residues are either down-regulated (α-
D-Galactosyl moieties) or redistributed (sialylated N-linked glycans) within the LEC 
glycocalyx following TNF- or CFA+Ag-induced inflammation. The down-regulation of 
α-D-Galactosyl moieties is associated with increased neutrophil numbers found within 
lymphatic vessels. Furthermore, HS and CCL21 are also redistributed within the LEC 
glycocalyx following inflammation. Finally, down-regulation of CCL21 expression by 
lymphatic vessels was found following TNF- or CFA+Ag-induced inflammation, and this 
is associated with the formation of a steeper chemokine gradient within the interstitium, 
presumably to provide chemotactic cues to guide leukocytes within the tissue towards 
lymphatic vessels. This down-regulation in CCL21 is also associated with the formation 
of a gradient within initial lymphatic vessels in the direction of flow, thus guiding 
neutrophils in the right direction. Clearly, the LEC glycocalyx and its molecular 
constituents are potential targets of glycan-centered therapeutic approaches for the 
prevention of pathogen dissemination through the lymphatic vessels. However, further 
studies have to be carried out in order to determine the exact constituents that mediate 
neutrophil migration into the lymphatic system. 
Limitations of the study 
In addition to the limitations discussed at the end of Chapter 3 in this thesis, another 
caveat is that confocal microscopy does not give a high enough resolution for 
distinguishing the different structures of the LEC glycocalyx. Furthermore, degradation 
of the sugar chains could have also occurred due to sample manipulation. To achieve 
higher resolution, the gold standard method for the visualisation of the glycocalyx – 
electron microscopy – could be used to further characterise its structure (e.g. thickness). 
Intravital confocal microcopy could also be used to identify the exact locations of the 
sugar chains within the LEC glycocalyx. However, labelling of glycocalyx structures with 
lectins are an accepted protocol as exemplified with numerous articles using this 
technique both in vivo (labelling of blood vasculature) and ex vivo (tissue sections) 
(Wang, 2007; Reitsma, 2017). 
220 
 
 : Investigating the roles of TNF and ICAM-1 in 
driving neutrophil intraluminal crawling following 
their migration into lymphatic vessels in vivo 
 Introduction 
Akin to the process of neutrophil migration into lymphatic vessels being massively 
understudied, investigations into subsequent neutrophil-lymphatic vessel interactions 
following their transmigration across the lymphatic endothelium is of greater paucity. To 
date, only one seminal study observing neutrophil crawling within lymphatic vessels 
exists (Hampton et al., 2015). The study mainly investigated the mechanisms of 
neutrophil migration from inflamed tissue into lymphoid organs following S. aureus 
infection. Therefore, migration of neutrophils into lymphatic vessels and their crawling 
parameters following inflammation were not studied in detail. LysM-eGFP mice were 
used to examine neutrophil interactions with lymphatic vessels following bacterial 
infection (Hampton et al., 2015). However, their data do not clearly show whether this is 
intraluminal crawling. 
Due to the scarcity of studies investigating neutrophil crawling within lymphatic vessels, 
the mechanisms of this phenomena has yet to be dissected. In light of this, possible 
mechanisms of this process could be inferred from current findings of intraluminal 
crawling of other leukocytes within lymphatic vessels. Up till now, majority of studies 
have focused on leukocyte (DCs in particular) crawling along the lymphatic endothelium 
towards lymph nodes (Nitschke et al., 2012; Sen et al., 2010; Tal et al., 2011); initiation 
of adaptive immune responses require DCs to carry antigens into lymph nodes. To do 
this, intravital microscopy (IVM) has been used as the main tool for observing leukocyte 
crawling behaviour. These studies showed that once within the lumen of initial lymphatic 
vessels, DCs actively crawl along the luminal side of the lymphatic endothelium guided 
by the directional flow of lymph. Interestingly, once reaching collecting lymphatics, DCs 
switch to passive drifting to exploit the faster lymph flow so as to rapidly reach draining 
lymph nodes (Tal et al., 2011). It has also recently been observed that integrin ligands of 
the adhesion molecules, ICAM-1 and VCAM-1, contribute to DC crawling over LECs 
(Barreiro et al., 2002; Carman et al., 2003; Teijeira et al., 2013). DC crawling within 
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lymphatic vessels resembles the inflammation-mediated integrin crawling of leukocytes 
within the lumen of blood postcapillary venules before transendothelial migration into 
the interstitial tissues occurs (Phillipson et al., 2006). Phillipson et al. demonstrated using 
time-lapse video-microscopy within blood vessels in WT mice that immediately upon 
neutrophil adhesion to the venular walls, a significant intraluminal crawling of all 
neutrophils to distant sites of inflammation was observed (Phillipson et al., 2006). 
However, mice deficient in the ICAM-1 integrin ligand, MAC-1, exhibited crawling 
impairments; this crawling was found to be mediated by ICAM-1 as when a blocking 
antibody against this adhesion molecule was used, neutrophils could no longer crawl in 
response to the chemoattractant, MIP-2 (Phillipson et al., 2006). 
Owing to the current lack of understanding regarding the specific mechanisms by which 
neutrophils crawl within the lumen of lymphatic vessels, this study set out to look at the 
dynamics of this crawling behaviour and reveal potential mechanisms by which this 
process occurs during inflammation in vivo. 
 Aims 
Neutrophil intraluminal crawling within lymphatic vessels has rarely been studied, thus 
leaving a plethora of neutrophil-LECs interactions to be unravelled. Hence, this chapter 
aims to investigate crawling behaviours of neutrophils within lymphatic vessels during 
TNF- or CFA+Ag-stimulation in vivo. This thesis has already shown TNF and CFA+Ag-
stimulation induces the migration of neutrophils into lymphatic vessels. Specifically, 
Chapter 4 of this thesis demonstrated the role of the CCL21:CCR7 chemokine axis in 
TNF-driven neutrophil migration into lymphatic vessels in vivo. Consequently, this 
chapter aimed to investigate the involvement of TNF signalling in driving neutrophil 
intraluminal crawling within lymphatic vessels. It also aimed to elucidate the mechanisms 
of neutrophil crawling within the luminal side of the lymphatic endothelium; in particular, 
the role of the adhesion molecule, ICAM-1, was considered as it has previously been 







Therefore, the specific aims of this chapter were to: 
 Use neutrophil reporter LysM-eGFP mice to track GFPhigh neutrophils using 
confocal IVM to observe the dynamics of TNF-induced intraluminal crawling 
within lymphatic vessels in vivo. 
 Use confocal IVM to investigate the role of TNF in driving neutrophil 
intraluminal crawling within lymphatic vessels of LysM-eGFP mice by using anti-
TNF blocking mAbs as a means of abolishing TNF signalling. 
 Visualise and investigate the expression of ICAM-1 on lymphatic vessels 
following TNF- or CFA+Ag-induced inflammation in vivo through the use of 
immunostaining and confocal microscopy analysis. 
 Investigate the relationship between TNF and ICAM-1 in driving neutrophil 
intraluminal crawling within lymphatic vessels. 
 Results 
 Confocal intravital microscopy to observe TNF-induced 
crawling of neutrophils within lymphatic vessels in real-time and 
in 4D in vivo 
Neutrophil interactions with lymphatic vessels in vivo, particularly post-migration across 
the lymphatic endothelium, upon TNF- or CFA+Ag-stimulation was first investigated in 
real-time. For this purpose, LysM-eGFP mice were given i.s injections of either 300 ng 
TNF (in 400 µl PBS) or an emulsion of CFA+Ag (200 µg of each in 300 µl total volume) 
for 4 h and 6 h, respectively. Following this, in vivo fluorescent-immunostaining with a 
non-inhibitory dose of anti-LYVE-1 mAbs was applied to the tissues to visualise 
lymphatic vessels to allow the tracking of GFPhigh neutrophils migrating into and within 
the lymphatic vasculature by confocal IVM. Mice were anaesthetised and cremaster 
muscles were exteriorised and pinned out flat over the optical window of a heated 
microscope stage. Z-stack images of a lymphatic vessel were captured every minute for 
90 min in order to capture neutrophil interactions with the luminal side of the lymphatic 
endothelium in 4D between the time frames of 4 – 5.5 h (for TNF stimulation) and 6 – 
7.5 h (for CFA+Ag-stimulation). These time frames were chosen to record events around 
the peak of neutrophil migration into lymphatic vessels as found in time-course 
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experiments, to allow neutrophil interactions with vessels to be observed. Tyrode’s salt 
solution was used to constantly superfuse cremaster muscles during all experiments. 
Following stimulation with TNF, neutrophils were observed crawling along the luminal 
side of the lymphatic (Figure 6.1 & Video 2). An example of confocal IVM analysis of 
a single neutrophil demonstrated that over the course of an hour, the neutrophil remained 
attached to the luminal side of the endothelium and continuously crawled along the vessel 
wall (Figure 6.1). Analysis of neutrophil crawling parameters within lymphatic vessels 
provided evidence that majority of these leukocytes moved in the direction towards 
collecting lymphatic vessels/lymph flow (63.5 ± 5.7 %) (Figure 6.2A), at a speed of 4.3 
± 0.2 μm/min (Figure 6.2C), and with a straightness index of 0.5 ± 3 (Figure 6.2D); 
whilst in contrast, cells going against lymph flow exhibited reduced displacement length, 
speed and straightness (Figure 6.2A-D).  
The results in this section demonstrated that TNF can not only trigger the migration of 
neutrophils into lymphatic vessels, but can also induce their intraluminal crawling along 
the luminal side of the lymphatic endothelium towards lymph flow in the direction of 






Figure 6.1: Dynamics of neutrophil crawling within lymphatic vessels of TNF-stimulated 
cremaster muscles in real-time in vivo. These are representative 3D-reconstructed still images 
of a live recording of a TNF-stimulated cremaster tissue from a LysM-eGFP mouse and 
immunostained with a non-blocking low dose of anti-LYVE-1 mAb (red) in vivo. The dynamics 
of neutrophil crawling within lymphatic vessels was then analysed by intravital confocal 
microscopy and IMARIS software. The top image illustrates the crawling of a neutrophil along 
the lumen of the lymphatic vessel endothelium at different time-points. The crawling path (colour-
coded line) and directionality (white arrow) of the neutrophil is shown on the image. The bottom 
panel images are a series of high magnification cross-sections of the main image at indicated time-
points illustrating the continuous attachment of the neutrophil to the lymphatic endothelium. Bars: 





Figure 6.2: Crawling parameters within lymphatic vessels of TNF-stimulated cremaster 
muscles in real time in vivo. Mice were subjected to TNF-induced inflammation of the cremaster 
muscle and the dynamics of neutrophil crawling within lymphatic vessels were analysed by 
intravital confocal microscopy. The resulting video was analysed using IMARIS software. (A) 
Percentage of neutrophils crawling in the direction of lymph flow (flow) or in the opposite 
direction (anti-flow). Directionality (B), speed (C), and straightness (D) of neutrophils crawling 
in the direction of lymph flow (flow) or opposite direction (anti-flow) of the cremaster lymphatic 
vessels. Data are expressed as mean ± SEM from 8 independent experiments. For the crawling 
parameter analysis, a total of 63 cells were quantified from 8 mice. Statistically significant 
differences between flow and anti-flow groups of crawling cells are indicated by asterisks: *, P < 




 Effects of TNF signalling on intraluminal crawling of neutrophils 
within lymphatic vessels following CFA+Ag-stimulation as 
observed by confocal intravital microscopy  
In order to look at the impact of TNF signalling on neutrophil migration into lymphatic 
vasculatures, mice were subjected to CFA+Ag-induced inflammation in the cremaster 
muscle as before; an anti-TNF blocking Ab or isotope control Ab was then injected 4 h 
post-i.s. injection and mice were prepared for confocal IVM as described at the start of 
this section. Neutrophil crawling behaviours within the lumen of lymphatic vessels were 
observed and compared between anti-TNF/isotype control-treated mice. Movements of 
neutrophils within lymphatic vessels were tracked and analyses showed that cells in mice 
stimulated with CFA+Ag and treated with the isotype control Ab were able to crawl freely 
along the luminal side of the lymphatic endothelium in the direction of lymph flow 
(Figure 6.3A & Video 3). In contrast, mice treated with anti-TNF blocking Ab exhibited 
neutrophils with crawling impairments; most, if not all, lost all sense of directionality, 
exhibited meandering crawling paths and were mostly rendered immobile once crossing 





Figure 6.3: The effect of TNF signalling on neutrophil intraluminal crawling within 
lymphatic vessels. LysM-eGFP mice were subjected to CFA+Ag-induced cremaster 
inflammation and immunostained in vivo i.s with non-blocking dose of anti-LYVE-1 mAb (red). 
Isotype control or anti-TNF blocking mAbs were i.s injected 4 h post-i.s. injection. (A) The 3D-
reconstructed image (left) is a representative still image at one time point of the IVM recording 
showing lymphatic-infiltrated neutrophils (green) and their associated crawling path (time-
coloured mapped line) and/or directionality (white arrow) in mice treated with isotype CTL Ab, 
as analysed by IMARIS software. The directionality plot (right) shows the crawling paths of 
lymphatic-infiltrated neutrophils in the X & Y planes of the lymphatic vessels from CTL Ab-
treated mice. Bar: 30 µm. (B) Representative still image (left) at one time point of the IVM 
recording showing lymphatic-infiltrated neutrophils (green) and their associated crawling path 
and/or directionality in mice treated with anti-TNF mAb, as analysed by IMARIS software. The 
directionality plot (right) shows the crawling paths of lymphatic-infiltrated neutrophils in the X 
& Y planes of the lymphatic vessels from anti-TNF mAb -treated mice. Bars: 30 µm.  A total of 




Analysis of neutrophil crawling parameters within lymphatic vessels provided evidence 
that in isotype control Ab-treated mice, majority of these leukocytes moved in the 
direction towards collecting lymphatic vessels/lymph flow (67.8 ± 3.8 %) (Figure 6.4A), 
at a further displacement length of 90.9 ± 10.6 um (Figure 6.4B), at a speed of 5.8 ± 0.3 
um/min (Figure 6.4C), and with a straightness index of 0.4 ± 0.04 (Figure 6.4D); whilst 
cells going against lymph flow had significantly reduced speed, directionality of 
movement and straightness (Figure 6.4A-D). Interestingly, analysis of neutrophil 
crawling parameters within lymphatic vessels of mice treated with the anti-TNF blocking 
Ab confirmed that they exhibited neutrophils that had lost all sense of directionality with 
significantly reduced speed, and straightness as compared to isotype control Ab-treated 
mice (Figure 6.4A-D). 
The results in this section suggest that during the acute phase of the inflammatory 






Figure 6.4: Crawling parameters of intraluminal crawling within lymphatic vessels of 
CFA+Ag-stimulated cremaster muscles in real time in vivo with TNF signalling-blockade. 
The effect of anti-TNF blocking mAb on neutrophil crawling along the luminal side of the 
lymphatic endothelium was analysed by intravital confocal microscopy (IVM) using LysM-eGFP 
mice subjected to CFA+Ag-induced cremaster inflammation. Isotype control or anti-TNF 
blocking mAbs were injected i.s. 4 h post-i.s. injection. (A) Quantification (in percentage) of 
neutrophils crawling in the direction of lymph flow (flow) or opposite direction (anti-flow) of the 
lymphatic vessel. Directionality (B), mean speed (C), and straightness (D) of neutrophils crawling 
in CTL mAb and anti-TNF treated groups. A total of 280 cells were analysed. Results are 
expressed as mean ± SEM of N = 4–9 mice (1-2 vessels analysed/mouse each mice representing 
one independent experiment). Significant differences between flow and anti-flow crawling cells 
are indicated by *, P < 0.05; ****, P < 0.0001. Significant differences between the CTL and anti–
TNF mAb treated groups are indicated by hash symbols: ##, P < 0.01; ###, P < 0.001; ####, P < 
0.0001. Statistical significance was determined using one-way ANOVA. 
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 Role of ICAM-1 in mediating TNF-induced neutrophil 
intraluminal crawling within lymphatic vessels 
To investigate the molecular mechanisms of TNF-dependent neutrophil intraluminal 
crawling within lymphatic vessels, the role of ICAM-1, an adhesion molecule known to 
support neutrophil crawling along both the luminal and abluminal surfaces of blood 
vessels was studied (Phillipson et al., 2006; Proebstl et al., 2012). ICAM-1 expression on 
cremaster lymphatic vessels under basal and inflamed conditions were first analysed by 
immunostaining methods. For this purpose, WT mice were stimulated with i.s injections 
of either 300 ng TNF (in 400 µl PBS) or an emulsion of CFA+Ag (200 µg of each in 300 
µl total volume) for 6 h and 8 h, respectively. Unstimulated control mice received i.s. 
injections of PBS (400 µl). At the end of the inflammation period, cremaster muscles 
were dissected away, fixed, permeabilised and immunostained with anti-LYVE-1 and 
anti-ICAM-1 (or isotype control) mAbs to label the lymphatic vasculatures and ICAM-1, 
respectively, for analysis by confocal microscopy and IMARIS software. 3D-
reconstructed images showed that ICAM-1 expression was up-regulated on lymphatic 
vessels in TNF- or CFA+Ag-stimulated tissues as compared to unstimulated tissues 
(Figure 6.5). These images also showed that TNF-stimulated tissues seemed to generally 
exhibit a higher and more heterogeneous expression of ICAM-1. Quantification of 
confocal images provided evidence of this up-regulation of ICAM-1 on stimulated 
tissues, with CFA+Ag resulting in an ~2-fold increase in expression, and TNF resulting 
in an even bigger (~3-fold) increase in ICAM-1 expression on lymphatic vessels, as 
compared to unstimulated controls (Figure 6.6). Staining with ICAM-1 isotype control 
Ab confirmed that the possibility of non-specific binding and autofluorescence was 





Figure 6.5: ICAM-1 expression on lymphatic endothelial cells in unstimulated, TNF and 
CFA+Ag-stimulated conditions in vivo. Cremaster muscles of C57BL/6 WT mice were 
stimulated with TNF or CFA+Ag (6 and 8 h, respectively) and immunostained with anti-LYVE-
1 (red) and anti-ICAM-1/isotype control mAbs (green)  to label the lymphatic vasculature and 
ICAM-1, respectively. The pictures are representative 3D-reconstructed confocal images of 
cremaster lymphatic vessels showing the expression of ICAM-1 on selected lymphatic vessels 
from a PBS-treated control (top panels), TNF-stimulated (middle panels) and CFA+Ag-
stimulated (bottom panels) animals. The left panels show both LYVE-1 and ICAM-1/isotype 





Figure 6.6: ICAM-1 expression on lymphatic vessels in unstimulated, TNF- or CFA+Ag-
stimulated cremaster muscles in vivo. The graph shows ICAM-1 expression (mean fluorescent 
intensity or MFI) on vessels from PBS-treated control, TNF-stimulated and CFA+Ag-stimulated 
cremaster muscles as quantified by IMARIS software. Data are expressed as mean ± SEM of N 
= 8-12 vessels/animals from 4-11 animals per group (7 independent experiments). Statistically 
significant differences between the staining of isotype control and anti-ICAM-1 Abs treated 
groups are indicated by asterisks: *, P < 0.05; ****, P < 0.0001. Significant differences between 
unstimulated and inflamed groups are indicated by hash signs: ##, P < 0.01; ####, P < 0.0001. 




Having discovered that TNF resulted in the biggest up-regulation of ICAM-1 on 
lymphatic vessels, TNF signalling upon CFA+Ag challenge was blocked using an anti-
TNF blocking mAb to see the effects of this on ICAM-1 expression. For this purpose, 
WT mice were stimulated with CFA+Ag as before and an anti-TNF blocking mAb or 
isotype control mAb was i.s injected 4 h post-i.s. injection. Eight hours post-i.s. injection, 
cremaster muscles were dissected away, fixed, permeabilised and immmunostained with 
anti-LYVE-1, anti-ICAM-1/isotype control mAb and MRP14 for confocal microscopy 
and IMARIS software analysis. Interestingly, 3D-reconstructed images showed a 
decrease in ICAM-1 expression in mice treated with the anti-TNF blocking mAb (Figure 
6.7A). Quantification of these images further confirmed these findings of a reduction 
(~2.5 fold less) in ICAM-1 expression on lymphatic vessels of mice treated with the anti-
TNF blocking mAb (Figure 6.7B). Intriguingly, when the relationship between ICAM-1 
expression and the number of neutrophils found within lymphatic vessels was 
investigated, a positive correlation between ICAM-1 expression and number of 
neutrophils present within lymphatic vessels was found, suggesting a role for ICAM-1 in 






Figure 6.7: TNF controls ICAM-1 expression on lymphatic endothelial cells in vivo. C57BL/6 
WT mice were stimulated with CFA+Ag and i.s injected with an anti-TNF blocking mAb/isotype 
CTL mAb was injected 4 h later. Eight hours post-i.s. injection, cremaster muscles were dissected 
away, fixed, permeabilised and immunostained with anti-LYVE-1 (red) and anti-ICAM-1/isotype 
control mAbs (green) to label the lymphatic vasculature and ICAM-1, respectively. (A) 
Representative 3D-reconstructed confocal images of cremaster lymphatic vessels showing the 
expression of ICAM-1 on selected lymphatic vessels from isotype CTL mAb-treated mice (top 
panels) and anti-TNF mAb--treated mice (bottom panels) animals. The right panels show both 
LYVE-1 and ICAM-1/isotype control staining, and the left panels shows only ICAM-1/Isotype 
control staining. Bar: 30 µm. (B) ICAM-1 expression on lymphatic vessels of CFA+Ag-
stimulated cremaster muscles from animals pre-treated with an anti-TNF blocking mAb or isotype 
CTL mAb injected 4 h post-i.s. injection. Data are expressed as mean ± SEM from at least 8-10 
vessels/animals, with 3-11 animals per group (at least 5 independent experiments). Statistically 
significant differences between the staining of isotype control- and anti-TNF Abs-treated groups 





Figure 6.8: Correlation between ICAM-1 expression and neutrophil migration into 
lymphatic vessels of TNF-stimulated WT mice. Graph showing correlation between MFI of 
ICAM-1 expression (y) and number of neutrophils within lymphatic vessels (×) in TNF-
stimulated WT mice as analysed by IMARIS software. Data are expressed as mean±SEM of n = 
28 (8-12 vessels/animals from 3 animals, 2 independent experiments). Statistical significance was 
determined using linear regression analysis: **, P < 0.01. 
 
These results are corroborated by previous findings from Dr Mathieu-Benoit Voisin, 
which provided evidence of the role of ICAM-1 in neutrophil crawling behaviour within 
lymphatic vessels (Appendix 7 & Videos 5/6/7). Functional assays were performed using 
local administration (4.5 h post-i.s. injection) of functional blocking antibodies against 
ICAM-1 or its leukocyte binding ligand, the integrin MAC-1, in CFA+Ag-stimulated 
cremaster muscles of  LysM-eGFP mice. Confocal IVM was then carried out to observe 
neutrophil crawling parameters. Of significance to the ICAM-1 data in the current study, 
Dr Voisin found that blocking either ICAM-1 or MAC-1 resulted in a significant 
reduction (~50%) in the speed of crawling, displacement length, and straightness, on the 
luminal side of the lymphatic endothelium (Figure 6.9). These results are reminiscent of 




Figure 6.9: The effect of anti–ICAM-1 and anti-MAC-1 blocking antibodies on neutrophil 
intraluminal crawling parameters. LysM-eGFP mice were subjected to CFA+Ag-induced 
cremaster inflammation for 6 h. Mice also received at 4.5hrs post inflammation an i.s. injection 
of non-blocking dose of anti-LYVE-1 (red) and anti-PECAM-1 mAbs (not shown on the image) 
for the visualisation of both the lymphatic and blood vasculatures. Ninety minutes later, tissues 
were exteriorised to perform time-lapse recordings of the neutrophil responses for 2 h by intravital 
confocal microscopy. The effect of blocking antibodies against ICAM-1 and MAC-1 (injected 
locally 90min before recordings) on neutrophil migration paths in the interstitium and lymphatic 
vessels was investigated and analysed using IMARIS software. (A-C) Neutrophil intraluminal 
crawling in blocking Ab-treated mice was quantified and compared to the responses obtained with 
an isotype CTL mAb. The three graphs show the mean speed (A), directionality (B) and 
straightness (C) of neutrophils crawling. A total of 280 cells were analysed. Results are expressed 
as mean ± SEM of N = 4–9 mice (1-2 vessels analysed/mouse for intravital confocal microscopy, 
each mice is a single experiment). Significant differences between blocking antibodies treated 
and control groups are indicated by *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. Significant 
differences between other groups are indicated by # (P < 0.05). Experiments and quantifications 




Overall, the results in this section, along with previous findings from Dr Voisin, identify 
ICAM-1 as an adhesion molecule that is up-regulated on lymphatic vessels following 
TNF- or CFA+Ag-stimulation; thus mediating neutrophil crawling along the luminal side 
of the lymphatic endothelium following inflammation. Additionally, the results here 






In order for leukocytes, such as antigen-bearing DCs, to travel to lymph nodes for the 
initiation of adaptive immune responses, they have to first migrate into tissue associated 
lymphatic vessels and crawl along the luminal side of the lymphatic endothelium of initial 
lymphatics, passively drift through the lumen of collecting lymphatics before finally 
reaching draining lymph nodes (Tal et al., 2011). Though the mechanisms of this 
phenomenon have only been characterised for DCs to a certain extent, studies 
investigating intraluminal crawling of neutrophils within lymphatic vessels preceding 
entry into draining lymph nodes have been thoroughly neglected. Chapter 4 of this thesis 
investigated the role of chemokine:chemokine receptor axes in neutrophil migration 
across the lymphatic endothelium into the lumen of lymphatic vessels; providing clear 
evidence that TNF signalling triggers this migration process in a strictly CCR7-dependent 
manner. Despite this, it is important to unravel the processes that occur after neutrophil 
entry into the lumen of lymphatic vessels and before their arrival in draining lymph nodes. 
Along with this, elucidating the mechanisms that drive these processes is also imperative 
as neutrophils have been shown to play roles in shaping adaptive immunity. The results 
from this chapter demonstrated that TNF could not only drive neutrophil migration into 
initial lymphatic vessels, but it could also induce their intraluminal crawling within 
lymphatic vessels. They have also demonstrated that during the acute phase of 
inflammatory response to CFA+Ag, TNF signalling is critical in controlling the 
directional crawling of neutrophils within lymphatic vessels. Collectively, corroborating 
data from previous findings by Dr Voisin with those from the current study, ICAM-1 was 
identified as a key mediator of neutrophil intraluminal crawling within lymphatic vessels.  
This chapter first sought to characterise neutrophil crawling behaviours within lymphatic 
vessels during inflammation with the use of confocal IVM. Observation of neutrophil 
intraluminal crawling events following TNF- or CFA+Ag-stimulation showed that they 
exhibited a characteristic crawling behaviour on the luminal side of the lymphatic 
endothelium, with their general movement going towards lymph flow in the direction of 
collecting lymphatic vessels. In line with this, Hampton et al. also observed neutrophil 
interactions with lymphatic vessels in a different model using S. aureus infection, 
although it is not clear from their data if the neutrophils are truly within the lumen of 
lymphatic vessels (Hampton et al., 2015). Additionally, they found that neutrophils 
frequently exhibited reverse direction of crawling although overall crawling paths were 
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not assessed in detail. In the current study, neutrophils were also observed reversing in 
direction during intraluminal crawling; however, examination of their overall crawling 
paths indicated they crawled in the general direction of lymph flow (white arrow, Figure 
6.1 & Video 2, Figure 6.3A & Video 3). An explanation for this random behaviour could 
be due to reduced lymph flow induced by the ketamine/xylazine anaesthesia used during 
the confocal IVM experiments. Alternatively, it could be attributable to the exteriorisation 
process of the tissue or just be a natural phenomenon. Indeed, more directional crawling 
of DCs within lymphatic vessels was observed when mice were anaesthetised with 1.5 % 
isoflurane, which had a lesser effect on lymphatic contraction (Tal et al., 2011). As no 
other studies looking at neutrophil intraluminal crawling behaviours within lymphatic 
vessels exist, the present study provides the first comprehensive characterisation of these 
crawling parameters within initial lymphatics. 
This chapter next investigated the effects of TNF signalling on intraluminal crawling of 
neutrophils within lymphatic vessels of CFA+Ag-stimulated mice as findings from 
previous chapters of this thesis demonstrated a critical role of TNF in driving neutrophil 
migration into lymphatic vessels. The use of anti-TNF blocking Abs resulted in crawling 
impairments of neutrophils; loss of directionality and meandering crawling paths were 
observed, with most neutrophils rendered immobile on the luminal side of the lymphatic 
endothelium. Subsequently, the molecular mechanisms of intraluminal crawling within 
lymphatic vessels were explored. The role of the adhesion molecule, ICAM-1, was 
examined due to previous findings of its importance in mediating neutrophil crawling 
along both the luminal and abluminal surfaces of postcapillary venules during the process 
of leukocyte recruitment to sites of inflammation (Phillipson et al., 2006). ICAM-1 has 
also been demonstrated to be key in DC migration from the skin to dLNs, suggesting the 
involvement of LEC-expressed ICAM-1 in this process (Xu et al., 2001). In the present 
study, ICAM-1 expression was up-regulated on lymphatic vessels of murine cremaster 
muscles following TNF- or CFA+Ag-stimulation; blocking TNF signalling with the use 
of functional blocking Abs resulted in its down-regulation. TNF has been shown to up-
regulate ICAM-1 expression on vascular ECs both in vivo and in vitro (Fingar et al., 1997; 
Yang et al., 2005). LECs express very low levels of ICAM-1 in uninflamed conditions, 
but can up-regulate this molecule upon TNF-stimulation in both human ECs in vitro 
(Johnson et al., 2006; Sawa et al., 2007) and mice (Figure 6.5). As CFA+Ag-stimulation 
was previously shown in Chapter 3 to result in the production of endogenous TNF within 
cremaster muscles, this could be an explanation as to why a lower level of ICAM-1 
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upregulation was seen on lymphatic vessels as compared to TNF-stimulation. The exact 
role of ICAM-1 in leukocyte migration into the lymphatic system is still unclear, although 
in vitro antibody blockade has been shown to inhibit both adhesion and transmigration 
responses of DCs through cultured human LECs (Johnson et al., 2006); in vivo, ICAM-1 
has been reported to mediate crawling of DCs along the lymphatic endothelium (Nitschke 
et al., 2012). Interestingly, a positive correlation was found in the present study between 
ICAM-1 expression and neutrophil migration into lymphatic vessels of mice during 
inflammation, which corroborates previous in vivo data involving DC migration across 
the lymphatic endothelium (Miteva et al., 2010)  
In conclusion, this chapter has shown that neutrophils crawl along the endothelium within 
initial lymphatics following a local inflammatory stimulus; a response that was TNF-
dependent. Confocal IVM by Dr Voisin showed that anti-ICAM-1 and anti-MAC-1 mAbs 
impaired neutrophil intraluminal crawling within lymphatic vessels as compared to the 
isotype control Abs (Appendix 7 & Videos 5/6/7). Thus, local blockade of ICAM-1 or 
its integrin ligand, MAC-1, inhibited this crawling response whilst their capacity to cross 
the lymphatic endothelium to gain entry into the lumen of lymphatic vessels were 
unaffected (Appendix 8). Interestingly, ICAM-1 blockade also resulted in a reduction of 
neutrophils numbers within dLNs as compared to when an isotype control Ab is used 
(Appendix 8); an explanation for this could be due to the inability of neutrophils to 
migrate towards dLNs due to their crawling response within initial lymphatics being 
inhibited. The results seen with local blockade of ICAM-1/MAC-1 is interesting as this 
mirrors findings from another study investigating neutrophil crawling within blood 
vessels; neutrophils were rendered immobile on the vascular endothelium following 
administration of anti-ICAM blocking Abs (Phillipson et al., 2006).  
Overall, this chapter has provided new insights into the processes that occur following 
neutrophil migration into lymphatic vessels, as well as the mechanisms underlying 
neutrophil crawling within these vessels during inflammation. This highlights potential 
and effective targets to manipulate the role of neutrophils in adaptive immune responses 
in vivo. 
Limitations of the study 
The limitations here are the same as those discussed at the end of Chapter 3 with an 
additional potential caveat. In summary, the use of mouse cremasters in the in vivo 
inflammatory models may not be as relevant to humans, albeit being a gold standard 
241 
 
method. The model also does not address possible sex differences in immune responses, 
however this can be remedied through the use of other vascular beds (e.g. ear or 
mesentery) in female mice. Furthermore, the use of CFA is not approved for use in 
humans but it mimics the classical immunisation protocols used in humans, which makes 
it appropriate for this study. Finally, the blocking antibodies against MAC-1 and ICAM-
1 used in this study could potentially alter the behaviour of neutrophils due to the fact 
they can bind to Fc receptors on these cells. To overcome this potential issue, the use of 
small molecule antagonists or conditional KO mice could be used instead. However, the 
use of an isotype control antibody in the current study provides evidence that the Fc 
receptor does not contribute to the response as tissues treated with the specific blocking 





 : General Discussion 
 Project Overview 
During inflammatory responses, the recruitment of neutrophils from the circulation to 
sites of inflammation is crucial in providing a critical first line of defence in the immune 
response against invading pathogens. However, recent accumulating evidence has shown 
that the role of neutrophils spans beyond the basic but fundamental immunological 
processes of innate immunity (Mocsai, 2013). Specifically, neutrophils have been 
implicated in the regulation of adaptive immunity following exposure to pathogens and 
antigen sensitisation (Abadie et al., 2005; Maletto et al., 2006; Mocsai, 2013; Yang et al., 
2010), through their ability to act as APCs (Iking-Konert et al., 2001), or through cytokine 
release for the activation of T and B lymphocytes (Abi Abdallah et al., 2011; Beauvillain 
et al., 2007; Cerutti et al., 2013), and DCs (Bennouna et al., 2003). 
Whilst the role of neutrophils in regulating adaptive immunity is now well-documented, 
the precise mechanisms underlying neutrophil migration into LNs via the initial 
lymphatics are still very poorly understood. Several studies have indicated that 
neutrophils within dLNs originate from tissue-associated lymphatic capillaries via the 
afferent lymphatic vessels (Abadie et al., 2005; Chtanova et al., 2008; Gorlino et al., 2014; 
Hampton et al., 2015), but the mechanisms associated with neutrophil migration into the 
lymphatic vasculature remained unclear. This study therefore aimed to elucidate some of 
the mechanisms by which neutrophils act to cross the initial lymphatic endothelium 
barrier and migrate into associated LNs. This work has shown that components of the 
LEC glycocalyx present on lymphatic vessels are regulated and redistributed during 
inflammation; this is particularly relevant as the glycocalyx has previously been 
implicated in the regulation of leukocyte adhesion during their recruitment to sites of 
inflammation (Reitsma et al., 2007). This work also provides evidence for the 
involvement of endogenous TNF and the molecular mechanisms associated with 
trafficking of neutrophils into, as well as within the lymphatic vasculature in vivo. 
Specifically, using a mouse model of antigen sensitisation and cytokine-induced 
inflammation of the cremaster muscle, this study has shown that TNF orchestrates the 
migration of neutrophils into lymphatic vessels in a CCR7-dependent manner, as well as 
their subsequent crawling along the luminal side of the lymphatic endothelium in an 
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ICAM-1/MAC-1 dependent manner. Collectively, the findings of this work provide 
evidence for a previously unknown role for TNF in orchestrating the sequential 
interactions of neutrophils with tissue-associated lymphatic vessels during the acute 
inflammatory response of antigen sensitisation. TNF as a potential target for the 
development of future therapeutic interventions to manipulate adaptive immune 
responses through the context of neutrophil trafficking into the lymphatic system is also 
highlighted. The following discussion gives an overview of our findings and discusses 
the potential role of components of the LEC glycocalyx, chemokine:chemokine receptor 
axes, and TNF in inducing neutrophil migration into initial lymphatic vessels and their 
subsequent intraluminal crawling along the lymphatic endothelium (Arokiasamy et al., 
2017). 
 Structure of murine cremaster muscle lymphatic vessels and 
neutrophil migration responses during TNF- or CFA+Ag-
induced inflammation in vivo. 
Previous studies have reported the structure of lymphatic vessels in various murine tissues 
(Baluk et al., 2007), but not in the cremaster muscle. Initial studies investigated the 
structure of lymphatic vessels through immunostaining of whole-mounted cremaster 
tissues from naïve WT C57ΒL/6 mice. These experiments showed that lymphatic vessels 
in murine cremaster muscles exhibited characteristic blind-ended lymphatic capillaries 
and the heterogeneous distribution of adhesion molecules made up of button-like 
junctions (VE-Cadherin) and flaps (PECAM-1). Additionally, lymphatic vessels in this 
tissue were shown to be made up of oak-leaf shaped cells. All of these results are in 
accordance with previous findings of the composition of initial lymphatics in other 
murine tissues (Baluk et al., 2007). Therefore, this indicates that majority of the lymphatic 
vessels looked at in the present study are initial capillary lymphatics. This is the first 
description of lymphatic vessels within murine cremaster muscles. 
Neutrophils undergo transmigration through blood vessel walls into the interstitium 
during leukocyte recruitment to sites of inflammation (Proebstl et al., 2012; Woodfin et 
al., 2009). Following this, neutrophils have been shown to migrate to dLNs via afferent 
lymphatics (Abadie et al., 2005; Gorlino et al., 2014; Hampton et al., 2015; Rigby et al., 
2015). However, the overall dynamics of these events occurring successively has not been 
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investigated, thus neutrophil migration responses were investigated following TNF and 
CFA+Ag-induced inflammation of the cremaster muscle.  
The results revealed that local injections of both these inflammatory mediators not only 
induced the migration of neutrophils across blood vessels, but also into lymphatic vessels 
and their associated dLNs in a time-dependent manner. In particular, tissue infiltrated 
neutrophils were found to rapidly migrate into lymphatic vessels within the first 16 h post-
i.s. injection, which provided us with an indication of suitable time-points to look at in 
subsequent studies. Although no other in vivo studies of the dynamics of neutrophil 
migration into lymphatic vessels currently exists, these results agree with an in vitro study, 
which showed that neutrophil migration across a monolayer of primary HDLECs also 
occurs in a time-dependent manner (Rigby et al., 2015). Interestingly, the rapid migration 
of neutrophils into lymphatic vessels was transient (peaking at 8 h post-i.s. injection) as 
compared to their extravasation from blood vessels, which continued to increase at 16 h 
post-i.s. injection. This suggests that not all neutrophils are capable of migrating through 
initial lymphatics and might indicate that only a sub-population of neutrophils that are 
amongst the first to be recruited to the tissue have the capacity to continue their journey 
to the lymphatics. This hypothesis is supported by a previous study by Beauvillain et al. 
that showed only a sub-population of blood neutrophils express CCR7 on their surface 
post-purification (Beauvillain et al., 2011). To support this hypothesis, our in vitro work 
demonstrated that only low doses of TNF resulted in significant CCR7 upregulation on 
the surface of neutrophils. Similarly, the generation of TNF in inflamed tissues in vivo 
was significantly detected in modest amount at 8 h, whilst the higher concentrations were 
found at 16 h post CFA+Ag stimulation. Altogether, our data could be an indication that 
neutrophils lose their capacity to migrate into lymphatic vessels if the release of TNF is 
too high through a modulation of their expression for CCR7 expression on the surface of 
neutrophils. However, further analyses are needed to confirm this hypothesis. 
Additionally, by combining confocal IVM and computer-assisted image processing with 
the use of IMARIS software, GFPhigh neutrophils could be directly visualised undergoing 
transmigration across the lymphatic endothelium in situ in the cremaster muscle, 
providing a platform to study in great detail interactions made between individual 
neutrophils and LECs. Such analyses were conducted on live cremaster tissue in 
anaesthetised LysM-eGFP mice (confocal IVM). This enabled the tracking of neutrophils 
in lymphatic vasculatures in real-time and in 4D, which provided valuable insight into the 
dynamics and mechanisms of neutrophil migration into lymphatic vessels in vivo. These 
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results showed that neutrophils in mice subjected to TNF-stimulation could be seen 
breaching the lymphatic endothelium at time-points analysed (4–5.5 h) before the peak 
of neutrophil migration into lymphatic vasculatures, and that this breaching process only 
took approximately 4.5 min, which is similar to the time taken for leukocytes to migrate 
through the vascular endothelium (Ley et al., 2007). Neutrophil migration across the 
lymphatic endothelium was not able to be observed at the time-points analysed (6–7.5 h) 
following CFA+Ag-stimulation, despite still being before the peak of neutrophil 
migration into lymphatic vessels. This could simply be due to the fact that most 
neutrophils had already undergone transmigration into lymphatic vessels by these time-
points. Moreover, as we are visually limited to one vessel segment per video from each 
confocal IVM experiment, we may be missing cells which are migrating across the 
lymphatic endothelium in other vessels of the cremaster muscle. 
 Endogenous TNF controls the entry of neutrophils into initial 
lymphatic vessels following antigen sensitisation in vivo. 
Findings from the studies above proved that both exogenous TNF and antigen 
sensitisation with an emulsion of CFA+Ag could induce a rapid but transient migration 
of neutrophils into the lymphatic vessels of murine cremaster muscles. Mouse cremaster 
muscles stimulated with an i.s. injection of an emulsion of CFA+Ag resulted in the rapid 
generation of endogenous TNF. Thus, the potential role of endogenous TNF in this 
response was investigated through the use of TNFRdbKO mice as a means of abolishing 
TNF signaling. The results showed that at 16 h post-i.s. injection with CFA+Ag, 
neutrophil migration into lymphatic vessels was impaired. This impaired response was 
also observed at the earlier time point of 8 h, thus eliminating the possibility that the 
reduction in neutrophil numbers observed at 16 h post-i.s. injection was due to the faster 
efflux of neutrophils from lymphatic vessels of the TNFRdbKO animals. Interestingly, 
TNF did not appear to mediate neutrophil extravasation from blood vessels into interstitial 
tissues, indicating a specific role for TNF in driving neutrophil migration into lymphatic 
vessels but not through blood vasculature at these time points. Furthermore, the use of 
chimeric mice exhibiting neutrophils deficient in both TNFRs in a WT microenvironment 
showed that TNF directly acts on leukocytes to induce this neutrophil migration response. 
These results demonstrate for the first time the direct involvement of TNF in triggering 
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the migration of neutrophils into tissue-associated lymphatic vessels upon antigen 
challenge in vivo (Figure 7.1).  
It is interesting to note that neutrophil extravasation across the blood vessels of 
TNFRdbKO mice is not affected despite the fact that TNF inhibitors have been 
successfully used to treat many chronic inflammatory diseases (e.g. RA, vasculitis and 
Crohn’s disease) by preventing leukocyte recruitment from the circulation (Taylor et al., 
2000; Little et al., 2006; Ghosh et al., 2003). An explanation for this could be that the 
present study makes use of an acute inflammatory model wherein TNF does not seem to 
contribute to the recruitment of neutrophils in vivo. Therapeutically, TNF inhibitors are 
mainly used to treat chronic inflammatory diseases in which these drugs have to be 
maintained systemically and requires time to take effect (Combe, 2010). 
 
Figure 7.1: Schematic illustration of TNF triggering the migration of neutrophils into initial 
lymphatic vessels upon antigen sensitisation. (1) I.s. injection of CFA+Ag leads to TNF release 
within the interstitium. (2) TNF binds to neutrophil-expressed TNFRI/II and directly triggers their 




 The LEC glycocalyx is regulated and undergoes redistribution 
following TNF-induced inflammation of the cremaster muscle 
The BEC glycocalyx has been widely studied and described (Reitsma et al., 2007), in 
contrast to the LEC glycocalyx. Apart from a recent study demonstrating the presence of 
a glycocalyx, similar to that of the BEC glycocalyx, on the luminal side of rat mesenteric 
collecting lymphatic vessels (Zolla et al., 2015), no other studies on the LEC glycocalyx 
exists. Thus, the present study investigated the regulation of the LEC glycocalyx of initial 
lymphatic vessels during inflammation by first probing for the presence of several known 
EC glycocalyx components. Initial studies investigated sugar residues expressed by 
lymphatic vessels with the use of carbohydrate-binding proteins called lectins. Staining 
of tissues with fluorescent lectins (IB4 and MAL-1, respectively) followed by confocal 
microscopy analysis, both of which are techniques used to visualise the BEC glycocalyx 
(Bai and Wang, 2014), revealed the presence of α-D-Galactosyl moieties and N-linked 
2,3 sialylated glycans (α2,3 SAs), respectively, within the glycocalyx of lymphatic 
vessels. Additionally, the results showed that α-D-Galactosyl moieties were cleaved on 
lymphatic vessels following TNF and CFA+Ag-induced inflammation of cremaster 
muscles. This response was associated with an increased number of neutrophils observed 
within lymphatic vessels; this suggests that cleavage of α-D-Galactosyl residues on 
lymphatic vessels may either potentially contribute to the mediation of neutrophil 
trafficking into lymphatics or that neutrophil interactions with the lymphatic endothelium 
during their migration across this barrier triggers this cleavage (Figure 7.2). In support 
of the former hypothesis, glycocalyx shedding induced as a conquence of TNF 
stimulation could be a potential explanation, as has been shown to be the case in the BEC 
glycocalyx, although the mechanisms of this remained unknown (Henry and Duling, 
2000; Chappell et al., 2009a). Chemokine receptors and adhesion molecules harboured 
within the glycocalyx could be exposed following TNF stimulation due to degradation of 
the enveloping glycocalyx (Chappell et al., 2008), thus could increase the accessibility of 
neutrophils to these molecules enabling the migration of more neutrophils. In support of 
the latter hypothesis, activated neutrophils have been shown to induce BEC glycocalyx 
damage through the production of ROS and proteases from their storage granules (van 
Golen et al., 2012). Further experiments will have to be done to see if neutrophil migration 
is affected by this cleavage, or if neutrophil migration across the lymphatic endothelium 




Figure 7.2: Hypothetical scenario in which cleavage of α-D-Galactosyl moieties mediates 
neutrophil migration across the lymphatic endothelium. (A) Under unstimulated conditions, 
α-D-Galactosyl moieties are present either in the lumen or abluminal side of the lymphatic 
endothelium as part of the LEC glycocalyx. (B) Following i.s. injection of CFA+Ag (which 
induces TNF release) or exogenous TNF, α-D-Galactosyl moieties are cleaved either as a direct 
consequence of TNF acting on the lymphatic endothelium or due to ROS/protease release by 
activated neutrophils as they migrate across the lymphatic endothelium. 
 
IB4 is widely used as a blood vasculature marker (Ernst and Christie, 2006), but in the 
context of lymphatics, our results have shown for the first time that α-D-Galactosyl 
residues of the LEC glycocalyx are cleaved with inflammation. In contrast, confocal 
microscopy analysis of MAL-1 staining showed no changes in overall expression of N-
linked α2,3 SAs on lymphatic vessels following inflammation, although it seems that 
redistribution of these SAs on lymphatic vessels occurred. α2,3 SAs expression was found 
near the edges of lymphatic vessels in TNF stimulated tissue, whereas this was not present 
in CFA+Ag stimulated tissues. In the BEC glycocalyx, SA redistribution has been shown 
to play key roles in permeability control during shear stress in vitro (Bai and Wang, 2014), 
thus redistribution of SAs observed in the LEC glycocalyx could potentially play similar 
roles in the regulation of lymphatic vessel permeability and function in the context of 
inflammation. Further studies will have to be carried out to determine the consequence of 
this redistribution on neutrophil trafficking into lymphatic vessels (see section 7.2.4 for 
potential experimental setups). Nevertheless, the presence of N-linked sialylated glycans 
on lymphatics implicates these vessels as potential targets for increased viral entry and 
their systemic dissemination. Certain viruses (influenza viruses, rotaviruses, 
adenoviruses) have been shown to use host-sialylated structures for binding to their target 
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host cell (Cashman et al., 2004; Dugan et al., 2008; Isa et al., 2006; Skehel and Wiley, 
2000). Furthermore, viral infections of LECs induces permeability (Gavrilovskaya et al., 
2012, 2013), thus binding of viruses to SAs on lymphatic vessels could potentially lead 
to increased viral entry. Alternatively, this increased permeability could also lead to the 
disruption of host pathogen clearance by potentially allowing other pathogens being 
transported within lymphatic vessels back into the interstitium. In support of this, 
pathogen release into the interstitium has previously been observed in senescent vessels 
exhibiting decreased glycocalyx coverage and increased permeability (Zolla et al., 2015). 
Additionally, numerous bacteria have also been demonstrated to make use of host-
sialylated acids to evade host immune responses through a strategy of ‘molecular 
mimicry’, and inhibition of opsonisation and their phagocytosis in vivo (Harvey et al., 
2001; Telang et al., 2001; Vogel and Frosch, 1999). The results from the present study 
thus implicate lymphatic vessels as having potential roles in immune evasion by such 
microbes and highlights the potential of these vessels as being therapeutic targets for the 
prevention of viral entry and their subsequent dissemination. 
The regulation of HS on lymphatic vessels was next investigated following TNF-
stimulation. HS is the most abundant GAG on ECs, and has been reported to be critical 
for chemokine mobilisation and functional presentation on both HEVs and the lymphatic 
endothelium during lymphocyte and DC homing to dLNs (Bao et al., 2010). 
Immunostaining and confocal microscopy analysis demonstrated that although there were 
no changes in total HS expression on lymphatic vessels in response to TNF, redistribution 
of this GAG on lymphatic vessels was observed. HS distribution on lymphatic vessels 
was far more homogenous and diffused, as compared to the patchy expression on vessels 
of unstimulated tissues. In the context of blood vessels, HS has been shown to be down-
regulated in an in vivo sepsis model of acute lung injury due to the production of 
heparanase by blood vascular endothelium activated by endogenous TNF; this was 
associated with increased neutrophil binding to blood vascular walls (Schmidt et al., 
2012). As no changes were seen in HS expression, further studies will have to be carried 
out to determine the exact function of its redistribution on lymphatic vessels in the context 
of neutrophil trafficking (see section 7.2.4.3 for potential experimental setups). An 
explanation for why we see no differences could simply be due to the fact that the present 
study has already shown variations in the distribution of sugars on the BEC and LEC 
glycocalyx, thus what is observed on blood vessels does not necessarily translate to the 
same observation on lymphatic vessels. Differences in the time-points looked at could 
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also be a factor; previous studies investigating changes in the BEC glycocalyx looked at 
far more acute time-points ranging from 0-90 minutes post-i.s. injection (Chappell et al., 
2009a; Chappell et al., 2009b; Schmidt et al., 2012), as compared to the present study (16 
h post-i.s. injection).  
HS binding of the lymphatic chemokine, CCL21, leads to its immobilisation and the 
formation of a chemotactic gradient that guides DCs within interstitial tissues towards 
lymphatic vessels (Weber et al., 2013). In addition, HS expression by HEVs controls 
CCL21 chemokine presentation to facilitate the homing of lymphocytes into lymphoid 
organs (Bao et al., 2010; Tsuboi et al., 2013). Investigations into CCL21 expression by 
lymphatic vessels show that expression levels decrease in response to TNF and CFA+Ag 
stimulation, despite no changes in total HS expression. Our results show the formation of 
a higher CCL21 chemokine concentration gradient during inflammation. As has been 
shown to be the case for DC migration within the interstitium (Weber et al., 2013), this 
CCL21 gradient formation presumable provides chemotactic cues to guide neutrophils 
within the tissue towards lymphatic vessels. Further studies will have to be carried out to 
determine if HS expressed by lymphatic vessels does indeed bind CCL21 for presentation 
to neutrophils (see section 7.2.4.3 for potential experimental setups). Overall, these results 
demonstrate the glycan-centred therapeutic potential of the LEC glycocalyx for the 
prevention of pathogen dissemination through the lymphatic vessels. However, further 
studies have to be carried out to elucidate the interplay between the 
redistribution/regulation of HS and CCL21 in mediating neutrophil trafficking into 




 TNF promotes the migration of neutrophils into lymphatic 
vessels in a strictly CCR7-dependent manner in vivo. 
 The CXCL1:CXCR1/2 and CXCL12/CXCR4 chemokine axes play 
no significant roles in neutrophil migration across the lymphatic 
endothelium during the acute phase of antigen sensitisation. 
To elucidate the mechanisms of neutrophil migration into lymphatic vessels, several 
chemokine:chemokine receptor axes were initially investigated. The CXCL1:CXCR1/2 
chemokine axis was investigated as another study demonstrated that the human neutrophil 
chemoattractant, CXCL8, is up-regulated in TNF stimulated HDLECs in vitro, and 
promotes neutrophil migration across a monolayer of human LECs (Rigby et al., 2015). 
In the mouse system, LECs isolated from mouse skin showed an up-regulation of the 
CXCL1 gene following 24 h of CFA-induced inflammation in vivo (Vigl et al., 2011). 
However, the present in vivo model of CFA+Ag-induced neutrophil trafficking into 
lymphatic vessels proved that this chemokine axis did not play any significant role in this 
process; CXCL1 blockade with the use of an anti-CXCL1 blocking mAb did not affect 
the capacity of neutrophils to migrate into lymphatic vessels. These data highlight 
differences between in vivo and in vitro models. Indeed, several studies have pointed to 
the importance of the microenvironment for LECs to retain their specific lymphatic 
characteristics that are lost in culture, such as the capacity to generate CCL21 (Amatschek 
et al., 2007; Wick et al., 2007).  
Additionally, the role of the CXCL12:CXCR4 axis was investigated since it was recently 
shown to be involved neutrophil trafficking into the lymphatic system following S. aureus 
infection. The results from the present study demonstrated that CXCR4 blockade with the 
CXCR4-specific inhibitor, AMD3100, did not significantly inhibit neutrophil migration 
into lymphatic vessels of CFA+Ag-stimulated cremaster muscles. An explanation for this 
conflicting data could be due to differences in the model and inflammatory pathway 
involved. S. aureus infection preferentially activates the TLR2 pathway in vivo (Kielian 
et al., 2005; Stenzel et al., 2008; Yimin et al., 2013), whereas CFA-stimulation activates 
the TLR4 pathway to induce an immune response (Kleinnijenhuis et al., 2011). In 
addition to this, activation of TNF and TLR4 signalling pathways have been shown to 
result in the down-regulation of CXCR4 on neutrophils, thus rendering them less 
responsive to CXCL12 stimulation (Bruhl et al., 2003; Kim et al., 2007). This supports 
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results from the present study where a down-regulation of CXCR4 expression on 
neutrophils was found in a model of CFA+Ag-induced inflammation. Taken together, 
these studies indicate that the pathway of activation may influence the molecular axis 
used for neutrophil migration into the lymphatic system. 
 The CCL21:CCR7 chemokine axis mediates neutrophil trafficking 
into the lymphatic system in vivo. 
The above findings highlighted the possibility that other chemokine:chemokine receptor 
axes may play regulatory roles in facilitating neutrophil migration across the lymphatic 
endothelium following the acute inflammatory response as induced by CFA+Ag in vivo. 
Thus, the potential involvement of the CCL21:CCR7 chemokine axis was investigated as 
it has been widely implicated in mediating DC/T cell migration into the lymphatic system 
(Johnson and Jackson, 2008). The role of CCR7 in neutrophil recruitment into the 
lymphatic system was first demonstrated in a mouse model of intradermal immunisation 
and in human neutrophils by Beauvillain et al. (Beauvillain et al., 2011). In accordance 
with their study, intracellular stores of CCR7 were detected in murine blood neutrophils. 
Beauvillain et al. also demonstrated that activation of these neutrophils through 
purification of BM-derived cells lead to the detection of CCR7 expression on the cell 
surface (Beauvillain et al., 2011). Similarly, the results in the present study showed that 
neutrophils recruited into inflamed tissues (i.e. inflamed cremaster muscles) had an up-
regulation of CCR7 expression on their cell surface as compared to blood neutrophils. 
Interestingly, TNF stimulation of murine blood neutrophils in vitro promoted the surface 
expression of CCR7; low concentrations of TNF were enough to initiate this response.  
This is further supported by a previous study showing a similar up-regulation of CCR7 
on human neutrophils in a tumour model (Eruslanov et al., 2014), although the 
mechanism and physiological consequences of this response in humans is still unclear. 
These results suggest that the priming of neutrophils for enhanced chemokine receptor 
expression was occurring post-i.s. injection. Thus, the potential involvement of GM-CSF 
and IL-17 in this priming process was investigated, having been previously shown to 
prime human neutrophils to migrate towards the chemokines, CCL19 and CCL21, in vitro 
(Beauvillain et al., 2011). However, we did not detect the generation of these cytokines 
in the cremaster muscle at any of the time-points analysed (0 h, 4 h, 8 h, 16 h and 24 h). 
Overall, these data suggests a predominant role of TNF in this response and may highlight 
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the importance of the origin of the cells analysed (e.g. BM vs. blood, tissue-infiltrated vs. 
naïve cells, murine vs. human leukocytes).  
CCR7KO mice were used to address the potential involvement of the CCL21:CCR7 
chemokine axis following both CFA+Ag and TNF stimulation; migration responses in 
these mice were compared with those of WT mice. The results showed that neutrophil 
migration across blood vasculatures was unaffected in CCR7KO mice as compared to 
WT mice at both 8 h and 16 h post-TNF/CFA+Ag stimulation. However, in comparison 
to WT mice, whilst neutrophil migration into lymphatic vessels of CCR7KO mice was 
partially inhibited (~75% reduction) following CFA+Ag stimulation, neutrophil 
migration into lymphatic vessels of these mice was strikingly completely suppressed 
(~97% reduction) in response to TNF stimulation. Whilst we appreciate that CCR7KO 
mice are constitutive knock-outs, deficient for CCR7 in all of their cells, the generation 
of chimeric mice exhibiting CCR7KO neutrophils further confirmed that in a WT 
microenvironment, CCR7KO neutrophils are unable to migrate into the lymphatic 
system. These results thus indicate the importance of TNF in promoting neutrophil 
migration into lymphatic vessels in a strictly CCR7-dependent manner (Figure 7.3).  
 
 
Figure 7.3: TNF triggers the migration of neutrophils into initial lymphatics in a strictly 
CCR7-dependent manner. (1) TNF stimulation induces surface expression of CCR7 on 
neutrophils in vitro and the formation of a CCL21 concentration gradient from the abluminal 
surface of the lymphatic endothelium into the interstitial tissue in vivo. (2) CCR7-expressing cells 
migrate along the CCL21 gradient. (3) Interactions between CCR7 and CCL21 on lymphatic 
endothelium results in the migration of neutrophils across the lymphatic endothelium into the 




 Increased levels of CXCL12 are responsible for neutrophil 
trafficking into dLNs of CCR7KO mice 
An interesting observation was made in the dLNs of CCR7KO mice under basal 
conditions. In comparison to WT mice, unstimulated CCR7KO mice exhibited 
approximately 25 times more neutrophils within their dLNs; inflammation of the 
cremaster muscles with TNF or following antigen sensitisation with an emulsion of 
CFA+Ag did not further increase the number of neutrophils found in the dLNs. As flow 
cytometry analysis showed no difference in the percentage of circulating neutrophils 
between WT and CCR7KO mice, this abnormal trafficking of neutrophils into the dLNs 
of CCRKO mice could be related to higher levels of CXCL12 expression found in the 
dLNs of these unstimulated mice as compared to WT dLNs. Additionally, whilst 
neutrophil expression levels of the CXCL12 receptor, CXCR4, were found to be similar 
in both genotypes, treatment with the CXCR4 antagonist AMD3100 significantly reduced 
the number of these leukocytes infiltrating CCR7KO dLNs, whereas neutrophil migration 
into initial lymphatics was not affected. The generation of chimeric mice exhibiting 
CCR7KO neutrophils in a WT microenvironment was able to address this abnormal 
trafficking of neutrophils into LNs. Taken together, these data not only supports the 
hypothesis that CXCR4 signalling contributes to neutrophil homing to LNs via HEVs 
(Gorlino et al., 2014), but also demonstrates for the first time that in steady-state, 
increased CXCL12 levels within LNs contribute to neutrophil migration via this route. 
 TNF is a key regulator of neutrophil crawling within initial 
lymphatic vessels through the induction of ICAM-1 up-
regulation in vivo. 
Having identified TNF as a key signal for promoting neutrophil trafficking into lymphatic 
vessels, its potential involvement in mediating other neutrophil-lymphatic vessel 
interactions was investigated. Studies looking at neutrophil responses following TNF 
stimulation (and CFA+Ag stimulation) were carried out in real-time using confocal IVM 
and LysM-eGFP mice through the tracking of GFPhigh neutrophils. Following TNF 
stimulation (and CFA+Ag stimulation), neutrophils were observed crawling along the 
luminal side of the lymphatic endothelium. Analysis of crawling parameters showed that 
majority of neutrophils crawled towards the directional flow of lymph. In contrast, 
neutrophils going against lymph flow exhibited reduced displacement length, speed and 
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straightness. In support of these data, a previous study also observed the crawling of 
neutrophils within lymphatic vessels, although there was no clear evidence as to whether 
this was intraluminal or abluminal crawling (Hampton et al., 2015). The results from the 
present study thus indicate that TNF is not only able to trigger the migration of neutrophils 
into lymphatics (as discussed above in section 7.1.4.2), but also shows for the first time 
that local inflammatory stimuli are able to induce the intraluminal crawling of neutrophils 
within initial lymphatic vessels in the direction of collecting lymphatics. The present 
study also provides the first comprehensive characterisation of neutrophil intraluminal 
crawling parameters within initial lymphatic vessels following inflammation. 
TNF is a prototypical pro-inflammatory cytokine that plays a key role in many immune 
responses, including cell recruitment and leukocyte activation (Cross et al., 2008; Dewas 
et al., 2003; Fujishima et al., 1993; Ginis and Tauber, 1990). It has also been implicated 
in the pathogenesis of numerous inflammatory conditions and autoimmune disorders, 
such as RA, lupus, psoriasis and atherosclerosis (Aringer and Smolen, 2008; Matsuno et 
al., 2002; Popa et al., 2007). TNF is not usually expressed under healthy conditions, but 
increased levels in serum and tissue are detected during inflammation and infectious 
conditions. Despite there being considerable evidence for the successful usage of TNF 
blockers in the treatment of certain chronic inflammatory conditions, anti-TNF therapy is 
associated with a heightened risk of opportunistic infections and poor vaccination 
responses in patients (Murdaca et al., 2015). Furthermore, their precise mechanism of 
action remains unclear, although the suppression of leukocyte recruitment and activation 
is considered to be a principle mode of action (Tracey et al., 2008). TNF is able to activate 
blood vascular EC (BECs), leading to the expression of both chemoattractants and 
adhesion molecules on the vascular endothelium (Pober, 2002). In particular, ICAM-1, 
an adhesion molecule demonstrated to be essential for neutrophil directional crawling 
during their recruitment through blood vessels (Phillipson et al., 2006; Proebstl et al., 
2012), has been shown to be up-regulated by BECs in response to TNF stimulation both 
in vivo and in vitro (Fingar et al., 1997; Leeuwenberg et al., 1992; Yang et al., 2005). At 
resting state, LECs express ICAM-1 at very low levels, but this is up-regulated following 
TNF stimulation in humans (Johnson and Jackson, 2010; Sawa et al., 2007). This up-
regulation was also observed in primary murine LECs from previous experiments (data 
not shown). ICAM-1 also plays a key role in DC adhesion and transmigration through 
HDLECs in vitro (Johnson et al., 2006), and has been shown to mediate crawling of DCs 
along the lymphatic endothelium in vivo (Nitschke et al., 2012). However, its role in 
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neutrophil trafficking within lymphatic vessels in vivo has yet to be determined. Thus, 
this formed the basis of subsequent investigations in the present study.  
Immunostaining for ICAM-1 on lymphatic vessels followed by confocal analysis showed 
that ICAM-1 was constitutively expressed in unstimulated tissues, but this expression was 
up-regulated in response to TNF and antigen sensitisation with an emulsion of CFA+Ag. 
This response was associated with increased neutrophil numbers found within initial 
lymphatics during inflammation, which is in accordance with a previous study involving 
DC migration across the lymphatic endothelium (Miteva et al., 2010). Interestingly, TNF 
blockade through the administration of anti-TNF mAbs in vivo inhibited this up-
regulation of ICAM-1 on initial lymphatic vessels. Furthermore, confocal IVM using 
LysM-eGFP mice demonstrated that TNF blockade in vivo following CFA+Ag 
stimulation resulted in neutrophil intraluminal crawling impairments, with majority of 
neutrophils being rendered immobile on the luminal side of the lymphatic endothelium 
due to losing all sense of directionality. Finally, previous results from my supervisor, Dr 
Voisin, demonstrated that ICAM-1 and MAC-1 blockade with blocking antibodies also 
resulted in impaired neutrophil intraluminal crawling within lymphatic vessels, whilst 
neutrophils’ capacity to cross the lymphatic endothelium from the interstitium remained 
unaffected. This response was also associated with a reduction of neutrophil numbers 
infiltrating the LNs. DCs migration from inflamed tissues to dLNs is well recognised as 
an important step in the initiation of adaptive immune responses (Randolph et al., 2008). 
However, it has been found that neutrophils are in fact the first immune cell type to reach 
LNs from sites of bacterial infection (Abadie et al., 2005). Thus, these results highlight 
potential and effective targets to manipulate the role of neutrophils in adaptive immune 
responses in vivo.  
Overall, these findings demonstrate for the first time that TNF and CFA+Ag stimulation 
induces the up-regulation of ICAM-1 expression by lymphatic vessels, thus enabling their 
intraluminal crawling on the luminal side of the lymphatic endothelium; a response that 




Figure 7.4: TNF induces ICAM-1/MAC-1 dependent intraluminal crawling through the 
upregulation of ICAM expression by initial lymphatic vessels. (A) Under unstimulated 
conditions, ICAM is constitutively expressed by the lymphatic endothelium. (B) Following i.s. 
injection of TNF, leading to up-regulation of ICAM-1 expression by the lymphatic endothelium. 
Neutrophil migration across the lymphatic endothelium occurs and mediates neutrophil crawling 





 Open questions and future perspectives 
 What is the source of endogenous TNF following antigen 
sensitisation?  
The present study demonstrated that antigen sensitisation of the cremaster muscle with 
an emulsion of CFA+Ag induced the rapid release of TNF in these tissues. Naturally, the 
next step would be to investigate the source of this TNF release. Indeed, recent studies 
conducted by Dr Voisin, has shown that mice depleted of tissue macrophages following 
the local delivery of clodronate liposomes (van Rooijen and Hendrikx, 2010) exhibited a 
significant reduction in TNF release as compared to control liposome-treated animals. 
Though significant, TNF release was not fully suppressed. This could be due to release 
from other cells or even activated neutrophils themselves. Although activated 
macrophages are thought to be the primary source of TNF (Arango Duque and 
Descoteaux, 2014; Parameswaran and Patial, 2010), neutrophils have been shown to be 
able to release TNF in different models of inflammation as induced by chemoattractants 
(Chou et al., 2010; Gaudreault and Gosselin, 2009; Finsterbusch et al., 2014), or other 
inflammatory mediators such as LPS (Dubravec et al., 1990), or upon exposure to 
Candida albicans (Bazzoni et al., 1991; Djeu et al., 1990). Furthermore, in an 
immunisation model using CFA+Ag, neutrophils recruited to LNs were shown to secrete 
TNF within these tissues (Maletto et al., 2006). Thus, further studies are needed to clarify 
whether they indeed secrete TNF in our model, or whether this pro-inflammatory 
cytokine is secreted by other cell types previously shown to do so, including ECs 
(Imaizumi et al., 2000), smooth muscle actin cells (Newman et al., 1996), fibroblasts 
(Fahey et al., 1995) and mast cells (Woolley and Tetlow, 2000). Specifically, to 
investigate the involvement of neutrophils in TNF release, ELISA and/or western blot 
analysis of tissue lysates from neutrophil-depleted tissues following the use of anti-GR-
1 mAbs (Daley et al., 2008) could be compared to control-depleted tissues. Alternatively, 
mice exhibiting neutrophil-specific deficiencies in both TNFRs could be used for these 
experiments. LECs have never been shown to secrete TNF, thus future work could 
involve investigating this in vitro by either using flow cytometry analysis of stimulated 




 Which TNF receptor is involved in CCR7 up-regulation on 
neutrophils and in mediating their migration into lymphatic 
vessels? 
The results from the present study have shown that TNF induces the up-regulation of 
CCR7 on neutrophils, and directly acts on leukocytes to trigger their migration across the 
lymphatic endothelium into the lumen of initial lymphatic vessels. However, the specific 
signalling mechanisms leading to this response remain unclear. Thus, it would be 
interesting to further investigate this and determine which of the two TNFRs (p55 or p75), 
or if both, are required for this response. Work that has been done during the course of 
this study has shown that neutrophils have surface expression of both TNFRs (Appendix 
9). Thus, future experiments could include the use of TNFR single KO mice instead of 
TNFRdbKO mice. Alternatively, confocal microscopy analysis of fixed tissues from 
stimulated WT mice receiving i.s. injections of TNFRI/II specific blockers or blocking 
Abs (Richter et al., 2013; Dong et al., 2016) to observe if neutrophil migration is 
suppressed with inhibition of either TNRI or TNFRII signalling. Alternatively, transgenic 
mice with targeted deletion of either the TNFRI or TNFRII gene could be used. 
Furthermore, in vitro studies involving pre-treatment of isolated neutrophils with 
TNFRI/II specific blockers or blocking Abs before TNF stimulation could be carried out 
to observe if inhibition of either TNFR signalling pathways results in a lack of CCR7 up-
regulation on the cell surface. Nystatin would have to be used in these experiments, as in 
the present study, to prevent endocytosis of CCR7. Finally, as a sub-population of 
neutrophils were found to express CCR7 following activation (Beauvillain et al., 2011), 
it would be interesting to extend these studies to an ex vitro/in vitro human model. 
Primary human LECs and human neutrophils could be isolated from tissues (e.g. skin) 
and blood, and transwell assays could be carried out with the use of TNFRI/II specific 
blockers or blocking Abs. Primary HDLECs could be grown on the underside 
of transwell filters before the addition of primed exogenous neutrophils (with GS-CSF 
and IL-17 [Beauvillain et al., 2011]) pre-treated with TNFRI/II specific blockers or 
blocking Abs to the top chamber, followed by the addition of exogenous TNF. 
Alternatively, neutrophils isolated from cantharidin-induced skin blisters could be used 
in these experiments and they would already be primed (Phong et al., 2011). Neutrophil 
migration responses across HDLECs could then be monitored to see if migration is 
suppressed with inhibition of either TNFRs, as compared to control treated cells. Flow 
cytometry analysis of isolated human neutrophils pre-treated with TNFRI/II specific 
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blockers or blocking Abs before TNF stimulation could also be carried out to observe if 
inhibition of either TNFR signalling pathways results in a lack of CCR7 up-regulation on 
the cell surface.  
 Does TNF-induced CCR7-dependent neutrophil migration into 
lymphatic vessels occur with other stimuli and during chronic 
inflammatory conditions? 
In the present study, the role of TNF in neutrophil migration into lymphatic vessels was 
demonstrated following antigen challenge. However, the effects of other inflammatory 
stimuli on the CCL21:CCR7 chemokine axis-dependent neutrophil migration should also 
be investigated in more detail, such as with the use of other inflammatory mediators (e.g. 
LPS or LTB4). Live bacteria or other pathogens (e.g. fungi) could also be tested although 
a previous study involving S. aureus challenge has demonstrated that the CCR7 
chemokine pathway is not involved in neutrophil migration to dLNs via afferent 
lymphatics (Gorlino et al., 2014). Similar studies like the ones used in the present study 
involving CCR7KO mice could be carried out to determine if other inflammatory stimuli 
also produce the same response. ELISAs could also be carried out to determine if TNF is 
produced within tissues following the use of these inflammatory stimuli.  
Additionally, as all investigated reactions to date have been acute inflammatory 
responses, it would be interesting to compare responses occurring during chronic 
inflammation. Neutrophil migration responses into lymphatic vessels could be studied in 
experimental mouse models of chronic inflammatory conditions, such as inflammatory 
bowel disease or autoimmune diseases (e.g. mouse model of collagen II induced arthritis), 
with the use of anti-CCR7 mAbs at specific time-points (i.e. after extravasation has 
occurred) to see if this pathway could be exploited for future therapeutic developments.  
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 What is the functional consequence of the regulation and 
redistribution of the LEC glycocalyx? 
 Is the LEC glycocalyx present on the luminal or abluminal (or both) 
sides of LECs? 
The vascular EC glycocalyx is present on the luminal side of ECs and plays a role in 
leukocyte extravasation from the blood into inflamed interstitial tissues (Reitsma et al., 
2007). Is the LEC glycocalyx therefore present mainly on the abluminal surface to 
mediate leukocyte migration into the lumen of lymphatic vessels? Our studies have shown 
using in vivo-live staining (non-permeabilised) and ex vivo-fixed staining (permeabilised) 
of tissues that both intracellular and surface expression is present, but whether this is 
mainly luminal or abluminal expression remains unclear from the data. This is due to the 
lack of natural lymph flow in harvested tissues, which results in lymphatic vessels 
collapsing and thus making it extremely difficult to determine if staining is abluminal or 
luminal. To elucidate this, further confocal IVM experiments could be carried out to 
visualise the LEC glycocalyx in real-time in vivo with a higher magnification. With this 
experimental set-up, natural lymph flow occurs and the structural integrity of lymphatic 
vessels are not compromised, which will enable us to have a clearer indication of 
abluminal or luminal expression of the LEC glycocalyx. To do this, LYVE-1 and the 
lectins would have to be i.s. administered to stain lymphatic vessels and the LEC 
glycocalyx. Furthermore, as only 2 lectins representing 2 sugar residues successfully 
stained lymphatic vessels in the present model, a wider panel of lectins could be tested 
out. This includes but is not limited to: succinylated wheat germ agglutinin (sWGA, 
specific for N-acetylglucosamine), helix pomatia (HP, specific for α-D sialic acid), 
peanut agglutinin (PNA, specific for gal β1, 3, N-acetylgalactosamine); all of these have 
been used to characterise the EC glycocalyx (Brouland et al., 1999; Nakanuma et al., 
1993). In addition, HS could also be i.s. injected in these experiments to observe the 
localisation of this GAG in relation to the sugar residues. Studies could include the pre-
treatment of TNF and CFA+Ag to observe changes in these components during 
inflammation, and a ×63 objective could be used for higher magnification in order to 
determine if the glycocalyx is situated on the abluminal or luminal side of the lymphatic 
endothelium. Neutrophil interactions with the LEC glycocalyx following TNF- 
or CFA+Ag-induced inflammation could also be investigated in real-time using confocal 
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IVM and LysM-eGFP mice in the above experiments to observe if GFPhigh neutrophils 
exhibit any preferential migration into lymphatic vessels at sites with high/low expression 
of sugar residues or HS. Confocal IVM could also be used to measure the changes in the 
thickness of the glycocalyx during inflammation, as compared to basal conditions. 
Finally, electron microscopy techniques could be used to visualise the LEC glycocalyx 
under both basal and inflamed conditions. This has previously been done in collecting 
lymphatics, with the results showing a glycocalyx spanning the luminal side of the 
lymphatic endothelium (Zolla et al., 2015). However, this has yet to be done in the initial 
lymphatics thus could be an interesting avenue to pursue.   
 Does the cleavage of α-D-Galactosyl residues on lymphatic vessels 
mediate neutrophil migration across the lymphatic endothelium? 
This study showed that a reduction in α-D-Galactosyl moieties on lymphatic vessels was 
correlated with an increased number of neutrophils found within the lumen of these 
vessels, thus suggesting that two possible scenarios were occurring: 1) cleavage of these 
sugars (presumably by indirect TNF signalling) could be mediating neutrophil migration 
across the lymphatic endothelium, or 2) neutrophil interactions with the lymphatic 
endothelium during their migration across may be causing this cleavage. Future 
experiments to test this out could include the use of in vivo (i.s.) administration of the 
enzyme, α-D-Galactosidase, followed by confocal analysis to look at neutrophil 
migration into lymphatic vessels of stimulated tissues, as compared to the responses in 
non-treated tissues. In addition, confocal IVM and LysM-eGFP mice could be used to 
look at these responses in real-time to observe if cleavage of these sugars results in an 
increased capacity of GFPhigh neutrophils to adhere to the surface of lymphatic vessels 
and migrate into the lumen of these vessels. Additionally, local depletion of neutrophils 
in the cremaster muscle could be carried out through i.s. injections of anti-GR-1 mAbs to 
see if the glycocalyx is cleaved following inflammation in the absence of neutrophils. The 
role of TNF in cleaving these sugar residues could be examined through the use of 
TNFRdbKO mice and neutrophil-depletion of the tissues before stimulation. Confocal 
analysis of lectin staining would allow us to observe if sugar residues are cleaved in the 
absence of TNF signalling, as compared to similarly treated WT animals. Finally, in vitro 
experiments could be carried out, starting with a monolayer of primary LECs. Stimulated 
exogenous neutrophils could then be added on the top of these LECs and removed/washed 
off before subsequently staining the LECs with IB4 and analysis by confocal microscopy. 
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Comparisons of IB4 staining could be made between LECs encountering exogenous 
neutrophils and LECs that are only subjected to the washing step to determine whether 
changes in α-D-Galactosyl residue expression occurs due to neutrophil interactions with 
the lymphatic endothelium. 
 Are CCL21 chemokine gradients formed within lymphatic vessels? 
Does this induce directional intraluminal crawling of neutrophils? 
This study showed that following TNF and CFA+Ag stimulation, most neutrophils 
crawled on the luminal side of the lymphatic endothelium in the general direction of 
lymph flow. Whilst it could be assumed that neutrophils were being directed towards 
collecting lymphatics by the natural flow of lymph, other factors may also affect the 
directionality of neutrophil crawling within lymphatic vessels. However, whether 
neutrophil crawling is a random process or follows a characteristic pattern remains 
unclear (Phillipson et al., 2006; Ryschich et al., 2006; Wojciechowski and Sarelius, 
2005). Perhaps mechanotaxis (driven by mechanical force of shear flow), or the 
formation of chemokine gradients leading to 
chemotaxis, chemokinesis and haptotaxis (attraction to chemokines attached to ECM) 
play roles in neutrophil intraluminal crawling. Other studies of neutrophil intraluminal 
crawling in blood vessels have shown that the crawling of neutrophils does not appear to 
be biased in the direction of blood flow, suggesting that crawling is not simply a result of 
the dragging motion due to hydrodynamic force displacement (Phillipson et al., 2006; 
Ryschich et al., 2006; Wojciechowski and Sarelius, 2005). It is now known that 
chemotactic gradients along the endothelium provide directional cues for leukocyte 
crawling, and ultimately TEM - the final step in the adhesion cascade (Massena et al., 
2010; Zimmerman et al., 1992). Specifically, HS has been shown to sequester the 
neutrophil chemoattractant, MIP-2, and present these chemokines on the luminal side of 
the blood vascular endothelium for chemotaxis-driven neutrophil crawling (Massena et 
al., 2010). Therefore, since HS was detected on lymphatic vessels in the present study, 
does it bind CCL21 for its presentation on the lymphatic endothelium? 
Recent quantifications by Dr Voisin of confocal images from this study showed that 
inflamed initial lymphatic vessels exhibited a gradient of CCL21 within the vessel in the 
direction of lymph flow. This gradient could explain why the majority of neutrophils 
crawl along the luminal side of the lymphatic endothelium in the direction of lymphatic 
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flow. Thus, further studies would have to be carried out to determine if this is due to HS-
dependent presentation of CCL21. Experiments could include the use of confocal IVM 
and i.s. injections of both an anti-HS Ab and anti-CCL21 Ab to provide further insights 
into the interactions of CCL21 and HS in real-time in vivo. Additionally, inflammation 
could be induced in the cremaster muscle before these confocal IVM experiments to 
address if the redistribution of HS observed on lymphatic vessels in the present study 
mimics the redistribution of CCL21 presentation in real-time in vivo. In 
vivo administration (i.s.) of the sugar degrading enzyme, heparanase, could also be used 
to remove HS on lymphatic vessels; tissues could then be collected and followed up 
with ex vivo-fixed staining of both HS and CCL21, followed by the use of confocal 
microscopy analysis to look at changes in their expression on lymphatic vessels as 
compared to non-treated mice. A heparanase inhibitor could also be used in similar 
experiments for comparison. Further functional studies could also be carried out by using 
LysM-eGFP mice and confocal IVM to track GFPhigh neutrophil interactions with 
lymphatic vessels following the i.s. administration of heparanase in the cremaster muscle 
in real-time. Alternatively, transgenic mice exhibiting impairments in HS synthesis could 
be used to look at neutrophil migration responses in vivo (Bao et al., 2010). In vitro studies 
could also be carried out to determine the functional importance of HS. Primary murine 
LECs could be grown on the underside of transwell filters, and either pre-treated with 
heparanase or transfected with siRNA targeting HS biosynthetic enzymes, before the 
addition of exogenous CCL21 to the bottom chamber and primed exogenous neutrophils 
(with GS-CSF and IL-17 [Beauvillain et al., 2011]) to the top chamber. Neutrophil 
migration responses across LECs could then be monitored to see if migration is inhibited 
as compared to control treated LECs.  
Finally, as ICAM-1 was found to play a key role in neutrophil intraluminal crawling 
within initial lymphatics in the present study, it would be interesting to see if a gradient 
of these adhesion molecule forms within the lumen of lymphatic vessels. Confocal IVM 
experiments could be carried out to visualise the expression of ICAM-1 on the luminal 
side of the lymphatic endothelium in real-time in vivo. A fluorescently conjugated anti-
ICAM-1 mAb would have to be intrascrotally injected into WT mice, and comparisons 
could be made between stimulated and unstimulated mice. This would give an indication 
as to whether the formation of an ICAM-1 gradient potentially guides neutrophil 




 Are ICAM-1/MAC-1 the only molecules involved in intraluminal 
neutrophil crawling on the luminal side of the lymphatic 
endothelium? What other molecules could be involved? 
This study demonstrated that TNF-dependent neutrophil crawling on the luminal side of 
the lymphatic endothelium following administration of a local inflammatory stimulus 
occurs through the upregulation of ICAM-1 on initial lymphatics, leading to ICAM-
1/MAC-1-dependent crawling. In blood vessels, the interaction of both these molecules 
has been shown to be critical for neutrophil crawling in response to CXCL2 (MIP-2) and 
TNF (Phillipson et al., 2006), ultimately leading to their successful transmigration across 
the vascular endothelium. However, before neutrophil crawling can occur, their firm 
adhesion and stabilisation to the luminal surface of the vascular endothelium is required. 
This has been shown to be dependent on the interaction of LFA-1 with ICAM-1 in vivo 
(Phillipson et al., 2006). Since the present study demonstrates that neutrophil intraluminal 
crawling within lymphatic vessels involves the same molecules as those involved in 
crawling within blood vessels, it would be interesting to see if the LFA-1/ICAM-1 
interactions also play roles within lymphatics. Thus, confocal IVM experiments involving 
the stimulation of LysM-eGFP mice and inhibition of LFA-1 with the use of blocking 
antibodies, or LFA-1 KO crossed with LysM-eGFP mice, could be carried out to analyse 
if LFA-1 mediated adhesion to the luminal side of the lymphatic endothelium is required 
for subsequent neutrophil intraluminal crawling within lymphatic vessels. Additionally, 
the role of ICAM-2, an adhesion molecule that binds both LFA-1 and MAC-1 (Li et al., 
1993; Xie et al., 1995), could also be explored. ICAM-2 is constitutively expressed on 
ECs and has been shown to have a key role in the regulation of neutrophil crawling 
dynamics within the lumen of blood vessels (Halai et al., 2014). Functional or genetic 
blockade of ICAM-2 in vivo resulted in aberrant and reduced neutrophil crawling velocity 
(Halai et al., 2014), which is similar to what we observed within initial lymphatics 
following ICAM-1 blockade. Thus, experiments involving ICAM-2 blockade through the 
use of blocking Abs or ICAM-2 KO mice crossed with LysM-eGFP mice could be carried 
out, and neutrophil crawling on the luminal side of the lymphatic endothelium could be 
observed in real-time using confocal IVM. It would also be interesting to investigate the 
potential formation of an ICAM-2 gradient within initial lymphatics following 
stimulation with the use of confocal IVM (as described for ICAM-1 at the end of section 
7.2.4.3), to determine if this plays a potential role in guiding neutrophils towards the 
direction of collecting lymphatics and LNs. 
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Finally, it has been recently demonstrated that HS-dependent haptotactic gradients of 
CCL21 mediate DC migration to dLNs in vivo (Weber et al., 2013), and that murine LECs 
generate a gradient of CCL21 when exposed to low shear stress, which is responsible for 
the directional crawling of DCs in vitro (Russo et al., 2016). Thus, HS and CCL21 could 
also potentially affect neutrophil interactions with the luminal side of the lymphatic 
endothelium in our model in vivo. This could be investigated via confocal IVM using 
stimulated LysM-eGFP mice crossed with those that have impaired HS biosynthesis, in 
addition to i.s. injection of a fluorescently-conjugated anti-CCL21 Ab to visualise this 
chemokine. This would allow us to observe GFPhigh neutrophils’ intraluminal crawling 
along the lymphatic endothelium in real-time in vivo in order to determine if HS-
dependent CCL21 presentation within the lumen occurs, and if HS-deficiency results in 






 Concluding remarks 
A greater understanding of the distinctive molecular mechanisms that control neutrophil 
recruitment to LNs via initial lymphatics would provide insight into the possible 
therapeutic avenues based on regulating neutrophil migration. In light of this, the present 
study has provided evidence for some of the mechanisms underlying neutrophil 
trafficking into and within initial lymphatic vessels of inflamed tissues. This study has 
shown that components of the LEC glycocalyx are regulated and redistributed during 
inflammation. The consequences of this on neutrophil migration into initial lymphatics 
are still unclear although it is tempting to speculate that modulation of the glycocalyx is 
key for this process, as this has been shown to be the case in neutrophil extravasation 
from blood vessels (Kolarova et al., 2014). More importantly, this study has demonstrated 
for the first time a predominant role for endogenous TNF in orchestrating both CCR7-
dependent migration of neutrophils into initial lymphatics and ICAM-1 dependent 
crawling on the luminal surface of the lymphatic endothelium during the acute phase of 
the inflammatory response, as induced by antigen sensitisation (Figure 7.5). Taken 
together, the findings of the present study identify TNF as a new molecular regulator of 
neutrophil migration into the lymphatic system in vivo and has also shed significant light 
onto a new potential mechanism of action – and limitations – for anti-TNF therapy. The 
findings also highlight potential and effective targets, which could very well be exploited 
for the optimisation of neutrophil-based vaccination strategies or for reshaping protective 
immune responses in vivo. Finally, potential therapeutic targets have been revealed, 
which may prove useful in preventing further dissemination of pathogens through the 
recirculation of antigen-bearing neutrophils via the lymphatic system, thus preventing the 
establishment of systemic infections that could lead to severe clinical conditions, such as 






Figure 7.5: Schematic diagram illustrating the dual mechanisms of action of TNF leading 
to trafficking of neutrophils into initial lymphatic vessels, and their subsequent intraluminal 
crawling upon acute inflammation in vivo. During the acute inflammatory response of the tissue 
following antigen sensitisation with an emulsion of CFA+Ag, endogenous TNF is released 
leading to the direct priming of freshly recruited neutrophils. CFA+Ag also leads to the formation 
of a gradient of CCL21 forming within the interstitial tissues. TNF allows neutrophils to be 
attracted to the lymphatic vessels, presumably through the CCL21 gradient formed within the 
interstitium, and triggers the migration of neutrophils into initial lymphatics in a CCR7-dependent 
manner (intravasation). Furthermore, endogenous TNF activates the lymphatic endothelium 
leading to an up-regulation of ICAM-1 expression, thus allowing neutrophils present within 
lymphatic vessels to adhere and crawl along the luminal side of the lymphatic endothelium in the 
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Appendix 1: Neutrophil migration response in the cremaster muscle following 
stimulation with CFA+Ag (CFA+Ag) for 8 h in WT, TNRdbKO and CCR7KO mice. 
WT, TNFRdbKO and CCR7KO mice were subjected to CFA+Ag-induced inflammation 
of the cremaster muscles. Controlled mice were injected with PBS. Eight hours later, the 
cremaster muscles were dissected away, fixed and immunostained for LYVE-1, PECAM-
1 and MRP14 to visualise the lymphatic vasculatures the endothelial cells junctions and 
neutrophils, respectively before analysis of the neutrophil migration responses by 
confocal microscopy. (A) Number of extravasated neutrophils in the cremaster muscles. 
(B) Number of neutrophils within the cremaster lymphatic vessels. Data are expressed as 
mean ± SEM from n = at least 4 animals per group. Statistically significant difference 
between stimulated and unstimulated animals are indicated by asterisks: **, P< 0.01; ***, 
P < 0.001; ****, P < 0.0001. Statistically significant difference between WT and KO 






Appendix 2: GM-CSF and IL-17 release in the cremaster muscle following CFA+Ag 
(CFA+Ag)-induced inflammation in vivo. Time-course of TNF release in the cremaster 
muscles of WT C57BL/6 mice following i.s injection of CFA+Ag and as quantified by 
ELISA. Mice were stimulated intrascrotally with CFA+Ag for different in vivo test 
periods before being sacrificed by cervical dislocation and their cremaster muscles 
isolated, snap-frozen and homogenised for use in ELISAs. (A) Time-course of GM-CSF 
release in the cremaster muscles of WT C57BL/6 mice. (B) Time-course of IL-17 release 
in the cremaster muscles of WT C57BL/6 mice. Data are expressed as mean ± SEM of N 
= 6-10 animals per group from 2 independent experiments. Statistical significance was 






Appendix 3: Representative binding of LEL (top) and SNA (bottom) to LECs of mice 
cremaster muscles. WT mice were subjected to BECs/LECs/lectin labelling using 
directly conjugated Alexa Fluor 488/555/647 non-blocking mAb to PECAM-1/LYVE-
1/lectin via cold staining. Tissues were analysed on a confocal microscope (Leica, 
Switzerland). Black boxes on images (left) indicate the region of vessel which is depicted 
on the zoomed-in images (right). (A) Ex vivo-live staining (Pre-fixation/perm-block) of 
LEL. (B)  Ex vivo-live staining (Pre-fixation/perm-block) of SNA. Bars = 50 µm. N = 4 






Appendix 4: Confirmation of lectin specificity. WT C57BL/6 mice were given i.s 
injections of PBS (400 µl) for 16 h before they were sacrificed by cervical dislocation 
and their cremaster muscles dissected away, fixed, permeabilised and placed in either 
PBS or 50 mM galactose solution to block competitively block IB4 lectin binding for 2 
hours. Tissues were then stained for IB4 (blue) and immunostained for LYVE-1 (red). 
Representative 3D reconstructed confocal images on the left show tissues that have not 
been treated with blocking doses of galactose. Images on the right show tissues that have 








Appendix 5: CCL21 expression in cremaster tissues 
C57BL/6 WT mice were given i.s injections of CFA+Ag (CFA+Ag) (200 μg in 300 µl 
IFA/OVA/PBS) and the inflammatory response allowed to develop for 16 h. Two hours 
before the end of the inflammation period, mice received an i.s. injection of anti-LYVE-
1 mAb and anti-CCL21 mAb/rabbit IgG isotype control Ab. CCL21 expression within 
lymphatic vessels was quantified using ImageJ. For ELISAs, cremaster muscles were 
dissected away at the end of the inflammatory period and snap-frozen before being 
homogenised. (A) CCL21 gradient within afferent lymphatic vessels. A surface intensity 
profile within the lymphatic vessels was generated in the direction of flow (100 µm 
length). Data are expressed as percentage change from the first measure pixel of the 
surface. (B) CCL21 expression within cremaster tissues of PBS and CFA+Ag stimulated 
mice as quantified by ELISAs. Results are from n = at least 4 animals per group from 3 
independent experiments (with 8-12 vessels per mouse for confocal images). (B) 





Appendix 6: ICAM-1 isotype control staining. Representative 3D confocal images of 
LVs (red) from whole mount ICAM-1 isotype control (green) immunostained tissues from 
WT mice administered with vehicle (left panel) and upon CFA+Ag stimulation (right 







Appendix 7: The effect of ICAM-1/MAC-1 blockade on neutrophil intraluminal 
crawling within lymphatic vessels. LysM-eGFP mice were subjected to CFA+Ag-
induced cremaster inflammation for 6hrs. At 4.5 h post inflammation, mice received an 
i.s. injection of non-blocking dose of anti-LYVE-1 (red) and anti-PECAM-1 mAbs (not 
shown on the image) for the visualisation of both the lymphatic and blood vasculatures. 
Ninety minutes later, tissues were exteriorised to perform time-lapse recordings of the 
neutrophil responses for 2 h by intravital confocal microscopy. The effect of blocking 
antibodies against ICAM-1 and MAC-1 (injected locally 90min before recordings) on 
neutrophil migration paths in lymphatic vessels was investigated and analysed using 
IMARIS software. The pictures (left panels) are representative 3D still images showing 
neutrophils (green) within the lymphatic vessels (red) and their respective crawling path 
(time-coloured mapped line) and/or directionality (white arrow) from mice pre-treated 
with an isotype control (A), anti-ICAM-1 (B) or anti-MAC-1 (C) mAbs. The 
directionality plot (right) shows the crawling paths of lymphatic-infiltrated neutrophils in 
the X & Y planes of the lymphatic vessels from CTL Ab-treated mice. Bar: 30 µm. The 
graphs (right panels) show the crawling paths of neutrophils in the X & Y planes of the 
lymphatic vessels from CTL Ab, anti-ICAM-1 and anti-MAC-1 mAbs treated groups. A 
total of 76 cells were analysed from 10 independent experiments. Bar: 30 µm. 





Appendix 8: The effect of anti–ICAM-1 and anti-MAC-1 blocking antibodies on 
neutrophil extravasation, and migration into lymphatic vessels and their associated 
dLNs. LysM-eGFP mice were subjected to CFA+Ag-induced cremaster inflammation for 
6 h. Mice also received at 4.5hrs post inflammation an i.s. injection of non-blocking dose 
of anti-LYVE-1 (red) and anti-PECAM-1 mAbs for the visualisation of both the 
lymphatic and blood vasculatures. Cremaster muscles were dissected way at the end of 
the inflammatory period, fixed, permeabilised and labelled with anti-MRP14 mAbs to 
visualise neutrophils. dLNs were dissected way at the end of the inflammatory period, 
fixed, permeabilised and labelled with anti-HEV, anti LYVE-1 and anti-MRP14 mAbs. 
Neutrophil migration responses was analysed using IMARIS software. The numbers of 
neutrophils in the interstitial tissue (A) and inside the lymphatic vessels (B) were 
quantified by confocal microscopy. (C) Neutrophil infiltration of cremaster dLNs was 
also quantified at the end of the experiment. Results are expressed as mean ± SEM of N 
= 4–9 mice (1-2 vessels analysed/mouse for intravital confocal microscopy, each mice is 
a single experiment). Significant differences between blocking antibodies treated and 
control groups are indicated by *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. Significant 
differences between other groups are indicated by # (P < 0.05). Experiments and 






Appendix 9: Neutrophil expression of TNFRI (p55) and TNFRII (p75). Blood 
leukocytes from WT C57BL/6 mice were immunostained for neutrophils specific markers 
(CD45+ Ly6G+) and their surface expression of TNFRs p55 and p75 were analysed by 
flow cytometry. The figure shows representative histograms of the fluorescence intensity 
for p55 (left, orange) and p75 (right, orange) of blood neutrophils as compared to the 
intensity of staining of isotype control mAb (red). N = 6-8 animals per group from at least 





(N.B. videos are stored on accompanying memory card) 
 
Video 1: Neutrophil breaching of the lymphatic endothelium following TNF 
stimulation. The video captures the breaching of the lymphatic endothelium by a 
neutrophil in a TNF-stimulated (300 ng/mouse i.s.) cremaster lymphatic vessel of a 
LysM-eGFP mouse (exhibiting GFP-labelled leukocytes (green). Cremaster muscles 
were immunostained in vivo for LECs with non-blocking dose of an Alexa555-labelled 
anti-LYVE-1 mAb (red). The video shows the migration of a neutrophil (in green and 
isolated from the rest of the inflammatory response by creating an isosurface on it using 
IMARIS software for clarity of the image) into the lumen of the lymphatic vessel 
(recorded from 2 h after injection of the cytokine). Images were captured every minute 
for 90 min. 
 
Video 2: TNF-induced intraluminal neutrophil crawling along the lumen of the 
lymphatic endothelium. The video captures the intraluminal crawling of neutrophils (in 
green) along the lymphatic endothelial cell wall in a TNF-stimulated (300 ng/mouse i.s.) 
cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes (green). 
Lymphatic vessels were immunostained in vivo with Alexa555-labelled anti–LYVE-1 
mAb (red) and Alexa647-labelled anti-PECAM-1 mAb (blue). Images were captured 
from 4 h post-i.s. injection at one stack per minute for a duration of 90 min. Still images 
of this video are shown in Figure 6.1. 
 
Video 3: Intraluminal neutrophil crawling with isotype control (IgG1, κ) mAb. The 
video captures the intraluminal crawling of several neutrophils (in green and isolated from 
the rest of the inflammatory response by creating an isosurface on them using IMARIS 
software for clarity of the image) along the LEC wall in a CFA+Ag-stimulated (200 
µg/mouse i.s.) cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes 
(green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an IgG1, κ isotype 
control (50 μg/mouse). The IgG1, κ isotype control mAb was injected i.s. 4 h post-i.s. 
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injection before exteriorisation of the cremaster muscles to perform intravital confocal 
microscopy 2 h later. At the end of the sequence, the track followed by the neutrophils 
during their crawling on the luminal side of the lymphatic endothelium is shown, 
alongside the displacement (arrow). Images were captured at one stack per minute for a 
duration of 90 min. A still image of this is shown in Figure 6.3A. 
 
Video 4: Intraluminal neutrophil crawling with anti-TNF blocking mAb. The video 
captures the intraluminal crawling of several neutrophils (in green and isolated from the 
rest of the inflammatory response by creating an isosurface on them using IMARIS 
software for clarity of the image) along the lymphatic endothelial cell wall in a CFA+Ag-
stimulated cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes 
(green) and immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-TNF blocking 
Ab (50 μg/mouse). The anti-TNF blocking Ab was injected i.s. 4 h post-i.s. injection 
before exteriorisation of the cremaster muscles to perform intravital confocal microscopy 
2 h later. At the end of the sequence, the track followed by the neutrophils during their 
crawling on the luminal side of the lymphatic endothelium is shown, alongside the 
displacement (arrow). Images were captured at one stack per minute for a duration of 90 
min. A still image of this is shown in Figure 6.3B.  
 
Video 5: Intraluminal neutrophil crawling with isotype control (IgG2b, κ) mAb. The 
video captures the intraluminal crawling of several neutrophils (in green and isolated from 
the rest of the inflammatory response by creating an isosurface on them using IMARIS 
software for clarity of the image) along the lymphatic endothelial cell wall in a CFA+Ag-
stimulated cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes 
(green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an IgG2b, κ isotype 
control (10 μg/mouse). Antibodies were injected i.s. 90min before exteriorisation of the 
cremaster muscles and visualisation by intravital confocal microscopy from 6hrs post 
inflammation. At the end of the sequence, the track followed by the neutrophils during 
their crawling on the luminal side of the lymphatic endothelium is shown, alongside the 
displacement (arrow). Images were captured at one stack per minute for a duration of 
90min. A still image of this is shown in Appendix 7A.  
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Video 6: Intraluminal neutrophil crawling with anti-ICAM-1 blocking mAb. The 
video captures the intraluminal crawling of several neutrophils (in green and isolated from 
the rest of the inflammatory response by creating an isosurface on them using IMARIS 
software for clarity of the image) along the lymphatic endothelial cell wall in a CFA+Ag-
stimulated cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes 
(green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-ICAM-1 
blocking mAb (10 μg/mouse). Antibodies were injected i.s. 90 min before exteriorisation 
of the cremaster muscles and visualisation by intravital confocal microscopy. At the end 
of the sequence, the track followed by the neutrophils during their crawling on the luminal 
side of the lymphatic endothelium is shown, alongside the displacement (arrow). Images 
were captured at one stack per minute for a duration of 90min. A still image of this is 
shown in Appendix 7B.  
 
Video 7: Intraluminal neutrophil crawling with anti-MAC-1 blocking mAb. The 
video captures the intraluminal crawling of several neutrophils (in green and isolated from 
the rest of the inflammatory response by creating an isosurface on them using IMARIS 
software for clarity of the image) along the lymphatic endothelial cell wall in a CFA+Ag-
stimulated cremaster of a LysM-eGFP mouse (exhibiting GFP-labelled leukocytes 
(green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-MAC-1 
blocking mAb (10 μg/mouse). Antibodies were injected i.s. 90 min before exteriorisation 
of the cremaster muscles and visualisation by intravital confocal microscopy. At the end 
of the sequence, the track followed by the neutrophils during their crawling on the luminal 
side of the lymphatic endothelium is shown, alongside the displacement (arrow). Images 
were captured at one stack per minute for a duration of 90 min. A still image of this is 
shown in Appendix 7C.  
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Endogenous TNFα orchestrates 
the trafficking of neutrophils into 
and within lymphatic vessels during 
acute inflammation
Samantha Arokiasamy1,2, Christian Zakian1, Jessica Dilliway1, Wen Wang2,*, 
Sussan Nourshargh1,* & Mathieu-Benoit Voisin1
Neutrophils are recognised to play a pivotal role at the interface between innate and acquired 
immunities following their recruitment to inflamed tissues and lymphoid organs. While neutrophil 
trafficking through blood vessels has been extensively studied, the molecular mechanisms regulating 
their migration into the lymphatic system are still poorly understood. Here, we have analysed 
neutrophil-lymphatic vessel interactions in real time and in vivo using intravital confocal microscopy 
applied to inflamed cremaster muscles. We show that antigen sensitisation of the tissues induces a rapid 
but transient entry of tissue-infiltrated neutrophils into lymphatic vessels and subsequent crawling 
along the luminal side of the lymphatic endothelium. Interestingly, using mice deficient in both TNF 
receptors p55 and p75, chimeric animals and anti-TNFα antibody blockade we demonstrate that tissue-
release of TNFα governs both neutrophil migration through the lymphatic endothelium and luminal 
crawling. Mechanistically, we show that TNFα primes directly the neutrophils to enter the lymphatic 
vessels in a strictly CCR7-dependent manner; and induces ICAM-1 up-regulation on lymphatic vessels, 
allowing neutrophils to crawl along the lumen of the lymphatic endothelium in an ICAM-1/MAC-1-
dependent manner. Collectively, our findings demonstrate a new role for TNFα as a key regulator of 
neutrophil trafficking into and within lymphatic system in vivo.
Neutrophils have classically been considered to be prototypical short-lived and terminally differentiated phago-
cytes involved in innate immune responses following their rapid recruitment at site of infections and acute 
inflammation1–3. Compared to other leukocytes, their life span does not exceed 1–5 days in the circulation4 
though several cytokines such as GM-CSF5,6, bacteria-derived products7, hypoxia8 or their migration through the 
blood vessel walls9,10 can significantly expand their life expectancy both in vivo and in vitro. Until recently, neu-
trophils were thought to end their life in inflamed tissues by apoptosis before being engulfed by other phagocytic 
cells to limit and resolve inflammation11,12. However, 45 years ago, neutrophils were detected within the lymphatic 
system13. It was suggested that this response represented a way for neutrophils to recirculate back into the blood 
vasculature; and their role in the lymphatic system was thus largely neglected. Recently, however, accumulating 
evidence has shown that the role of neutrophils spans beyond the basic but fundamental immunological pro-
cesses of innate immunity14. Specifically, neutrophils can actively participate in the regulation of adaptive immu-
nity following exposure to pathogens and antigens sensitisation14–17 by means of antigen presentation or cytokine 
release for stimulating T- and B-lymphocytes18–22 as well as DCs23.
While their role in regulating adaptive immunity is now well documented, few studies have investigated the 
mechanisms associated with neutrophil migration into the lymphatic vasculature. A clue to this phenomenon 
was first suggested through neutrophil localisation in the draining lymph nodes (dLNs) within the capsula and 
carrying fluorescently-labelled antigens or pathogens from the sites of antigen-sensitisation or infection15,16,24. 
These results indicated their provenance from tissue-associated lymphatic capillaries via afferent lymphatic ves-
sels. Furthermore, antigen-bearing neutrophils trafficking to dLNs preceded the influx of other professional 
antigen-presenting cells such as DCs and macrophages25; and blocking their entry or depleting mice in circulating 
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Figure 1. Dynamics of neutrophil migration into cremaster muscle lymphatics upon TNFα-stimulation. 
The dynamics of neutrophil migration into the tissue and lymphatic vessels was analysed by intravital confocal 
microscopy in TNFα -stimulated mouse cremaster muscles. (a) Representative 3D-reconstructed still image  
(2 μ m cross-section) from a LysM-GFP × α SMA-CherryRFP mouse [exhibiting both endogenous GFP-
fluorescent neutrophils (green) and RFP-fluorescent pericytes/smooth muscle cells (red) and immunostained 
with a non-blocking anti-PECAM-1 mAb (blue)] cremaster tissue showing a neutrophil within the lymphatic 
vessel (yellow arrow) post TNFα -stimulation. (b) Time-course of neutrophil extravasation in TNFα -stimulated 
cremaster muscles. (c) Time-course of neutrophil migration into lymphatic vessels upon TNFα -stimulation. 
(d) Total neutrophil-infiltrate in dLNs upon TNFα -stimulation. (e) Representative 3D-reconstructed still image 
of a post-capillary venule and an adjacent lymphatic vessel from a LysM-GFP mouse (immunostained with 
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neutrophils reduced T-cell proliferation in vivo26, confirming a critical role for these leukocyte in the development 
of adequate adaptive immune responses. Recently, neutrophils have also been shown to migrate directly into the 
LNs from the blood circulation via high endothelial venules (HEVs). The molecular signature of these migratory 
responses is however unclear; and there are currently conflicting data in the literature regarding the chemotaxis 
pathway involved in this phenomenon. A role for CCR7 in neutrophil migration into the LNs of immunised 
animals was first demonstrated27, while other studies have implicated the CXCR4:CXCL12 axis and Sphingosine-
1-Phosphate26,28. Leukocyte integrins and selectins have also been implicated in neutrophil trafficking to LNs28, 
though their exact contribution to cell migration through afferent lymphatic vessels near sites of inflammation 
in vivo is still unclear.
Despite these seminal but conflicting reports, further investigations are required to fully understand the 
mechanisms associated with this response. Here we provide evidence for the involvement of TNFα in the traf-
ficking of neutrophils into but also within the lymphatic vasculature in vivo. Specifically, using a mouse model of 
antigen sensitisation and cytokine-induced inflammation of the cremaster muscle, we demonstrate that TNFα 
orchestrates both neutrophil migration into lymphatic vessels in a CCR7-dependent manner and their subse-
quent crawling along the lymphatic endothelium in an ICAM-1/MAC-1-dependent manner. Collectively, the 
present findings identify a previously unknown role for TNFα in orchestrating sequential interactions of neu-
trophils with tissue-associated lymphatic vessels during the acute inflammatory response of antigen sensitisa-
tion; and highlight TNFα as a potential target for the manipulation of neutrophil regulation of adaptive immune 
responses within the lymphatic system.
Results
TNFα promotes neutrophil migration into lymphatic vessels of murine cremaster muscles. 
Neutrophil migration into the lymphatic system has been described in models of infections and immunisation 
sensitisation15,16,24,27, but the mechanisms associated with this response are not fully understood and somewhat 
controversial. For this purpose, we studied neutrophil-lymphatic vessel interactions in vivo using a mouse model 
of cremaster muscle inflammation, allowing the direct visualisation in 3- and 4- dimensions of cell-cell inter-
actions by high-resolution confocal microscopy. Whole-mount cremaster tissues of mice immunostained for 
LYVE-1 and PECAM-1/VE-Cadherin, showed the presence of a unidirectional network of lymphatic vessels 
with characteristic blind-ended lymphatic capillaries and collecting afferent vessels made up of oak-leaf shaped 
lymphatic endothelial cells (LEC) (Supplementary Fig. S1) as previously described in other tissues29,30. Following 
tissue-stimulation with exogenous TNFα , neutrophils were rapidly detected in the lumen of lymphatic vessels 
(Fig. 1a). Detailed analysis of TNFα -stimulated tissues demonstrated a time-dependent migration of neutrophils 
out of blood vessels post TNFα -administration (Fig. 1b). This response was associated with a rapid and transient 
migration of neutrophils into lymphatic vessels at 8 hrs post-inflammation (Fig. 1c), as well as into the cremaster 
muscle draining lymph nodes (dLNs) (Fig. 1d). We then went on to analyse in vivo and in real time the dynam-
ics of neutrophil-lymphatic vessel interactions in the cremaster muscle of the neutrophil reporter LysM-GFP 
mice upon TNFα -stimulation. For this purpose, in vivo fluorescent-immunostaining with non-blocking anti-PE-
CAM-1 and/or a non-inhibitory dose of anti-LYVE-1 mAbs was applied to the tissues to visualise endothelial 
cells and lymphatic vessels, respectively, to allow the tracking of GFPhigh neutrophils responses into the lymphatic 
vasculature by intravital confocal microscopy. With this technique, neutrophils were seen to migrate rapidly 
(4.5 ± 0.6 min) through LECs (Fig. 1e and Videos 1 and 2). Furthermore, we observed that following their entry 
into the lymphatic vessels, intravasated neutrophils were firmly attached to the LECs and were crawling along the 
luminal surface of the lymphatic endothelium. (Fig. 1f and Video 3). Analysis of neutrophil crawling dynamics 
showed that 63.7 ± 5.7% of the neutrophils crawl along the luminal surface of the LECs in the direction of the 
lymphatic flow at a speed of 4.3 ± 0.2 μ m/min; while the few neutrophils venturing against the natural direction 
of lymphatic flow showed a reduced crawling speed, displacement length and straightness (Fig. 1g–j).
Collectively, these results demonstrate that the cytokine TNFα induces the migration of neutrophils into lym-
phatic vessels and promotes their crawling along the luminal aspect of LECs in vivo.
TNFα controls the entry of neutrophils into lymphatic vessels following antigen sensitisation. 
Having observed the efficacy of exogenous TNFα in inducing neutrophil migration into lymphatic vessels, we 
next investigated the potential role of endogenous TNFα in this response in a model of antigen sensitisation. 
non-blocking anti-PECAM-1 mAb (blue)]. The right panel images illustrate a time-lapse series of 2 μ m-thick 
cross-sections along the z-plane (dotted-yellow arrow) showing the migration of two neutrophils (Cell-1 & 
Cell-2) into the lymphatic vessel. (f) Representative 3D-reconstructed still image of a lymphatic vessel from a 
TNFα -stimulated cremaster tissue of a LysM-GFP mouse and immunostained with an anti-LYVE-1 mAb (red) 
in vivo. Neutrophil crawling path (colour-coded line) and directionality (white arrow) is shown on the image. 
The bottom panel images are a series of high magnification cross-sections of the main image at indicated time-
points illustrating the continuous attachment of the neutrophil to the lymphatic endothelium. (g) Percentage 
of neutrophils crawling in the afferent direction (flow) or in the opposite direction (anti-flow). Speed (h), 
directionality (i) and straightness (j) of neutrophils crawling in the afferent (flow) or opposite direction (anti-
flow) of the cremaster lymphatic vessels. Data are expressed as mean ± SEM from 5–12 animals per group  
(at least 5 independent experiments). For the crawling parameter analysis, a total of 63 cells were quantified 
from 8 mice. Statistically significant differences between stimulated and unstimulated treatment groups are 
indicated by asterisks: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Significant differences between 
responses at different time points are indicated by hash symbols: #P < 0.05; ####P < 0.0001. Bar = 10 μ m.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:44189 | DOI: 10.1038/srep44189
For this purpose, we first analysed the migration response of neutrophils into the dLNs of mice subjected to 
skin inflammation with an emulsion of an antigen in Complete Freund’s Adjuvant (CFA+ Ag), reproducing the 
classical immunisation procedure. Injection of CFA+ Ag induced a time-dependent increase in the number of 
neutrophils in the dLNs (namely inguinal and lumbar LNs) as compared to non-dLN (i.e. axillary LNs) (Fig. 2a). 
This model was then extended to the cremaster muscle to look at neutrophil-lymphatic vessel interactions 
in vivo. Quantification of neutrophil migration responses through blood and into lymphatic vasculatures showed 
a time-dependent increase in the number of neutrophils (Fig. 2b,c), both peaking at 8 hrs post-inflammation. 
This response was associated with an increase in neutrophil infiltration of the dLNs of the cremaster muscles but 
not of non-dLNs (Fig. 2d). Because of the low incidence of cells (less than 1% of total LN-infiltrated leukocytes as 
observed by flow cytometry) and to exclude from the analysis the increase of circulating neutrophils due to CFA+ 
Ag-induced neutrophilia (Fig. S2), we performed detailed analysis of whole-mount dLNs immunostained for 
HEVs (blood vasculature), LYVE-1 (lymphatic vasculature) and MRP14 (neutrophils) by confocal microscopy. 
We showed that ~60% of neutrophils (Fig. 2e) at 8 hrs post-inflammation were within LYVE-1+ vessels. At 16 hrs 
Figure 2. Neutrophil rapidly migrates into lymphatic system of the cremaster muscle during antigen 
sensitisation in vivo. Neutrophil migration into the lymphatic system was induced in WT animals following 
antigen sensitisation with complete Freund’s adjuvant (CFA+ Ag). (a) Time course of neutrophil migration into 
draining LNs (inguinal) or non-draining LNs (axillary) of mice injected intradermally with CFA+ Ag and as 
analysed by flow cytometry. (b) Time course of CFA+ Ag-induced neutrophil extravasation in mice injected 
intra-scrotally with CFA+ Ag as visualised by confocal microscopy. (c) Time course of CFA+ Ag-induced 
neutrophil intravasation into the cremaster lymphatic vessels of WT mice as visualised by confocal microscopy. 
(d) Time course of neutrophil migration into draining and non-draining LNs in mice as analysed by flow 
cytometry. (e) Quantification of neutrophil localisation in the dLNs of mice stimulated intra-scrotally with CFA 
(8 or 16 hrs) or with PBS (control), and as analysed by confocal microscopy. Data are represented as percentages 
of neutrophils present in the HEV, LYVE-1+ vessels and in the stroma of the LNs. Data are expressed as 
mean ± SEM of N = 5–12 animals (~10 images per cremasters for confocal microscopy) per group from at least 
5–10 experiments. Statistically significant differences between stimulated and control groups or between WT 
and TNFRdbKO mice are indicated by asterisks: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Significant 
differences between other groups are indicated by hash symbols: ##P < 0.01; ####P < 0.0001.
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Figure 3. TNFα instruct the neutrophils to migrate into the lymphatic system upon antigen sensitisation. 
Neutrophil migration into the lymphatic system of the cremaster muscle following antigen sensitisation with 
complete Freund’s adjuvant (CFA+ Ag) was induced in WT and TNFRdbKO animals as well as in chimeric 
animals exhibiting neutrophils deficient in TNFRs. (a) Time course of TNFα release in the cremaster muscles 
of WT mice following intra-scrotal injection of CFA+ Ag and as quantified by ELISA. (b) TNFα release in mice 
subjected to clodronate liposome-induced macrophage depletion. (c) Number of extravasated neutrophils in 
cremaster muscles of WT and TNFRdbKO mice at 16 hrs post-CFA+ Ag-stimulation as quantified by confocal 
microscopy. (d) Number of neutrophils within cremaster lymphatic vessels of WT and TNFRdbKO mice 
at 16 hrs post-CFA+ Ag-stimulation as quantified by confocal microscopy. (e) Percentage of neutrophils in 
dLNs of WT and TNFRdbKO mice at 16 hrs post-CFA+ Ag-stimulation as quantified by flow cytometry. (f) 
Number of extravasated neutrophils in cremaster muscles at 16 hrs post-CFA+ Ag-stimulation from chimeric 
animals receiving bone marrow transplant from WT or TNFRdbKO donor mice and as quantified by confocal 
microscopy. (g) Number of neutrophils within cremaster lymphatic vessels at 16 hrs post-CFA+ Ag-stimulation 
from chimeric animals receiving bone marrow transplant from WT or TNFRdbKO donor mice and as 
quantified by confocal microscopy. (h) Number of neutrophils found in the dLNs of chimeric animals receiving 
bone marrow transplant from WT or TNFRdbKO donor mice as quantified by confocal microscopy 16 hrs post-
CFA+ Ag-stimulation. Data are expressed as mean ± SEM of N = 5–12 animals per group from at least 5–10 
experiments. Statistically significant differences between stimulated and control groups or between WT and 
TNFRdbKO mice are indicated by asterisks: *P < 0.05; **P < 0.01; ****P < 0.0001.
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Figure 4. TNFα promotes CCR7-dependent migration of neutrophils into lymphatic vessels in vivo.  
(a) Analysis by flow cytometry of CCR7 expression (intracellular and cell-surface) on neutrophils isolated 
from the blood circulation, CFA+ Ag-stimulated-cremaster muscles and dLNs of WT and CCR7KO animals. 
(b) CCR7 surface expression on tissue-infiltrated neutrophils from WT and TNFRdbKO mice subjected to 
CFA+ Ag-induced inflammation. (c–e) WT and CCR7KO mice were subjected to TNFα -induced cremaster 
muscle inflammation and neutrophil responses in the tissue and dLNs was assessed by confocal microscopy 
16 hrs post-inflammation. (c) Number of extravasated neutrophils in of WT and CCR7KO mice. (d) Number of 
intravasated neutrophils in lymphatic vessels of cremaster muscles from WT and CCR7KO mice. (e) Neutrophil 
number in the cremaster dLNs of WT and CCR7KO animals. (f–k) WT, CCR7KO mice or CCR7KO-neutrophil 
chimeric animals were subjected to antigen sensitisation (CFA+ Ag) and neutrophil responses in the cremaster 
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post-inflammation, only ~25% of the neutrophils were found in this location while ~58% of the cells were found 
in the LN stroma. Overall, only a minority of the neutrophils were found within the HEVs at these time-points. 
These data suggest that the early and rapid migration of neutrophils into dLNs may occur via afferent lymphatics.
Interestingly, CFA+ Ag-stimulation of cremaster muscles induced a rapid release of TNFα in tissues from 8 hrs 
onward and reaching the maximum response at 16 hrs post-inflammation (Fig. 3a). Furthermore, mice depleted 
in resident phagocytes (i.e. macrophages) following the local delivery of clodronate liposomes exhibited a reduc-
tion in TNFα release as compared to control liposome-treated animals (Fig. 3b). To investigate the functional role 
of endogenous TNFα during CFA+ Ag-inflammation, neutrophil migration responses were quantified in mice 
deficient in both TNFR p55 and P75 receptors (TNFRdKO mice). These studies showed that while neutrophil 
extravasation into tissues was similar between WT and TNFRdbKO mice (Supplementary Figs S3a and Fig. 3c), 
neutrophil migration into cremaster lymphatic vessels was reduced by 84% and 75% in KO animals at 8 hrs and 
16 hrs post-inflammation, respectively (Supplementary Fig. S3b and Fig. 3d). This response was associated with a 
reduced (~64%) neutrophil-infiltration of the dLNs (Fig. 3e). In order to address the origin of cell type respond-
ing to the endogenous release of TNFα during inflammation and promoting neutrophil migration into the lym-
phatic vessels, we generated chimeric animals. For this purpose, lethally irradiated WT mice were reconstituted 
with bone marrow hematopoietic cells from either WT or TNFRdbKO animals before being subjected to antigen 
sensitisation (Supplementary Fig. S4). Similarly to full TNRFdbKO mice, the neutrophil migration response into 
the lymphatic system was impaired in chimeric animals exhibiting WT vasculature and tissue-resident cells but 
neutrophils deficient in TNFRs, as compared to the control group; while extravasation through blood vessels was 
not affected (Fig. 3f–h).
Together these data demonstrate that endogenous TNFα directly primes the leukocytes to trigger the migra-
tion of neutrophils into tissue-associated lymphatic vessels post-antigen sensitisation in vivo.
TNFα promotes CCR7-dependent migration of neutrophils into lymphatic vessels in vivo. 
Having identified a role for endogenous TNFα in controlling the entry of neutrophils into lymphatic vessels, we 
then went on to decipher the molecular mechanism involved and more specifically which chemokine/chemok-
ine axis was associated with this response. We first investigated the role of CXCL1 on neutrophil trafficking 
into the lymphatic vasculature in vivo, as the human equivalent of this chemokine has been shown recently to 
promote neutrophil migration through a monolayer of lymphatic endothelial cells in vitro31. However, local 
delivery of anti-CXCL1 blocking antibody did not affect the migration of neutrophil into the lymphatic vascu-
lature of inflamed cremaster muscles in vivo (Supplementary Fig. S5a–c). We then went on to analyse the role of 
CXCR4:CXCL12 axis shown previously to promote the entry of neutrophils into the lymphatic system in different 
inflammatory models26,28. Similarly to CXCL1-blockade, local injection the CXCR4 specific inhibitor AMD3100 
did not significantly influenced the capacity of neutrophils to migrate into the lymphatic vessels upon antigen sen-
sitisation (Supplementary Fig. S5d–f). In fact, analysis of blood circulating leukocytes by flow cytometry showed 
that while CFA+ Ag-inflammation induced neutrophilia in both AMD3100- and vehicle-treated mice as com-
pared to unstimulated animals (Fig. S5g), CXCR4 surface expression was down-regulated with the inflammation 
(Fig. S5h). Collectively, these results suggest that the chemotactic axes CXCL12:CXCR4 and CXCL1:CXCR1/2 
do not play a significant role in neutrophil recruitment into the lymphatic vessels during the acute inflammatory 
response as induced by CFA+ Ag in vivo.
Finally, the potential involvement of the CCL21/CCR7 axis, widely linked with DC/T-cell migration into the 
lymphatic system32 was then explored in our model despite conflicting studies regarding the role of CCR7 in neu-
trophils26,27. The expression of CCR7 on blood-born, cremaster tissue-infiltrated and dLN-infiltrated neutrophils, 
was first examined by flow cytometry post CFA+ Ag-induced inflammation (Fig. 4a). WT blood neutrophils did 
not express CCR7 on their surface, we could detect intracellular stores of the molecule. Interestingly, neutrophils 
isolated from CFA+ Ag-inflamed cremaster muscles showed a small but significant expression of CCR7 on their 
cell surface. Interestingly, this upregulation of CCR7 on tissue-infiltrated neutrophils was absent in TNFRdbKO 
as compared to WT littermates (Fig. 4b). Furthermore, stimulation of mouse blood neutrophils with low concen-
trations of TNFα in vitro induced the surface expression of CCR7 (Supplementary Fig. S6). Having found that 
tissue-infiltrated neutrophils up-regulate CCR7 on their cell surface, we hypothesised that this chemokine recep-
tor may mediate the migration of neutrophils through lymphatic vessels of the cremaster muscles. To address this, 
we initially looked at neutrophil migration responses in both WT and CCR7KO animals following TNFα stimula-
tion. Interestingly, while neutrophil extravasation into tissues was not affected (Fig. 4c), trafficking of neutrophils 
muscle and dLNs (16 hrs post-inflammation) was assessed by confocal microscopy. (f) Number of extravasated 
neutrophils in inflamed cremaster muscles of WT and CCR7KO mice. (g) Number of intravasated neutrophils 
in cremaster lymphatic vessels of WT and CCR7KO mice. (h) Neutrophil number in the cremaster dLNs of WT 
and CCR7KO mice. (i) Number of neutrophils recruited to the cremaster muscles from lethally irradiated WT 
animals receiving bone marrow transplant from either WT or CCR7KO donor mice. (j) Number of neutrophils 
within cremaster lymphatic vessels post-CFA+ Ag-stimulation from lethally irradiated WT animals receiving 
bone marrow transplant from either WT or CCR7KO donor mice. (k) Neutrophil number in the cremaster 
dLNs from lethally irradiated WT animals receiving bone marrow transplant from either WT or CCR7KO 
donor mice. Data are expressed as mean ± SEM of N = 7–12 animals per group (from at least 5 independent 
experiments). Statistically significant differences between stimulated/specific mAb and unstimulated treatment/
isotype control groups are indicated by asterisks: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Significant 
differences between responses in WT vs. CCR7KO animals (or between different tissues) are indicated by hash 
symbols: #P < 0.05; ##P < 0.01; ###P < 0.001; ####P < 0.0001.
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into cremaster muscle lymphatic vessels was completely inhibited in CCR7KO animals as compared to WT ani-
mals (~97% suppression) (Fig. 4d). With regard to their infiltration into cremaster dLNs, TNFα induced an 
increase of neutrophils compared to control group (Fig. 4e). However, in TNFα -stimulated CCR7KO mice, the 
number of neutrophils into the dLNs was comparable to the levels found in unstimulated animals. Similarly, while 
neutrophil extravasation in response to CFA+ Ag was unaffected in CCR7KO mice (Supplementary Fig. S3a and 
Fig. 4f), neutrophil migration into lymphatic vessels was suppressed by ~86% and 75% in CCR7KO animals as 
compared to WT mice in this model at 8 and 16 hrs post-inflammation, respectively (Supplementary Fig. S3b and 
Fig. 4g). Furthermore, and in contrast to WT animals, the level of dLN-infiltrated neutrophils was not increased 
in CCR7KO mice after stimulation with CFA+ Ag (Fig. 4h). Of note, CCR7KO animals exhibited ~25 times more 
Figure 5. TNFα controls the crawling of neutrophils into the lymphatic vessels in vivo. The effect of anti- 
TNFα blocking mAb on neutrophil crawling along the luminal side of the lymphatic endothelium was analysed 
by intravital confocal microscopy (IVM) using LysM-GFP mice subjected to CFA+ Ag-induced cremaster 
inflammation and immunostained in vivo with a non-blocking dose of Alexa555-conjugated anti-LYVE-1 mAb. 
Isotype control or anti- TNFα blocking mAbs were injected i.s. 4 hrs post-inflammation. (a) The pictures are 
representative still images at one time point of the IVM recording showing lymphatic-infiltrated neutrophils 
(green) and their associated crawling path (time-coloured mapped line) and/or directionality (arrow) as 
analysed by IMARIS software (LYVE-1 with an opacity filter of 5% to see the intravasated leukocytes) from 
CTL (left panel) or anti- TNFα (right panel) mAb-treated groups. (b) The graphs show the crawling paths of 
lymphatic-infiltrated neutrophils in the X & Y planes of the lymphatic vessels from CTL mAb (left panel) and 
anti- TNFα mAb (right panel) treated groups. (c) Quantification (in percentage) of neutrophils crawling in the 
afferent (flow) or opposite direction (anti-flow) of the lymphatic vessel. Mean speed (d), directionality (e) and 
straightness (f) of neutrophils crawling in CTL mAb and anti- TNFα treated groups. A total of 280 cells were 
analysed. Results are expressed as mean ± SEM of N = 4–9 mice (each mouse representing one independent 
experiment). Significant differences between flow and anti-flow crawling cells are indicated by *P < 0.05; 
****P < 0.0001. Significant differences between the CTL and anti– TNFα mAb treated groups are indicated by 
hash symbols: ##P < 0.01; ###P < 0.001; ####P < 0.0001. Bar = 20 μ m.
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LN-infiltrated neutrophils than WT mice in unstimulated conditions, a response related to a higher expression 
of CXCL12 in the LNs of CCR7KO animals as compared to WT mice (Supplementary Fig. S7), suggesting a 
compensatory mechanism during the development of these GM mice. Furthermore, using the specific inhibitor 
of CXCR4 (receptor for CXCL12), AMD3100, we could reduce the number of neutrophils present in the LNs of 
CCR7KO animals (Supplementary Fig. S7). To overcome the abnormal trafficking of neutrophils into the LNs in 
CCR7KO animals, we generated chimeric animals by injecting lethally irradiated WT mice with bone marrow 
cells from CCR7KO animals (or WT bone marrow cells as control). This resulted in the generation of animals 
exhibiting CCR7KO circulating neutrophils in a WT environment. Similarly to a full KO, chimeric exhibiting 
CCR7KO neutrophils showed a reduced migration of these leukocytes (~76% reduction) into the lymphatic vas-
culature of the cremaster muscle upon antigen challenge while neutrophil recruitment from the blood into the 
tissue was similar to the control chimeric group (Fig. 4i–j). Interestingly, CCR7KO-neutrophil chimeric animals 
also showed a reduced number of neutrophils infiltrating the dLNs (~62%) as compared to control littermate 
(Fig. 4k); suggesting that neutrophils from CCR7KO donor cells are not able to migrate efficiently into the LNs 
of the WT recipient mice.
Collectively, these data demonstrate that TNFα mediates CCR7-dependent migration of neutrophils into 
afferent lymphatic vessels.
Figure 6. TNFα controls ICAM-1 expression on lymphatic endothelial cells in vivo. Cremaster muscles of 
WT mice were stimulated with TNFα or CFA+ Ag (6–8 hrs) and immunostained with Alexa555-conjugated 
anti-LYVE-1 and Alexa488-conjugated anti-ICAM-1 (or an isotype control) mAbs to label the lymphatic 
vasculature and ICAM-1, respectively. (a) The pictures are representative confocal images of cremaster 
lymphatic vessels showing the expression of ICAM-1 on selected lymphatic vessels from a PBS-treated control 
(left panels), TNFα -stimulated (middle panels) and CFA+ Ag-stimulated (right panels) animals. (b) ICAM-1 
expression (mean fluorescent intensity or MFI) on vessels from PBS-treated control, TNFα -stimulated and 
CFA+ Ag-stimulated cremaster muscles as quantified by IMARIS software. (c) ICAM-1 expression on lymphatic 
vessels of CFA+ Ag-stimulated cremaster muscles from animals pre-treated with an anti- TNFα blocking 
mAb or isotype CTL mAb injected 4 hrs post-inflammation. Data are expressed as mean ± SEM of N = 8–12 
vessels/animals from 4 animals per group (3 independent experiments). Statistically significant differences 
between the staining of isotype control and anti-ICAM-1 Abs treated groups are indicated by asterisks: 
*P < 0.05; ****P < 0.0001. Significant differences between unstimulated and inflamed groups are indicated by 
hash symbols: ##P < 0.01; ####P < 0.0001. Bar = 50 μ m.Results are expressed as mean ± SEM of N = 4–9 mice 
(1–2 vessels analysed/mouse for intravital confocal microscopy, each mice is a single experiment). Significant 
differences between blocking antibodies treated and control groups are indicated by *P < 0.05; ***P < 0.001; 
****P < 0.0001. Significant differences between other groups are indicated by #(P < 0.05). Bar = 30 μ m.
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Figure 7. Neutrophil crawling along the lymphatic endothelium is ICAM-1/MAC-1 dependent. LysM-GFP 
mice were subjected to CFA+ Ag-induced cremaster inflammation for 6 hrs. Mice also received at 4.5 hrs post 
inflammation an i.s. injection of non-blocking dose of Alexa555-conjugated anti-LYVE-1 (red) and Alexa647-
conjugated anti-PECAM-1 mAbs (not shown on the image) for the visualisation of both the lymphatic and 
blood vasculatures. Ninety minutes later, tissues were exteriorised to perform time-lapse recordings of the 
neutrophil responses for 2 hrs by intravital confocal microscopy. The effect of blocking antibodies against 
ICAM-1 and MAC-1 (injected locally 90 min before recordings) on neutrophil migration paths in the 
interstitium and lymphatic vessels was investigated and analysed using IMARIS software. (a) The pictures 
are representative 3D still images showing neutrophils (green) within the lymphatic vessels (red) and their 
respective crawling path (time-coloured mapped line) and directionality (arrow) from mice pre-treated with an 
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TNFα also controls the crawling of neutrophils along the luminal side of afferent lymphatic 
endothelium. Using intravital confocal microscopy we observed that TNFα -induced inflammation results 
in neutrophils crawling along the lymphatic endothelium (Fig. 1f and Video 3). Similarly to TNFα -stimulation, 
CFA+ Ag led to neutrophil crawling along the lumen of LECs (Video 4). The majority of these leukocytes moved 
in the direction towards collecting lymphatic vessels/lymph flow (67.8 ± 3.8%) at a speed of 5.8 ± 0.2 μ m/min 
and with a straightness index of 0.40 ± 0.04; while cells going against lymph flow direction had reduced speed 
and directionality of movement (Fig. 5 and Video 5). Interestingly, the favoured directionality of neutrophils was 
associated with the establishment of a gradient of CCL21 within the lymphatic vessel in the direction of the lymph 
flow during inflammation (Supplementary Fig. S8). Furthermore, when an anti-TNFα blocking antibody was 
injected 4 hrs post-CFA + Ag-stimulation, the few neutrophils present within the lymphatic lumen completely 
lost their directional motility. Cells did not show any preferential direction of migration but exhibited instead 
a meandering crawling path associated with reduced speed and directionality as compared to isotype control 
treated animals.
These data suggest that, during the acute phase of the inflammatory response to CFA+ Ag, TNFα controls the 
directional crawling of neutrophils within the lymphatic vessels.
ICAM-1 mediates TNFα-induced neutrophil crawling within lymphatic vessels. To investigate 
the molecular mechanisms of neutrophil intraluminal crawling in lymphatics, we studied the role of ICAM-1, 
an adhesion molecule known to support neutrophil crawling along both the luminal33 and abluminal34 surfaces 
of blood vessels. In initial studies we analysed ICAM-1 expression on cremaster lymphatics under basal and 
inflamed conditions by immunostaining. Both TNFα and CFA+ Ag induced an up-regulation of ICAM-1 expres-
sion in vivo as compared to vehicle-treated animals (Fig. 6a,b). Interestingly, when CFA+ Ag-stimulated cremas-
ter muscles were pre-treated with an anti- TNFα blocking antibody, the expression of ICAM-1 on lymphatics 
was reduced as compared to the control antibody-treated group (Fig. 6c). To further assess the role of ICAM-1 in 
neutrophil crawling behaviour within the lymphatic vessels, we performed functional assays using local admin-
istration (injected 4.5 hrs post-inflammation) of functional blocking antibodies against ICAM-1 or its leukocyte 
binding partner, the integrin MAC-1 in CFA+ Ag-stimulated cremaster muscles of LysM-GFP mice. Both anti–
ICAM-1 and anti–MAC-1 mAbs impaired neutrophil intraluminal crawling within lymphatics as compared to 
an isotype control Ab (Fig. 7a,b and Video 6/7/8). Specifically, blocking ICAM-1 or MAC-1 resulted in a ~50% 
reduction in the speed of crawling, displacement length and straightness within the luminal side of lymphatic 
endothelium (Fig. 7c–e). In contrast, interstitial migration was not affected by these treatments. Overall, while the 
time and route of delivery of the blocking antibodies had no effect on leukocyte extravasation from blood vessels 
and migration into lymphatic vessels, respectively (Fig. 7f,g), blocking the intraluminal crawling of neutrophils 
within lymphatic vessels resulted in a reduction in the number of neutrophils infiltrating the dLNs (Fig. 7h).
Collectively, the present findings identify ICAM-1 as an adhesion molecule that mediates neutrophil crawling 
along the lymphatic endothelium and identify TNFα as a key regulator of neutrophil directional motility within 
lymphatic vessels in vivo.
Discussion
It is now well established that neutrophils contribute to the shaping of the adaptive immunity against many for-
eign antigens or infectious agents following their rapid migration into the lymphatic system15,19,35. However, the 
mechanisms of his migratory behaviour are poorly understood. In the present study we have identified a previ-
ously unknown role for endogenous TNFα in orchestrating neutrophil trafficking into and within the lymphatic 
vasculature of inflamed tissues in vivo. Specifically, we demonstrate that in a mouse model of antigen sensiti-
sation, endogenous TNFα directly instructs the neutrophils to migrate into the lymphatic vessels in a strictly 
CCR7-dependent manner and also induces their subsequent directional crawling along the lumen of the lym-
phatic endothelium as mediated by ICAM-1 up-regulation on lymphatic endothelial cells. The new mechanisms 
of TNFα action on neutrophil-lymphatic interactions are summarised in Fig. 8.
In initial studies aimed at investigating TNFα -induced neutrophil trafficking into extravascular tissues, we 
noted that tissue infiltrated neutrophils could rapidly migrate into lymphatic vessels. These studies were then 
extended to a model of antigen sensitisation characterised by the generation of endogenous TNFα . This reac-
tion was also associated with rapid neutrophil migration into lymphatic vessels, a response that was impaired 
in mice deficient in both TNF receptors p55 and p75. Interestingly, TNFα did not appear to mediate neutrophil 
extravasation from blood vessels into tissues, indicating a specific role for TNFα in driving neutrophil motility 
isotypic control (CTL, top panel), anti-ICAM-1 (middle panel) or anti-MAC-1 (bottom panel) mAbs.  
(b) The graphs show the crawling paths of neutrophils in the X & Y planes of the lymphatic vessels from CTL 
Ab, anti-ICAM-1 and anti-MAC-1 mAbs treated groups. (c-e) The effect of anti–ICAM-1 and anti-MAC-1 
blocking antibodies on neutrophil migration parameters (i.e. interstitial and intraluminal crawling) was 
quantified and compared to the responses obtained with an isotype CTL mAb. The three graphs show the mean 
speed (c), directionality (d) and straightness (e) of neutrophils crawling. A total of 280 cells were analysed. 
The numbers of neutrophils in the interstitial tissue (f) and inside the lymphatic vessels (g) were quantify 
by confocal microscopy. (h) Neutrophil infiltration of cremaster dLNs was also quantified at the end of the 
experiment.Results are expressed as mean ± SEM of N = 4–9 mice (1–2 vessels analysed/mouse for intravital 
confocal microscopy, each mice is a single experiment). Significant differences between blocking antibodies 
treated and control groups are indicated by *P < 0.05; ***P < 0.001; ****P < 0.0001. Significant differences 
between other groups are indicated by #(P < 0.05). Bar = 30 μ m.
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into lymphatic vessels but not through blood vasculature. Furthermore, using chimeric animals we showed that 
TNFα acts directly of the leukocytes to induce this neutrophil migration response.
In the present study, we clearly demonstrated that the TNFα -driven migration of neutrophils into lymphatic 
vessels is strictly CCR7-dependent. The role of CCR7 in neutrophil recruitment to the lymphatic system was 
demonstrated both in a mouse model of intradermal immunisation and in human neutrophils by Beauvillain 
et al.27. In accordance with their study, we only detected intracellular stores of CCR7 in murine blood neutro-
phils, but not on their cell surface. However our results shows that neutrophils recruited into inflamed tissues 
up-regulated CCR7 on their surface as compared to blood circulating cells. A study by Eruslanov et al. have 
shown similar up-regulation of CCR7 on human neutrophils in a tumour model36, though the mechanism and 
physiological consequences of this response in human is still unclear. Our current data suggests priming of neu-
trophils for enhanced chemokine receptor expression. While GM-CSF and IL-17 have been shown to prime 
human neutrophils to migrate toward the chemokines CCL21 and CCL19 in vitro27, we did not detect the gener-
ation of these cytokines in the inflamed cremaster muscles at any time-point analysed (Supplementary Fig. S9). 
However, TNFRdbKO tissue-infiltrated neutrophils did not show an increase in CCR7 expression on neutrophils 
in vivo; while low concentrations of TNFα promoted the surface expression of CCR7 on murine blood neutro-
phils in vitro. Altogether these data suggest a predominant role of TNFα in this response and may highlight the 
importance of the origin of the cells analysed (e.g. bone marrow vs blood, tissue-infiltrated vs naïve cells, murine 
vs. human leukocytes). Interestingly, we observed that CCR7KO animals exhibited a high basal level of neutro-
phils within the LNs of naïve animals as compared to WT mice; and inflammation of the cremaster muscles with 
TNFα or following antigen sensitisation did not increase further the number of neutrophils found in the LNs. 
This abnormal trafficking of neutrophils into the LNs of these mice could be related to a higher expression of 
CXCL12 in naïve CCR7KO dLNs as compared to WT dLNs. CXCR4 expression was similar in both genotypes, 
however, CXCR4 antagonist treatment reduced significantly the number of these leukocytes infiltrating CCR7KO 
dLNs, while their migration into the afferent lymphatics was not affected (Supplementary Fig. S7). These data 
support the hypothesis that CXCR4 signalling contributes to neutrophil homing in LN through HEV28.
Since the role for CCR7 in neutrophils trafficking has been contentious to date, we have also investigated other 
chemokine/chemokine receptor axes in this phenomenon, such as the CXCL12/CXCR4 axis. This axis was shown 
recently to be involved in neutrophil trafficking to the lymphatic system in a model of bacterial infection with S. 
aureus26. However, our data demonstrate that CXCR4 blockade did not significantly inhibit neutrophil migration 
into cremaster lymphatic vessels upon CFA+ Ag-stimulation (Supplementary Fig. S5). Such differences between 
their study and ours could be related to the model and inflammatory pathway involved: S. aureus infection may 
Figure 8. Schematic diagram illustrating the dual mechanisms of action of TNFα leading to the trafficking 
of neutrophils into and within the lymphatic vasculature upon acute inflammation in vivo. During the 
acute inflammatory response of the tissue following antigen sensitisation, endogenous TNFα release primed 
the freshly recruited neutrophils. This cytokine allow these leukocytes to be attracted to the lymphatic vessels 
in a CCR7 dependent manner (intravasation). Furthermore, endogenous TNFα also stimulate the lymphatic 
endothelium to express ICAM-1 on their surface, allowing the neutrophils present in the lymphatic vessels to 
adhere and crawl along the luminal side in the correct direction toward the flow of the vessel.
www.nature.com/scientificreports/
13Scientific RepoRts | 7:44189 | DOI: 10.1038/srep44189
preferentially activates the toll-like receptor 2 (TLR2) pathway in vivo37–40. Recently, TLR2 was shown to be asso-
ciated with CXCR4 in lipid rafts of monocytes to induce signalling41, a response not yet investigated for neu-
trophils. In contrast, the TLR4 pathway is involved in M. tuberculosis infections, LPS or CFA stimulation42; and 
TLR4 ligands can induce TNFα release more rapidly than TLR2 agonists in vitro43. Finally, both TNFα 44 and 
TLR4 activation45 have been shown to down-regulate the expression of CXCR4 on neutrophils, rendering them 
less responsive to CXCL12 stimulation. This supports our observation of a similar down-regulation of CXCR4 
expression by neutrophils in our inflammatory model (Supplementary Fig. S5). Furthermore, CXCR4 is highly 
expressed on a subclass of ageing neutrophils rather than healthy mature cells46. Altogether, these observations 
may indicate that different sub-populations of neutrophils or their pathway of activation might be important for 
the molecular axis used for their migration into the lymphatic system.
Another study has shown that the potent neutrophil-chemoattractant CXCL8 was up-regulated in 
TNFα -stimulated human dermal endothelial cells in vitro; and promotes neutrophil migration through a mon-
olayer of human LECs31. In the mouse system, LECs isolated from mouse skin showed an upregulation of CXCL1 
gene upon inflammation47. However, our in vivo model of TNFα -induced neutrophil trafficking into lymphatic 
vessels, clearly indicated the predominant role of CCR7 in this phenomenon. Furthermore local treatment with 
an anti-CXCL1 blocking mAb did not affect the capacity of neutrophils to enter the lymphatic system upon 
inflammation in vivo. These data highlight differences between in vivo and in vitro models. Indeed, several studies 
pointed to the importance of the microenvironment for the LECs to retain their specific lymphatic character-
istic that are lost in culture such as the capacity to generate CCL2148,49. Similarly to a mouse model of contact 
hypersensitivity47, we did not observed a change in total CCL21 expression between naïve and inflamed animals 
(Supplementary Fig. S8). We however noticed that lymphatic vessels exhibited higher expression of CCL21 as 
compared to the interstitial tissue with the establishment of a gradient that could direct the neutrophils toward 
the vessels in vivo. The formation of a gradient of CCL21 driving the migration of DCs within the LNs has been 
recently reported in the literature50.
Having identified TNFα as a key signal for promoting neutrophil trafficking to the lymphatic vessels, the 
potential involvement of this cytokine in mediating other neutrophil-lymphatic vessel interactions was investi-
gated. TNFα is the prototypical pro-inflammatory cytokine playing a key role in many immune responses such 
as cell recruitment and leukocyte activation. It is also involved in numerous pathological conditions and auto-
immune disorders such as rheumatoid arthritis, lupus, psoriasis and atherosclerosis and there is now considera-
ble evidence for successful use of TNFα blockers for the treatment of certain chronic inflammatory conditions. 
However, anti- TNFα therapy is associated with a heightened risk of serious infections and poor vaccination 
responses in patients51. Furthermore, the mechanism through which these drugs work is not fully known; though 
suppressing leukocyte recruitment and activation is considered to be a principle mode of action52. In our acute 
model of cremasteric inflammation however, we neither genetic deficiency for TNFα signalling nor antibody 
blockade inhibited neutrophil recruitment to the tissue, suggesting different roles for TNFα in acute vs chronic 
inflammation. During physiological conditions, TNFα can prime blood vascular endothelial cells (BECs) to pres-
ent both adhesion molecules and chemoattractants in order to induce leukocyte migration. Specifically, TNFα 
has been shown to up-regulate ICAM-1 expression on BECs both in vivo and in vitro, an adhesion molecule 
essential for neutrophil directional crawling during their recruitment through blood vessels33,34. Lymphatic 
endothelial cells (LECs) express very low levels of ICAM-1 in uninflamed condition, but can up-regulate this 
molecule upon TNFα -stimulation in both humans53,54 and mice (Fig. 6). The exact role of ICAM-1 in leukocyte 
migration into the lymphatic system is however controversial: in vitro antibody blockade inhibits both adhesion 
and transmigration responses of DCs through cultured human LECs53, and in vivo ICAM-1 have been reported 
to mediate crawling of DCs along the lymphatic endothelium55. In contrast, DC interstitial migration was not 
affected in mice exhibiting leukocyte-specific deletion of ICAM-1-ligand integrins56. In the present study, we 
have observed that neutrophils crawl along the luminal surface of the lymphatic endothelium following a local 
inflammatory stimulus. This response was associated with a formation of a gradient of CCL21 within the vessel 
(Supplementary Fig. S8e). This gradient could explain why the majority of neutrophils crawl along in the direc-
tion of the lymphatic flow. Interestingly, Russo et al., have recently demonstrated that in vitro, murine LECs 
generate a gradient of CCL21 when exposed to low sheer stress and that this gradient was responsible for the 
directionality of crawling of DCs57. In our model, the neutrophil crawling response (as well as ICAM-1 upreg-
ulation) was blocked when mice received an injection of an anti-TNFα blocking antibody. Furthermore, local 
blockade of ICAM-1 or MAC-1 inhibited this crawling response while interstitial migration of the leukocytes and 
their capacity to enter the lymphatic vessels were unaffected. Overall, the local injection of blocking antibodies 
inhibiting neutrophil-lymphatic endothelium luminal interactions resulted in a reduction of neutrophil numbers 
infiltrating the LNs, highlighting potential and effective targets to manipulate the role of neutrophils in adaptive 
immune responses in vivo.
In conclusion, the data presented here provide an insight into the mechanisms underlying neutrophil traf-
ficking into and within lymphatic vessels of inflamed tissues. Specifically, we have unravelled a predominant role 
for endogenous TNFα in orchestrating both CCR7-dependent migration of neutrophils into afferent lymphatics 
and ICAM-1-dependent crawling on the luminal surface of lymphatic endothelium during the acute phase of 
the inflammatory response as induced by antigen sensitisation. Overall, our findings identify TNFα as a new 
molecular regulator of neutrophil migration into the lymphatic system that may provide the opportunity for the 
development of improved immunisation protocols but also highlight a new potential mechanism of action - and 
limitations - for anti- TNFα therapy.
Methods
Reagents. Recombinant murine TNFα purchased from R&D Systems, Complete Freund’s Adjuvant from 
AMSbio, Ovalbumin and AMD3100 from Sigma; and chick Collagen II from MB Biosciences. The following 
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primary antibodies were used for immunofluorescence labelling for confocal imaging and confocal IVM: rat 
anti–mouse LYVE-1 mAb (clone ALY7; eBioscience); non-blocking rat anti–mouse PECAM-1 Ab (clone C390, 
eBioscience); rat anti–mouse ICAM-1 mAb (clone YN1/1.4.7; purified and Alexa 488-conjugated, eBioscience); 
rat anti–mouse MAC-1 mAb (clone M1/70, BioLegend); monoclonal rat anti–mouse MRP14 mAb (clone 2B10; 
a gift from N. Hogg, Cancer Research UK, London, UK); rat anti-mouse Ly6G mAb (clone 1A8, Alexa 647-con-
jugated, Biolegend); rat anti-mouse CXCR4 mAb (clone 2B11, PE-conjugated, eBioscience), rat anti-mouse/
human High Endothelial Venule mAb (MECA-79, Alexa 488-conjugated eBioscience), rat anti-mouse CCR7 
mAb (clone 4B12, Alexa 488- or biotin-conjugated, eBioscience); rat anti-mouse CD45.2 mAb (clone 104, PE/
Cy7-conjugated, Biolegend), rat anti-mouse TNFα mAb (clone MP6-XT22, Biolegend), anti-mouse CCL21, anti-
mouse CXCL1 and anti-mouse CXCL12 mAbs (R&D systems), polyclonal goat anti–mouse TNFR p55 and p75 
Abs (R&D Systems). The following purified antibodies were used as isotype-matched control Abs: rat IgG1, IgG2a 
and IgG2b (Biolegend). Unlabelled antibodies were directly conjugated Alexa Fluor dyes using Molecular Probes 
Alexa Fluor Monoclonal Antibody Labeling kit (Invitrogen) for confocal microscopy analysis.
Animals. Male mice (8–12 weeks) wild-type (WT, Charles Rivers), CCR7 knockout (CCR7KO, JAXLab), 
LysM-EGFP ki (LysM-GFP), LysM-EGFP ki × CCR7 ko (LysM-GFP/CCR7KO) (all on a C57BL/6 background) 
and TNFRdb knockout (TNF receptors p55 and p75 double knockout mice, JAXLab) mice were used for these 
experiments. Only heterozygote LysM-GFP animals exhibiting fluorescent myeloid cells (neutrophils comprising 
the highest percentage of GFP high cells) were used for this study with the permission of T. Graf (Albert Einstein 
College of Medicine, Bronx, NY). These animals were provided by M. Sperandio (Ludwig Maximilians University, 
Munich, Germany) and bred in-house in individually ventilated cages; and facilities were regularly monitored 
for health status and infections. Chimeric mice deficient in leukocyte TNFR p55 and p75 or were generated by 
lethal irradiation of C57BL/6 WT mice (5.5 Gy twice, 4 h apart) and injection of bone marrow cells (1.5 × 106 
cells/recipient i.v.) from TNFRdbKO mice. C57BL/6 WT littermates receiving WT bone marrow were used as 
controls. The phenotype of blood circulating neutrophils in chimeric animals was then assess by flow cytome-
try (Fig. S4). Similar protocol was used for the generation of chimeric animals exhibiting CCR7KO leukocytes 
following the injection of donor LysM-GFP/CCR7KO bone marrow cells into lethally irradiated WT recipient 
animals. Depletion of tissue-resident macrophages of the cremaster muscles was achieved by 3 consecutive i.s. 
injections of clodronate liposomes (Encapsula NanoSciences LLC; 250 μ g/mouse, 20 hrs apart) prior to the induc-
tion of inflammation. With this protocol we achieved ~85.9% of depletion as quantified by flow cytometry (data 
not shown). All experiments were approved by the local biological service unit Ethical Committee at Queen Mary 
University of London and carried out under the Home Office Project Licenses (70/7884 & 70/8264) according to 
the guidelines of the United Kingdom Animals Scientific Procedures Act (1986). At the end of all in vivo exper-
iments, animals were humanely killed by cervical dislocation in accordance with UK Home Office regulations.
Induction of cremaster inflammation. WT C57BL/6 male mice (8–12 weeks old) were sedated with 
30 μl intramuscular (i.m.) injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) in saline before their cre-
master muscles were stimulated via intrascrotal (i.s.) injection of TNFα (300 ng/400 μ l PBS) or an emulsion of 
CFA (200 μg/300 μ l per mouse) and ovalbumin or chick collagen II (200 μ g per mouse). Control mice received 
300–400 μ l of PBS via i.s. injection. In some experiments, mice were pre-treated locally with the CXCR4 inhibitor 
AMD3100 or vehicle (10 mg/kg, 250 μ l, i.s. 4 hrs post-inflammation) prior to the visualisation of the inflammatory 
response. Several time points following TNFα /CFA+ Ag stimulation were investigated over the course of 48 hrs.
Confocal Microscopy. Intravital confocal microscopy. LysM-GFP mice were stimulated with i.s. injec-
tion of either TNFα or CFA+ Ag and the inflammatory response was allowed to develop for 4 (TNFα ) to 6 hrs 
(CFA+ Ag) before visualisation of the response by intravital confocal microscopy. In some experiments, CFA+ 
Ag-stimulated animals were pre-treated with a local (i.s.) injection of the following blocking antibodies 90 to 
120 min before surgery: anti- TNFα or rat IgG1κ isotype control mAbs (50 μ g/mouse), anti-ICAM-1/anti-MAC-1 
mAbs or rat IgG2b isotype control mAbs (10 μ g/mouse) along with non-blocking dose of an anti-LYVE-1 mAb 
(2 μ g/mouse, Alexa555 conjugated) and/or a non-blocking anti-PECAM-1 mAb (2 μ g/mouse, Alexa647 con-
jugated) to label the lymphatic and blood vasculatures, respectively. Thirty minutes before surgery, mice were 
sedated with i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Following surgery, cremaster mus-
cles were imaged with a Leica SP5 or SP8 confocal microscope58 for another 90 min with a superfusion of warm 
Tyrode’s solution. Images were acquired every minute with the use of a 20 × water-dipping objective (NA:1.0) 
with sequential scanning of different channels at a resolution of 1024 × 700 pixels in the x × y plane and 0.7 μ m 
steps in z-direction. 4D confocal image sequences were then analysed offline using IMARIS software (Bitplane, 
Switzerland), enabling the dynamic interaction of neutrophils with lymphatic vessels be observed, tracked, and 
quantified as previously described34.
Confocal microscopy on fixed tissue. Following immunostaining, the cremaster muscles were imaged with a 
Leica SP8 confocal microscope with the use of a 20 × water-dipping objective (NA:1.0). Images of post-capillary 
venules and lymphatic vessels (at least 6 vessels per tissue) were attained with the use of sequential scanning of 
different channels at every 0.52 μ m of tissue depth at a resolution of 1024 × 470 and 1024 × 800 pixels in the 
x × y plane, respectively. This resolution of pixels correspond to a voxel size of 0.24 × 0.24 × 0.5 μ m in x × y × z. 
Post-capillary venules and lymphatic vessels were imaged at a zoom factor of × 1.9 and × 1.2, respectively. 
Quantification of neutrophil transmigration and intravasation into lymphatic vessels were analysed with the 
3D-reconstructing image processing software IMARIS. Transmigrated neutrophils were defined as the num-
ber of neutrophils present in the extravascular tissue across a 300 μ m blood vessel segment and within 50 μ m 
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from each side of the venule of interest. Data was expressed as the number of neutrophils per volume of tissue. 
Intravasated neutrophils were defined as the number of neutrophils present inside the lymphatic vessels and data 
were expressed as the number of neutrophils per given volume of lymphatic vessel quantified by IMARIS Software 
by creating an isosurface representing exclusively the LYVE-1 positive lymphatic endothelium. To assess ICAM-1 
and CCL21 expression on lymphatic vessels, specific primary antibodies or control isotype-matched antibodies 
were injected i.s. 1 hr prior to the exteriorisation of the cremaster muscles; and following the analysis of tissues 
by confocal microscopy, the mean fluorescence intensity (MFI) of the staining for molecule of interest was deter-
mined using IMARIS software on the LYVE-1 isofurface as determined by IMARIS software. Intensity profiles 
for CCL21 expression along a certain distance (10 μ m away from or 100 μ m within the lymphatic vessel) was per-
formed using Image J. For the LNs, halved samples were imaged with a Leica SP8 confocal microscope with the 
use of a 10 × water-dipping objective (NA:0.3). Images (12 images per pair of LNs per mouse) were obtained with 
the use of sequential scanning of different channels at every 5.8 μ m of tissue depth at a resolution of 1024 × 1024 
pixels in the x × y plane, corresponding to a voxel size of 0.91 × 0.91 × 5.8 μ m in x × y × z. Quantification of neu-
trophil recruitment into the inguinal LNs were analysed with the 3D-reconstructing image processing software 
IMARIS. Recruited neutrophils were defined as the number of neutrophils per volume of tissue, excluding (unless 
specified) the blood circulating neutrophils present in HEVs.
Flow cytometry. Whole blood and single cell suspension from (collagenase + DNAse)-digested cremaster 
muscles and LNs of CFA+ Ag-stimulated WT and CCR7KO animals, were fluorescently labelled with conjugated 
antibodies against CD45.2, Ly6G, CD11c, CD3ε , CCR7, CXCR4, TNFRp55, TNFRp75 or the appropriate isotype 
control antibodies (0.2–2 μ g/ml, various fluorochromes) and DAPI (for viability) for at least 1 hr at 4 °C. Viable 
leukocytes were identified by FSC and SSC characteristics and CD45.2 positive and DAPI negative staining. 
Neutrophils were identified based on Ly6G high staining. In some experiments, blood leukocytes where incu-
bated at 37 C in RPMI medium (supplemented with 10% FCS and 2 mM of L-Glutamin) with various concentra-
tion of TNFα (1, 10 or 100 ng/ml) for 4 hrs in the presence of 50 μ M of Nystatin (Sigma, an endocytosis inhibitor) 
prior to immunofluorescence staining. Samples were analysed using a BD LSR-Fortessa (BD Biosciences) and 
FlowJo analysis software (Treestar). In some studies the intracellular expression of CCR7 was performed using 
the Cytofix/Cytoperm kit (BD) according to the manufacturer’s recommendations.
ELISA. Snap frozen cremaster tissues from WT mice stimulated with CFA+ Ag were transferred into 
screw-top tubes containing homogenising beads along with 500 μ l homogenising buffer (1% Triton™ X-100, 1% 
protease inhibitor, PBS) prior to being placed in a high-throughput tissue homogeniser, Precellys® 24 (Precellys, 
Derbyshire, UK), for 3 cycles of 20 s homogenisation at 6500 r.p.m with 40 s rest between each cycle. Homogenised 
samples were then frozen at − 80 °C for 1 h before being thawed and centrifuged for 5 min at 10,000 g using a tab-
letop centrifuge. The supernatant was taken and used to quantify the release of TNFα , GM-CSF, IL-17, CCL21, 
CCL19 and CXCL12 by ELISA (eBioscience, Hatfield, UK or R&D Systems, UK) according to the manufacturer’s 
protocol.
Statistical analysis. Data are presented as mean ± S.E.M per mouse. Significant differences between mul-
tiple groups were identified by one-way analysis of variance (ANOVA), followed by Newman-Keuls Multiple 
Comparison Test or a two-way analysis of variance (ANOVA) followed by Holm-Sidak Multiple Comparison 
Test when at least 2 different independent variables are being compared. Whenever two groups were compared 
Student’s t test was used. P-values < 0.05 were considered significant.
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Neutrophil breaching of the lymphatic endothelium in a TNF-stimulated tissue (Figure 1e). The video 
shows a cremaster lymphatic vessel of a LysM-GFP mouse (exhibiting GFP-labelled leukocytes 
(green), immunostained in vivo for ECs with Alexa647-labelled anti-PECAM-1 mAb (blue) and 
stimulated with TNF (300ng/mouse i.s.). The video shows the migration of a neutrophil (recorded from 
4hrs after injection of the cytokine) into the lumen of the lymphatic vessel. Images were captured every 
minute for 90min. Still images are shown in Fig. 1e. 
 
Video 2 
Neutrophil breaching of the lymphatic endothelium in a TNF-stimulated (300ng/mouse i.s.) cremaster 
lymphatic vessel of a LysM-GFP mouse (exhibiting GFP-labelled leukocytes (green), and 
immunostained in vivo for LECs with non-blocking dose of an Alexa555-labelled anti-LYVE-1 mAb 
(red). The video shows the migration of a neutrophil (in green and isolated from the rest of the 
inflammatory response by creating an isosurface on it using IMARIS software for clarity of the image) 
into the lumen of the lymphatic vessel (recorded from 2hrs after injection of the cytokine). Images were 
captured every minute for 90min. 
 
Video 3 
Intraluminal neutrophil crawling along the lumen of the lymphatic endothelium (Figure 1f). The video 
captures the intraluminal crawling of neutrophils (in green) along the lymphatic endothelial cell wall in 
a TNF-stimulated cremaster of a LysM-GFP mouse (exhibiting GFP-labelled leukocytes (green). 
Lymphatic vessels were immunostained in vivo with Alexa555-labelled anti–LYVE-1 mAb (red) and 
Alexa647-labelled anti-PECAM-1 mAb (blue). Images were captured from 4hrs post-inflammation at 
one stack per minute for a duration of 90 min. Still images of this video are shown in Fig. 1f. 
 
Video 4 
Intraluminal neutrophil crawling with isotype control (IgG1, κ) mAb (Figure 5a). The video captures 
the intraluminal crawling of several neutrophils (in green and isolated from the rest of the inflammatory 
response by creating an isosurface on them using IMARIS software for clarity of the image) along the 
lymphatic endothelial cell wall in a CFA+Ag-stimulated cremaster of a LysM-GFP mouse (exhibiting 
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GFP-labelled leukocytes (green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb 
(red) and Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an IgG1, κ isotype control 
(50μg/mouse). The IgG1, κ isotype control mAb was injected i.s. 4hrs post inflammation before 
exteriorisation of the cremaster muscles to perform intravital confocal microscopy 2hrs later. At the end 
of the sequence, the track followed by the neutrophils during their crawling on the luminal side of the 
lymphatic endothelium is shown, alongside the displacement (arrow). Images were captured at one 
stack per minute for a duration of 90min. A still image of this is shown in Fig. 5a.  
 
Video 5 
Intraluminal neutrophil crawling with anti-TNF blocking mAb (Figure 5a). The video captures the 
intraluminal crawling of several neutrophils (in green and isolated from the rest of the inflammatory 
response by creating an isosurface on them using IMARIS software for clarity of the image) along the 
lymphatic endothelial cell wall in a CFA+Ag-stimulated cremaster of a LysM-GFP mouse (exhibiting 
GFP-labelled leukocytes (green) and immunostained in vivo with Alexa555–labelled anti–LYVE-1 
mAb (red) and Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-TNF blocking 
Ab (50μg/mouse). The anti-TNF blocking Ab was injected i.s. 4hrs post-inflammation before 
exteriorisation of the cremaster muscles to perform intravital confocal microscopy 2hrs later. At the end 
of the sequence, the track followed by the neutrophils during their crawling on the luminal side of the 
lymphatic endothelium is shown, alongside the displacement (arrow). Images were captured at one 
stack per minute for a duration of 90min. A still image of this is shown in Fig. 5a.  
 
Video 6 
Intraluminal neutrophil crawling with isotype control (IgG2b, κ) mAb (Figure 7a). The video captures 
the intraluminal crawling of several neutrophils (in green and isolated from the rest of the inflammatory 
response by creating an isosurface on them using IMARIS software for clarity of the image) along the 
lymphatic endothelial cell wall in a CFA+Ag-stimulated cremaster of a LysM-GFP mouse (exhibiting 
GFP-labelled leukocytes (green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb 
(red) and Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an IgG2b, κ isotype control 
(10μg/mouse). Antibodies were injected i.s. 90min before exteriorisation of the cremaster muscles and 
visualisation by intravital confocal microscopy from 6hrs post inflammation. At the end of the sequence, 
the track followed by the neutrophils during their crawling on the luminal side of the lymphatic 
endothelium is shown, alongside the displacement (arrow). Images were captured at one stack per 





Intraluminal neutrophil crawling with anti-ICAM-1 blocking mAb (Figure 7a). The video captures the 
intraluminal crawling of several neutrophils (in green and isolated from the rest of the inflammatory 
response by creating an isosurface on them using IMARIS software for clarity of the image) along the 
lymphatic endothelial cell wall in a CFA+Ag-stimulated cremaster of a LysM-GFP mouse (exhibiting 
GFP-labelled leukocytes (green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb 
(red) and Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-ICAM-1 blocking 
mAb (10μg/mouse). Antibodies were injected i.s. 90min before exteriorisation of the cremaster muscles 
and visualisation by intravital confocal microscopy. At the end of the sequence, the track followed by 
the neutrophils during their crawling on the luminal side of the lymphatic endothelium is shown, 
alongside the displacement (arrow). Images were captured at one stack per minute for a duration of 
90min. A still image of this is shown in Fig. 7a.  
 
Video 8 
Intraluminal neutrophil crawling with anti-MAC-1 blocking mAb (Figure 7a). The video captures the 
intraluminal crawling of several neutrophils (in green and isolated from the rest of the inflammatory 
response by creating an isosurface on them using IMARIS software for clarity of the image) along the 
lymphatic endothelial cell wall in a CFA+Ag-stimulated cremaster of a LysM-GFP mouse (exhibiting 
GFP-labelled leukocytes (green) immunostained in vivo with Alexa555–labelled anti–LYVE-1 mAb 
(red) and Alexa647-labelled anti-PECAM-1 mAb (blue), in the presence of an anti-MAC-1 blocking 
mAb (10μg/mouse). Antibodies were injected i.s. 90min before exteriorisation of the cremaster muscles 
and visualisation by intravital confocal microscopy. At the end of the sequence, the track followed by 
the neutrophils during their crawling on the luminal side of the lymphatic endothelium is shown, 
alongside the displacement (arrow). Images were captured at one stack per minute for a duration of 






































Figure S1: Lymphatic architecture of the cremasteric tissue 
(a) Representative 3D-reconstructed confocal image of a whole-mount fixed cremaster muscle of a 
C57BL/6 WT animal and immunostained with antibodies against LYVE-1 (Alexa555-conjugated, red), 
PECAM-1 (Alexa488-conjugated, green) and MRP14 (Alexa647-conjugated, blue) to visualise the 
lymphatic vessels, the endothelial cell junctions and neutrophils, respectively, showing the presence of 
a fully developed lymphatic vasculature in this tissue with blind-ended lymphatic capillary vessels 
(arrow). (b) Representative confocal image of a fixed cremasteric lymphatic vessel immunostained for 
VE-Cadherin (Alexa555-conjugated, red) and PECAM-1 (Alexa647-conjugated, blue). The inserts on 
the right area show a magnified view of the heterogeneous distribution of the adhesion molecules (with 
VE-cadherin-rich buttons and PECAM-1-rich flaps) expressed by the endothelial cells of the 

















Figure S2: Blood neutrophilia following stimulation of the cremaster muscles with CFA+Ag. 
Percentage of neutrophils with the blood circulation of WT mice subjected to cremaster muscle 
inflammation with CFA+Ag as analysed by flow cytometry. Data are expressed as mean±SEM from 4 
independent experiments. Statistically significant differences between the stimulated and control groups 















Figure S3: neutrophil migration response in the cremaster muscle following stimulation with 
CFA+Ag for 8hrs in WT, TNRdbKO and CCR7KO mice 
WT, TNFRdbKO and CCR7KO mice were subjected to CFA+Ag-induced inflammation of the 
cremaster muscles. Controlled mice were injected with PBS. Eight hours later, the cremaster muscles 
were dissected away, fixed and immunostained for LYVE-1, PECAM-1 and MRP14 to visualise the 
lymphatic vasculatures the endothelial cells junctions and neutrophils, respectively before analysis of 
the neutrophil migration responses by confocal microscopy. (a) Number of extravasated neutrophils in 
the cremaster muscles. (b) Number of neutrophils within the cremaster lymphatic vessels. Data are 
expressed as mean±SEM from n = at least 4 animals per group. Statistically significant difference 
between stimulated and unstimulated animals are indicated by asterisks: **, P< 0.01; ***, P < 0.001; 
****, P < 0.0001. Statistically significant difference between WT and KO animals are indicated by 
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Figure S4: Phenotypic analysis of blood neutrophils from TNFRs chimeric animals 
Blood leukocytes from TNFRdbKO or chimeric animals were immunostained for neutrophils specific 
markers (CD45+ Ly6G+) and their surface expression of TNFR p55 and p75 were analysed by flow 
cytometry. The figure shows representative histograms of the fluorescence intensity for P75 (a) and 
P55 (b) of blood neutrophils from lethally irradiated WT mice and reconstituted with TNFRdbKO 
(TNFRdbKO  WT) or WT (WTWT) bone marrow hematopoietic cells (blue) and compared to the 



































Neither CXCL1:CXCR1/2 nor CXCL12:CXCR4 axes play a significant role in neutrophil 
migration across the lymphatic endothelium during antigen sensitisation.  
WT mice were subjected to CFA+Ag-induced inflammation of the cremaster muscles. Four hours later, 
mice received an i.s. injection of an anti-CXCL1 blocking mAb (or an isotype control mAb) or the 
CXCR4 specific inhibitor AMD3100 (or vehicle as control). At the end of the inflammation period, 
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cremaster muscles were dissected away, fixed and immunostained for LYVE-1, PECAM-1 and MRP14 
to visualise the lymphatic vasculatures the endothelial cells junctions and neutrophils, respectively 
before analysis of the neutrophil migration responses by confocal microscopy. (a) Number of 
extravasated neutrophils in the cremaster muscles of unstimulated and CFA+Ag-stimulated (8hrs) mice 
injected with anti-CXCL1 blocking antibody or isotype control. (b) Number of neutrophils within the 
cremaster lymphatic vessels of unstimulated and CFA+Ag-stimulated (8hrs) mice injected with anti-
CXCL1 blocking antibody or isotype control. (c) Number of neutrophils found in the dLNs of the 
cremastermuscle of unstimulated and CFA+Ag-stimulated (8hrs) mice injected with anti-CXCL1 
blocking antibody or isotype control. (d) Number of extravasated neutrophils in inflamed cremaster 
muscles of unstimulated and CFA+Ag-stimulated (16hrs) mice treated with AMD3100 or vehicle 
control. (e) Number of neutrophils within the cremaster lymphatic vessels of unstimulated and 
CFA+Ag-stimulated (16hrs) mice treated with AMD3100 or vehicle control. (f) Number of neutrophils 
found within the dLNs of unstimulated and CFA+Ag-stimulated (16hrs) mice treated with AMD3100 
or vehicle control. (g) Percentage of neutrophils into the blood circulation as assessed by flow 
cytometry. (h) Surface expression of CXCR4 (RFI) on blood circulating neutrophils as assessed by flow 
cytometry. Data are expressed as mean±SEM from at least 4 independent experiments with n = 5-12 
animals per group. Statistically significant difference between stimulated and unstimulated animals are 















Figure S6: low dose of TNFα induces CCR7 expression on blood neutrophils in vitro. 
Whole blood leukocytes from WT and CCR7KO animals were stimulated in vitro with different doses 
of TNFα for 4hrs in the presence of the endocytic inhibitor, nystatin (50 µM). Expression of CCR7 on 
the surface of neutrophils was then assessed by flow cytometry. Dotted line represent the RFI of the 
isotype control antibody. Data are expressed as mean±SEM from 7 independent experiments (at least 7 
mice per condition). Statistically significant difference specific CCR7 staining and isotope control 
antibody are indicated by asterisks: **, P< 0.01. Data were analysed using a two-way analysis of 
variance (ANOVA), followed by Holm-Sidak's multiple comparisons test. Statistically significant 
difference TNFα-stimulated cells and PBS control group are indicated by dash symbols: #, P< 0.05, ### 
P < 0.001. Statistically significant difference TNFα-stimulated cells and PBS control group are 




Figure S7:  













Figure S7: CXCL12:CXCR4 axis is responsible for the high number of neutrophils found into the 
lymph nodes of CCR7KO mice under steady state condition. 
Neutrophil migration into the lymphatic system of the cremaster muscle following antigen sensitisation 
with complete Freund’s adjuvant (CFA+Ag) was induced in WT and TNFRdbKO animals as well as in 
chimeric animals exhibiting neutrophils deficient for CCR7. (a) Percentage of circulating neutrophils 
in naïve WT and CCR7KO animals, as quantified by flow cytometry. (b) Surface expression of CXCR4 
on circulating neutrophils from WT and CCR7KO animals, as quantified by flow cytometry. (c) 
CXCL12 expression in the LNs of naïve WT and CCR7KO mice, as quantified by ELISA. (d) Number 
of extravasated neutrophils in inflamed cremaster muscles of unstimulated and CFA+Ag-stimulated 
CCR7KO mice treated with AMD3100 or the vehicle. (e) Number of neutrophils within the cremaster 
lymphatic vessels of unstimulated and CFA+Ag-stimulated CCR7KO mice treated with AMD3100 or 
the vehicle. (f) Number of neutrophils found into the dLNs of unstimulated and CFA+Ag-stimulated 
CCR7KO mice treated with AMD3100 or the vehicle. Data are expressed as mean±SEM with 5-12 
animals per group. Statistically significant differences between stimulated and unstimulated treatment 
groups are indicated by asterisks: *, P < 0.05; **, P < 0.01. Significant differences between responses 























Figure S8: CCL21 expression in the tissue. 
WT mice were subjected to CFA+Ag-induced inflammation of the cremaster muscles for 8hrs before 
harvesting the tissues for subsequent analysis for the expression of CCL21. (a) Quantification of CCL21 
generation in the tissue of naïve and stimulated mice by ELISA. (b) WT mice subjected to CFA+Ag-
induced inflammation also received a local (i.s.) injection of the anti-TNFα blocking antibody (or an 
isotype control antibody, 50µg/mouse) before quantifying the expression of CCL21 by ELISA. (c) In 
some experiments, at the end of the inflammatory period (8hrs), tissues were fixed and whole-mount 
immunostained for Lyve-1 and CCL21 (or isotype control antibody) before being analysed by confocal 
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microscopy. The intensity of staining for CCL21 was then quantified within both the lymphatic vessels 
and the interstitial tissue using IMARIS software. (d) A line intensity profile was generated 
perpendicular to the direction of the vessel (10 lines/vessel) from the abluminal surface into the tissue 
(10 µm length) to look at a potential gradient of CCL21 guiding the leukocytes toward lymphatic 
vessels. Data are presented as percentage change from the first pixel of the line. (e) Similarly, a surface 
intensity profile within the lymphatic vessels was generated in the direction of the flow (100 µm length). 
Data are presented as percentage change from the first measured pixels of the surface. Data are 
expressed as mean±SEM from at least with 4 animals per group (with at least 5 vessels per mouse fore 
confocal images). Statistically significant differences for CCL21 staining between the isotype control 
antibody vs. anti-CCL21 Ab (c) and for the intensity profiles from the first pixel to the last pixel 
measured (d & e) are indicated by asterisks: *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Significant 
differences between the interstitial tissue vs. the lymphatic vessels and unstimulated vs. stimulated, are 














Figure S9: IL-17 and GM-CSF release upon antigen stimulation of the cremaster muscle. 
Time course of IL17 (left panel) and GM-CSF (right panel) generated in the cremaster muscles of WT 
mice following intra-scrotal injection of CFA+Ag and as quantified by ELISA. Data are expressed as 
mean±SEM from 6-10 mice (from 4 independent experiments). 
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